[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_response": "A synonym for Acrokeratosis paraneoplastica is \"acrokeratosis paraneoplastic syndrome\".",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrokeratosis paraneoplastica is also known as \"acrokeratosis paraneoplastic syndrome\".",
    "llama-2-7b-chat-hf_fact": [
      "Acrokeratosis paraneoplastica is also known as \"acrokeratosis paraneoplastic syndrome\"."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-chat-hf_response": "Weaver syndrome and Sotos syndrome are both genetic disorders that affect brain development and can cause intellectual disability, growth delays, and other physical abnormalities. However, they are distinct conditions with different genetic causes and clinical features.\nWeaver syndrome is caused by mutations in the PHLPP2 gene, which codes for a protein involved in the regulation of protein phosphatase 1 (PP1). PP1 is a key enzyme that regulates various cellular processes, including cell signaling, protein synthesis, and DNA repair. Weaver syndrome is characterized by intellectual disability, seizures, delayed speech and language development, and a distinctive facial appearance with a prominent forehead, widely spaced eyes, and a small jaw.\nSotos syndrome, on the other hand, is caused by mutations in the NSD1 gene, which codes for a protein involved in the regulation of chromatin structure and gene expression. Sotos syndrome is characterized by intellectual disability, growth delays, distinctive facial features, and an increased risk of various medical problems, including heart defects, vision problems, and immune system disorders.\nWhile both Weaver syndrome and Sotos syndrome can cause intellectual disability and growth delays, the clinical features of the two conditions are distinct. Weaver syndrome typically presents with more mild symptoms, while Sotos syndrome can have more severe and widespread effects on brain development and function.",
    "llama-2-7b-chat-hf_fact_raw": "1. Weaver syndrome is caused by mutations in the PHLPP2 gene.\n2. Protein phosphatase 1 (PP1), regulated by PHLPP2, is a key enzyme involved in cellular processes such as cell signaling, protein synthesis, and DNA repair.\n3. Sotos syndrome is caused by mutations in the NSD1 gene.\n4. Sotos syndrome is associated with an increased risk of heart defects, vision problems, and immune system disorders.\n5. Weaver syndrome and Sotos syndrome both affect brain development and can cause intellectual disability and growth delays.",
    "llama-2-7b-chat-hf_fact": [
      "Weaver syndrome is caused by mutations in the PHLPP2 gene.",
      "Protein phosphatase 1 (PP1), regulated by PHLPP2, is a key enzyme involved in cellular processes such as cell signaling, protein synthesis, and DNA repair.",
      "Sotos syndrome is caused by mutations in the NSD1 gene.",
      "Sotos syndrome is associated with an increased risk of heart defects, vision problems, and immune system disorders.",
      "Weaver syndrome and Sotos syndrome both affect brain development and can cause intellectual disability and growth delays."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Weaver syndrome is caused by mutations in the EZH2 gene, not the PHLPP2 gene.\n2. TRUE: Protein phosphatase 1 (PP1) is regulated by a different gene (not PHLPP2) and is indeed a key enzyme involved in various cellular processes including cell signaling, protein synthesis, and DNA repair.\n3. TRUE: Sotos syndrome is indeed caused by mutations in the NSD1 gene.\n4. UNKNOWN: While Sotos syndrome is associated with an increased risk of a variety of health issues, including overgrowth and learning disabilities, specific associations with heart defects, vision problems, and immune system disorders require further clarification as these are not the primary characteristics used to define the syndrome. Some individuals with Sotos syndrome may experience these problems, but they are not defining features of the syndrome and the risk levels can vary.\n5. TRUE: Both Weaver syndrome and Sotos syndrome are associated with brain development issues, which can result in intellectual disability and growth delays.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-7b-chat-hf_response": "JASPAR (Junket Algorithm for the Prediction of Transcription Factor Binding Sites in DNA) is a widely used database of transcription factor binding site (TFBS) predictions. Here are some of the major releases of the JASPAR database:\n1. JASPAR Release 1.0 (1999): This was the first release of the JASPAR database, which contained TFBS predictions for 17 transcription factors.\n2. JASPAR Release 2.0 (2003): This release expanded the database to include predictions for 61 transcription factors and introduced a new algorithm for predicting TFBSs.\n3. JASPAR Release 3.0 (2007): This release included improvements to the prediction algorithms and the addition of new transcription factors, bringing the total number of predicted TFBSs to 147.\n4. JASPAR Release 4.0 (2010): This release introduced a new feature called \"JASPAR-TS,\" which allows users to predict the binding sites of transcription factors in a given DNA sequence.\n5. JASPAR Release 5.0 (2013): This release included improvements to the prediction algorithms and the addition of new transcription factors, bringing the total number of predicted TFBSs to 213.\n6. JASPAR Release 6.0 (2016): This release introduced a new algorithm for predicting TFBSs and improved the accuracy of the predictions.\n7. JASPAR Release 7.0 (2019): This release included the integration of new data and improved algorithms, leading to more accurate predictions of TFBSs.\n8. JASPAR Release 8.0 (2022): This is the latest release of the JASPAR database, which includes improvements to the prediction algorithms and the addition of new transcription factors, bringing the total number of predicted TFBSs to 333.\nIt's worth noting that the JASPAR database has been updated regularly since its inception, with new releases incorporating new data and improvements to the prediction algorithms.",
    "llama-2-7b-chat-hf_fact_raw": "1. JASPAR Release 1.0 was launched in 1999 with TFBS predictions for 17 transcription factors.\n2. The database was expanded in the JASPAR Release 2.0 in 2003 to include predictions for 61 transcription factors.\n3. By JASPAR Release 3.0 in 2007, the number of predicted TFBSs had increased to 147.\n4. JASPAR Release 4.0 was introduced in 2010 and featured \"JASPAR-TS\" for predicting transcription factor binding sites in DNA sequences.\n5. The latest release mentioned is JASPAR Release 8.0 in 2022, by which the database grew to include predictions for 333 transcription factors.",
    "llama-2-7b-chat-hf_fact": [
      "JASPAR Release 1.0 was launched in 1999 with TFBS predictions for 17 transcription factors.",
      "The database was expanded in the JASPAR Release 2.0 in 2003 to include predictions for 61 transcription factors.",
      "By JASPAR Release 3.0 in 2007, the number of predicted TFBSs had increased to 147.",
      "JASPAR Release 4.0 was introduced in 2010 and featured \"JASPAR-TS\" for predicting transcription factor binding sites in DNA sequences.",
      "The latest release mentioned is JASPAR Release 8.0 in 2022, by which the database grew to include predictions for 333 transcription factors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: JASPAR (the open-access database of transcription factor-binding profiles) Release 1.0 was launched in 2004, not 1999, with initial profiles for 123 transcription factors.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: JASPAR Release 4.0 was introduced in 2010, but there is no specific mention of \"JASPAR-TS.\" It offered an update with new data and web services but did not specifically highlight a feature named \"JASPAR-TS.\"\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-7b-chat-hf_response": "The KP4 protein is a protein encoded by the KP4 gene in the herpes simplex virus (HSV). It is a key regulator of the viral lytic cycle and plays a crucial role in the transition from the latent to the lytic phase of infection. The KP4 protein inhibits the activity of the viral gene expression machinery, specifically the transcriptional activator ICP0, and thereby prevents the expression of early lytic genes. In addition, KP4 protein also interacts with and inhibits the activity of the viral DNA polymerase, further contributing to the regulation of viral gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. The KP4 protein is encoded by the KP4 gene in the herpes simplex virus (HSV).\n2. KP4 protein is a regulator of the viral lytic cycle.\n3. KP4 protein plays a role in the transition from latent to lytic phase of HSV infection.\n4. KP4 protein inhibits the activity of the viral transcriptional activator ICP0.\n5. KP4 protein interacts with and inhibits the activity of the viral DNA polymerase.",
    "llama-2-7b-chat-hf_fact": [
      "The KP4 protein is encoded by the KP4 gene in the herpes simplex virus (HSV).",
      "KP4 protein is a regulator of the viral lytic cycle.",
      "KP4 protein plays a role in the transition from latent to lytic phase of HSV infection.",
      "KP4 protein inhibits the activity of the viral transcriptional activator ICP0.",
      "KP4 protein interacts with and inhibits the activity of the viral DNA polymerase."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The KP4 protein is not encoded by a gene in the herpes simplex virus (HSV); it is a killer protein from the Ustilago maydis virus KP4, which is a fungal virus.\n2. FALSE [correction]: As KP4 is not a protein of the herpes simplex virus, it is not a regulator of the viral lytic cycle in HSV.\n3. FALSE [correction]: KP4 protein, not being associated with the herpes simplex virus, does not play a role in the transition from latent to lytic phase of HSV infection.\n4. FALSE [correction]: The KP4 protein, being unrelated to the herpes simplex virus, does not inhibit the activity of the viral transcriptional activator ICP0, which is an HSV protein.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-7b-chat-hf_response": "Yes, DITPA (N-[4-[2-(7-Chloro-2-quinolinyl)ethyl]phenyl]-1,3,5-triazacyclohexane-2,4,6-trione) is a synthetic thyroid hormone analog that has been utilized in both experimental and clinical studies. DITPA is a potent agonist of the thyroid hormone receptor, and it has been used to investigate the role of thyroid hormones in various physiological processes, including metabolism, growth, and development.\nIn experimental studies, DITPA has been used to:\n1. Investigate the mechanisms of thyroid hormone action: DITPA has been used to study the effects of thyroid hormones on various cellular processes, including gene expression, protein synthesis, and metabolism.\n2. Model thyroid hormone deficiencies: DITPA has been used to study the effects of thyroid hormone deficiencies on various physiological processes, such as growth and development.\n3. Investigate the role of thyroid hormones in cancer: DITPA has been used to study the effects of thyroid hormones on cancer cell growth and development.\n4. Evaluate the efficacy of thyroid hormone replacement therapy: DITPA has been used to evaluate the efficacy of thyroid hormone replacement therapy in treating hypothyroidism.\nIn clinical studies, DITPA has been used to:\n1. Diagnose hypothyroidism: DITPA has been used to diagnose hypothyroidism in patients with thyroid hormone deficiencies.\n2. Monitor thyroid hormone replacement therapy: DITPA has been used to monitor the effectiveness of thyroid hormone replacement therapy in treating hypothyroidism.\n3. Investigate the effects of thyroid hormones on various diseases: DITPA has been used to investigate the effects of thyroid hormones on various diseases, including cancer, cardiovascular disease, and cognitive function.\nOverall, DITPA is a valuable tool for investigating the mechanisms of thyroid hormone action and for evaluating the efficacy of thyroid hormone",
    "llama-2-7b-chat-hf_fact_raw": "1. DITPA (N-[4-[2-(7-Chloro-2-quinolinyl)ethyl]phenyl]-1,3,5-triazacyclohexane-2,4,6-trione) is a synthetic thyroid hormone analog.\n2. DITPA has been utilized in both experimental and clinical studies.\n3. DITPA acts as a potent agonist of the thyroid hormone receptor.\n4. In experimental studies, DITPA has been used to model thyroid hormone deficiencies and to investigate the role of thyroid hormones in cancer.\n5. In clinical studies, DITPA has been used to diagnose and monitor the treatment of hypothyroidism.",
    "llama-2-7b-chat-hf_fact": [
      "DITPA (N-[4-[2-(7-Chloro-2-quinolinyl)ethyl]phenyl]-1,3,5-triazacyclohexane-2,4,6-trione) is a synthetic thyroid hormone analog.",
      "DITPA has been utilized in both experimental and clinical studies.",
      "DITPA acts as a potent agonist of the thyroid hormone receptor.",
      "In experimental studies, DITPA has been used to model thyroid hormone deficiencies and to investigate the role of thyroid hormones in cancer.",
      "In clinical studies, DITPA has been used to diagnose and monitor the treatment of hypothyroidism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: DITPA is not a synthetic thyroid hormone analog. It is a chemical that can mimic some actions of thyroid hormones, but its chemical structure is not similar to that of thyroid hormones.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: DITPA is not typically used to diagnose and monitor the treatment of hypothyroidism. Clinical studies may focus more on evaluating its potential therapeutic effects, such as in the treatment of heart conditions, rather than on diagnosis and monitoring of hypothyroidism.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-7b-chat-hf_response": "COUGER (Cytoscape Ontology-based Gene Regulatory Event) is a tool in the Cytoscape platform that allows users to analyze and visualize gene regulatory events, such as gene expression, promoter methylation, and histone modification, in a genomic context. It provides a framework for understanding the complex interactions between genetic and epigenetic events and their impact on gene expression.\nCOUGER integrates data from various sources, including ChIP-seq, RNA-seq, and methylation array data, and uses ontologies to organize and interpret the data. It can be used to identify patterns and trends in gene regulation, to predict the effects of genetic or epigenetic changes on gene expression, and to identify potential drug targets or therapeutic strategies.\nIn summary, COUGER is a powerful tool for analyzing and interpreting gene regulatory events in a genomic context, and can be used to gain insights into the complex interactions between genetic and epigenetic factors and their impact on gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. COUGER stands for Cytoscape Ontology-based Gene Regulatory Event.\n2. COUGER is used to analyze and visualize gene regulatory events like gene expression, promoter methylation, and histone modification.\n3. The tool integrates data from sources such as ChIP-seq, RNA-seq, and methylation array data.\n4. COUGER uses ontologies to organize and interpret genetic and epigenetic data.\n5. It can be used to identify potential drug targets or therapeutic strategies.",
    "llama-2-7b-chat-hf_fact": [
      "COUGER stands for Cytoscape Ontology-based Gene Regulatory Event.",
      "COUGER is used to analyze and visualize gene regulatory events like gene expression, promoter methylation, and histone modification.",
      "The tool integrates data from sources such as ChIP-seq, RNA-seq, and methylation array data.",
      "COUGER uses ontologies to organize and interpret genetic and epigenetic data.",
      "It can be used to identify potential drug targets or therapeutic strategies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The correct acronym is COGRER, which stands for Cytoscape Open-source Genomics Resource Explorer.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-7b-chat-hf_response": "Yes, there are drugs available for the treatment of tick-borne encephalitis (TBE). The most commonly used drugs for TBE include:\n1. Antiviral medications: Ribavirin, an antiviral drug, is the most commonly used treatment for TBE. It can help reduce the severity of symptoms and shorten the duration of illness.\n2. Corticosteroids: Corticosteroids, such as prednisone, may be prescribed to reduce inflammation in the brain and alleviate symptoms such as headache, fever, and confusion.\n3. Immunoglobulins: In some cases, immunoglobulins (antibodies) may be given to help boost the body's immune system and fight the virus.\n4. Supportive care: Supportive care, such as intravenous fluids, oxygen therapy, and pain management, may also be provided to help manage symptoms and prevent complications.\nIt is important to note that the choice of treatment depends on the severity and location of the infection, as well as the patient's overall health. In some cases, a combination of these treatments may be used. It is important to consult a healthcare professional for proper diagnosis and treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ribavirin is an antiviral drug used as a treatment for tick-borne encephalitis.\n2. Corticosteroids, such as prednisone, may be prescribed to treat tick-borne encephalitis.\n3. Immunoglobulins can be administered to help boost the immune system against tick-borne encephalitis.\n4. Supportive care options for tick-borne encephalitis may include intravenous fluids, oxygen therapy, and pain management.\n5. The treatment approach for tick-borne encephalitis varies based on the severity and location of the infection, as well as the patient's health condition.",
    "llama-2-7b-chat-hf_fact": [
      "Ribavirin is an antiviral drug used as a treatment for tick-borne encephalitis.",
      "Corticosteroids, such as prednisone, may be prescribed to treat tick-borne encephalitis.",
      "Immunoglobulins can be administered to help boost the immune system against tick-borne encephalitis.",
      "Supportive care options for tick-borne encephalitis may include intravenous fluids, oxygen therapy, and pain management.",
      "The treatment approach for tick-borne encephalitis varies based on the severity and location of the infection, as well as the patient's health condition."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ribavirin is not typically used to treat tick-borne encephalitis; it's more commonly used to treat hepatitis C and some types of viral hemorrhagic fevers.\n2. TRUE: Corticosteroids may sometimes be used to reduce inflammation in the central nervous system caused by tick-borne encephalitis.\n3. UNKNOWN: While immunoglobulins are used for some infections and conditions, their use specifically for tick-borne encephalitis as a standard treatment is unclear without more context. Passive immunization with specific immunoglobulins is a possible experimental treatment, but not established as standard care.\n4. TRUE: Supportive care options like those listed are often used to manage symptoms of tick-borne encephalitis.\n5. TRUE: The treatment approach for tick-borne encephalitis indeed varies depending on the severity of the disease, the affected region of the body, and the patient’s overarching health status.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-7b-chat-hf_response": "There are several genome browsers and databases available for DNA shape annotations. Some of the popular ones include:\n1. 4D-Nucleome: A comprehensive database of 3D chromatin structures in various organisms, including humans.\n2. Hi-C: A database of chromosome conformation capture (3C) data, which provides information on the spatial proximity of genomic regions.\n3. Chromosome Conformation and Dynamics (ChiCD): A database of chromosome conformation capture (3C) data, which provides information on the spatial proximity of genomic regions.\n4. 3D Genome Browser: A web-based tool for visualizing and analyzing 3D chromatin structures in various organisms.\n5. Genome3D: A database of 3D chromatin structures in various organisms, including humans.\n6. Chromatin Interaction Map (ChIA-Map): A database of chromosome conformation capture (3C) data, which provides information on the spatial proximity of genomic regions.\n7. Topological Domain Database (TOPO-DB): A database of topological domain structures in various organisms, which provides information on the 3D organization of chromosomes.\n8. Chromosome Structure and Function (CSF): A database of 3D chromatin structures in various organisms, including humans.\nThese databases provide valuable information on the spatial organization of chromosomes and its implications for gene regulation, chromosome stability, and cellular function.",
    "llama-2-7b-chat-hf_fact_raw": "1. 4D-Nucleome is a database of 3D chromatin structures in various organisms, including humans.\n2. Hi-C is a database that provides information on the spatial proximity of genomic regions through chromosome conformation capture (3C) data.\n3. Chromosome Conformation and Dynamics (ChiCD) provides chromosome conformation capture (3C) data.\n4. 3D Genome Browser is a web-based tool for visualizing and analyzing 3D chromatin structures in various organisms.\n5. Topological Domain Database (TOPO-DB) provides information on the 3D organization of chromosomes in various organisms.",
    "llama-2-7b-chat-hf_fact": [
      "4D-Nucleome is a database of 3D chromatin structures in various organisms, including humans.",
      "Hi-C is a database that provides information on the spatial proximity of genomic regions through chromosome conformation capture (3C) data.",
      "Chromosome Conformation and Dynamics (ChiCD) provides chromosome conformation capture (3C) data.",
      "3D Genome Browser is a web-based tool for visualizing and analyzing 3D chromatin structures in various organisms.",
      "Topological Domain Database (TOPO-DB) provides information on the 3D organization of chromosomes in various organisms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: 4D Nucleome is not just a database, but a project that aims to understand the principles underlying nuclear organization in space and time, the role nuclear organization plays in gene expression and cellular function, and how changes in nuclear organization affect normal development as well as various diseases.\n2. FALSE [correction]: Hi-C is not a database, but a chromosome conformation capture technique that provides information on the spatial proximity of genomic regions.\n3. TRUE (assuming the database is correctly named \"Chromosome Conformation and Dynamics\" and not \"ChiCD\")\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-7b-chat-hf_response": "The EZH2 gene has been associated with several syndromes, including:\n1. Rubinstein-Taybi syndrome: This is a rare genetic disorder characterized by intellectual disability, growth retardation, facial dysmorphism, and various other congenital anomalies. EZH2 mutations are found in approximately 50% of Rubinstein-Taybi syndrome cases.\n2. Pallister-Hall syndrome: This is a rare genetic disorder characterized by intellectual disability, short stature, facial dysmorphism, and various other congenital anomalies. EZH2 mutations are found in approximately 20% of Pallister-Hall syndrome cases.\n3. Coffin-Lowry syndrome: This is a rare genetic disorder characterized by intellectual disability, growth retardation, facial dysmorphism, and various other congenital anomalies. EZH2 mutations are found in approximately 10% of Coffin-Lowry syndrome cases.\n4. Smith-Magenis syndrome: This is a rare genetic disorder characterized by intellectual disability, growth retardation, facial dysmorphism, and various other congenital anomalies. EZH2 mutations have been identified in a small proportion of Smith-Magenis syndrome cases.\n5. Cri du chat syndrome: This is a rare genetic disorder characterized by a distinctive cry at birth, intellectual disability, growth retardation, and various other congenital anomalies. EZH2 mutations have been identified in a small proportion of Cri du chat syndrome cases.\nIt's worth noting that the frequency and distribution of EZH2 mutations may vary depending on the specific syndrome and the size and population of the study.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the EZH2 gene are associated with approximately 50% of Rubinstein-Taybi syndrome cases.\n2. EZH2 gene mutations are found in about 20% of cases of Pallister-Hall syndrome.\n3. Approximately 10% of Coffin-Lowry syndrome cases are associated with mutations in the EZH2 gene.\n4. A small proportion of Smith-Magenis syndrome cases have been identified with EZH2 mutations.\n5. EZH2 mutations have been identified in a small proportion of Cri du chat syndrome cases.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the EZH2 gene are associated with approximately 50% of Rubinstein-Taybi syndrome cases.",
      "EZH2 gene mutations are found in about 20% of cases of Pallister-Hall syndrome.",
      "Approximately 10% of Coffin-Lowry syndrome cases are associated with mutations in the EZH2 gene.",
      "A small proportion of Smith-Magenis syndrome cases have been identified with EZH2 mutations.",
      "EZH2 mutations have been identified in a small proportion of Cri du chat syndrome cases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations in the CREBBP gene are associated with approximately 50-60% of Rubinstein-Taybi syndrome cases, not the EZH2 gene.\n2. FALSE [correction]: Pallister-Hall syndrome is primarily associated with mutations in the GLI3 gene, not the EZH2 gene.\n3. FALSE [correction]: Coffin-Lowry syndrome is typically associated with mutations in the RPS6KA3 gene, not the EZH2 gene.\n4. UNKNOWN: While Smith-Magenis syndrome primarily involves mutations in the RAI1 gene or deletions of the 17p11.2 region, it is not clear from the provided statements if EZH2 mutations have been identified in a small proportion of cases.\n5. UNKNOWN: Cri du chat syndrome is characterized by a deletion of the end of the short (p) arm of chromosome 5; the statement regarding EZH2 mutations in Cri du chat syndrome cases is not clear without additional context.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_response": "There are several human proteins that are known to undergo a dimer-to-tetramer transition, including:\n1. p53: The tumor suppressor protein p53 undergoes a dimer-to-tetramer transition in response to DNA damage, leading to the activation of its transcriptional activity.\n2. c-Jun: The transcription factor c-Jun also undergoes a dimer-to-tetramer transition, which is involved in the regulation of gene expression and cellular proliferation.\n3. FosB: The transcription factor FosB is a downstream target of the signaling pathway activated by chronic exposure to stressors such as corticosteroids, and it undergoes a dimer-to-tetramer transition in response to these signals.\n4. CREB: The transcription factor CREB (cAMP-response element-binding protein) undergoes a dimer-to-tetramer transition in response to changes in intracellular cAMP levels, leading to the activation of its transcriptional activity.\n5. NF-κB: The transcription factor NF-κB (nuclear factor kappa B) undergoes a dimer-to-tetramer transition in response to signals such as cytokines and growth factors, leading to the activation of its transcriptional activity.\n6. STAT3: The transcription factor STAT3 (signal transducer and activator of transcription 3) undergoes a dimer-to-tetramer transition in response to signals such as cytokines and growth factors, leading to the activation of its transcriptional activity.\n7. HIF1α: The transcription factor HIF1α (hypoxia-inducible factor 1 alpha) undergoes a dimer-to-tetramer transition in response to changes in oxygen availability, leading to the activation of its transcriptional activity.\n8. FOXO: The transcription factor FOXO (forkhead box O) undergoes a dimer-to-tetramer transition in response to changes in cellular redox state, leading to the activation of its transcriptional activity.\n9. PPARγ: The",
    "llama-2-7b-chat-hf_fact_raw": "1. The tumor suppressor protein p53 undergoes a dimer-to-tetramer transition in response to DNA damage.\n2. The transcription factor c-Jun undergoes a dimer-to-tetramer transition, which is associated with the regulation of gene expression and cellular proliferation.\n3. FosB, a transcription factor, undergoes a dimer-to-tetramer transition that is triggered by chronic exposure to stressors like corticosteroids.\n4. CREB (cAMP-response element-binding protein) undergoes a dimer-to-tetramer transition responsive to changes in intracellular cAMP levels.\n5. NF-κB (nuclear factor kappa B) undergoes a dimer-to-tetramer transition in reaction to signals such as cytokines and growth factors.\n",
    "llama-2-7b-chat-hf_fact": [
      "The tumor suppressor protein p53 undergoes a dimer-to-tetramer transition in response to DNA damage.",
      "The transcription factor c-Jun undergoes a dimer-to-tetramer transition, which is associated with the regulation of gene expression and cellular proliferation.",
      "FosB, a transcription factor, undergoes a dimer-to-tetramer transition that is triggered by chronic exposure to stressors like corticosteroids.",
      "CREB (cAMP-response element-binding protein) undergoes a dimer-to-tetramer transition responsive to changes in intracellular cAMP levels.",
      "NF-κB (nuclear factor kappa B) undergoes a dimer-to-tetramer transition in reaction to signals such as cytokines and growth factors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The transcription factor c-Jun forms a dimer, particularly as part of the AP-1 complex with c-Fos. This dimerization is associated with the regulation of gene expression and cellular proliferation, but c-Jun does not typically undergo a dimer-to-tetramer transition as part of its function.\n3. FALSE [correction]: FosB is a component of the AP-1 transcription factor complex and interacts with Jun proteins to form a heterodimer. There is no widely recognized dimer-to-tetramer transition for FosB triggered by chronic exposure to stressors like corticosteroids.\n4. FALSE [correction]: CREB does not undergo a dimer-to-tetramer transition. CREB functions typically as a transcription factor that can bind DNA as a monomer in response to the elevation of intracellular cAMP levels. Upon binding cAMP response elements (CRE), it recruits co-activators to facilitate transcription.\n5. FALSE [correction]: NF-κB is a dimeric transcription factor that does not undergo a dimer-to-tetramer transition. It is usually present in the cytoplasm in an inactive state, bound to inhibitory proteins (IκBs). In response to signals such as cytokines and growth factors, NF-κB becomes activated and translocates to the nucleus, but it remains a dimer.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-7b-chat-hf_response": "One protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is BCL-2 (B-cell lymphoma 2). BCL-2 is a family of proteins that play a crucial role in regulating apoptosis by modulating the permeability of the outer mitochondrial membrane, allowing cytochrome c to release and activate caspases. BCL-2 has been shown to interact with PLN and prevent its ubiquitination and degradation, thereby inhibiting apoptosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. BCL-2 (B-cell lymphoma 2) interacts with phospholamban (PLN).\n2. BCL-2 is an anti-apoptotic protein.\n3. BCL-2 regulates apoptosis by modulating the permeability of the outer mitochondrial membrane.\n4. BCL-2 interaction with PLN prevents PLN's ubiquitination and degradation.\n5. The inhibition of ubiquitination and degradation of PLN by BCL-2 helps to inhibit apoptosis.",
    "llama-2-7b-chat-hf_fact": [
      "BCL-2 (B-cell lymphoma 2) interacts with phospholamban (PLN).",
      "BCL-2 is an anti-apoptotic protein.",
      "BCL-2 regulates apoptosis by modulating the permeability of the outer mitochondrial membrane.",
      "BCL-2 interaction with PLN prevents PLN's ubiquitination and degradation.",
      "The inhibition of ubiquitination and degradation of PLN by BCL-2 helps to inhibit apoptosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nWhile statements 2 and 3 are facts about BCL-2 being an anti-apoptotic protein that regulates apoptosis by modulating the permeability of the mitochondrial membrane, statements 1, 4, and 5 are specific and would require a specific biological context or reference to research findings to validate their accuracy. Without the context or specific research findings, it is not possible to determine the truthfulness of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-7b-chat-hf_response": "Yes, several clinical trials have shown that vitamin D supplementation can reduce the incidence of falls in older people. Here are some examples:\n1. A 2010 Cochrane review of 16 randomized controlled trials found that vitamin D supplementation significantly reduced the risk of falls in older adults, with a pooled relative risk reduction of 37% (95% CI 23-52).\n2. A 2012 randomized controlled trial published in the Journal of the American Geriatrics Society found that vitamin D and calcium supplementation reduced the incidence of falls in community-dwelling older adults with vitamin D deficiency (n=120).\n3. A 2014 randomized controlled trial published in the Journal of Gerontology found that vitamin D supplementation reduced the incidence of falls in older adults with cognitive impairment (n=137).\n4. A 2016 meta-analysis published in the Journal of Bone and Mineral Research found that vitamin D supplementation was associated with a reduced risk of falls in older adults (n=36,329).\nIt is important to note that while these studies suggest a potential benefit of vitamin D supplementation in reducing the incidence of falls in older people, the evidence is not yet conclusive, and more research is needed to confirm these findings and establish the optimal dosage and duration of supplementation. Additionally, it is important to consult with a healthcare professional before starting any supplement regimen.",
    "llama-2-7b-chat-hf_fact_raw": "1. A 2010 Cochrane review of 16 randomized controlled trials indicated that vitamin D supplementation significantly reduced the risk of falls in older adults by 37%.\n2. A 2012 randomized controlled trial published in the Journal of the American Geriatrics Society concluded that vitamin D and calcium supplementation reduced the incidence of falls in community-dwelling older adults with vitamin D deficiency.\n3. A 2014 randomized controlled trial published in the Journal of Gerontology demonstrated that vitamin D supplementation reduced the incidence of falls in older adults with cognitive impairment.\n4. A 2016 meta-analysis published in the Journal of Bone and Mineral Research associated vitamin D supplementation with a reduced risk of falls in older adults.\n5. The evidence from the clinical trials mentioned suggests a potential benefit of vitamin D supplementation in reducing the incidence of falls in older people, but the evidence is not conclusive, prompting a need for further research.",
    "llama-2-7b-chat-hf_fact": [
      "A 2010 Cochrane review of 16 randomized controlled trials indicated that vitamin D supplementation significantly reduced the risk of falls in older adults by 37%.",
      "A 2012 randomized controlled trial published in the Journal of the American Geriatrics Society concluded that vitamin D and calcium supplementation reduced the incidence of falls in community-dwelling older adults with vitamin D deficiency.",
      "A 2014 randomized controlled trial published in the Journal of Gerontology demonstrated that vitamin D supplementation reduced the incidence of falls in older adults with cognitive impairment.",
      "A 2016 meta-analysis published in the Journal of Bone and Mineral Research associated vitamin D supplementation with a reduced risk of falls in older adults.",
      "The evidence from the clinical trials mentioned suggests a potential benefit of vitamin D supplementation in reducing the incidence of falls in older people, but the evidence is not conclusive, prompting a need for further research."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: A 2010 Cochrane review indicated that vitamin D supplementation, when combined with calcium, significantly reduced the risk of falls (by 17%), but not by 37%.\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-7b-chat-hf_response": "Yes, there is an association between Jarid2 and miR-155 in Th17 cells. Studies have shown that Jarid2 is a direct target of miR-155 and that miR-155 regulates Jarid2 expression in Th17 cells. This regulation plays a crucial role in the differentiation and function of Th17 cells, which are involved in the immune response to infection and inflammation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Jarid2 is a direct target of miR-155 in Th17 cells.\n2. miR-155 regulates Jarid2 expression in Th17 cells.\n3. The regulation of Jarid2 by miR-155 plays a crucial role in the differentiation of Th17 cells.\n4. The regulation of Jarid2 by miR-155 plays a crucial role in the function of Th17 cells.\n5. Th17 cells are involved in the immune response to infection and inflammation.",
    "llama-2-7b-chat-hf_fact": [
      "Jarid2 is a direct target of miR-155 in Th17 cells.",
      "miR-155 regulates Jarid2 expression in Th17 cells.",
      "The regulation of Jarid2 by miR-155 plays a crucial role in the differentiation of Th17 cells.",
      "The regulation of Jarid2 by miR-155 plays a crucial role in the function of Th17 cells.",
      "Th17 cells are involved in the immune response to infection and inflammation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThese statements are consistent with the current understanding of microRNA (miR) and Th17 cell biology. miR-155 is known to regulate various targets in immune cells, including Th17 cells. Jarid2 has been identified as a target of miR-155, and this regulation can indeed play crucial roles in the differentiation and function of Th17 cells. Th17 cells are a subtype of T helper cells involved in the immune response to infection and inflammation, particularly in autoimmune diseases.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-7b-chat-hf_response": "The human HoxD cluster contains 9 genes: Hoxd-1 to Hoxd-9.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human HoxD cluster contains 9 genes.\n2. The genes in the human HoxD cluster are named from Hoxd-1 to Hoxd-9.",
    "llama-2-7b-chat-hf_fact": [
      "The human HoxD cluster contains 9 genes.",
      "The genes in the human HoxD cluster are named from Hoxd-1 to Hoxd-9."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The human HoxD cluster contains 9 genes, which are named HoxD1 to HoxD13, inclusive, but skipping 3 numbers (HoxD3, HoxD6 and HoxD11) which don't exist, thus actually having 10 genes in total.\n2. FALSE [correction]: The genes in the human HoxD cluster are named from HoxD1 to HoxD13, with some numbers skipped, as there are no genes named HoxD3, HoxD6, or HoxD11.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-7b-chat-hf_response": "Casein kinase 1 (CK1) is a serine/threonine kinase that plays a crucial role in various cellular processes, including signal transduction, metabolism, and gene regulation. The phosphorylation consensus motifs for CK1 are:\n1. Ser/Thr-Pro-X-X-Ser/Thr (where X is any amino acid)\nThis motif is recognized by the catalytic subunit of CK1 and is involved in the phosphorylation of downstream targets.\n2. Ser/Thr-Gly-X-X-Ser/Thr\nThis motif is also recognized by the catalytic subunit of CK1 and is involved in the phosphorylation of downstream targets.\n3. Ser-X-X-Ser/Thr-X-X-Ser/Thr (where X is any amino acid)\nThis motif is recognized by the regulatory subunit of CK1 and is involved in the activation of the enzyme by binding to specific phosphorylation sites.\n4. Ser-X-X-X-Ser/Thr-X-X-Ser/Thr (where X is any amino acid)\nThis motif is recognized by the regulatory subunit of CK1 and is involved in the regulation of CK1 activity.\nIt's worth noting that these consensus motifs are not exclusive to CK1 and can be found in other kinases as well.",
    "llama-2-7b-chat-hf_fact_raw": "1. Casein kinase 1 (CK1) is a serine/threonine kinase.\n2. The consensus motif Ser/Thr-Pro-X-X-Ser/Thr is recognized by the catalytic subunit of CK1 for phosphorylation of targets.\n3. The consensus motif Ser/Thr-Gly-X-X-Ser/Thr is recognized by the catalytic subunit of CK1 for phosphorylation of targets.\n4. The consensus motif Ser-X-X-Ser/Thr-X-X-Ser/Thr is recognized by the regulatory subunit of CK1 and is involved in enzyme activation.\n5. The consensus motif Ser-X-X-X-Ser/Thr-X-X-Ser/Thr is recognized by the regulatory subunit of CK1 and is involved in regulating CK1 activity.",
    "llama-2-7b-chat-hf_fact": [
      "Casein kinase 1 (CK1) is a serine/threonine kinase.",
      "The consensus motif Ser/Thr-Pro-X-X-Ser/Thr is recognized by the catalytic subunit of CK1 for phosphorylation of targets.",
      "The consensus motif Ser/Thr-Gly-X-X-Ser/Thr is recognized by the catalytic subunit of CK1 for phosphorylation of targets.",
      "The consensus motif Ser-X-X-Ser/Thr-X-X-Ser/Thr is recognized by the regulatory subunit of CK1 and is involved in enzyme activation.",
      "The consensus motif Ser-X-X-X-Ser/Thr-X-X-Ser/Thr is recognized by the regulatory subunit of CK1 and is involved in regulating CK1 activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The correct consensus motif recognized by the catalytic subunit of CK1 for phosphorylation of targets is not well-defined by the Ser/Thr-Pro-X-X-Ser/Thr sequence.\n3. FALSE [correction]: The consensus motif typically recognized by CK1 for the phosphorylation of targets is Ser/Thr-X-X-Ser/Thr or a variant, where \"X\" represents any amino acid, but not specifically Ser/Thr-Gly-X-X-Ser/Thr.\n4. UNKNOWN (The statement seems to describe a consensus motif for CK1, but CK1 is commonly referenced as a monomeric enzyme without separate regulatory subunits, and the exact motif mentioned is not a well-defined consensus sequence for enzyme activation.)\n5. UNKNOWN (Similar to statement 4, CK1 is usually described as monomeric, and so it does not have a separate regulatory subunit. The exact motif is not clearly associated with regulation of CK1 activity, and information is vague without additional context.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-7b-chat-hf_response": "The ASPH (aspartate beta-hydroxylase) gene in humans encodes several different proteins/isoforms, including:\n1. Aspartate beta-hydroxylase (ASPH): This is the primary isoform encoded by the ASPH gene, which plays a crucial role in the biosynthesis of the neurotransmitter serotonin.\n2. Tissue inhibitor of metalloproteinases 1 (TIMP1): A splice variant of the ASPH gene, TIMP1 is a potent inhibitor of matrix metalloproteinases (MMPs), which are enzymes involved in the breakdown of the extracellular matrix.\n3. Neprilysin (NEP): A splice variant of the ASPH gene, NEP is a protease that degrades various neurotransmitters, including serotonin, dopamine, and norepinephrine.\n4. Prothrombin (F2): A splice variant of the ASPH gene, Prothrombin is a clotting factor in the blood coagulation cascade.\nThese different isoforms/proteins are produced through alternative splicing of the ASPH gene, which allows for the generation of multiple functional proteins from a single gene.",
    "llama-2-7b-chat-hf_fact_raw": "1. The ASPH gene encodes the primary isoform aspartate beta-hydroxylase, involved in serotonin biosynthesis.\n2. Tissue inhibitor of metalloproteinases 1 (TIMP1) is encoded by the ASPH gene as a splice variant and inhibits matrix metalloproteinases.\n3. Neprilysin (NEP) is a protease encoded as a splice variant of the ASPH gene and degrades neurotransmitters such as serotonin, dopamine, and norepinephrine.\n4. The ASPH gene encodes a splice variant named Prothrombin (F2), which acts as a clotting factor in blood coagulation.\n5. The different isoforms/proteins produced by the ASPH gene result from alternative splicing.",
    "llama-2-7b-chat-hf_fact": [
      "The ASPH gene encodes the primary isoform aspartate beta-hydroxylase, involved in serotonin biosynthesis.",
      "Tissue inhibitor of metalloproteinases 1 (TIMP1) is encoded by the ASPH gene as a splice variant and inhibits matrix metalloproteinases.",
      "Neprilysin (NEP) is a protease encoded as a splice variant of the ASPH gene and degrades neurotransmitters such as serotonin, dopamine, and norepinephrine.",
      "The ASPH gene encodes a splice variant named Prothrombin (F2), which acts as a clotting factor in blood coagulation.",
      "The different isoforms/proteins produced by the ASPH gene result from alternative splicing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The ASPH gene encodes the enzyme aspartate beta-hydroxylase, but this enzyme is involved in the post-translational hydroxylation of aspartyl residues in certain proteins, not serotonin biosynthesis. Serotonin biosynthesis is mainly attributed to the tryptophan hydroxylase enzymes.\n2. FALSE [correction]: Tissue inhibitor of metalloproteinases 1 (TIMP1) is an inhibitor of the matrix metalloproteinases, but it is not encoded by the ASPH gene. TIMP1 is encoded by its own gene, also known as TIMP1.\n3. FALSE [correction]: Neprilysin (NEP) is indeed a protease that degrades neurotransmitters such as serotonin, dopamine, and norepinephrine, but it is not a splice variant of the ASPH gene. NEP is encoded by the MME gene, not ASPH.\n4. FALSE [correction]: Prothrombin, also known as factor II (F2), is a clotting factor in blood coagulation, but it is not encoded by the ASPH gene. Prothrombin is encoded by the F2 gene.\n5. TRUE: Different isoforms/proteins can indeed arise from alternative splicing of a single gene, albeit the specific isoforms and proteins mentioned in statements 2, 3, and 4 are not produced by alternative splicing of the ASPH gene.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-7b-chat-hf_response": "Empagliflozin was FDA approved on June 28, 2014.",
    "llama-2-7b-chat-hf_fact_raw": "1. Empagliflozin was FDA approved on June 28, 2014.",
    "llama-2-7b-chat-hf_fact": [
      "Empagliflozin was FDA approved on June 28, 2014."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Empagliflozin was FDA approved on August 1, 2014.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-7b-chat-hf_response": "Loss of the protein Lon1 in the plant Arabidopsis leads to various developmental and physiological abnormalities, including:\n1. Delayed seed germination and seedling growth: Lon1-deficient plants have slower seed germination and reduced seedling growth compared to wild-type plants.\n2. Altered leaf morphology: Lon1-deficient leaves are often smaller and have a different shape than those of wild-type plants.\n3. Reduced stem elongation: Lon1-deficient stems are shorter than those of wild-type plants, indicating a role for Lon1 in regulating stem elongation.\n4. Impaired flowering time: Lon1-deficient plants flower later than wild-type plants, suggesting a role for Lon1 in regulating floral development.\n5. Increased sensitivity to abiotic stress: Lon1-deficient plants are more sensitive to drought and salt stress than wild-type plants, indicating a role for Lon1 in protecting against stress.\n6. Altered hormone regulation: Lon1-deficient plants have altered levels of various hormones, including ethylene, auxin, and cytokinin, which may contribute to the observed developmental abnormalities.\n7. Changes in gene expression: Lon1-deficient plants exhibit altered expression of various genes involved in different cellular processes, including cell division, differentiation, and stress response.\n8. Increased DNA damage: Lon1-deficient plants have higher levels of DNA damage, as indicated by increased levels of DNA double-strand breaks and impaired repair of these breaks.\n9. Reduced tolerance to oxidative stress: Lon1-deficient plants are more susceptible to oxidative stress, as indicated by increased levels of reactive oxygen species (ROS) and reduced levels of antioxidant enzymes.\n10. Altered protein function: Lon1-deficient plants have altered levels and activity of various proteins involved in different cellular processes, including protein degradation, protein synthesis, and protein folding.",
    "llama-2-7b-chat-hf_fact_raw": "1. Lon1-deficient Arabidopsis plants exhibit delayed seed germination and reduced seedling growth in comparison to wild-type plants.\n2. Lon1-deficient Arabidopsis plants have leaves that are smaller and differently shaped than those of wild-type plants.\n3. The stems of Lon1-deficient Arabidopsis plants are shorter than those of wild-type plants.\n4. Lon1-deficient Arabidopsis plants flower later than wild-type plants.\n5. Lon1-deficient Arabidopsis plants exhibit increased sensitivity to drought and salt stress relative to wild-type plants.",
    "llama-2-7b-chat-hf_fact": [
      "Lon1-deficient Arabidopsis plants exhibit delayed seed germination and reduced seedling growth in comparison to wild-type plants.",
      "Lon1-deficient Arabidopsis plants have leaves that are smaller and differently shaped than those of wild-type plants.",
      "The stems of Lon1-deficient Arabidopsis plants are shorter than those of wild-type plants.",
      "Lon1-deficient Arabidopsis plants flower later than wild-type plants.",
      "Lon1-deficient Arabidopsis plants exhibit increased sensitivity to drought and salt stress relative to wild-type plants."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nGiven the specificity of the statements about Lon1-deficient Arabidopsis plants, one would need access to specific scientific research or source material to verify these claims. Without that context, it is impossible to determine the accuracy of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-7b-chat-hf_response": "Yes, linker histones are present in the yeast genome. In fact, yeast has three linker histones: H3K5ac, H3K27ac, and H3K4me3. These linker histones play a crucial role in organizing chromatin structure and regulating various cellular processes, including transcriptional elongation, gene expression, and DNA repair.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-7b-chat-hf_response": "There is some evidence to suggest that drinking tomato juice may help lower cholesterol levels. Tomato juice contains a compound called lycopene, which has been shown to have cholesterol-lowering properties.\nLycopene is a powerful antioxidant that has been shown to reduce the amount of low-density lipoprotein (LDL) cholesterol, also known as \"bad\" cholesterol, in the blood. High levels of LDL cholesterol are associated with an increased risk of heart disease, so reducing these levels can help to lower this risk.\nSome studies have shown that drinking tomato juice can help to lower cholesterol levels. For example, a study published in the Journal of Nutrition found that drinking 100 ml of tomato juice per day for 12 weeks reduced LDL cholesterol levels by 12% in healthy adults. Another study published in the European Journal of Clinical Nutrition found that drinking 200 ml of tomato juice per day for 6 months reduced LDL cholesterol levels by 15% in people with high cholesterol.\nHowever, it's important to note that these studies were small and more research is needed to confirm these findings. Additionally, it's worth noting that tomato juice is not a magic bullet for lowering cholesterol levels, and it should be used in conjunction with other lifestyle changes, such as a healthy diet and regular exercise, to help manage cholesterol levels.\nIn summary, while there is some evidence to suggest that tomato juice may help lower cholesterol levels, more research is needed to confirm these findings and to determine the optimal dosage and duration of tomato juice consumption for cholesterol-lowering effects. As with any dietary intervention, it's important to consult with a healthcare professional before making significant changes to your diet.",
    "llama-2-7b-chat-hf_fact_raw": "1. Tomato juice contains a compound called lycopene, which has been shown to have cholesterol-lowering properties.\n2. Lycopene has been shown to reduce the amount of low-density lipoprotein (LDL) cholesterol in the blood.\n3. A study in the Journal of Nutrition reported that drinking 100 ml of tomato juice per day for 12 weeks reduced LDL cholesterol levels by 12% in healthy adults.\n4. Another study from the European Journal of Clinical Nutrition found that drinking 200 ml of tomato juice per day for 6 months reduced LDL cholesterol levels by 15% in people with high cholesterol.\n5. High levels of low-density lipoprotein (LDL) cholesterol are associated with an increased risk of heart disease.",
    "llama-2-7b-chat-hf_fact": [
      "Tomato juice contains a compound called lycopene, which has been shown to have cholesterol-lowering properties.",
      "Lycopene has been shown to reduce the amount of low-density lipoprotein (LDL) cholesterol in the blood.",
      "A study in the Journal of Nutrition reported that drinking 100 ml of tomato juice per day for 12 weeks reduced LDL cholesterol levels by 12% in healthy adults.",
      "Another study from the European Journal of Clinical Nutrition found that drinking 200 ml of tomato juice per day for 6 months reduced LDL cholesterol levels by 15% in people with high cholesterol.",
      "High levels of low-density lipoprotein (LDL) cholesterol are associated with an increased risk of heart disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - Tomato juice does contain lycopene, a compound with various health benefits, including potential cholesterol-lowering properties.\n2. TRUE - Lycopene has been reported to help reduce levels of LDL cholesterol, which is often referred to as \"bad\" cholesterol.\n3. UNKNOWN - Without access to specific details from the Journal of Nutrition, it's not possible to verify the accuracy of the statement regarding the study's findings.\n4. UNKNOWN - Similarly, without specific details from the European Journal of Clinical Nutrition, the accuracy of the statement about this study's findings cannot be confirmed.\n5. TRUE - It is well-established in medical literature that high levels of LDL cholesterol are linked to an increased risk of developing heart disease.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-7b-chat-hf_response": "Hsp70 and Hsp110 are heat shock proteins that play a role in regulating mRNA stability by interacting with mRNAs and influencing their degradation. Hsp70 can bind to mRNAs and promote their degradation by the RNA exosome complex, while Hsp110 can also bind to mRNAs and inhibit their degradation by the RNA exosome. By modulating mRNA stability, these proteins can regulate gene expression in response to cellular stress.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hsp70 and Hsp110 are types of heat shock proteins.\n2. These proteins interact with mRNAs, affecting their stability.\n3. Hsp70 can promote the degradation of mRNAs by the RNA exosome complex.\n4. Hsp110 can bind to mRNAs and inhibit their degradation by the RNA exosome.\n5. By affecting mRNA stability, Hsp70 and Hsp110 can regulate gene expression in response to cellular stress.",
    "llama-2-7b-chat-hf_fact": [
      "Hsp70 and Hsp110 are types of heat shock proteins.",
      "These proteins interact with mRNAs, affecting their stability.",
      "Hsp70 can promote the degradation of mRNAs by the RNA exosome complex.",
      "Hsp110 can bind to mRNAs and inhibit their degradation by the RNA exosome.",
      "By affecting mRNA stability, Hsp70 and Hsp110 can regulate gene expression in response to cellular stress."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Hsp70 and Hsp110 primarily interact with other proteins, not mRNAs. They help in folding of newly synthesized polypeptides and stabilization of preexistent proteins.\n3. FALSE [correction]: Hsp70 does not typically promote the degradation of mRNAs by the RNA exosome complex. It is primarily involved in protein folding and stabilization.\n4. UNKNOWN: The typical function of Hsp110 is as a nucleotide exchange factor for Hsp70, aiding in protein folding, but there is limited information about a direct role in binding to mRNAs and inhibiting their degradation by the RNA exosome.\n5. TRUE: Heat shock proteins, including Hsp70 and Hsp110, can regulate gene expression indirectly through their role in the folding and stabilization of proteins that are involved in gene expression pathways and thus can have an effect in response to cellular stress.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-7b-chat-hf_response": "Deiodinases are enzymes that play a crucial role in regulating the activity of thyroid hormones in various tissues, including skeletal muscle. There are three isoforms of deiodinases present in skeletal muscle:\n1. Deiodinase type 1 (D1): D1 is the primary deiodinase isoform in skeletal muscle, and it is responsible for converting T4 to T3. T3 is the active form of thyroid hormone that plays a crucial role in regulating muscle metabolism and growth.\n2. Deiodinase type 2 (D2): D2 is also present in skeletal muscle and plays a minor role in converting T4 to reverse T3 (rT3). rT3 is an inactive form of thyroid hormone that can inhibit the activity of T3.\n3. Deiodinase type 3 (D3): D3 is present in small amounts in skeletal muscle and plays a role in the regulation of thyroid hormone activity in the brain and other tissues.\nOverall, the balance between the activities of these deiodinases in skeletal muscle plays a critical role in regulating the activity of thyroid hormones and maintaining proper muscle function.",
    "llama-2-7b-chat-hf_fact_raw": "1. Deiodinase type 1 (D1) is present in skeletal muscle and converts T4 to T3.\n2. Deiodinase type 2 (D2) is present in skeletal muscle and plays a role in converting T4 to reverse T3 (rT3).\n3. Deiodinase type 3 (D3) is present in skeletal muscle and is involved in thyroid hormone regulation.\n4. T3 is the active form of thyroid hormone that is involved in muscle metabolism and growth.\n5. Reverse T3 (rT3) is an inactive form of thyroid hormone.",
    "llama-2-7b-chat-hf_fact": [
      "Deiodinase type 1 (D1) is present in skeletal muscle and converts T4 to T3.",
      "Deiodinase type 2 (D2) is present in skeletal muscle and plays a role in converting T4 to reverse T3 (rT3).",
      "Deiodinase type 3 (D3) is present in skeletal muscle and is involved in thyroid hormone regulation.",
      "T3 is the active form of thyroid hormone that is involved in muscle metabolism and growth.",
      "Reverse T3 (rT3) is an inactive form of thyroid hormone."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Deiodinase type 1 (D1) is not primarily present in skeletal muscle; it is mainly present in the liver and kidney and converts T4 to T3.\n2. FALSE [correction]: Deiodinase type 2 (D2) is present in the central nervous system, thyroid, and brown adipose tissue but not primarily in skeletal muscle; D2 also converts T4 to the active form T3, not to reverse T3 (rT3).\n3. UNKNOWN: While deiodinase type 3 (D3) does play a role in thyroid hormone regulation, specifically in inactivating thyroid hormones by converting T4 to rT3 and T3 to 3,3'-diiodothyronine (T2), the specific expression and role in skeletal muscle can vary and may not be as prominent as in other tissues.\n4. TRUE: T3 is the active form of thyroid hormone that regulates metabolism and has significant effects on muscle growth and development.\n5. TRUE: Reverse T3 (rT3) is an inactive form of thyroid hormone that does not have the metabolic active effects of T3.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-7b-chat-hf_response": "Inflammatory caspase proteins are a group of proteins that play a role in the regulation of inflammation. Some examples of inflammatory caspase proteins include:\n1. Caspase-1: Also known as interleukin-1 beta (IL-1β) converter, this enzyme is involved in the processing and activation of pro-inflammatory cytokines, such as IL-1β and tumor necrosis factor-alpha (TNF-α).\n2. Caspase-4: Also known as interleukin-18 (IL-18) inducer, this enzyme is involved in the processing and activation of pro-inflammatory cytokines, such as IL-18.\n3. Caspase-5: Also known as cell death-associated protein 1 (CAD), this enzyme is involved in the regulation of programmed cell death (apoptosis) and inflammation.\n4. Caspase-6: Also known as apoptosis-related CPP32-like protein (ARC), this enzyme is involved in the regulation of programmed cell death (apoptosis) and inflammation.\n5. Caspase-7: Also known as apoptotic CPP32-like protein (APO-1), this enzyme is involved in the regulation of programmed cell death (apoptosis) and inflammation.\n6. Caspase-8: Also known as Fas-associated protein with death domain (FADD), this enzyme is involved in the regulation of programmed cell death (apoptosis) and inflammation, particularly in response to the death receptor Fas.\n7. Caspase-9: Also known as Bcl-2-associated death protein (BID), this enzyme is involved in the regulation of programmed cell death (apoptosis) and inflammation, particularly in response to the pro-apoptotic protein Bcl-2.\n8. Caspase-12: Also known as inflammasome-activating protein (IAP), this enzyme is involved in the regulation of inflammasome activation and the release of pro-inflammatory cytokines, such as inter",
    "llama-2-7b-chat-hf_fact_raw": "1. Caspase-1 is involved in the processing and activation of pro-inflammatory cytokines, such as IL-1β and TNF-α.\n2. Caspase-4 is involved in the processing and activation of pro-inflammatory cytokines, such as IL-18.\n3. Caspase-5, also known as CAD, is involved in the regulation of programmed cell death (apoptosis) and inflammation.\n4. Caspase-8 is involved in the regulation of programmed cell death (apoptosis) and inflammation in response to the death receptor Fas.\n5. Caspase-12 is involved in the regulation of inflammasome activation and the release of pro-inflammatory cytokines.",
    "llama-2-7b-chat-hf_fact": [
      "Caspase-1 is involved in the processing and activation of pro-inflammatory cytokines, such as IL-1β and TNF-α.",
      "Caspase-4 is involved in the processing and activation of pro-inflammatory cytokines, such as IL-18.",
      "Caspase-5, also known as CAD, is involved in the regulation of programmed cell death (apoptosis) and inflammation.",
      "Caspase-8 is involved in the regulation of programmed cell death (apoptosis) and inflammation in response to the death receptor Fas.",
      "Caspase-12 is involved in the regulation of inflammasome activation and the release of pro-inflammatory cytokines."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Caspase-4, along with caspase-5, is involved in the innate immune response to bacterial infections and the processing of pro-inflammatory cytokines, such as IL-18, but not typically attributed to having a major role in the activation of IL-1β; caspase-1 is primarily responsible for the activation of IL-1β.\n3. FALSE [correction]: Caspase-5 is not known as CAD. CAD, which stands for caspase-activated DNase, is involved in the DNA fragmentation during apoptosis. Caspase-5 is involved in the regulation of inflammation and is part of the inflammasome complex, similar to caspase-1.\n4. TRUE\n5. FALSE [correction]: Caspase-12 is known to modulate inflammation by negatively regulating the inflammasome and has been shown to affect the release of pro-inflammatory cytokines, but its precise role is more associated with attenuation rather than activation of inflammasome responses.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-7b-chat-hf_response": "Yes, there is a link between Aurora B kinase and the Polycomb protein Ring1B. Ring1B is a component of the Polycomb repressive complex 2 (PRC2), which is involved in the epigenetic regulation of gene expression by modifying histone H3 lysine 27 (H3K27) into a repressive mark.\nAurora B kinase has been shown to interact with Ring1B and regulate its activity. Aurora B kinase phosphorylates Ring1B at specific sites, which can modulate its interaction with other proteins and impact its ability to recruit and activate the PRC2 complex.\nIn addition, Ring1B has been shown to play a role in the regulation of Aurora B kinase activity. For example, Ring1B can inhibit the activity of Aurora B kinase by binding to and sequestering its substrate, the histone H3.\nOverall, the interaction between Aurora B kinase and Ring1B is complex and multifaceted, and further research is needed to fully understand the mechanisms by which these proteins interact and impact each other's function.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ring1B is a component of the Polycomb repressive complex 2 (PRC2).\n2. PRC2 is involved in the epigenetic regulation of gene expression by modifying histone H3 lysine 27 (H3K27) into a repressive mark.\n3. Aurora B kinase interacts with Ring1B and regulates its activity.\n4. Aurora B kinase phosphorylates Ring1B at specific sites.\n5. Ring1B can inhibit the activity of Aurora B kinase by binding to its substrate, the histone H3.",
    "llama-2-7b-chat-hf_fact": [
      "Ring1B is a component of the Polycomb repressive complex 2 (PRC2).",
      "PRC2 is involved in the epigenetic regulation of gene expression by modifying histone H3 lysine 27 (H3K27) into a repressive mark.",
      "Aurora B kinase interacts with Ring1B and regulates its activity.",
      "Aurora B kinase phosphorylates Ring1B at specific sites.",
      "Ring1B can inhibit the activity of Aurora B kinase by binding to its substrate, the histone H3."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ring1B is a component of the Polycomb repressive complex 1 (PRC1), not PRC2.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Ring1B does not inhibit the activity of Aurora B kinase by binding to histone H3. Rather, it is part of PRC1, which ubiquitinates histone H2A lysine 119, and it does not directly interact with histone H3 as an inhibitor. Aurora B kinase's primary substrates and mechanisms of action are distinct from the function of Ring1B.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-7b-chat-hf_response": "Non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are sequences that are not part of the standard splice site consensus sequences, but are still recognized by the splicing machinery. Some of the most frequent non-canonical sequence motifs found in vertebrates include:\nDonor splice site motifs:\n* GU-rich sequences: GU-rich sequences are found in the intron and are recognized by the splicing machinery as a signal to initiate splicing.\n* AG-rich sequences: AG-rich sequences are found in the intron and are recognized by the splicing machinery as a signal to terminate splicing.\n* G/C-rich sequences: G/C-rich sequences are found in the intron and are recognized by the splicing machinery as a signal to initiate splicing.\n* A/T-rich sequences: A/T-rich sequences are found in the intron and are recognized by the splicing machinery as a signal to terminate splicing.\nAcceptor splice site motifs:\n* GU-rich sequences: GU-rich sequences are found in the acceptor splice site and are recognized by the splicing machinery as a signal to initiate splicing.\n* AG-rich sequences: AG-rich sequences are found in the acceptor splice site and are recognized by the splicing machinery as a signal to terminate splicing.\n* G/C-rich sequences: G/C-rich sequences are found in the acceptor splice site and are recognized by the splicing machinery as a signal to initiate splicing.\n* A/T-rich sequences: A/T-rich sequences are found in the acceptor splice site and are recognized by the splicing machinery as a signal to terminate splicing.\nIt's important to note that the frequency and distribution of these motifs can vary depending on the organism and the specific gene being studied. Additionally, some non-canonical motifs may be specific to certain types of splicing, such as alternative splicing or constitutive splicing.",
    "llama-2-7b-chat-hf_fact_raw": "1. Non-canonical sequence motifs at donor and acceptor splice sites in vertebrates are recognized by the splicing machinery despite not being part of the standard splice site consensus sequences.\n2. GU-rich sequences are among the frequent non-canonical sequences found at donor splice sites in vertebrates.\n3. AG-rich sequences are among the frequent non-canonical sequences found at donor splice sites in vertebrates.\n4. GU-rich sequences are among the frequent non-canonical sequences found at acceptor splice sites in vertebrates.\n5. AG-rich sequences are among the frequent non-canonical sequences found at acceptor splice sites in vertebrates.",
    "llama-2-7b-chat-hf_fact": [
      "Non-canonical sequence motifs at donor and acceptor splice sites in vertebrates are recognized by the splicing machinery despite not being part of the standard splice site consensus sequences.",
      "GU-rich sequences are among the frequent non-canonical sequences found at donor splice sites in vertebrates.",
      "AG-rich sequences are among the frequent non-canonical sequences found at donor splice sites in vertebrates.",
      "GU-rich sequences are among the frequent non-canonical sequences found at acceptor splice sites in vertebrates.",
      "AG-rich sequences are among the frequent non-canonical sequences found at acceptor splice sites in vertebrates."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Non-canonical sequence motifs at donor and acceptor splice sites in vertebrates can indeed be recognized by the splicing machinery, which sometimes allows for variations from the standard consensus sequences.\n2. TRUE: GU-rich sequences are among the non-canonical sequences that can be found at donor splice sites in vertebrates.\n3. FALSE [correction]: AG-rich sequences are typically associated with acceptor splice sites, not donor splice sites.\n4. FALSE [correction]: GU-rich sequences are generally associated with donor splice sites in vertebrates, not acceptor splice sites.\n5. TRUE: AG-rich sequences are among the non-canonical sequences that can be found at acceptor splice sites in vertebrates.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-7b-chat-hf_response": "The phosphorylation of S6K1 by Akt is an event that results in its acetylation.",
    "llama-2-7b-chat-hf_fact_raw": "1. The phosphorylation of S6K1 leads to its acetylation.\n2. Akt is responsible for the phosphorylation of S6K1.",
    "llama-2-7b-chat-hf_fact": [
      "The phosphorylation of S6K1 leads to its acetylation.",
      "Akt is responsible for the phosphorylation of S6K1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The phosphorylation of S6K1 does not directly lead to its acetylation. Phosphorylation and acetylation are two distinct types of post-translational modifications, usually carried out by different enzymes.\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-7b-chat-hf_response": "Episodic ataxia type 6 (EA6) is a rare genetic disorder that is caused by mutations in the CACNA1A gene. The CACNA1A gene encodes a subunit of the calcium channel alpha-1A subunit, which is involved in the regulation of neuronal excitability and is critical for the proper functioning of the nervous system. Mutations in the CACNA1A gene lead to a decrease in the function of the calcium channel, resulting in the characteristic episodic ataxia symptoms.",
    "llama-2-7b-chat-hf_fact_raw": "1. Episodic ataxia type 6 (EA6) is a rare genetic disorder.\n2. The cause of EA6 is mutations in the CACNA1A gene.\n3. The CACNA1A gene encodes the alpha-1A subunit of a calcium channel.\n4. Mutations in the CACNA1A gene affect the regulation of neuronal excitability.\n5. The decrease in function of the calcium channel due to mutations leads to the symptoms of episodic ataxia.",
    "llama-2-7b-chat-hf_fact": [
      "Episodic ataxia type 6 (EA6) is a rare genetic disorder.",
      "The cause of EA6 is mutations in the CACNA1A gene.",
      "The CACNA1A gene encodes the alpha-1A subunit of a calcium channel.",
      "Mutations in the CACNA1A gene affect the regulation of neuronal excitability.",
      "The decrease in function of the calcium channel due to mutations leads to the symptoms of episodic ataxia."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Episodic ataxia type 6 (EA6) is caused by mutations in the SLC1A3 gene, not the CACNA1A gene.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-7b-chat-hf_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that add a methyl group to histone proteins, which can alter their interaction with DNA and affect chromatin structure and gene expression. While the specific functions of chromomethylases in animals are not as well understood as those in plants, there is evidence that they play important roles in regulating chromatin dynamics and gene expression in various organisms, including mammals. For example, some chromomethylases have been implicated in the regulation of gene expression during development, cell differentiation, and cellular stress responses. Additionally, alterations in chromomethylase activity have been linked to various diseases, including cancer and neurological disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromomethylases are enzymes found in animal genomes.\n2. Chromomethylases add a methyl group to histone proteins.\n3. The addition of a methyl group by chromomethylases can affect chromatin structure and gene expression.\n4. Chromomethylases are implicated in the regulation of gene expression during development, cell differentiation, and cellular stress responses in mammals.\n5. Alterations in chromomethylase activity have been linked to various diseases, including cancer and neurological disorders.",
    "llama-2-7b-chat-hf_fact": [
      "Chromomethylases are enzymes found in animal genomes.",
      "Chromomethylases add a methyl group to histone proteins.",
      "The addition of a methyl group by chromomethylases can affect chromatin structure and gene expression.",
      "Chromomethylases are implicated in the regulation of gene expression during development, cell differentiation, and cellular stress responses in mammals.",
      "Alterations in chromomethylase activity have been linked to various diseases, including cancer and neurological disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Chromomethylases are enzymes found in plant genomes, not typically in animal genomes.\n2. FALSE [correction]: Chromomethylases typically add a methyl group to DNA, not to histone proteins.\n3. TRUE: The addition of a methyl group by enzymes that modify chromatin, including DNA methyltransferases, can affect chromatin structure and gene expression.\n4. FALSE [correction]: Since chromomethylases are not found in animal genomes as per statement 1, they are not implicated in regulation of gene expression during development, cell differentiation, and cellular stress responses in mammals. Such regulatory roles are attributed to other types of methyltransferases in animals.\n5. UNKNOWN: While alterations in DNA methyltransferase activity have been linked to various diseases, including cancer and neurological disorders, this statement is specifically about chromomethylases, which are plant enzymes, and thus the linkage of their alteration to human diseases cannot be established without the appropriate context.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-7b-chat-hf_response": "Here are some popular packages in R/Bioconductor for transcription factor binding site (TFBS) analysis:\n1. ChromHMM: This package uses a hidden Markov model (HMM) to predict TFBSs in DNA sequences. It can also be used to predict the binding affinity of TFs to their target sites.\n2. TFBS: This package provides a comprehensive set of tools for TFBS prediction, including the prediction of both protein-binding sites and the specificity of TFs.\n3. TRANSFAC: This package uses a Bayesian approach to predict TFBSs and can also be used to predict the binding affinity of TFs to their target sites.\n4. Prodigal: This package predicts TFBSs in DNA sequences using a Bayesian approach and can also be used to predict the binding affinity of TFs to their target sites.\n5. GREAT: This package uses a Bayesian approach to predict TFBSs and can also be used to predict the binding affinity of TFs to their target sites.\n6. HISAT2: This package uses a spliced aligner to predict TFBSs and can also be used to predict the binding affinity of TFs to their target sites.\n7. STAR: This package uses a spliced aligner to predict TFBSs and can also be used to predict the binding affinity of TFs to their target sites.\n8. DeepSEA: This package uses a deep learning approach to predict TFBSs and can also be used to predict the binding affinity of TFs to their target sites.\n9. DeepBind: This package uses a deep learning approach to predict TFBSs and can also be used to predict the binding affinity of TFs to their target sites.\n10. ChromatinHMM: This package uses a HMM to predict TFBSs and can also be used to predict the binding affinity of TFs to their target sites.\nThese packages can be used to analyze TFBSs in various organisms, including humans, and can be used for a variety of applications, such as understanding gene regulation, predicting disease susceptibility, and identifying potential drug targets.",
    "llama-2-7b-chat-hf_fact_raw": "1. ChromHMM is a package in R/Bioconductor that predicts transcription factor binding sites using a hidden Markov model.\n2. The TFBS package in R/Bioconductor provides tools for predicting transcription factor binding sites.\n3. TRANSFAC is an R/Bioconductor package that uses a Bayesian approach to predict transcription factor binding sites.\n4. GREAT is an R/Bioconductor package that predicts transcription factor binding sites through a Bayesian approach.\n5. DeepSEA is an R/Bioconductor package that uses deep learning to predict transcription factor binding sites.",
    "llama-2-7b-chat-hf_fact": [
      "ChromHMM is a package in R/Bioconductor that predicts transcription factor binding sites using a hidden Markov model.",
      "The TFBS package in R/Bioconductor provides tools for predicting transcription factor binding sites.",
      "TRANSFAC is an R/Bioconductor package that uses a Bayesian approach to predict transcription factor binding sites.",
      "GREAT is an R/Bioconductor package that predicts transcription factor binding sites through a Bayesian approach.",
      "DeepSEA is an R/Bioconductor package that uses deep learning to predict transcription factor binding sites."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ChromHMM is a computational tool for learning chromatin states using a Hidden Markov Model but it is not a package in R/Bioconductor, and it is not primarily focused on predicting transcription factor binding sites (TFBS) but rather on characterizing chromatin states.\n2. TRUE\n3. FALSE [correction]: TRANSFAC is not an R/Bioconductor package; it is a database of transcription factors and their DNA binding sites. The package that uses Bayesian networks for TFBS prediction is called BCRANK, PRIORITY, or BayesPI, not TRANSFAC.\n4. FALSE [correction]: GREAT is a tool for genomic region enrichment analysis rather than a package in R/Bioconductor for predicting transcription factor binding sites, and it does not use a Bayesian approach for TFBS prediction. GREAT is used for linking genomic regions with biological terms and potential target genes.\n5. FALSE [correction]: DeepSEA is a deep learning-based framework for predicting the effects of non-coding variants on DNA sequences, including transcription factor binding sites, among other features. However, it is not an R/Bioconductor package; it is a standalone framework with its programming methods.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-7b-chat-hf_response": "Here are some clinical trials related to the prevention of sarcopenia:\n1. \"Effects of Resistance Training on Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" (2019) - This study published in the Journal of the American Geriatrics Society found that resistance training can help prevent sarcopenia in older adults.\n2. \"Exercise and Nutrition Interventions to Prevent Sarcopenia: A Systematic Review and Meta-Analysis\" (2019) - This study published in the Journal of the American Medical Directors Association found that both exercise and nutrition interventions can help prevent sarcopenia in older adults.\n3. \"The Effects of Omega-3 Supplementation on Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" (2019) - This study published in the Journal of the American Geriatrics Society found that omega-3 supplementation may help prevent sarcopenia in older adults.\n4. \"The Role of Vitamin D in the Prevention of Sarcopenia: A Systematic Review and Meta-Analysis\" (2019) - This study published in the Journal of the American Geriatrics Society found that vitamin D supplementation may help prevent sarcopenia in older adults.\n5. \"Effects of Resveratrol Supplementation on Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" (2019) - This study published in the Journal of the American Geriatrics Society found that resveratrol supplementation may help prevent sarcopenia in older adults.\n6. \"The Effect of Tai Chi Exercise on Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" (2019) - This study published in the Journal of the American Geriatrics Society found that tai chi exercise may help prevent sarcopenia in older adults.\n7. \"The Role of Probiotics in the Prevention of Sarcopenia: A Systematic Review and Meta-Analysis\" (2019) - This study published in the Journal of the American Geriatrics",
    "llama-2-7b-chat-hf_fact_raw": "1. The study \"Effects of Resistance Training on Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" reports that resistance training can help prevent sarcopenia in older adults.\n2. The study \"Exercise and Nutrition Interventions to Prevent Sarcopenia: A Systematic Review and Meta-Analysis\" indicates that exercise and nutrition interventions can prevent sarcopenia in older adults.\n3. The study \"The Effects of Omega-3 Supplementation on Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" suggests that omega-3 supplementation may prevent sarcopenia in older adults.\n4. The study \"The Role of Vitamin D in the Prevention of Sarcopenia: A Systematic Review and Meta-Analysis\" concludes that vitamin D supplementation may help prevent sarcopenia in older adults.\n5. The study \"The Effect of Tai Chi Exercise on Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" finds that tai chi exercise may help prevent sarcopenia in older adults.",
    "llama-2-7b-chat-hf_fact": [
      "The study \"Effects of Resistance Training on Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" reports that resistance training can help prevent sarcopenia in older adults.",
      "The study \"Exercise and Nutrition Interventions to Prevent Sarcopenia: A Systematic Review and Meta-Analysis\" indicates that exercise and nutrition interventions can prevent sarcopenia in older adults.",
      "The study \"The Effects of Omega-3 Supplementation on Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" suggests that omega-3 supplementation may prevent sarcopenia in older adults.",
      "The study \"The Role of Vitamin D in the Prevention of Sarcopenia: A Systematic Review and Meta-Analysis\" concludes that vitamin D supplementation may help prevent sarcopenia in older adults.",
      "The study \"The Effect of Tai Chi Exercise on Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" finds that tai chi exercise may help prevent sarcopenia in older adults."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nI do not have access to specific study contents or conclusions, and thus cannot verify the truthfulness of the statements about the findings of these studies. These statements would need to be checked against the actual study results to determine their accuracy.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several databases of molecular recognition features in membrane proteins, including:\n1. The Membrane Protein Database (MPD): This database contains information on the structural and functional properties of membrane proteins, including their membrane-spanning domains, transmembrane helices, and binding sites for small molecules and other ligands.\n2. The Protein Data Bank (PDB): This database contains structural data on a wide range of proteins, including membrane proteins, and includes information on their three-dimensional structures, dynamics, and interactions with other molecules.\n3. The Membrane Protein Structural Alignment (MPSA): This database provides a collection of aligned structural models of membrane proteins, allowing for the comparison of different protein structures and the identification of conserved features and functional sites.\n4. The Membrane Protein Interaction Database (MPI): This database contains information on the interactions between membrane proteins and other molecules, including small molecules, peptides, and other proteins.\n5. The Membrane Protein Function Prediction (MPFP): This database provides predictive models of the functions of membrane proteins based on their structural and sequence data.\n6. The Membrane Protein-Ligand Interaction Database (MPI-LIB): This database contains information on the interactions between membrane proteins and ligands, including small molecules, peptides, and other proteins.\n7. The Membrane Protein-Protein Interaction Database (MPPI): This database contains information on the interactions between membrane proteins and other proteins, including protein-protein interactions that occur within the membrane or across the membrane.\n8. The Membrane Protein-Nucleic Acid Interaction Database (MPNA): This database contains information on the interactions between membrane proteins and nucleic acids, including DNA and RNA.\nThese databases provide valuable resources for studying the structure, function, and interactions of membrane proteins, and can be used to inform the design and development of therapeutic agents targeting these proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Membrane Protein Database (MPD) contains information on the structural and functional properties of membrane proteins.\n2. The Protein Data Bank (PDB) holds structural data on a variety of proteins, including membrane proteins.\n3. The Membrane Protein Structural Alignment (MPSA) offers a collection of aligned structural models of membrane proteins.\n4. The Membrane Protein Interaction Database (MPI) provides information on interactions between membrane proteins and other molecules.\n5. The Membrane Protein Function Prediction (MPFP) includes predictive models of membrane protein functions based on structural and sequence data.",
    "llama-2-7b-chat-hf_fact": [
      "The Membrane Protein Database (MPD) contains information on the structural and functional properties of membrane proteins.",
      "The Protein Data Bank (PDB) holds structural data on a variety of proteins, including membrane proteins.",
      "The Membrane Protein Structural Alignment (MPSA) offers a collection of aligned structural models of membrane proteins.",
      "The Membrane Protein Interaction Database (MPI) provides information on interactions between membrane proteins and other molecules.",
      "The Membrane Protein Function Prediction (MPFP) includes predictive models of membrane protein functions based on structural and sequence data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe responses to statements 3, 4, and 5 are \"UNKNOWN\" because, without specific reference to a database or resource with those exact names (Membrane Protein Structural Alignment (MPSA), Membrane Protein Interaction Database (MPI), and Membrane Protein Function Prediction (MPFP)), it's unclear whether such databases or resources exist or if the provided names are entirely accurate. Additionally, these descriptions could be referring to functionalities within a broader database or resource rather than independent entities.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-7b-chat-hf_response": "Yes, rivaroxaban is metabolized in the kidneys. Rivaroxaban is metabolized by the liver and kidneys, with the liver being the primary site of metabolism. The kidneys play a secondary role in metabolizing rivaroxaban, with the enzyme uridine diphosphate glucuronosyltransferase (UGT) being responsible for glucuronidation of the drug. This metabolism helps to reduce the activity of rivaroxaban and increase its elimination from the body.",
    "llama-2-7b-chat-hf_fact_raw": "1. Rivaroxaban is metabolized in the kidneys.\n2. The liver is the primary site of metabolism for rivaroxaban.\n3. The kidneys play a secondary role in the metabolism of rivaroxaban.\n4. Uridine diphosphate glucuronosyltransferase (UGT) enzyme is responsible for the glucuronidation of rivaroxaban.\n5. Metabolism by the liver and kidneys helps reduce the activity of rivaroxaban and increase its elimination from the body.",
    "llama-2-7b-chat-hf_fact": [
      "Rivaroxaban is metabolized in the kidneys.",
      "The liver is the primary site of metabolism for rivaroxaban.",
      "The kidneys play a secondary role in the metabolism of rivaroxaban.",
      "Uridine diphosphate glucuronosyltransferase (UGT) enzyme is responsible for the glucuronidation of rivaroxaban.",
      "Metabolism by the liver and kidneys helps reduce the activity of rivaroxaban and increase its elimination from the body."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Rivaroxaban is mostly eliminated by the kidneys, but it is not metabolized there; it is metabolized in the liver.\n2. TRUE\n3. FALSE [correction]: The kidneys play a secondary role in the elimination of rivaroxaban, but not in its metabolism.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-7b-chat-hf_response": "TR alpha 2 regulates the expression of several genes in the heart, including:\n1. Atrial natriuretic factor (ANF): TR alpha 2 regulates the expression of ANF, a hormone that helps regulate blood pressure and fluid balance.\n2. Beta-myosin heavy chain (MHC-β): TR alpha 2 regulates the expression of MHC-β, a protein that plays a critical role in muscle contraction.\n3. Calmodulin (CaM): TR alpha 2 regulates the expression of CaM, a protein that helps regulate muscle contraction and relaxation.\n4. Cardiac troponin I (cTnI): TR alpha 2 regulates the expression of cTnI, a protein that plays a critical role in muscle contraction.\n5. GATA4: TR alpha 2 regulates the expression of GATA4, a transcription factor that plays a critical role in the development and maintenance of the cardiac conduction system.\n6. GATA6: TR alpha 2 regulates the expression of GATA6, a transcription factor that plays a critical role in the development and maintenance of the cardiac conduction system.\n7. Hypoxia-inducible factor (HIF) alpha: TR alpha 2 regulates the expression of HIF-α, a transcription factor that plays a critical role in response to hypoxia.\n8. Myosin-binding protein C (MYBPC): TR alpha 2 regulates the expression of MYBPC, a protein that plays a critical role in muscle contraction.\n9. Nuclear factor of kappa light chain enhancer in B cells 2 (NF-κB2): TR alpha 2 regulates the expression of NF-κB2, a transcription factor that plays a critical role in inflammation.\n10. Phospholamban (PLN): TR alpha 2 regulates the expression of PLN, a protein that plays a critical role in regulating calcium handling in the heart.\nThese genes are just a few examples of the many genes that are regulated by TR alpha 2 in the heart. The specific genes regulated by TR alpha 2 can vary depending on the cell type and the specific signaling pathway being studied.",
    "llama-2-7b-chat-hf_fact_raw": "1. TR alpha 2 regulates the expression of Atrial natriuretic factor (ANF) in the heart.\n2. TR alpha 2 regulates the expression of Beta-myosin heavy chain (MHC-β) in the heart.\n3. TR alpha 2 regulates the expression of Calmodulin (CaM) in the heart.\n4. TR alpha 2 regulates the expression of Cardiac troponin I (cTnI) in the heart.\n5. TR alpha 2 regulates the expression of GATA4 in the heart.",
    "llama-2-7b-chat-hf_fact": [
      "TR alpha 2 regulates the expression of Atrial natriuretic factor (ANF) in the heart.",
      "TR alpha 2 regulates the expression of Beta-myosin heavy chain (MHC-β) in the heart.",
      "TR alpha 2 regulates the expression of Calmodulin (CaM) in the heart.",
      "TR alpha 2 regulates the expression of Cardiac troponin I (cTnI) in the heart.",
      "TR alpha 2 regulates the expression of GATA4 in the heart."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided involve specific molecular biology information that is not commonly known or verified without referencing up-to-date scientific literature or databases. TR alpha 2 refers to a specific thyroid hormone receptor, but the regulation of specific genes such as ANF, MHC-β, CaM, cTnI, and GATA4 by this receptor would require confirmation from scientific studies or expert analysis in the field of molecular cardiology.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-7b-chat-hf_response": "Here are some of the available biomedical question answering systems:\n1. Biomedical Informatic Systems (BIS): BIS is a comprehensive database of biomedical question answering systems that provides a centralized platform for accessing and evaluating these systems.\n2. PubMedQA: PubMedQA is a biomedical question answering system that uses natural language processing techniques to answer questions based on the content of the PubMed database.\n3. BioASQ: BioASQ is a benchmarking platform for biomedical question answering systems that provides a collection of questions and a set of evaluation metrics to assess the performance of these systems.\n4. GeneAnswer: GeneAnswer is a gene-centric question answering system that uses natural language processing and machine learning techniques to answer questions about genes and gene functions.\n5. Med2RDF: Med2RDF is a biomedical question answering system that uses the Resource Description Framework (RDF) to represent biomedical knowledge and answer questions based on this knowledge.\n6. BioPortal: BioPortal is a biomedical question answering system that provides a range of tools for searching and analyzing biomedical literature, including a question answering functionality.\n7. Biomedical Question Answering System (BQAS): BQAS is a biomedical question answering system that uses natural language processing and machine learning techniques to answer questions based on a large corpus of biomedical text.\n8. BioQA: BioQA is a biomedical question answering system that uses natural language processing and machine learning techniques to answer questions based on a large corpus of biomedical text.\n9. MedQA: MedQA is a biomedical question answering system that uses natural language processing and machine learning techniques to answer questions based on the Medline database.\n10. Biomedical Text Mining (BTM): BTM is a biomedical question answering system that uses natural language processing and machine learning techniques to mine biomedical text and answer questions based on the extracted information.\nIt's worth noting that this is not an exhaustive list, and there are many other biomedical question answering systems available, each with its own strengths and weaknesses.",
    "llama-2-7b-chat-hf_fact_raw": "1. PubMedQA is a biomedical question answering system that uses natural language processing to answer questions based on the PubMed database.\n2. BioASQ is a benchmarking platform for biomedical question answering systems providing questions and evaluation metrics.\n3. GeneAnswer is a gene-centric question answering system that uses natural language processing and machine learning.\n4. Med2RDF is a biomedical question answering system that uses the Resource Description Framework to represent knowledge.\n5. BioPortal provides tools for searching and analyzing biomedical literature, including question answering functionality.",
    "llama-2-7b-chat-hf_fact": [
      "PubMedQA is a biomedical question answering system that uses natural language processing to answer questions based on the PubMed database.",
      "BioASQ is a benchmarking platform for biomedical question answering systems providing questions and evaluation metrics.",
      "GeneAnswer is a gene-centric question answering system that uses natural language processing and machine learning.",
      "Med2RDF is a biomedical question answering system that uses the Resource Description Framework to represent knowledge.",
      "BioPortal provides tools for searching and analyzing biomedical literature, including question answering functionality."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: PubMedQA is not an actual biomedical question answering system; it is a dataset for developing biomedical question answering systems.\n2. TRUE\n3. UNKNOWN (The statement could be true as there are various question answering systems with similar names like GeneMANIA or GeneCards, but without specific knowledge about \"GeneAnswer,\" it cannot be verified.)\n4. UNKNOWN (While Med2RDF seems to hint at a biomedical question answering system, it actually stands for medication to RDF, which is a system to convert medication information into RDF format, not specifically a question answering system.)\n5. FALSE [correction]: BioPortal is not primarily a tool for searching and analyzing biomedical literature; it is a repository of biomedical ontologies that provides ontology-based access to terminology and resources, but it does not include question answering functionality.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-7b-chat-hf_response": "The transcription factor that activates the bethanechol pathway is NF-κB (Nuclear Factor Kappa B).",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-7b-chat-hf_response": "There are several technologies that are commonly used for enrichment of phosphorylated peptides in global quantitative phosphoproteomic analyses. These include:\n1. TiO2-based enrichment: This method uses titanium dioxide (TiO2) to selectively bind phosphorylated peptides based on their charge and hydrophilicity.\n2. IMAC (Immobilized Metal Affinity Chromatography): This method uses metal ions, such as copper or nickel, immobilized on a resin to bind phosphorylated peptides.\n3. Cation exchange (CE) chromatography: This method uses a cation exchange resin to separate phosphorylated peptides based on their charge.\n4. Hydrophilic interaction liquid chromatography (HILIC): This method uses a hydrophilic resin to separate phosphorylated peptides based on their hydrophilicity.\n5. Reversed-phase HPLC: This method uses a reversed-phase resin to separate phosphorylated peptides based on their hydrophobicity.\n6. Gel-based enrichment: This method uses a gel matrix to capture phosphorylated peptides based on their size and charge.\n7. Microfluidic-based enrichment: This method uses microfluidic devices to capture phosphorylated peptides based on their size and charge.\n8. Nanoscale enrichment: This method uses nanoscale materials, such as nanoparticles or nanotubes, to capture phosphorylated peptides based on their size and charge.\n9. Protein G-based enrichment: This method uses protein G to bind phosphorylated peptides based on their phosphorylation state.\n10. Magnetic nanoparticle-based enrichment: This method uses magnetic nanoparticles to capture phosphorylated peptides based on their charge and hydrophilicity.\nIt's worth noting that each technology has its own advantages and disadvantages, and the choice of technology will depend on the specific research question and experimental design.",
    "llama-2-7b-chat-hf_fact_raw": "1. Titanium dioxide (TiO2)-based enrichment is used to bind phosphorylated peptides based on their charge and hydrophilinity in phosphoproteomic analyses.\n2. Immobilized Metal Affinity Chromatography (IMAC) utilizes metal ions immobilized on a resin to bind phosphorylated peptides.\n3. Cation exchange (CE) chromatography separates phosphorylated peptides based on their charge.\n4. Hydrophilic interaction liquid chromatography (HILIC) separates phosphorylated peptides based on their hydrophilicity.\n5. Reversed-phase HPLC separates phosphorylated peptides based on their hydrophobicity.",
    "llama-2-7b-chat-hf_fact": [
      "Titanium dioxide (TiO2)-based enrichment is used to bind phosphorylated peptides based on their charge and hydrophilinity in phosphoproteomic analyses.",
      "Immobilized Metal Affinity Chromatography (IMAC) utilizes metal ions immobilized on a resin to bind phosphorylated peptides.",
      "Cation exchange (CE) chromatography separates phosphorylated peptides based on their charge.",
      "Hydrophilic interaction liquid chromatography (HILIC) separates phosphorylated peptides based on their hydrophilicity.",
      "Reversed-phase HPLC separates phosphorylated peptides based on their hydrophobicity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Titanium dioxide (TiO2) enrichment is used to bind phosphorylated peptides primarily based on their affinity for the metal oxide rather than their charge or hydrophilicity.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-7b-chat-hf_response": "Palmini classification is used to rate the severity of intellectual disability. It is a system used to classify intellectual disability based on the severity of cognitive and adaptive functioning deficits.",
    "llama-2-7b-chat-hf_fact_raw": "1. Palmini classification is used to rate the severity of intellectual disability.\n2. The classification system is based on the severity of cognitive functioning deficits.\n3. The classification system is based on the severity of adaptive functioning deficits.",
    "llama-2-7b-chat-hf_fact": [
      "Palmini classification is used to rate the severity of intellectual disability.",
      "The classification system is based on the severity of cognitive functioning deficits.",
      "The classification system is based on the severity of adaptive functioning deficits."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Palmini classification is not used to rate the severity of intellectual disability; it is used for classifying types and severities of epileptic seizures.\n2. FALSE [correction]: Since Palmini classification is associated with epileptic seizures and not intellectual disability, it is not based on the severity of cognitive functioning deficits in the context of intellectual disability.\n3. FALSE [correction]: Similarly, as the Palmini classification pertains to epilepsy, it does not base its system on the severity of adaptive functioning deficits related to intellectual disability.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-7b-chat-hf_response": "Yes, some viruses have been implicated in the etiology of human subacute thyroiditis. Subacute thyroiditis is an inflammatory condition of the thyroid gland that can occur in response to various triggers, including viral infections.\nSome viruses that have been linked to the development of subacute thyroiditis include:\n1. Viruses that affect the thyroid gland directly:\nSome viruses, such as the thyroid gland-specific virus (TGSV), have been shown to directly infect the thyroid gland and cause inflammation. TGSV is a member of the parvovirus family and is the most common virus to infect the thyroid gland.\n2. Viruses that affect the immune system:\nViruses that affect the immune system, such as Epstein-Barr virus (EBV), can also contribute to the development of subacute thyroiditis. EBV is a common herpesvirus that is known to cause infectious mononucleosis and has been linked to various autoimmune diseases, including subacute thyroiditis.\n3. Viruses that are transmitted through blood transfusions:\nIn rare cases, subacute thyroiditis can be caused by viruses that are transmitted through blood transfusions. For example, a study published in the New England Journal of Medicine in 2009 found that some cases of subacute thyroiditis were linked to exposure to the hepatitis B virus through blood transfusions.\nIt's important to note that the exact mechanisms by which viruses contribute to the development of subacute thyroiditis are not yet fully understood and may involve complex interactions between the virus, the immune system, and the thyroid gland. Further research is needed to determine the exact role of viruses in the etiology of this condition.",
    "llama-2-7b-chat-hf_fact_raw": "1. Some viruses have been implicated in the etiology of human subacute thyroiditis, an inflammatory condition of the thyroid gland.\n2. The thyroid gland-specific virus (TGSV), a member of the parvovirus family, can directly infect the thyroid gland and cause inflammation.\n3. Epstein-Barr virus (EBV), a common herpesvirus, has been linked to the development of subacute thyroiditis and is known to affect the immune system.\n4. A study published in the New England Journal of Medicine in 2009 found that cases of subacute thyroiditis were linked to exposure to the hepatitis B virus through blood transfusions.\n5. The exact mechanisms by which viruses contribute to the development of subacute thyroiditis are not yet fully understood and require further research.",
    "llama-2-7b-chat-hf_fact": [
      "Some viruses have been implicated in the etiology of human subacute thyroiditis, an inflammatory condition of the thyroid gland.",
      "The thyroid gland-specific virus (TGSV), a member of the parvovirus family, can directly infect the thyroid gland and cause inflammation.",
      "Epstein-Barr virus (EBV), a common herpesvirus, has been linked to the development of subacute thyroiditis and is known to affect the immune system.",
      "A study published in the New England Journal of Medicine in 2009 found that cases of subacute thyroiditis were linked to exposure to the hepatitis B virus through blood transfusions.",
      "The exact mechanisms by which viruses contribute to the development of subacute thyroiditis are not yet fully understood and require further research."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There is no established thyroid gland-specific virus (TGSV) known to directly infect the thyroid gland; the mention of TGSV is not recognized in the context of viral thyroiditis.\n3. TRUE\n4. FALSE [correction]: A study linking subacute thyroiditis to the hepatitis B virus through blood transfusions in 2009 in the New England Journal of Medicine is not a known published finding. While blood transfusions can have risks, there is no specific established link between hepatitis B virus from blood transfusions and subacute thyroiditis.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-7b-chat-hf_response": "Yes, STAT3 is involved in EIF2AK2-dependent suppression of autophagy. EIF2AK2 (also known as eukaryotic translation initiation factor 2-alpha kinase 2) is a kinase that phosphorylates and inhibits the translation initiation factor eIF2α, leading to suppression of global protein synthesis and induction of autophagy. STAT3 (Signal Transducer and Activator of Transcription 3) is a transcription factor that is involved in the regulation of various cellular processes, including inflammation and autophagy. Studies have shown that STAT3 is activated downstream of EIF2AK2 and plays a role in the regulation of EIF2AK2-dependent autophagy suppression. Specifically, STAT3 phosphorylation is required for the maintenance of autophagy suppression and the prevention of cell death during EIF2AK2-mediated autophagy suppression.",
    "llama-2-7b-chat-hf_fact_raw": "1. EIF2AK2 phosphorylates and inhibits the translation initiation factor eIF2α.\n2. The inhibition of eIF2α by EIF2AK2 leads to the suppression of global protein synthesis.\n3. The suppression of global protein synthesis by EIF2AK2 leads to the induction of autophagy.\n4. STAT3 is activated downstream of EIF2AK2.\n5. STAT3 phosphorylation is required for the maintenance of autophagy suppression during EIF2AK2-mediated autophagy suppression.",
    "llama-2-7b-chat-hf_fact": [
      "EIF2AK2 phosphorylates and inhibits the translation initiation factor eIF2α.",
      "The inhibition of eIF2α by EIF2AK2 leads to the suppression of global protein synthesis.",
      "The suppression of global protein synthesis by EIF2AK2 leads to the induction of autophagy.",
      "STAT3 is activated downstream of EIF2AK2.",
      "STAT3 phosphorylation is required for the maintenance of autophagy suppression during EIF2AK2-mediated autophagy suppression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: STAT3 is not directly activated downstream of EIF2AK2; instead, other pathways are typically involved in STAT3 activation. EIF2AK2, also known as PKR, is primarily involved in the response to viral infection and does not directly activate STAT3.\n5. FALSE [correction]: Since Statement 4 is incorrect in stating that STAT3 is activated downstream of EIF2AK2, the statement regarding the requirement of STAT3 phosphorylation for the maintenance of autophagy suppression during EIF2AK2-mediated action is also incorrect. Moreover, EIF2AK2 does not mediate autophagy suppression; it is involved in the induction of autophagy.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-7b-chat-hf_response": "Theatre is a software tool used for genomic analysis, specifically for the analysis of chromatin structure and epigenetic marks. It was developed by the lab of Eric Davidson at the University of California, San Francisco.\nTheatre is designed to analyze the spatial organization of chromatin and epigenetic marks at the level of individual cells, allowing researchers to gain insights into the regulatory mechanisms that control gene expression. The tool can be used to analyze a variety of genomic data types, including:\n1. ChIP-seq data: Theatre can be used to identify regions of the genome that are bound by specific transcription factors or other proteins, and to understand the spatial organization of these binding events.\n2. DNA methylation data: Theatre can be used to identify regions of the genome that are methylated or unmethylated, and to understand the spatial organization of these marks.\n3. Histone modification data: Theatre can be used to identify regions of the genome that are modified by specific histone modifications, such as histone 3 lysine 4 trimethylation (H3K4me3) or histone 3 lysine 27 trimethylation (H3K27me3), and to understand the spatial organization of these marks.\n4. RNA sequencing data: Theatre can be used to identify regions of the genome that are actively transcribed, and to understand the spatial organization of gene expression.\nThe usage of Theatre software tool for genomic analysis includes:\n1. Identifying regions of the genome that are bound by specific transcription factors or other proteins.\n2. Understanding the spatial organization of chromatin structure and epigenetic marks.\n3. Identifying regions of the genome that are actively transcribed.\n4. Analyzing the regulatory mechanisms that control gene expression.\n5. Identifying the interactions between different regulatory elements and their target genes.\n6. Understanding the role of chromatin structure and epigenetic marks in gene regulation.\n7. Identifying the differences in chromatin structure and epigenetic marks between different cell types or tissues.\n8. Analyzing the effects of different stimuli or drugs on chromatin structure and epigenetic marks.\n9. Identifying the regulatory elements that are responsible for the specific gene expression patterns.\n10",
    "llama-2-7b-chat-hf_fact_raw": "1. Theatre is a software tool used for genomic analysis, particularly focused on chromatin structure and epigenetic marks.\n2. The Theatre software tool was developed by the lab of Eric Davidson at the University of California, San Francisco.\n3. Theatre can be utilized to identify regions of the genome that are bound by specific transcription factors or proteins.\n4. It can analyze genomic data types like ChIP-seq data, DNA methylation data, histone modification data, and RNA sequencing data.\n5. The tool can help in understanding the spatial organization of chromatin and epigenetic marks.",
    "llama-2-7b-chat-hf_fact": [
      "Theatre is a software tool used for genomic analysis, particularly focused on chromatin structure and epigenetic marks.",
      "The Theatre software tool was developed by the lab of Eric Davidson at the University of California, San Francisco.",
      "Theatre can be utilized to identify regions of the genome that are bound by specific transcription factors or proteins.",
      "It can analyze genomic data types like ChIP-seq data, DNA methylation data, histone modification data, and RNA sequencing data.",
      "The tool can help in understanding the spatial organization of chromatin and epigenetic marks."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific information about a software tool named \"Theatre\" for genomic analysis, we can't determine the truth of this statement.\n2. FALSE [correction]: Eric Davidson was associated with the California Institute of Technology (Caltech), not the University of California, San Francisco (UCSF). However, without specific information on whether a tool named Theatre was developed in his lab, this statement can't be confirmed as true even after the correction.\n3. UNKNOWN: The capabilities of the Theatre software tool for genomic analysis are not verifiable without more information or context.\n4. UNKNOWN: The ability of the Theatre software tool to analyze various genomic data types like ChIP-seq data, DNA methylation data, histone modification data, and RNA sequencing data cannot be determined without additional information.\n5. UNKNOWN: The statement about the Theatre tool's utility in understanding the spatial organization of chromatin and epigenetic marks requires more context or information to be verified as true or false.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-7b-chat-hf_response": "The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences is O(n^2), where n is the length of the shorter sequence. This is because the algorithm compares each element of the shorter sequence with every element of the longer sequence, resulting in a total of n^2 comparisons.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Smith-Waterman algorithm has an execution time (complexity) of O(n^2).\n2. The execution time complexity of the Smith-Waterman algorithm is based on the length of the shorter sequence, denoted as n.\n3. The Smith-Waterman algorithm involves comparing each element of the shorter sequence with every element of the longer sequence.\n4. The Smith-Waterman algorithm results in a total of n^2 comparisons for two sequences.",
    "llama-2-7b-chat-hf_fact": [
      "The Smith-Waterman algorithm has an execution time (complexity) of O(n^2).",
      "The execution time complexity of the Smith-Waterman algorithm is based on the length of the shorter sequence, denoted as n.",
      "The Smith-Waterman algorithm involves comparing each element of the shorter sequence with every element of the longer sequence.",
      "The Smith-Waterman algorithm results in a total of n^2 comparisons for two sequences."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The Smith-Waterman algorithm indeed has quadratic time complexity, commonly denoted as O(n^2), where n is the length of the shorter sequence involved in the alignment.\n2. FALSE [correction]: The execution time complexity of the Smith-Waterman algorithm is actually based on the product of the lengths of the two sequences being aligned. If the lengths are denoted as m and n, where m ≥ n, then the complexity is O(m*n).\n3. TRUE: The Smith-Waterman algorithm involves comparing elements of one sequence with elements of the other sequence to find the optimal local alignment, effectively involving such pairwise comparisons.\n4. FALSE [correction]: The Smith-Waterman algorithm results in a total of m*n comparisons for two sequences of lengths m and n. Therefore, the number of comparisons is based on the product of the lengths of both sequences, not just the square of the length of the shorter sequence.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-7b-chat-hf_response": "FLVCR1 is a member of the solute carrier (SLC) family of transport proteins. Specifically, it is a member of the SLC12 family, which is also known as the hydroxyl-carboxylate carrier family.",
    "llama-2-7b-chat-hf_fact_raw": "1. FLVCR1 is a member of the SLC (solute carrier) family of transport proteins.\n2. FLVCR1 is part of the SLC12 family within the solute carrier family.",
    "llama-2-7b-chat-hf_fact": [
      "FLVCR1 is a member of the SLC (solute carrier) family of transport proteins.",
      "FLVCR1 is part of the SLC12 family within the solute carrier family."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: FLVCR1 is not a member of the SLC (solute carrier) family of transport proteins. It is part of the Major Facilitator Superfamily.\n2. FALSE [correction]: Since FLVCR1 is not part of the SLC family of transport proteins, it cannot be within the SLC12 family or any other SLC subgroup.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_response": "GATA-1 is a transcription factor that plays a crucial role in regulating gene expression in various cell types, including hematopoietic cells. The biotinylation tagging approach has been used to identify GATA-1 interacting partners in various studies. Here are some of the GATA-1 interacting partners that have been identified using this approach:\n1. HDAC1: GATA-1 was shown to interact with histone deacetylase 1 (HDAC1) in a study published in the journal Nature in 2003.\n2. p300: GATA-1 was found to interact with the histone acetyltransferase p300 in a study published in the journal Cell in 2007.\n3. CBF1: GATA-1 was shown to interact with the transcription factor CBF1 in a study published in the journal Cell in 2010.\n4. KAT2A: GATA-1 was found to interact with the lysine acetyltransferase KAT2A in a study published in the journal Nature Communications in 2017.\n5. RBBP4: GATA-1 was shown to interact with the RNA-binding protein RBBP4 in a study published in the journal Nature Structural & Molecular Biology in 2018.\n6. H3K27ac: GATA-1 was found to interact with histone H3 lysine 27 acetyltransferase (H3K27ac) in a study published in the journal Nature Communications in 2019.\n7. TFIIA: GATA-1 was shown to interact with the transcription factor IIA (TFIIA) in a study published in the journal Cell Reports in 2020.\nThese studies demonstrate that GATA-1 interacts with a variety of proteins involved in transcriptional regulation, chromatin modification, and RNA processing, highlighting the complexity of GATA-1's regulatory network.",
    "llama-2-7b-chat-hf_fact_raw": "1. GATA-1 was shown to interact with histone deacetylase 1 (HDAC1) in a study published in Nature in 2003.\n2. GATA-1 was found to interact with the histone acetyltransferase p300 in a study published in Cell in 2007.\n3. GATA-1 was shown to interact with the transcription factor CBF1 in a study published in Cell in 2010.\n4. GATA-1 was found to interact with the lysine acetyltransferase KAT2A in a study published in Nature Communications in 2017.\n5. GATA-1 was shown to interact with the RNA-binding protein RBBP4 in a study published in Nature Structural & Molecular Biology in 2018.",
    "llama-2-7b-chat-hf_fact": [
      "GATA-1 was shown to interact with histone deacetylase 1 (HDAC1) in a study published in Nature in 2003.",
      "GATA-1 was found to interact with the histone acetyltransferase p300 in a study published in Cell in 2007.",
      "GATA-1 was shown to interact with the transcription factor CBF1 in a study published in Cell in 2010.",
      "GATA-1 was found to interact with the lysine acetyltransferase KAT2A in a study published in Nature Communications in 2017.",
      "GATA-1 was shown to interact with the RNA-binding protein RBBP4 in a study published in Nature Structural & Molecular Biology in 2018."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe first two statements are accurate references to scientific studies, assuming they correspond to actual publications and findings from those years. The subsequent statements about GATA-1 interactions specified to particular years and journals require access to the respective articles to verify, and such details are not common knowledge nor accessible without further research.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-7b-chat-hf_response": "TAF10 interacts with the GATA1 transcription factor to facilitate the recruitment of RNA polymerase II (RNAPII) to the promoter region of target genes and to modulate the activity of GATA1 in regulating gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-7b-chat-hf_response": "Yes, there are several decision support systems (DSS) available for chronic pain management. A DSS is a computer-based system that provides healthcare professionals with clinical decision-making support by analyzing patient data and providing recommendations for diagnosis, treatment, and management of chronic pain. Here are some examples of DSS for chronic pain management:\n1. Chronic Pain Management Decision Support System (CPM-DSS): This system was developed by the University of Washington and provides a comprehensive framework for managing chronic pain. It includes clinical decision rules, clinical practice guidelines, and a knowledge base of pain management strategies.\n2. PainCare: This DSS was developed by the University of California, Los Angeles (UCLA) and provides a comprehensive approach to chronic pain management. It includes a pain assessment tool, treatment recommendations, and a database of pain management strategies.\n3. PainPathways: This DSS was developed by the University of Washington and provides a comprehensive framework for managing chronic pain. It includes clinical decision rules, clinical practice guidelines, and a knowledge base of pain management strategies.\n4. Chronic Pain Management System (CPMS): This system was developed by the University of California, San Francisco (UCSF) and provides a comprehensive approach to chronic pain management. It includes a pain assessment tool, treatment recommendations, and a database of pain management strategies.\n5. Pain-Q: This DSS was developed by the University of California, San Diego (UCSD) and provides a comprehensive approach to chronic pain management. It includes a pain assessment tool, treatment recommendations, and a database of pain management strategies.\n6. Pain Management Decision Support System (PMDSS): This system was developed by the University of Texas Health Science Center at Houston and provides a comprehensive framework for managing chronic pain. It includes clinical decision rules, clinical practice guidelines, and a knowledge base of pain management strategies.\n7. Chronic Pain Management Toolkit (CPMT): This system was developed by the University of Florida and provides a comprehensive approach to chronic pain management. It includes a pain assessment tool, treatment recommendations, and a database of pain management strategies.\n8. Pain Management and Research Network (PMRN):",
    "llama-2-7b-chat-hf_fact_raw": "1. Decision support systems (DSS) for chronic pain management provide clinical decision-making support for healthcare professionals by analyzing patient data.\n2. The Chronic Pain Management Decision Support System (CPM-DSS) was developed by the University of Washington.\n3. PainCare, a decision support system for chronic pain management, was developed by the University of California, Los Angeles (UCLA).\n4. The Chronic Pain Management System (CPMS) was developed by the University of California, San Francisco (UCSF).\n5. The Pain Management Decision Support System (PMDSS) was created by the University of Texas Health Science Center at Houston.",
    "llama-2-7b-chat-hf_fact": [
      "Decision support systems (DSS) for chronic pain management provide clinical decision-making support for healthcare professionals by analyzing patient data.",
      "The Chronic Pain Management Decision Support System (CPM-DSS) was developed by the University of Washington.",
      "PainCare, a decision support system for chronic pain management, was developed by the University of California, Los Angeles (UCLA).",
      "The Chronic Pain Management System (CPMS) was developed by the University of California, San Francisco (UCSF).",
      "The Pain Management Decision Support System (PMDSS) was created by the University of Texas Health Science Center at Houston."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWhile the first statement about Decision Support Systems (DSS) is true regarding their purpose, there is not enough specific information provided to confirm whether the named institutions developed the corresponding systems mentioned in statements 2 through 5. These details would need to be verified with credible sources.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-7b-chat-hf_response": "Angiogenin is a secreted protein that localizes to the cytoplasm and nucleus of cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. Angiogenin is a protein that localizes to the cytoplasm of cells.\n2. Angiogenin also localizes to the nucleus of cells.\n3. Angiogenin is a secreted protein.",
    "llama-2-7b-chat-hf_fact": [
      "Angiogenin is a protein that localizes to the cytoplasm of cells.",
      "Angiogenin also localizes to the nucleus of cells.",
      "Angiogenin is a secreted protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-7b-chat-hf_response": "Ranolazine does not directly affect kinase signaling activation in the heart. Its primary mechanism of action is to inhibit the activity of the enzyme ATP-sensitive potassium (KATP) channels, which are involved in the regulation of cardiac ion homeostasis and excitation-contraction coupling in the heart. By inhibiting KATP channels, ranolazine reduces the influx of potassium ions into the cardiac myocyte, leading to a decrease in the duration of the action potential and a decrease in the force of contraction. This can be beneficial in treating certain heart conditions, such as angina pectoris, where the heart muscle is not receiving enough oxygen due to reduced blood flow.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ranolazine primarily inhibits the activity of ATP-sensitive potassium (KATP) channels in the heart.\n2. KATP channels are involved in the regulation of cardiac ion homeostasis and excitation-contraction coupling.\n3. Inhibition of KATP channels by ranolazine leads to reduced influx of potassium ions into cardiac myocytes.\n4. Ranolazine can decrease the duration of action potentials in cardiac cells.\n5. Ranolazine usage can be beneficial in treating angina pectoris by reducing the force of cardiac contractions.",
    "llama-2-7b-chat-hf_fact": [
      "Ranolazine primarily inhibits the activity of ATP-sensitive potassium (KATP) channels in the heart.",
      "KATP channels are involved in the regulation of cardiac ion homeostasis and excitation-contraction coupling.",
      "Inhibition of KATP channels by ranolazine leads to reduced influx of potassium ions into cardiac myocytes.",
      "Ranolazine can decrease the duration of action potentials in cardiac cells.",
      "Ranolazine usage can be beneficial in treating angina pectoris by reducing the force of cardiac contractions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ranolazine primarily inhibits the late sodium (Na+) current in the heart, not the activity of ATP-sensitive potassium (KATP) channels.\n2. TRUE\n3. FALSE [correction]: Since ranolazine primarily inhibits the late sodium current and not KATP channels, its effect does not directly involve reducing the influx of potassium ions into cardiac myocytes.\n4. TRUE: By inhibiting the late sodium current, ranolazine can decrease the duration of action potentials in cardiac cells, as it affects the intracellular sodium concentration and consequently the calcium levels due to the sodium-calcium exchanger.\n5. FALSE [correction]: Ranolazine is beneficial in treating angina pectoris, not by reducing the force of cardiac contractions but by helping to improve the efficiency of oxygen usage by the heart, thereby alleviating symptoms of angina.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-7b-chat-hf_response": "No, the regulation of Vsr endonuclease is not independent of the growth phase of bacteria. Vsr endonuclease activity is positively regulated during the stationary phase of bacterial growth, when the cell is under stress and needs to repair DNA damage. In this phase, the expression of the gene encoding Vsr endonuclease is upregulated, leading to increased enzyme activity and the degradation of DNA damage.",
    "llama-2-7b-chat-hf_fact_raw": "1. The regulation of Vsr endonuclease is not independent of the growth phase of bacteria.\n2. Vsr endonuclease activity is positively regulated during the stationary phase of bacterial growth.\n3. During the stationary phase, bacteria experience cell stress and need to repair DNA damage.\n4. The expression of the gene encoding Vsr endonuclease is upregulated in the stationary phase.\n5. Increased enzyme activity of Vsr endonuclease leads to the degradation of DNA damage during the stationary phase.",
    "llama-2-7b-chat-hf_fact": [
      "The regulation of Vsr endonuclease is not independent of the growth phase of bacteria.",
      "Vsr endonuclease activity is positively regulated during the stationary phase of bacterial growth.",
      "During the stationary phase, bacteria experience cell stress and need to repair DNA damage.",
      "The expression of the gene encoding Vsr endonuclease is upregulated in the stationary phase.",
      "Increased enzyme activity of Vsr endonuclease leads to the degradation of DNA damage during the stationary phase."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Increased enzyme activity of Vsr endonuclease does not lead to the degradation of DNA but rather to the repair of specific DNA mismatches resulting from deamination.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several computational tools that can be used for the prediction of beta-barrel transmembrane proteins. Some of the commonly used tools include:\n1. BepiPred: BepiPred is a web server that uses a combination of sequence analysis and structure-based methods to predict the presence of beta-barrel transmembrane domains in proteins. It uses a machine learning algorithm to classify amino acid residues into different types based on their hydrophobicity and other features.\n2. TMHMM: TMHMM is a widely used tool for predicting transmembrane helices in proteins. It uses a combination of sequence analysis and structure-based methods to predict the presence of transmembrane helices and their orientation in the membrane.\n3. PredictProtein: PredictProtein is a web server that can be used to predict the structure and function of proteins. It includes tools for predicting transmembrane helices, and it uses a combination of sequence analysis and structure-based methods to make its predictions.\n4. SignalP: SignalP is a tool for predicting the presence of signal peptides in proteins. While it does not specifically predict beta-barrel transmembrane proteins, it can be used in combination with other tools to identify potential membrane proteins.\n5. Membrane Protein Structure Prediction (MPSP): MPSP is a web server that can be used to predict the three-dimensional structure of beta-barrel transmembrane proteins. It uses a combination of sequence analysis and structure-based methods to make its predictions.\n6. PHD-TOPO: PHD-TOPO is a tool for predicting the topology of transmembrane proteins. It uses a combination of sequence analysis and structure-based methods to predict the arrangement of transmembrane helices in the membrane.\n7. TM-align: TM-align is a tool for aligning multiple transmembrane protein structures. It can be used to identify conserved regions in beta-barrel transmembrane proteins and to predict their structure.\n8. TM-pred: TM-pred is a tool for predicting the presence and orientation of transmembrane helices in proteins. It uses a combination of sequence analysis and structure-based methods to make its predictions.\n9. Transmembrane Helix",
    "llama-2-7b-chat-hf_fact_raw": "1. BepiPred is a web server that predicts beta-barrel transmembrane domains in proteins using sequence analysis, structure-based methods, and a machine learning algorithm.\n2. TMHMM predicts transmembrane helices in proteins through sequence and structure-based methods.\n3. PredictProtein is a tool that predicts the structure and function of proteins and includes predictions for transmembrane helices.\n4. Membrane Protein Structure Prediction (MPSP) is a web server for predicting the three-dimensional structure of beta-barrel transmembrane proteins.\n5. PHD-TOPO predicts the topology of transmembrane proteins by determining the arrangement of transmembrane helices.",
    "llama-2-7b-chat-hf_fact": [
      "BepiPred is a web server that predicts beta-barrel transmembrane domains in proteins using sequence analysis, structure-based methods, and a machine learning algorithm.",
      "TMHMM predicts transmembrane helices in proteins through sequence and structure-based methods.",
      "PredictProtein is a tool that predicts the structure and function of proteins and includes predictions for transmembrane helices.",
      "Membrane Protein Structure Prediction (MPSP) is a web server for predicting the three-dimensional structure of beta-barrel transmembrane proteins.",
      "PHD-TOPO predicts the topology of transmembrane proteins by determining the arrangement of transmembrane helices."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Membrane Protein Structure Prediction (MPSP) is not specifically described in the provided statements, and without additional context, it's not clear if it's a web server for predicting the three-dimensional structure of beta-barrel transmembrane proteins or another type of transmembrane proteins. Typically, tools like MPSP are used for predicting the 3D structure of various types of membrane proteins, which might include beta-barrels, helical transmembrane proteins, or others.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-7b-chat-hf_response": "Galassi classification is used to classify developmental disorders, specifically those related to chromosomal abnormalities.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-7b-chat-hf_response": "Shapiro syndrome, also known as Shapiro-Olivecrona syndrome, is a rare genetic disorder that affects the development of the nervous system and other systems in the body. Here are some common features of Shapiro syndrome:\n1. Neurological problems: The most common feature of Shapiro syndrome is neurological problems, which can include seizures, intellectual disability, and movement disorders such as ataxia and chorea.\n2. Distinctive facial features: People with Shapiro syndrome may have distinctive facial features, including a small head, narrow eyes, and a short nose.\n3. Growth delays: Children with Shapiro syndrome may experience growth delays, both in terms of height and weight.\n4. Skeletal abnormalities: Shapiro syndrome can cause a range of skeletal abnormalities, including joint contractures, scoliosis, and other skeletal deformities.\n5. Developmental delays: Children with Shapiro syndrome may experience delays in reaching developmental milestones, such as sitting, standing, and walking.\n6. Vision problems: Some people with Shapiro syndrome may experience vision problems, including cataracts, glaucoma, and other eye disorders.\n7. Hearing loss: Hearing loss is a common feature of Shapiro syndrome, and can range from mild to profound.\n8. Respiratory problems: Shapiro syndrome can cause a range of respiratory problems, including respiratory infections, sleep apnea, and other breathing difficulties.\n9. Cardiovascular problems: Some people with Shapiro syndrome may experience cardiovascular problems, including heart defects and abnormal heart rhythms.\n10. Increased risk of infections: People with Shapiro syndrome may be at increased risk of infections, particularly respiratory infections, due to their immune system dysfunction.\nIt's important to note that the severity of Shapiro syndrome can vary widely between individuals, and not all individuals will experience all of these features. If you have concerns about your child's health, it's important to consult with a",
    "llama-2-7b-chat-hf_fact_raw": "1. Shapiro syndrome is a rare genetic disorder that affects the development of the nervous system and other systems in the body.\n2. Common neurological problems in Shapiro syndrome include seizures, intellectual disability, and movement disorders such as ataxia and chorea.\n3. People with Shapiro syndrome may exhibit distinctive facial features, such as a small head, narrow eyes, and a short nose.\n4. Shapiro syndrome can lead to skeletal abnormalities like joint contractures, scoliosis, and other skeletal deformities.\n5. Hearing loss is one of the common features of Shapiro syndrome, ranging from mild to profound.",
    "llama-2-7b-chat-hf_fact": [
      "Shapiro syndrome is a rare genetic disorder that affects the development of the nervous system and other systems in the body.",
      "Common neurological problems in Shapiro syndrome include seizures, intellectual disability, and movement disorders such as ataxia and chorea.",
      "People with Shapiro syndrome may exhibit distinctive facial features, such as a small head, narrow eyes, and a short nose.",
      "Shapiro syndrome can lead to skeletal abnormalities like joint contractures, scoliosis, and other skeletal deformities.",
      "Hearing loss is one of the common features of Shapiro syndrome, ranging from mild to profound."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Shapiro syndrome is characterized by the triad of recurrent spontaneous hypothermia, hyperhidrosis, and agenesis of the corpus callosum, not necessarily the development of the nervous system and other systems as a whole.\n2. UNKNOWN: The typical neurological problems associated with Shapiro syndrome are not specified, but common features include hypo- or hyperthermia and agenesis of the corpus callosum which may lead to variable neurological problems; seizures and ataxia can occur but are not definitive.\n3. FALSE [correction]: People with Shapiro syndrome do not have a defined set of distinctive facial features; instead, the syndrome is primarily characterized by its core symptoms (hypothermia, hyperhidrosis, and agenesis of the corpus callosum).\n4. UNKNOWN: Shapiro syndrome is mainly related to neurological symptoms and agenesis of the corpus callosum; skeletal abnormalities are not typically a feature of the syndrome, though individuals may have other coincidental skeletal problems.\n5. UNKNOWN: Hearing loss is not typically described as a common feature of Shapiro syndrome. The common features are more related to temperature regulation and sweaty episodes, associated with the agenesis of the corpus callosum.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-7b-chat-hf_response": "BRAG1 (BRAG-1-related gene 1) is associated with Charcot-Marie-Tooth disease (CMT), a group of inherited disorders that affect the peripheral nervous system. Mutations in the BRAG1 gene have been identified as a cause of some forms of CMT.",
    "llama-2-7b-chat-hf_fact_raw": "1. BRAG1 is associated with Charcot-Marie-Tooth disease (CMT).\n2. Charcot-Marie-Tooth disease affects the peripheral nervous system.\n3. Mutations in the BRAG1 gene can cause some forms of Charcot-Marie-Tooth disease.",
    "llama-2-7b-chat-hf_fact": [
      "BRAG1 is associated with Charcot-Marie-Tooth disease (CMT).",
      "Charcot-Marie-Tooth disease affects the peripheral nervous system.",
      "Mutations in the BRAG1 gene can cause some forms of Charcot-Marie-Tooth disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: It is not BRAG1 but PMP22, GJB1, MFN2, MPZ, among others, that are genes more commonly associated with Charcot-Marie-Tooth disease.\n2. TRUE\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-7b-chat-hf_response": "The main inhibitor of protein phosphatase 1 (PP1) is called protein phosphatase 1 inhibitor 1 (PP1I1).",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-7b-chat-hf_response": "Adaptive mutagenesis, also known as stationary-phase mutagenesis, in Bacillus subtilis involves the mutation of genes in response to environmental stress, particularly during stationary phase. There are several mechanisms that underlie this process:\n1. DNA damage response: DNA damage can occur during stationary phase due to various factors, including the accumulation of reactive oxygen species (ROS) and the degradation of DNA repair machinery. In response to this damage, the cell activates the DNA damage response, which can lead to the mutation of nearby genes.\n2. Genomic rearrangements: During stationary phase, the cell can undergo genome rearrangements, such as gene deletions, duplications, and translocations. These events can result in the mutation of genes and lead to the adaptation of the organism to the stressful environment.\n3. RNA-mediated mutagenesis: RNA molecules, such as small RNAs and non-coding RNAs, can base-pair with specific DNA sequences and induce mutations through mechanisms such as RNA-guided DNA methylation or RNA-induced genetic silencing.\n4. Horizontal gene transfer: During stationary phase, bacteria can exchange genetic material with other cells, leading to the acquisition of new genes and mutations. This process, known as horizontal gene transfer, can provide the cell with new genetic material that can help it adapt to the stressful environment.\n5. Mutator phenotype: Some mutations can lead to a mutator phenotype, where the cell becomes more prone to mutations due to defects in DNA repair machinery. This can result in an increased ability to adapt to stressful environments through the accumulation of beneficial mutations.\nIn summary, adaptive mutagenesis in Bacillus subtilis involves a complex interplay of different mechanisms, including DNA damage response, genomic rearrangements, RNA-mediated mutagenesis, horizontal gene transfer, and mutator phenotype. These mechanisms allow the cell to adapt to stressful environments and survive in a changing environment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Adaptive mutagenesis in Bacillus subtilis involves mutation of genes in response to environmental stress during the stationary phase.\n2. DNA damage in Bacillus subtilis during stationary phase can lead to a DNA damage response that may cause the mutation of nearby genes.\n3. Genomic rearrangements in Bacillus subtilis can occur during stationary phase, resulting in gene mutations.\n4. RNA molecules in Bacillus subtilis can induce mutations through mechanisms such as RNA-guided DNA methylation or RNA-induced genetic silencing.\n5. Horizontal gene transfer during stationary phase in Bacillus subtilis enables the cell to acquire new genes and mutations.",
    "llama-2-7b-chat-hf_fact": [
      "Adaptive mutagenesis in Bacillus subtilis involves mutation of genes in response to environmental stress during the stationary phase.",
      "DNA damage in Bacillus subtilis during stationary phase can lead to a DNA damage response that may cause the mutation of nearby genes.",
      "Genomic rearrangements in Bacillus subtilis can occur during stationary phase, resulting in gene mutations.",
      "RNA molecules in Bacillus subtilis can induce mutations through mechanisms such as RNA-guided DNA methylation or RNA-induced genetic silencing.",
      "Horizontal gene transfer during stationary phase in Bacillus subtilis enables the cell to acquire new genes and mutations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Adaptive mutagenesis is a process in which organisms, including Bacillus subtilis, can increase their mutation rates in response to environmental stress, often observed during the stationary phase when resources are limited.\n2. TRUE: In Bacillus subtilis, DNA damage during the stationary phase can indeed lead to a DNA damage response, which may result in mutations.\n3. TRUE: Genomic rearrangements, such as inversions, deletions, and insertions, can occur in bacteria like Bacillus subtilis during the stationary phase and can result in gene mutations.\n4. FALSE [correction]: While RNA molecules can play various roles in gene expression regulation and can affect gene functions, RNA-guided DNA methylation and RNA-induced genetic silencing are more characteristic of eukaryotic organisms, and there is no established mechanism by which RNA molecules directly induce mutations in Bacillus subtilis through such mechanisms.\n5. TRUE: Horizontal gene transfer is a process in which bacteria, including Bacillus subtilis, can acquire new genes from other organisms, which can occur during any phase of bacterial growth, including the stationary phase. This process can lead to the acquisition of new genetic traits and mutations.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-7b-chat-hf_response": "Erucism, also known as erythrocytosis, is a condition characterized by an increase in the number of red blood cells (RBCs) in the blood. There are several possible causes of erucism, including:\n1. Genetic disorders: Some genetic disorders, such as polycythemia vera, can cause erucism.\n2. Chronic hypoxia: Prolonged exposure to low oxygen levels can stimulate the production of RBCs.\n3. Chronic inflammation: Inflammation can lead to the production of erythropoietin (EPO), a hormone that stimulates the production of RBCs.\n4. Cancer: Some types of cancer, such as kidney cancer, can cause erucism by producing EPO.\n5. Other medical conditions: Certain medical conditions, such as hypothyroidism and anemia, can also cause erucism.\n6. Medications: Certain medications, such as anabolic steroids, can increase the production of RBCs.\n7. Infections: Some infections, such as malaria, can cause erucism by stimulating the production of RBCs.\n8. Nutritional deficiencies: Deficiencies in iron, folate, and vitamin B12 can lead to erucism.\n9. Chronic fatigue syndrome: Some studies suggest that erucism may be a feature of chronic fatigue syndrome.\n10. Other factors: Other factors that may contribute to erucism include chronic stress, sleep disorders, and exposure to toxins.\nIt is important to note that the exact cause of erucism in an individual may depend on the underlying medical condition or disorder. A healthcare professional can help determine the underlying cause of erucism and develop an appropriate treatment plan.",
    "llama-2-7b-chat-hf_fact_raw": "1. Erucism is characterized by an increase in the number of red blood cells in the blood.\n2. Genetic disorders such as polycythemia vera can cause erucism.\n3. Chronic hypoxia can stimulate the production of red blood cells, leading to erucism.\n4. Chronic inflammation can lead to the production of erythropoietin (EPO), which stimulates the production of red blood cells.\n5. Certain types of cancer, like kidney cancer, can cause erucism by producing erythropoietin (EPO).",
    "llama-2-7b-chat-hf_fact": [
      "Erucism is characterized by an increase in the number of red blood cells in the blood.",
      "Genetic disorders such as polycythemia vera can cause erucism.",
      "Chronic hypoxia can stimulate the production of red blood cells, leading to erucism.",
      "Chronic inflammation can lead to the production of erythropoietin (EPO), which stimulates the production of red blood cells.",
      "Certain types of cancer, like kidney cancer, can cause erucism by producing erythropoietin (EPO)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Erucism is not characterized by an increase in the number of red blood cells; it is the term for the adverse reaction caused by caterpillar or moth larvae hairs. The correct term for an increase in the number of red blood cells is erythrocytosis or polycythemia.\n2. FALSE [correction]: Genetic disorders such as polycythemia vera can cause erythrocytosis or polycythemia, not erucism.\n3. FALSE [correction]: Chronic hypoxia can stimulate the production of red blood cells, leading to erythrocytosis or polycythemia, not erucism.\n4. TRUE: Chronic inflammation can indeed lead to the production of erythropoietin (EPO), which stimulates the production of red blood cells.\n5. TRUE: Certain types of cancer, like kidney cancer, can cause erythrocytosis by producing erythropoietin (EPO), though the term 'erucism' is not correct for this condition.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-7b-chat-hf_response": "Hydrochlorothiazide (HCTZ) is a diuretic medication that is commonly used to treat a variety of conditions, including:\n1. Hypertension (high blood pressure): HCTZ is used to lower blood pressure in patients with mild to moderate hypertension.\n2. Heart failure: HCTZ can help reduce fluid buildup and improve symptoms in patients with heart failure.\n3. Edema (swelling): HCTZ is used to treat edema (swelling) caused by fluid buildup in the body, which can occur due to various conditions such as liver disease, kidney disease, or cancer.\n4. Nephrotic syndrome: HCTZ can help reduce the amount of protein lost in the urine in patients with nephrotic syndrome, a condition characterized by excessive protein loss in the urine.\n5. Diabetic nephropathy: HCTZ can help slow the progression of diabetic nephropathy, a complication of diabetes that can lead to kidney damage and failure.\n6. Renal tubular acidosis: HCTZ can help correct the acid-base balance in the body by increasing the excretion of hydrogen ions in the urine.\n7. Cystinuria: HCTZ can help reduce the amount of cystine in the urine in patients with cystinuria, a condition that causes cystine to be excreted in the urine.\n8. Hyperaldosteronism: HCTZ can help reduce the amount of aldosterone in the body, which can help treat conditions such as primary aldosteronism and secondary aldosteronism.\n9. Hypokalemia: HCTZ can help increase potassium levels in the body, which can help treat hypokalemia (low potassium levels).\n10. Other conditions: HCTZ may also be used to treat other conditions such as migraines, urticaria, and angioedema.\nIt is important to note that HCTZ may have different indications and contraindications in different countries and regions, and it is always best to consult with a healthcare professional for specific information and advice.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrochlorothiazide (HCTZ) is used to treat hypertension (high blood pressure).\n2. Hydrochlorothiazide can be used to reduce fluid buildup and improve symptoms in patients with heart failure.\n3. Hydrochlorothiazide is indicated for the treatment of edema caused by various conditions such as liver disease, kidney disease, or cancer.\n4. Hydrochlorothiazide can assist in reducing the amount of protein lost in the urine for patients with nephrotic syndrome.\n5. Hydrochlorothiazide is sometimes used to slow the progression of diabetic nephropathy.",
    "llama-2-7b-chat-hf_fact": [
      "Hydrochlorothiazide (HCTZ) is used to treat hypertension (high blood pressure).",
      "Hydrochlorothiazide can be used to reduce fluid buildup and improve symptoms in patients with heart failure.",
      "Hydrochlorothiazide is indicated for the treatment of edema caused by various conditions such as liver disease, kidney disease, or cancer.",
      "Hydrochlorothiazide can assist in reducing the amount of protein lost in the urine for patients with nephrotic syndrome.",
      "Hydrochlorothiazide is sometimes used to slow the progression of diabetic nephropathy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Hydrochlorothiazide is not typically used to reduce the amount of protein lost in the urine for patients with nephrotic syndrome. Other medications, such as ACE inhibitors or ARBs, are more commonly used for this purpose.\n5. FALSE [correction]: Hydrochlorothiazide is not specifically used to slow the progression of diabetic nephropathy. ACE inhibitors or ARBs are the preferred options for this condition to protect kidney function.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-7b-chat-hf_response": "Yes, silicon has been used in the treatment of incontinence. Silicon-based materials have been developed and used in various applications, including:\n1. Urinary incontinence: Silicon-based materials have been used to create devices that can help to strengthen the muscles in the pelvic floor, which can help to improve bladder control and reduce the risk of incontinence.\n2. Prostate surgery: Silicon-based materials have been used to create devices that can help to reduce the risk of complications during prostate surgery, such as urinary incontinence.\n3. Wound healing: Silicon-based materials have been used to create devices that can help to promote wound healing and reduce the risk of infection.\n4. Bone grafting: Silicon-based materials have been used to create devices that can help to promote bone growth and healing in the treatment of bone fractures and other bone disorders.\n5. Drug delivery: Silicon-based materials have been used to create devices that can help to deliver drugs in a targeted and controlled manner, which can help to improve the effectiveness of treatments and reduce the risk of side effects.\n6. Cancer treatment: Silicon-based materials have been used to create devices that can help to deliver drugs directly to cancer cells, which can help to improve the effectiveness of treatments and reduce the risk of side effects.\n7. Neurological disorders: Silicon-based materials have been used to create devices that can help to treat neurological disorders, such as epilepsy and Parkinson's disease.\n8. Cardiovascular disease: Silicon-based materials have been used to create devices that can help to treat cardiovascular disease, such as heart failure and atherosclerosis.\n9. Ophthalmic disorders: Silicon-based materials have been used to create devices that can help to treat ophthalmic disorders, such as cataracts and glaucoma.\n10. Orthopedic disorders: Silicon-based materials have been used to create devices that can help to treat orthopedic disorders, such as osteoarthritis and fractures.\nIt is important to note that the use of silicon-",
    "llama-2-7b-chat-hf_fact_raw": "1. Silicon-based materials have been developed for use in devices to strengthen muscles in the pelvic floor for the treatment of urinary incontinence.\n2. Silicon-based materials have been used in devices to reduce the risk of urinary incontinence post-prostate surgery.\n3. Silicon-based materials have been used in devices that promote wound healing and reduce infection risks.\n4. Silicon-based materials have been utilized in the creation of devices that aid in bone growth and healing for bone fractures and disorders.\n5. Silicon-based materials have been involved in the manufacturing of devices for targeted drug delivery to improve treatment efficacy and minimize side effects.",
    "llama-2-7b-chat-hf_fact": [
      "Silicon-based materials have been developed for use in devices to strengthen muscles in the pelvic floor for the treatment of urinary incontinence.",
      "Silicon-based materials have been used in devices to reduce the risk of urinary incontinence post-prostate surgery.",
      "Silicon-based materials have been used in devices that promote wound healing and reduce infection risks.",
      "Silicon-based materials have been utilized in the creation of devices that aid in bone growth and healing for bone fractures and disorders.",
      "Silicon-based materials have been involved in the manufacturing of devices for targeted drug delivery to improve treatment efficacy and minimize side effects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nSilicon-based materials are widely used in the medical field and the statements given are consistent with their known applications. Silicones are known for their versatility and biocompatibility, making them suitable for various uses like strengthening muscles in the pelvic floor, reducing incontinence post-prostate surgery, promoting wound healing, aiding in bone growth and healing, and in targeted drug delivery systems. However, it is important to note that the specific applications and effectiveness of these materials can vary based on the device design and clinical use.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-7b-chat-hf_response": "There is a potential association between the moon cycle and the rupture risk of intracranial aneurysms. Some studies have suggested that the incidence of rupture of intracranial aneurysms may be higher during the full moon than during other times of the month. This phenomenon has been observed in several studies, including a 2017 meta-analysis of 14 observational studies that found a significant association between the full moon and rupture of intracranial aneurysms.\nThe exact mechanism behind this association is not fully understood, but several theories have been proposed. One theory is that the increased blood pressure during the full moon, caused by the gravitational pull of the moon, may increase the pressure within an intracranial aneurysm and increase the likelihood of rupture. Another theory is that the changes in blood flow and vessel diameter that occur during the full moon may affect the stability of the aneurysm wall and increase the risk of rupture.\nIt is important to note that the association between the moon cycle and rupture risk of intracranial aneurysms is still a topic of debate, and more research is needed to confirm these findings and to understand the underlying mechanisms. Additionally, it is important to note that the risk of rupture of an intracranial aneurysm is not directly related to the moon cycle, and other factors such as the size and location of the aneurysm, as well as the patient's age and medical history, are much more important in determining the risk of rupture.",
    "llama-2-7b-chat-hf_fact_raw": "1. Some studies have observed a potential association between the moon cycle and the rupture risk of intracranial aneurysms.\n2. There is a suggestion that the incidence of intracranial aneurysm rupture may be higher during the full moon than at other times of the month.\n3. A 2017 meta-analysis of 14 observational studies found a significant association between the full moon and rupture of intracranial aneurysms.\n4. Theories exist that propose a potential influence of the moon cycle on blood pressure and blood flow, which could affect the stability of an intracranial aneurysm.\n5. Despite observations, the association between the moon cycle and rupture risk of intracranial aneurysms is a debated topic and requires further research for confirmation.",
    "llama-2-7b-chat-hf_fact": [
      "Some studies have observed a potential association between the moon cycle and the rupture risk of intracranial aneurysms.",
      "There is a suggestion that the incidence of intracranial aneurysm rupture may be higher during the full moon than at other times of the month.",
      "A 2017 meta-analysis of 14 observational studies found a significant association between the full moon and rupture of intracranial aneurysms.",
      "Theories exist that propose a potential influence of the moon cycle on blood pressure and blood flow, which could affect the stability of an intracranial aneurysm.",
      "Despite observations, the association between the moon cycle and rupture risk of intracranial aneurysms is a debated topic and requires further research for confirmation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-7b-chat-hf_response": "No, HuR protein does not directly regulate the splicing process. HuR (also known as ELAVL1) is a protein that is involved in the regulation of mRNA stability and translation, but it does not play a role in the splicing process. Splicing is the process by which introns (non-coding regions) are removed from pre-mRNA and exons (coding regions) are joined together to form mature mRNA. HuR protein is involved in the regulation of mRNA stability and translation by binding to specific sequences in the 3' untranslated region (UTR) of target mRNAs and preventing their degradation.",
    "llama-2-7b-chat-hf_fact_raw": "1. HuR protein, also known as ELAVL1, does not directly regulate the splicing process.\n2. HuR protein is involved in the regulation of mRNA stability and translation.\n3. Splicing is the process by which introns are removed from pre-mRNA and exons are joined together to form mature mRNA.\n4. HuR protein regulates mRNA by binding to specific sequences in the 3' untranslated region (UTR) of target mRNAs.\n5. HuR protein's binding to target mRNAs prevents their degradation.",
    "llama-2-7b-chat-hf_fact": [
      "HuR protein, also known as ELAVL1, does not directly regulate the splicing process.",
      "HuR protein is involved in the regulation of mRNA stability and translation.",
      "Splicing is the process by which introns are removed from pre-mRNA and exons are joined together to form mature mRNA.",
      "HuR protein regulates mRNA by binding to specific sequences in the 3' untranslated region (UTR) of target mRNAs.",
      "HuR protein's binding to target mRNAs prevents their degradation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: HuR protein, or ELAVL1, is primarily known for its role in regulating mRNA stability and translation and does not directly regulate splicing. \n2. TRUE: HuR protein is indeed involved in the regulation of mRNA stability and translation.\n3. TRUE: Splicing is accurately described as the process of removing introns from pre-mRNA and joining exons to form mature mRNA.\n4. TRUE: HuR protein is known to regulate mRNA by binding to specific sequences often found in the 3' UTR of target mRNAs.\n5. TRUE: One of the functions of HuR protein binding to target mRNAs is to typically prevent their degradation.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-7b-chat-hf_response": "Prothymosin alpha (ProT) is a small protein that plays a crucial role in the regulation of various cellular processes, including cell proliferation, differentiation, and survival. The c-terminal peptide of ProT, also known as ProT-CT, has been shown to have several distinct functions:\n1. Cell cycle regulation: ProT-CT can inhibit the activity of cyclin-dependent kinases (CDKs), which are key regulators of the cell cycle, thereby arresting the cell cycle at the G1/S transition.\n2. Apoptosis: ProT-CT has been shown to inhibit the induction of apoptosis by various pro-apoptotic factors, such as Bax and Bak, and can protect cells against chemotherapy-induced apoptosis.\n3. DNA damage response: ProT-CT can repair DNA double-strand breaks by interacting with the Ku70/80 complex and promoting the assembly of the DNA repair machinery.\n4. Nuclear factor kappa B (NF-κB) activation: ProT-CT can inhibit the activation of NF-κB, a transcription factor that regulates the expression of genes involved in inflammation and immune response.\n5. Autophagy: ProT-CT has been shown to inhibit autophagy, a cellular process that helps to maintain cellular homeostasis by degrading damaged or dysfunctional cellular components.\n6. Stem cell maintenance: ProT-CT has been shown to promote the maintenance of stem cells by inhibiting the differentiation of stem cells and promoting their proliferation.\n7. Tumor suppressor activity: ProT-CT has been shown to have tumor suppressor activity in various cancer models, and it is thought to play a role in the regulation of cellular processes that are involved in cancer development and progression.\nIn summary, ProT-CT has a wide range of functions in the cell, including cell cycle regulation, apoptosis, DNA damage response, NF-κB activation, autophagy, stem cell maintenance, and tumor suppressor activity.",
    "llama-2-7b-chat-hf_fact_raw": "1. The c-terminal peptide of Prothymosin alpha, ProT-CT, can inhibit the activity of cyclin-dependent kinases and arrest the cell cycle at the G1/S transition.\n2. ProT-CT has been shown to inhibit the induction of apoptosis by pro-apoptotic factors.\n3. ProT-CT can repair DNA double-strand breaks by interacting with the Ku70/80 complex.\n4. ProT-CT can inhibit the activation of the transcription factor Nuclear factor kappa B (NF-κB).\n5. ProT-CT has been shown to inhibit autophagy.",
    "llama-2-7b-chat-hf_fact": [
      "The c-terminal peptide of Prothymosin alpha, ProT-CT, can inhibit the activity of cyclin-dependent kinases and arrest the cell cycle at the G1/S transition.",
      "ProT-CT has been shown to inhibit the induction of apoptosis by pro-apoptotic factors.",
      "ProT-CT can repair DNA double-strand breaks by interacting with the Ku70/80 complex.",
      "ProT-CT can inhibit the activation of the transcription factor Nuclear factor kappa B (NF-κB).",
      "ProT-CT has been shown to inhibit autophagy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Prothymosin alpha (ProTα) is a nuclear protein implicated in cell proliferation, and its c-terminal peptide, ProT-CT, can indeed inhibit cyclin-dependent kinases (CDKs), which are critical regulators of the cell cycle, thereby arresting the cell cycle at the G1/S transition.\n\n2. TRUE: ProT-CT has been reported to inhibit the induction of apoptosis by various pro-apoptotic factors, which suggests that ProT-CT could have cytoprotective properties.\n\n3. UNKNOWN: The interaction of ProT-CT with the Ku70/80 complex, which plays a role in non-homologous end joining (NHEJ), a pathway for repairing DNA double-strand breaks (DSBs), is specific and requires additional scientific references to confirm or deny.\n\n4. TRUE: ProT-CT has been shown in some studies to inhibit the activation of NF-κB, which is a transcription factor involved in the regulation of immune response, cell survival, and other essential cellular processes.\n\n5. UNKNOWN: The effect of ProT-CT on autophagy is not widely established or may be context-dependent. Additional information would be required to accurately determine the truth of this statement.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-7b-chat-hf_response": "The peptide that plays a pivotal role in human cystatin C fibrillization is the amino acid sequence RRQARRR.",
    "llama-2-7b-chat-hf_fact_raw": "1. The peptide that plays a pivotal role in human cystatin C fibrillization is the amino acid sequence RRQARRR.",
    "llama-2-7b-chat-hf_fact": [
      "The peptide that plays a pivotal role in human cystatin C fibrillization is the amino acid sequence RRQARRR."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The peptide that plays a pivotal role in human cystatin C fibrillization is the amino acid sequence LVEALYL.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-7b-chat-hf_response": "Yes, the concentration of protein HIF-1α increases after the administration of the cytoprotective prodrug ethyol (amifostine). Ethyol is a prodrug that is converted into the active compound amifostine, which has been shown to increase the expression of hypoxia-inducible factor 1 alpha (HIF-1α) in various cell types, including cancer cells. HIF-1α is a transcription factor that plays a critical role in response to hypoxia and is involved in the regulation of various cellular processes, including angiogenesis, glucose metabolism, and cell survival.",
    "llama-2-7b-chat-hf_fact_raw": "1. The concentration of protein HIF-1α increases after the administration of the prodrug ethyol (amifostine).\n2. Ethyol is converted into the active compound amifostine.\n3. Amifostine has been shown to increase the expression of hypoxia-inducible factor 1 alpha (HIF-1α) in various cell types.\n4. Hypoxia-inducible factor 1 alpha (HIF-1α) is a transcription factor involved in the cellular response to hypoxia.\n5. HIF-1α regulates various cellular processes, including angiogenesis, glucose metabolism, and cell survival.",
    "llama-2-7b-chat-hf_fact": [
      "The concentration of protein HIF-1α increases after the administration of the prodrug ethyol (amifostine).",
      "Ethyol is converted into the active compound amifostine.",
      "Amifostine has been shown to increase the expression of hypoxia-inducible factor 1 alpha (HIF-1α) in various cell types.",
      "Hypoxia-inducible factor 1 alpha (HIF-1α) is a transcription factor involved in the cellular response to hypoxia.",
      "HIF-1α regulates various cellular processes, including angiogenesis, glucose metabolism, and cell survival."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific scientific research or data referenced, it's not possible to verify whether the concentration of HIF-1α increases after the administration of the prodrug ethyol (amifostine).\n2. FALSE [correction]: Ethyol is another name for the drug amifostine. It is not converted into amifostine because ethyol and amifostine are the same compound. Amifostine is converted by alkaline phosphatase enzymes into its active form, WR-1065, in tissues.\n3. UNKNOWN: The statement may be true, but specific studies or evidence need to be cited to confirm that amifostine increases the expression of HIF-1α in various cell types.\n4. TRUE: Hypoxia-inducible factor 1 alpha (HIF-1α) is indeed a transcription factor that plays a key role in the cellular response to hypoxia.\n5. TRUE: HIF-1α is known to regulate various cellular processes, including angiogenesis (the formation of new blood vessels), glucose metabolism, and cell survival, particularly under hypoxic conditions.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-7b-chat-hf_response": "Set7 is a histone methyltransferase that deposits histone H3 lysine 4 trimethylation (H3K4me3) marks on histone H3.",
    "llama-2-7b-chat-hf_fact_raw": "1. Set7 is a histone methyltransferase.\n2. Set7 deposits histone H3 lysine 4 trimethylation (H3K4me3) marks.\n3. These marks are deposited on histone H3.",
    "llama-2-7b-chat-hf_fact": [
      "Set7 is a histone methyltransferase.",
      "Set7 deposits histone H3 lysine 4 trimethylation (H3K4me3) marks.",
      "These marks are deposited on histone H3."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Set7 deposits histone H3 lysine 4 monomethylation (H3K4me1) marks.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-7b-chat-hf_response": "Hepcidin is a protein that is involved in the regulation of iron metabolism, and it has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hepcidin is a protein involved in the regulation of iron metabolism.\n2. Hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact": [
      "Hepcidin is a protein involved in the regulation of iron metabolism.",
      "Hepcidin has 4 disulfide bridges."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Hepcidin typically has 8 cysteine residues that form 4 disulfide bridges.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-7b-chat-hf_response": "The protein encoded by the gene DNAJC11 is localized to the mitochondria.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein encoded by the gene DNAJC11 is localized to the mitochondria.",
    "llama-2-7b-chat-hf_fact": [
      "The protein encoded by the gene DNAJC11 is localized to the mitochondria."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n\nExplanation: Without specific information on the gene DNAJC11 and its protein product, I cannot confirm the localization of its protein. Proteins encoded by genes can have various localizations within a cell, and localization generally requires experimental evidence or reference to authoritative scientific databases or literature.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-7b-chat-hf_response": "Yes, ultraconserved elements (UCEs) are depleted among copy number variants (CNVs). CNVs are genomic regions that are duplicated or deleted in a copy number manner, and they often involve genes that are important for various biological processes. UCEs, on the other hand, are short, highly conserved sequences that are found throughout the genome and are thought to be involved in regulating gene expression.\nStudies have shown that UCEs are enriched in regions of the genome that are not affected by CNVs, suggesting that these elements are less likely to be disrupted by copy number changes. In fact, one study found that UCEs were depleted among CNVs in a sample of individuals with intellectual disability, suggesting that these elements may be particularly important for maintaining genome stability.\nThe reason why UCEs are depleted among CNVs is not fully understood, but it is thought to be related to the fact that UCEs are often located in regions of the genome that are highly conserved across species, and that CNVs are more likely to occur in regions that are less conserved. Additionally, UCEs may be more sensitive to changes in copy number due to their high conservation, which could make them more prone to disruption by CNVs.\nOverall, the depletion of UCEs among CNVs suggests that these elements play a critical role in maintaining genome stability and that their disruption may have important consequences for human health.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ultraconserved elements (UCEs) are depleted among copy number variants (CNVs).\n2. CNVs can involve genomic regions that are important for various biological processes.\n3. UCEs are short, highly conserved sequences thought to be involved in regulating gene expression.\n4. Studies have indicated that UCEs are enriched in regions of the genome that are not affected by CNVs.\n5. A study found that UCEs were depleted among CNVs in a sample of individuals with intellectual disability.",
    "llama-2-7b-chat-hf_fact": [
      "Ultraconserved elements (UCEs) are depleted among copy number variants (CNVs).",
      "CNVs can involve genomic regions that are important for various biological processes.",
      "UCEs are short, highly conserved sequences thought to be involved in regulating gene expression.",
      "Studies have indicated that UCEs are enriched in regions of the genome that are not affected by CNVs.",
      "A study found that UCEs were depleted among CNVs in a sample of individuals with intellectual disability."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Ultraconserved elements (UCEs) are indeed known to be depleted among copy number variants (CNVs), as they are highly conserved sequences that are under strong selective pressure. This means changes, including CNVs, are less likely to occur within these regions.\n2. TRUE: CNVs can involve genomic regions that are essential for a range of biological processes, including development, immune system function, and more. They may contribute to genetic diversity as well as various diseases.\n3. TRUE: UCEs are short, highly conserved sequences across different species, and they are thought to play a role in gene regulation.\n4. TRUE: Due to their high level of conservation and importance in regulatory functions, studies have indicated that UCEs tend to be enriched in regions of the genome that CNVs less frequently affect.\n5. TRUE: If this statement is referencing a specific study, and such a study exists and found that UCEs were indeed depleted among CNVs in a sample of people with intellectual disability, this would be consistent with the understanding that UCEs are generally underrepresented in CNVs. This specific assertion would need to be verified by the actual study, but the general concept aligns with current scientific knowledge about UCEs and CNVs.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-7b-chat-hf_response": "Has2 (Haspin) is a kinase that plays a crucial role in the regulation of mitotic progression. The substrate of Has2 during mitosis is the protein Kinase A (PKA). Has2 phosphorylates and activates PKA, which in turn regulates various cellular processes during mitosis, including the progression from G2/M phase to M phase.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-7b-chat-hf_response": "Viroid replication is a unique mechanism of replication that does not involve the synthesis of new DNA or RNA. Instead, viroids replicate by recombination, a process in which the viroid molecule is broken and then reassembled into a new molecule. This process occurs through a mechanism that is not yet fully understood and is thought to involve the interaction of viroids with host cell factors.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-7b-chat-hf_response": "Fibronectin is not a commonly used serum biomarker for Duchenne muscular dystrophy (DMD). While fibronectin is a protein that is involved in various cellular processes, including cell adhesion and migration, its levels in the blood are not typically used as a diagnostic marker for DMD.\nThere are several established serum biomarkers for DMD, including:\n1. Dystrophin: The lack of dystrophin protein in the muscles of individuals with DMD is a hallmark of the disease. Measuring the levels of dystrophin in the blood can help diagnose DMD and monitor the progression of the disease.\n2. CK: Creatine kinase (CK) is an enzyme that is involved in muscle metabolism. Elevated levels of CK in the blood can indicate muscle damage or disease, including DMD.\n3. CK-MB: Creatine kinase-MB (CK-MB) is a specific isoform of CK that is primarily found in the heart. Elevated levels of CK-MB in the blood can indicate muscle damage or disease, including DMD.\n4. Lactate dehydrogenase (LDH): LDH is an enzyme that is involved in muscle metabolism. Elevated levels of LDH in the blood can indicate muscle damage or disease, including DMD.\n5. Aldolase: Aldolase is an enzyme that is involved in glycolysis. Elevated levels of aldolase in the blood can indicate muscle damage or disease, including DMD.\nIt is important to note that these biomarkers are not specific to DMD and can be elevated in other muscle disorders or conditions. Therefore, a comprehensive diagnostic evaluation, including clinical evaluation, imaging studies, and genetic testing, is necessary for accurate diagnosis and management of DMD.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fibronectin is not a commonly used serum biomarker for Duchenne muscular dystrophy (DMD).\n2. Measuring the levels of dystrophin in the blood can help diagnose DMD and monitor the progression of the disease.\n3. Elevated levels of creatine kinase (CK) in the blood can indicate muscle damage or disease, including DMD.\n4. Creatine kinase-MB (CK-MB) is an isoform of CK that is primarily found in the heart, and elevated levels can indicate muscle damage or disease, including DMD.\n5. Elevated levels of lactate dehydrogenase (LDH) in the blood can indicate muscle damage or disease, including DMD.",
    "llama-2-7b-chat-hf_fact": [
      "Fibronectin is not a commonly used serum biomarker for Duchenne muscular dystrophy (DMD).",
      "Measuring the levels of dystrophin in the blood can help diagnose DMD and monitor the progression of the disease.",
      "Elevated levels of creatine kinase (CK) in the blood can indicate muscle damage or disease, including DMD.",
      "Creatine kinase-MB (CK-MB) is an isoform of CK that is primarily found in the heart, and elevated levels can indicate muscle damage or disease, including DMD.",
      "Elevated levels of lactate dehydrogenase (LDH) in the blood can indicate muscle damage or disease, including DMD."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Fibronectin is not commonly listed among the primary serum biomarkers for Duchenne muscular dystrophy (DMD). Biomarkers such as creatine kinase (CK) are more commonly used to detect muscle damage related to DMD.\n2. FALSE [correction]: Measuring the levels of dystrophin in the blood is not practical for diagnosing DMD or monitoring its progression, because dystrophin is located within muscle cells and is typically not found in the blood. Genetic testing and muscle biopsy are common methods for diagnosing DMD.\n3. TRUE: Elevated levels of creatine kinase (CK) are indeed indicative of muscle damage and are commonly used as a biomarker for muscle diseases, including DMD, as CK leaks into the blood when muscle fibers are damaged.\n4. TRUE: Creatine kinase-MB (CK-MB) is an isoform of CK that is primarily found in cardiac muscle, and elevated levels are often associated with heart damage. However, because patients with DMD can develop cardiac muscle damage, CK-MB can also be elevated in the context of this disease, although it is not as specific for skeletal muscle damage as other CK isoforms.\n5. TRUE: Elevated levels of lactate dehydrogenase (LDH) in the blood can be a sign of muscle damage or disease, including DMD. LDH is found in many types of body tissues, including muscle, and elevated levels may indicate tissue damage.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-7b-chat-hf_response": "The DeepBlue epigenomic data server contains data from several major epigenome projects, including:\n1. The ENCODE (ENCyclopedia Of DNA Elements) Project: This project is a large-scale effort to map all of the functional elements in the human genome.\n2. The Roadmap Epigenomics Project: This project aims to create a comprehensive map of the epigenetic marks on the human genome and their functional implications.\n3. The Epigenome-wide Association Study (EWAS) Project: This project involves scanning the entire genome for epigenetic marks that are associated with specific diseases or traits.\n4. The Human Epigenome Project: This project aims to create a comprehensive map of the epigenetic marks on the human genome and their functional implications.\n5. The Mouse Epigenome Project: This project aims to create a comprehensive map of the epigenetic marks on the mouse genome and their functional implications.\n6. The Arabidopsis Epigenome Project: This project aims to create a comprehensive map of the epigenetic marks on the Arabidopsis thaliana genome and their functional implications.\n7. The Yeast Epigenome Project: This project aims to create a comprehensive map of the epigenetic marks on the Saccharomyces cerevisiae genome and their functional implications.\n8. The Drosophila Epigenome Project: This project aims to create a comprehensive map of the epigenetic marks on the Drosophila melanogaster genome and their functional implications.\n9. The Zebrafish Epigenome Project: This project aims to create a comprehensive map of the epigenetic marks on the Danio rerio genome and their functional implications.\n10. The Human Placenta Epigenome Project: This project aims to create a comprehensive map of the epigenetic marks on the human placenta and their functional implications.\nThese projects have generated a large amount of data on the epigenetic marks present in various organisms, including their distribution, distribution, and functional implications. The data from these projects are stored in the DeepBlue epigenomic data server and are available for researchers to access and analyze.",
    "llama-2-7b-chat-hf_fact_raw": "1. The DeepBlue epigenomic data server contains data from the ENCODE (ENCyclopedia Of DNA Elements) Project.\n2. The Roadmap Epigenomics Project data is included in the DeepBlue epigenomic data server.\n3. The DeepBlue epigenomic data server holds data from the Epigenome-wide Association Study (EWAS) Project.\n4. The Human Epigenome Project data is available in the DeepBlue epigenomic data server.\n5. The Mouse Epigenome Project is one of the epigenome projects whose data is stored in the DeepBlue epigenomic data server.",
    "llama-2-7b-chat-hf_fact": [
      "The DeepBlue epigenomic data server contains data from the ENCODE (ENCyclopedia Of DNA Elements) Project.",
      "The Roadmap Epigenomics Project data is included in the DeepBlue epigenomic data server.",
      "The DeepBlue epigenomic data server holds data from the Epigenome-wide Association Study (EWAS) Project.",
      "The Human Epigenome Project data is available in the DeepBlue epigenomic data server.",
      "The Mouse Epigenome Project is one of the epigenome projects whose data is stored in the DeepBlue epigenomic data server."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements about the specific contents of the DeepBlue epigenomic data server would require up-to-date information about the server's data holdings or an authoritative source to confirm which projects' data it includes. If it's widely known that the server contains data from ENCODE and the Roadmap Epigenomics Project, then these statements can be considered true. However, without more information on the inclusion of data from the EWAS Project, the Human Epigenome Project, and the Mouse Epigenome Project, the veracity of these statements cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-7b-chat-hf_response": "The tool that employs self-organizing maps for analyzing synonymous codon usage is called \"CodonVar.\"",
    "llama-2-7b-chat-hf_fact_raw": "1. \"CodonVar\" is a tool that employs self-organizing maps for analyzing synonymous codon usage.",
    "llama-2-7b-chat-hf_fact": [
      "\"CodonVar\" is a tool that employs self-organizing maps for analyzing synonymous codon usage."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-7b-chat-hf_response": "MINDY-1 (Microtubule-Associated Protein 1 light chain 1, also known as EB1) is a protein that plays a crucial role in the regulation of microtubule dynamics and cellular behavior. It is a plus-end tracking protein that binds to the plus ends of microtubules and helps to maintain their stability and organization. MINDY-1 has been implicated in various cellular processes, including cell division, intracellular transport, and cell signaling. It is also a potential therapeutic target for various diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. MINDY-1 is a protein involved in the regulation of microtubule dynamics and cellular behavior.\n2. It is also known as Microtubule-Associated Protein 1 light chain 3, or EB1.\n3. MINDY-1 functions as a plus-end tracking protein that binds to the plus ends of microtubules.\n4. The protein is involved in cellular processes like cell division, intracellular transport, and cell signaling.\n5. MINDY-1 is considered a potential therapeutic target for diseases such as cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact": [
      "MINDY-1 is a protein involved in the regulation of microtubule dynamics and cellular behavior.",
      "It is also known as Microtubule-Associated Protein 1 light chain 3, or EB1.",
      "MINDY-1 functions as a plus-end tracking protein that binds to the plus ends of microtubules.",
      "The protein is involved in cellular processes like cell division, intracellular transport, and cell signaling.",
      "MINDY-1 is considered a potential therapeutic target for diseases such as cancer and neurodegenerative disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: Microtubule-Associated Protein 1 light chain 3, or LC3, is associated with autophagy and is different from EB1 which is an abbreviation for End Binding 1, a protein that associates with the plus ends of microtubules. Neither of these is the same as MINDY-1.\n3. FALSE [correction]: MINDY-1 is not reported as a plus-end tracking protein. This functionality is characteristic of proteins such as EB1. MINDY-1's exact function in microtubule dynamics needs specific clarification, but based on its name, it is not typically associated with this function.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-7b-chat-hf_response": "There are several software packages available for the analysis of conserved genomic loci, including:\n1. PhyloBayes: A Bayesian phylogenetic software package for inferring the evolutionary history of genomic regions.\n2. PhastCons: A program for inferring conserved non-coding sequences in a genome.\n3. GERP: A program for identifying conserved genomic regions based on a hidden Markov model.\n4. ConServ: A tool for identifying conserved genomic regions and predicting their functional implications.\n5. Prodigal: A program for predicting conserved non-coding RNA elements in a genome.\n6. CNS: A tool for identifying conserved non-coding RNA elements in a genome.\n7. PANTHER: A program for identifying conserved non-coding RNA elements and predicting their functional implications.\n8. HMMER: A program for identifying conserved genomic regions using a hidden Markov model.\n9. MUSCLE: A multiple sequence alignment tool that can be used to identify conserved genomic regions.\n10. MAFFT: A multiple sequence alignment tool that can be used to identify conserved genomic regions.\nThese software packages can be used to identify and analyze conserved genomic loci, and to predict their functional implications.",
    "llama-2-7b-chat-hf_fact_raw": "1. PhyloBayes is a software package designed for Bayesian phylogenetic analyses of genomic regions.\n2. PhastCons is used for inferring conserved non-coding sequences in genomes.\n3. GERP is a program that identifies conserved genomic regions using a hidden Markov model.\n4. MUSCLE is a multiple sequence alignment tool that can identify conserved genomic regions.\n5. MAFFT is also a multiple sequence alignment tool used for identifying conserved genomic regions.",
    "llama-2-7b-chat-hf_fact": [
      "PhyloBayes is a software package designed for Bayesian phylogenetic analyses of genomic regions.",
      "PhastCons is used for inferring conserved non-coding sequences in genomes.",
      "GERP is a program that identifies conserved genomic regions using a hidden Markov model.",
      "MUSCLE is a multiple sequence alignment tool that can identify conserved genomic regions.",
      "MAFFT is also a multiple sequence alignment tool used for identifying conserved genomic regions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: MUSCLE is a multiple sequence alignment tool, but it is not specifically for identifying conserved genomic regions. Instead, it aligns sequences based on their evolutionary relationships.\n5. FALSE [correction]: MAFFT is a multiple sequence alignment tool, but like MUSCLE, it is not designed specifically to identify conserved genomic regions, although aligned sequences can be analyzed to infer conservation.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_response": "The PIEZO2 gene has been associated with several diseases, including:\n1. Hypertension: Mutations in the PIEZO2 gene have been identified as a cause of hypertension, a condition characterized by high blood pressure.\n2. Nephrocalcinosis: PIEZO2 mutations can lead to an accumulation of calcium in the kidneys, a condition known as nephrocalcinosis, which can cause kidney damage and disease.\n3. Kidney disease: PIEZO2 mutations have been linked to various kidney diseases, including chronic kidney disease and end-stage renal disease.\nPlease note that this is not an exhaustive list, and PIEZO2 mutations may be associated with other diseases as well.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the PIEZO2 gene have been identified as a cause of hypertension.\n2. PIEZO2 mutations can lead to nephrocalcinosis, a condition where calcium accumulates in the kidneys.\n3. Variants of the PIEZO2 gene have been linked to various kidney diseases, including chronic kidney disease and end-stage renal disease.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the PIEZO2 gene have been identified as a cause of hypertension.",
      "PIEZO2 mutations can lead to nephrocalcinosis, a condition where calcium accumulates in the kidneys.",
      "Variants of the PIEZO2 gene have been linked to various kidney diseases, including chronic kidney disease and end-stage renal disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations in the PIEZO2 gene have been identified as a cause of certain musculoskeletal and neurological disorders, not hypertension.\n2. UNKNOWN\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-7b-chat-hf_response": "ERAP1-ERAP2 dimerization promotes the efficient processing of double-stranded RNA (dsRNA) to small interfering RNA (siRNA) and microRNA (miRNA), which are important for RNA interference (RNAi) and the regulation of gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-7b-chat-hf_response": "R-spondin 1 and Noggin are both involved in the regulation of BMP signaling, which is important for the proper development and maintenance of the gallbladder. In non-damaged gallbladders, R-spondin 1 and Noggin work together to regulate the proliferation and differentiation of gallbladder epithelial cells, and to maintain the proper structure and function of the gallbladder. Specifically, R-spondin 1 promotes the proliferation of gallbladder epithelial cells, while Noggin inhibits their differentiation. This balance of R-spondin 1 and Noggin activity is important for the proper maintenance of the gallbladder and its ability to store and release bile in response to nutrient availability.",
    "llama-2-7b-chat-hf_fact_raw": "1. R-spondin 1 and Noggin regulate BMP signaling in the gallbladder.\n2. The regulation of BMP signaling by R-spondin 1 and Noggin is important for the proper development and maintenance of the gallbladder.\n3. In non-damaged gallbladders, R-spondin 1 promotes the proliferation of gallbladder epithelial cells.\n4. Noggin inhibits the differentiation of gallbladder epithelial cells in non-damaged gallbladders.\n5. The balance between R-spondin 1 and Noggin activities is crucial for the gallbladder's function to store and release bile.",
    "llama-2-7b-chat-hf_fact": [
      "R-spondin 1 and Noggin regulate BMP signaling in the gallbladder.",
      "The regulation of BMP signaling by R-spondin 1 and Noggin is important for the proper development and maintenance of the gallbladder.",
      "In non-damaged gallbladders, R-spondin 1 promotes the proliferation of gallbladder epithelial cells.",
      "Noggin inhibits the differentiation of gallbladder epithelial cells in non-damaged gallbladders.",
      "The balance between R-spondin 1 and Noggin activities is crucial for the gallbladder's function to store and release bile."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe correctness of these statements depends on specific scientific research findings that are not universally known facts. To validate such statements, one would need to consult the relevant scientific literature on the biology of the gallbladder and the role of the mentioned signaling molecules (R-spondin 1 and Noggin) in its development and function. Without specific context or sources to verify these claims, the truthfulness of these statements cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-7b-chat-hf_response": "Yes, NADPH oxidase 5 (NOX5) requires a subunit called p47phox for its function. p47phox is a crucial subunit that forms the catalytic core of NOX5 and is necessary for the enzyme's activity.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-7b-chat-hf_response": "Furin and hepcidin are connected in the regulation of iron metabolism. Furin is a protease that cleaves the precursor form of hepcidin, a hormone produced in the liver that regulates iron absorption and distribution in the body. The cleavage of hepcidin by furin leads to its activation and the subsequent inhibition of iron absorption in the duodenum and the release of iron from stores in the liver. This connection helps to regulate iron homeostasis in the body and prevent iron overload.",
    "llama-2-7b-chat-hf_fact_raw": "1. Furin is a protease.\n2. Furin cleaves the precursor form of hepcidin.\n3. Hepcidin is a hormone produced in the liver that regulates iron absorption and distribution in the body.\n4. The cleavage of hepcidin by furin leads to its activation.\n5. Activated hepcidin inhibits iron absorption in the duodenum and the release of iron from stores in the liver.",
    "llama-2-7b-chat-hf_fact": [
      "Furin is a protease.",
      "Furin cleaves the precursor form of hepcidin.",
      "Hepcidin is a hormone produced in the liver that regulates iron absorption and distribution in the body.",
      "The cleavage of hepcidin by furin leads to its activation.",
      "Activated hepcidin inhibits iron absorption in the duodenum and the release of iron from stores in the liver."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Furin does not cleave the precursor form of hepcidin; it cleaves various protein precursors, but hepcidin is not one of its substrates.\n3. TRUE\n4. FALSE [correction]: Since furin doesn't cleave hepcidin, it is not responsible for its activation.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-7b-chat-hf_response": "The largest metabolic gene cluster in yeast is the glycolytic pathway, which is composed of 16 genes involved in the breakdown of glucose to produce energy.",
    "llama-2-7b-chat-hf_fact_raw": "1. The largest metabolic gene cluster in yeast is the glycolytic pathway.\n2. The glycolytic pathway in yeast is composed of 16 genes.\n3. The genes in the glycolytic pathway are involved in the breakdown of glucose.\n4. The breakdown of glucose in the glycolytic pathway is for the purpose of producing energy.",
    "llama-2-7b-chat-hf_fact": [
      "The largest metabolic gene cluster in yeast is the glycolytic pathway.",
      "The glycolytic pathway in yeast is composed of 16 genes.",
      "The genes in the glycolytic pathway are involved in the breakdown of glucose.",
      "The breakdown of glucose in the glycolytic pathway is for the purpose of producing energy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: The glycolytic pathway in yeast typically involves 10 genes that encode the enzyme for each step of the pathway.\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-7b-chat-hf_response": "The role of LMT lncRNA (Loss of Heterozygosity in Microcephaly and Brain Tumors) is not well understood, as it is a recently identified lncRNA and there is limited research available on its function. However, studies have suggested that LMT lncRNA may play a role in the regulation of gene expression, particularly in the context of brain development and cancer.\nOne study found that LMT lncRNA is overexpressed in certain types of brain tumors, and that its expression is associated with poor prognosis. Another study found that LMT lncRNA regulates the expression of genes involved in cellular processes such as cell division and differentiation.\nOverall, while the exact role of LMT lncRNA is still being studied, it is clear that it plays an important role in the regulation of gene expression and may be involved in the development and progression of certain diseases, including brain tumors.",
    "llama-2-7b-chat-hf_fact_raw": "1. LMT lncRNA (Loss of Heterozygosity in Microcephaly and Brain Tumors) is a recently identified long non-coding RNA.\n2. There is limited research available on the function of LMT lncRNA.\n3. Studies suggest that LMT lncRNA may play a role in the regulation of gene expression in brain development and cancer.\n4. LMT lncRNA is overexpressed in certain types of brain tumors.\n5. The expression of LMT lncRNA is associated with poor prognosis in certain brain tumors.",
    "llama-2-7b-chat-hf_fact": [
      "LMT lncRNA (Loss of Heterozygosity in Microcephaly and Brain Tumors) is a recently identified long non-coding RNA.",
      "There is limited research available on the function of LMT lncRNA.",
      "Studies suggest that LMT lncRNA may play a role in the regulation of gene expression in brain development and cancer.",
      "LMT lncRNA is overexpressed in certain types of brain tumors.",
      "The expression of LMT lncRNA is associated with poor prognosis in certain brain tumors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific information on when LMT lncRNA was identified or scientific literature to confirm its discovery timeframe, it's not possible to determine the truthfulness of this statement.\n2. TRUE: This is a plausible statement, as it's common for newly identified lncRNAs to have limited research initially.\n3. TRUE: Based on the name (Loss of Heterozygosity in Microcephaly and Brain Tumors), it is reasonable to infer that LMT lncRNA is involved in brain-related conditions, and lncRNAs are generally known to be involved in gene expression regulation.\n4. UNKNOWN: Without specific scientific studies or data, it's not possible to verify the expression levels of LMT lncRNA in brain tumors.\n5. UNKNOWN: This statement makes a specific claim about prognosis which requires empirical evidence and scientific studies to confirm, therefore without that data, the truthfulness cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-7b-chat-hf_response": "There are several R packages and bioconductor packages that can be used for performing SNP (Single Nucleotide Polymorphism) enrichment analysis. Some of the commonly used packages include:\n1. `SNPset`: This package provides a comprehensive set of tools for SNP analysis, including enrichment analysis. It uses a Bayesian approach to detect overrepresented SNPs in a given dataset.\n2. `SNP_Enrichment`: This package provides a variety of tools for SNP enrichment analysis, including a non-parametric test for detecting overrepresented SNPs.\n3. `GSEA`: This package (GSEA = Gene Set Enrichment Analysis) is a popular tool for identifying gene sets that are overrepresented in a given dataset. It can be used for SNP enrichment analysis by comparing the genes near the SNPs to a predefined set of gene sets.\n4. `Pathway Studio`: This package provides a comprehensive set of tools for pathway analysis, including enrichment analysis. It can be used to identify overrepresented pathways in a given dataset of SNPs.\n5. `Plink`: This package is a popular tool for genome-wide association studies (GWAS) and can be used for SNP enrichment analysis by comparing the genotype frequencies of the SNPs in the dataset to a reference panel.\nThese are just a few examples of the many R packages and bioconductor packages available for SNP enrichment analysis. The choice of package will depend on the specific requirements of the analysis and the nature of the dataset being analyzed.",
    "llama-2-7b-chat-hf_fact_raw": "1. The `SNPset` package is used for SNP analysis, including enrichment analysis, and utilizes a Bayesian approach.\n2. The `SNP_Enrichment` package provides tools for SNP enrichment analysis with a non-parametric test.\n3. The `GSEA` package is used for Gene Set Enrichment Analysis and can be applied to SNP enrichment.\n4. The `Pathway Studio` package offers tools for pathway analysis, which includes enrichment analysis for SNPs.\n5. The `Plink` package is used for genome-wide association studies and is applicable for SNP enrichment analysis.",
    "llama-2-7b-chat-hf_fact": [
      "The `SNPset` package is used for SNP analysis, including enrichment analysis, and utilizes a Bayesian approach.",
      "The `SNP_Enrichment` package provides tools for SNP enrichment analysis with a non-parametric test.",
      "The `GSEA` package is used for Gene Set Enrichment Analysis and can be applied to SNP enrichment.",
      "The `Pathway Studio` package offers tools for pathway analysis, which includes enrichment analysis for SNPs.",
      "The `Plink` package is used for genome-wide association studies and is applicable for SNP enrichment analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: There is limited context to ascertain the specific features of the `SNPset` package, including whether it indeed utilizes a Bayesian approach.\n2. FALSE [correction]: There is no `SNP_Enrichment` package documented in the current bioinformatics resources. It's possible that the package being referred to is another with a similar function but a different name.\n3. TRUE: The `GSEA` (Gene Set Enrichment Analysis) package is indeed used for identifying gene sets that are statistically significantly enriched in a list of genes, and it can be adapted for SNP set analysis.\n4. UNKNOWN: Without further context, it's uncertain whether a package called `Pathway Studio` exists and offers tools for enrichment analysis for SNPs. 'Pathway Studio' generally refers to a web-based application or a software suite by Elsevier for pathway analysis, but its specific package functionalities in this context are unclear.\n5. TRUE: The `Plink` (or PLINK) package is a widely-used tool in bioinformatics for genome-wide association studies (GWAS), and it does indeed have features that can be used for analyzing SNP data, including SNP enrichment analysis.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-7b-chat-hf_response": "Radial glial cells are specified to become ependymal cells through a complex interplay of signaling pathways and molecular mechanisms. The key players involved in this process include:\n1. Notch signaling: Notch is a critical regulator of radial glial cell fate and is essential for the specification of radial glial cells to ependymal cells. Notch signaling promotes the expression of ependymal-specific genes and regulates the expression of genes involved in the maintenance of radial glial cell identity.\n2. Wnt signaling: Wnt signaling also plays a crucial role in regulating the specification of radial glial cells to ependymal cells. Wnt signaling promotes the expression of genes involved in the maintenance of ependymal cell identity and regulates the expression of genes involved in the specification of radial glial cells.\n3. BMP signaling: BMP signaling is also involved in the specification of radial glial cells to ependymal cells. BMP signaling promotes the expression of genes involved in the maintenance of ependymal cell identity and regulates the expression of genes involved in the specification of radial glial cells.\n4. Shh signaling: Shh signaling is also involved in the specification of radial glial cells to ependymal cells. Shh signaling regulates the expression of genes involved in the maintenance of ependymal cell identity and promotes the expression of genes involved in the specification of radial glial cells.\n5. EGFR signaling: EGFR signaling is also involved in the specification of radial glial cells to ependymal cells. EGFR signaling promotes the expression of genes involved in the maintenance of ependymal cell identity and regulates the expression of genes involved in the specification of radial glial cells.\n6. FGF signaling: FGF signaling is also involved in the specification of radial glial cells to ependymal cells. FGF signaling promotes the expression of genes involved in the maintenance of ependymal cell identity and regulates the expression of genes involved in the specification of radial glial cells.\n7. Sox2: Sox2 is a transcription factor that is essential for the maintenance of radial glial cell identity and the specification of radial glial cells to ep",
    "llama-2-7b-chat-hf_fact_raw": "1. Notch signaling is a critical regulator of radial glial cell fate and is essential for the specification of radial glial cells to ependymal cells.\n2. Wnt signaling plays a crucial role in regulating the specification of radial glial cells to ependymal cells.\n3. BMP signaling is involved in the specification of radial glial cells to ependymal cells.\n4. Shh signaling is involved in the specification of radial glial cells to ependymal cells.\n5. EGFR signaling is involved in the specification of radial glial cells to ependymal cells.",
    "llama-2-7b-chat-hf_fact": [
      "Notch signaling is a critical regulator of radial glial cell fate and is essential for the specification of radial glial cells to ependymal cells.",
      "Wnt signaling plays a crucial role in regulating the specification of radial glial cells to ependymal cells.",
      "BMP signaling is involved in the specification of radial glial cells to ependymal cells.",
      "Shh signaling is involved in the specification of radial glial cells to ependymal cells.",
      "EGFR signaling is involved in the specification of radial glial cells to ependymal cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Notch signaling is indeed known to be a critical regulator in the fate of neural progenitor cells, including radial glial cells, and is essential for the specification of various cell types in the brain, including ependymal cells.\n2. UNKNOWN: While Wnt signaling is an important pathway for various aspects of nervous system development, its role in the specific regulation of radial glial cell fate to ependymal cells would require specific evidence from developmental neurobiology literature.\n3. TRUE: BMP (Bone Morphogenetic Protein) signaling has been shown to be involved in the specification of radial glial cells to ependymal cells.\n4. UNKNOWN: Shh (Sonic Hedgehog) signaling is indeed crucial for the regulation of various cell fate decisions in the developing nervous system, but its direct role in the specific specification of radial glial cells to ependymal cells is not universally established and would depend on specific scientific findings.\n5. UNKNOWN: EGFR (Epidermal Growth Factor Receptor) signaling plays a role in the development of the nervous system and in gliogenesis, yet the statement about its specific involvement in the specification of radial glial cells to ependymal cells would need backing from targeted study results within neurodevelopmental biology.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-7b-chat-hf_response": "Triple negative gliomas are a type of glioma that lack expression of the tumor suppressor proteins P53, EGFR, and MIB1. These proteins are commonly targeted by chemotherapy and are used as markers for diagnosis and prognosis in glioma. Triple negative gliomas are aggressive and tend to have a poorer prognosis compared to gliomas that express these proteins. They are often associated with a higher risk of recurrence and are more likely to be resistant to chemotherapy and radiation therapy.",
    "llama-2-7b-chat-hf_fact_raw": "1. Triple negative gliomas lack expression of the proteins P53, EGFR, and MIB1.\n2. P53, EGFR, and MIB1 are used as markers for diagnosis and prognosis in gliomas.\n3. Triple negative gliomas are considered to be more aggressive than gliomas that express P53, EGFR, and MIB1.\n4. Triple negative gliomas tend to have a poorer prognosis compared to other gliomas.\n5. Triple negative gliomas are usually associated with a higher risk of recurrence.",
    "llama-2-7b-chat-hf_fact": [
      "Triple negative gliomas lack expression of the proteins P53, EGFR, and MIB1.",
      "P53, EGFR, and MIB1 are used as markers for diagnosis and prognosis in gliomas.",
      "Triple negative gliomas are considered to be more aggressive than gliomas that express P53, EGFR, and MIB1.",
      "Triple negative gliomas tend to have a poorer prognosis compared to other gliomas.",
      "Triple negative gliomas are usually associated with a higher risk of recurrence."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Triple negative gliomas lack expression of the proteins IDH1, 1p/19q co-deletion, and ATRX, not P53, EGFR, and MIB1.\n2. TRUE\n3. UNKNOWN: The statement is plausible, as \"triple negative\" status in cancers often implies a more aggressive nature, but without specific context or data regarding gliomas with these triple negative markers, it is difficult to confirm.\n4. UNKNOWN: Similarly, without specific data, it is difficult to confirm the prognosis of triple negative gliomas compared to other gliomas.\n5. UNKNOWN: As with the aggressiveness and prognosis, the risk of recurrence for triple negative gliomas compared to other gliomas cannot be confirmed without specific data or context.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-7b-chat-hf_response": "TOPAZ1 (Topoisomerase II-associated protein A1) is a protein that is involved in the regulation of DNA topology and chromosome segregation during cell division. It is a component of the spindle assembly checkpoint, which ensures proper chromosome alignment and separation during mitosis. TOPAZ1 is a protein that interacts with topoisomerase II and other proteins to regulate the relaxation of DNA supercoils and the formation of the spindle fibers that separate chromosomes during cell division.",
    "llama-2-7b-chat-hf_fact_raw": "1. TOPAZ1 stands for Topoisomerase II-associated protein A1.\n2. TOPAZ1 is involved in the regulation of DNA topology.\n3. It plays a role in chromosome segregation during cell division.\n4. TOPAZ1 is a component of the spindle assembly checkpoint.\n5. The protein interacts with topoisomerase II to regulate the relaxation of DNA supercoils.",
    "llama-2-7b-chat-hf_fact": [
      "TOPAZ1 stands for Topoisomerase II-associated protein A1.",
      "TOPAZ1 is involved in the regulation of DNA topology.",
      "It plays a role in chromosome segregation during cell division.",
      "TOPAZ1 is a component of the spindle assembly checkpoint.",
      "The protein interacts with topoisomerase II to regulate the relaxation of DNA supercoils."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TOPAZ1 typically does not stand for Topoisomerase II-associated protein A1. There is no standard acronym TOPAZ1 associated with Topoisomerase II in scientific literature. However, without context of a specific scientific study or novel nomenclature, it's difficult to provide a definitive correction.\n2. UNKNOWN: Without additional context or confirmation that TOPAZ1 refers to a protein linked with Topoisomerase II or another protein involved in DNA topology, it's not possible to confirm this statement. \n3. UNKNOWN: Similar to statement 2, without further context, it is not possible to confirm whether TOPAZ1 plays a role in chromosome segregation during cell division.\n4. UNKNOWN: Again, without proper context or source material that defines TOPAZ1 as part of the spindle assembly checkpoint, this statement remains unclear.\n5. UNKNOWN: Since it's unclear what TOPAZ1 refers to, we cannot confirm its interaction with topoisomerase II regarding the regulation of DNA supercoils.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-7b-chat-hf_response": "The expression of GATA-1 isoforms is controlled by the GATA-1 gene.",
    "llama-2-7b-chat-hf_fact_raw": "1. The GATA-1 gene controls the expression of GATA-1 isoforms.",
    "llama-2-7b-chat-hf_fact": [
      "The GATA-1 gene controls the expression of GATA-1 isoforms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-7b-chat-hf_response": "MIRA-seq is a sequencing-based method used to identify and quantify miRNAs (microRNAs) in a sample. MIRA-seq stands for \"MicroRNA Identification and Quantification by Sequencing.\" It is a next-generation sequencing (NGS) technology that allows for the simultaneous analysis of thousands of miRNAs in a single run, providing a comprehensive picture of the miRNA landscape in a given sample.\nThe MIRA-seq protocol typically involves the following steps:\n1. Sample preparation: The sample is first prepared by isolating the RNA from the cells or tissue of interest.\n2. Library preparation: The RNA is then converted into a sequencing library using a series of enzymatic reactions and chemical modifications.\n3. Sequencing: The sequencing library is then loaded onto a sequencing machine, such as an Illumina or Illumina X Ten, where it is sequenced using a technique called single-end or paired-end sequencing.\n4. Data analysis: The raw sequencing data is then analyzed using specialized software to identify and quantify the miRNAs present in the sample.\nMIRA-seq has several advantages over other methods for miRNA analysis, including its high sensitivity and specificity, as well as its ability to analyze thousands of miRNAs in a single run. It has been used to study a wide range of biological processes, including cancer, development, and immunology.",
    "llama-2-7b-chat-hf_fact_raw": "1. MIRA-seq is used to identify and quantify microRNAs (miRNAs) in a sample.\n2. MIRA-seq stands for \"MicroRNA Identification and Quantification by Sequencing.\"\n3. MIRA-seq is a next-generation sequencing (NGS) technology.\n4. The MIRA-seq protocol typically involves sample preparation, library preparation, sequencing, and data analysis.\n5. MIRA-seq can analyze thousands of miRNAs in a single run.",
    "llama-2-7b-chat-hf_fact": [
      "MIRA-seq is used to identify and quantify microRNAs (miRNAs) in a sample.",
      "MIRA-seq stands for \"MicroRNA Identification and Quantification by Sequencing.\"",
      "MIRA-seq is a next-generation sequencing (NGS) technology.",
      "The MIRA-seq protocol typically involves sample preparation, library preparation, sequencing, and data analysis.",
      "MIRA-seq can analyze thousands of miRNAs in a single run."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: MIRA-seq stands for \"Methylated CpG Island Recovery Assay\" followed by sequencing; it is not specifically for microRNAs (miRNAs).\n3. TRUE\n4. TRUE\n5. FALSE [correction]: MIRA-seq is not specifically used for miRNAs analysis; thus, it would not analyze thousands of miRNAs in a single run. It is generally used for identifying methylated DNA regions.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-7b-chat-hf_response": "ARCALYST (rilonacept) is a prescription medication used to treat cryopyrin-associated periodic syndromes (CAPS), which are a group of rare genetic disorders that can cause recurring episodes of fever, pain, and swelling. Specifically, ARCALYST is approved for the treatment of cryopyrin-associated periodic syndrome (CAPS), including familial cold autoinflammatory syndrome (FCAS) and migraine-like headaches associated with CAPS.",
    "llama-2-7b-chat-hf_fact_raw": "1. ARCALYST (rilonacept) is a prescription medication.\n2. ARCALYST is used to treat cryopyrin-associated periodic syndromes (CAPS).\n3. CAPS are a group of rare genetic disorders.\n4. CAPS can cause recurring episodes of fever, pain, and swelling.\n5. ARCALYST is approved for the treatment of familial cold autoinflammatory syndrome (FCAS) and migraine-like headaches associated with CAPS.",
    "llama-2-7b-chat-hf_fact": [
      "ARCALYST (rilonacept) is a prescription medication.",
      "ARCALYST is used to treat cryopyrin-associated periodic syndromes (CAPS).",
      "CAPS are a group of rare genetic disorders.",
      "CAPS can cause recurring episodes of fever, pain, and swelling.",
      "ARCALYST is approved for the treatment of familial cold autoinflammatory syndrome (FCAS) and migraine-like headaches associated with CAPS."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: ARCALYST is approved for the treatment of FCAS, which is one of the conditions under CAPS, but it is not approved for migraine-like headaches specifically associated with CAPS. It is also approved for Muckle-Wells syndrome, which is another form of CAPS, but its approval for headache symptoms related to CAPS has not been explicitly stated in the available information.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-7b-chat-hf_response": "Robertsonian translocations involve the exchange of genetic material between two acrocentric chromosomes, which are defined as chromosomes that have their centromere near their telomeres. Of the 23 human chromosomes, the following acrocentric chromosomes are involved in Robertsonian translocations:\n1. Chromosome 13\n2. Chromosome 14\n3. Chromosome 15\n4. Chromosome 16\nThese chromosomes are more prone to translocations due to their compact structure and proximity to the centromere, which makes it easier for genetic material to exchange between them.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrocentric chromosomes have their centromere near their telomeres.\n2. Human chromosome 13 is involved in Robertsonian translocations.\n3. Human chromosome 14 is involved in Robertsonian translocations.\n4. Human chromosome 15 is involved in Robertsonian translocations.\n5. Human chromosome 16 is involved in Robertsonian translocations.",
    "llama-2-7b-chat-hf_fact": [
      "Acrocentric chromosomes have their centromere near their telomeres.",
      "Human chromosome 13 is involved in Robertsonian translocations.",
      "Human chromosome 14 is involved in Robertsonian translocations.",
      "Human chromosome 15 is involved in Robertsonian translocations.",
      "Human chromosome 16 is involved in Robertsonian translocations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAcrocentric chromosomes have their centromere situated closer to one end than the other, creating a long arm and a notable short arm. Chromosomes 13, 14, 15, 16, and 22 in humans are considered acrocentric and can be involved in Robertsonian translocations.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-7b-chat-hf_response": "There are several R packages that can be used for the identification of pediatric brain tumors, including:\n1. `pediatricbraintumor`: This package provides a comprehensive set of tools for the analysis of pediatric brain tumors, including gene expression analysis, survival analysis, and mutation analysis.\n2. `brainTumor`: This package provides a set of functions for the analysis of brain tumors, including gene expression analysis, survival analysis, and mutation analysis.\n3. `rptk`: This package provides a set of functions for the analysis of retinoblastoma gene mutations, which are commonly found in pediatric brain tumors.\n4. `pediatric`: This package provides a set of functions for the analysis of pediatric cancers, including brain tumors.\n5. `cancer`: This package provides a set of functions for the analysis of various types of cancer, including brain tumors.\n6. `genefunction`: This package provides a set of functions for the analysis of gene expression and mutation in various types of cancer, including brain tumors.\n7. `limma`: This package provides a set of functions for the analysis of gene expression data, which can be used to identify differentially expressed genes in pediatric brain tumors.\n8. `edgeR`: This package provides a set of functions for the analysis of RNA sequencing data, which can be used to identify differentially expressed genes in pediatric brain tumors.\n9. `ggplot2`: This package provides a set of functions for the visualization of gene expression data, which can be used to identify patterns of gene expression in pediatric brain tumors.\n10. `survival`: This package provides a set of functions for the analysis of survival data, which can be used to identify genes that are associated with poor prognosis in pediatric brain tumors.\nIt's worth noting that the specific R package you choose will depend on the type of analysis you want to perform and the data you have available.",
    "llama-2-7b-chat-hf_fact_raw": "1. The `pediatricbraintumor` R package includes tools for gene expression analysis, survival analysis, and mutation analysis in pediatric brain tumors.\n2. The `brainTumor` R package offers functions for gene expression analysis, survival analysis, and mutation analysis of brain tumors.\n3. The `rptk` R package provides functions for analyzing retinoblastoma gene mutations, which are common in pediatric brain tumors.\n4. The `limma` R package includes functions for analyzing gene expression data to identify differentially expressed genes in pediatric brain tumors.\n5. The `edgeR` R package comes with functions for RNA sequencing data analysis to identify differentially expressed genes in pediatric brain tumors.",
    "llama-2-7b-chat-hf_fact": [
      "The `pediatricbraintumor` R package includes tools for gene expression analysis, survival analysis, and mutation analysis in pediatric brain tumors.",
      "The `brainTumor` R package offers functions for gene expression analysis, survival analysis, and mutation analysis of brain tumors.",
      "The `rptk` R package provides functions for analyzing retinoblastoma gene mutations, which are common in pediatric brain tumors.",
      "The `limma` R package includes functions for analyzing gene expression data to identify differentially expressed genes in pediatric brain tumors.",
      "The `edgeR` R package comes with functions for RNA sequencing data analysis to identify differentially expressed genes in pediatric brain tumors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific information about the `pediatricbraintumor` R package, it's not possible to confirm or refute the functionality it provides.\n2. UNKNOWN: The existence and functionality of the `brainTumor` R package cannot be confirmed without more specific information.\n3. UNKNOWN: The `rptk` R package's features cannot be confirmed without more information. Retinoblastoma gene mutations are indeed related to pediatric cancers, but it is unclear whether `rptk` is designed specifically for the analysis of such mutations in pediatric brain tumors.\n4. TRUE: The `limma` R package is widely used for analyzing gene expression data, including identifying differentially expressed genes, which may encompass studies on pediatric brain tumors.\n5. TRUE: The `edgeR` R package is indeed utilized for RNA sequencing data analysis, which can be used to identify differentially expressed genes, including in the context of pediatric brain tumors.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-7b-chat-hf_response": "No, NEMO (Nuclear Envelope-Associated Matrix-Organizing) is not a zinc finger protein. NEMO is a protein that plays a crucial role in the immune system, specifically in the activation of the NF-κB signaling pathway. It does not contain any zinc finger domains, which are a characteristic feature of zinc finger proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. NEMO is not a zinc finger protein.\n2. NEMO plays a crucial role in the immune system.\n3. NEMO is involved in the activation of the NF-κB signaling pathway.\n4. NEMO does not contain zinc finger domains.",
    "llama-2-7b-chat-hf_fact": [
      "NEMO is not a zinc finger protein.",
      "NEMO plays a crucial role in the immune system.",
      "NEMO is involved in the activation of the NF-κB signaling pathway.",
      "NEMO does not contain zinc finger domains."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-7b-chat-hf_response": "Yes, TFIIS (Transcription Factor IIS) plays a role in nucleosome positioning. TFIIS is a transcription factor that helps to regulate the initiation of transcription in eukaryotic cells, particularly during the process of transcription elongation. TFIIS has been shown to interact with nucleosomes and can affect their positioning on DNA, thereby influencing the accessibility of the transcriptional machinery to the DNA template. Specifically, TFIIS has been shown to displace nucleosomes from the promoter region of actively transcribed genes, allowing for the recruitment of RNA polymerase and other transcription factors. This process is important for the proper regulation of gene expression and ensures that RNA polymerase can access the DNA template to initiate transcription.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFIIS is a transcription factor that regulates the initiation of transcription in eukaryotic cells.\n2. TFIIS interacts with nucleosomes and can influence their positioning on DNA.\n3. TFIIS has been shown to displace nucleosomes from the promoter regions of actively transcribed genes.\n4. Displacement of nucleosomes by TFIIS allows for the recruitment of RNA polymerase and other transcription factors.\n5. This interaction between TFIIS and nucleosomes is important for proper regulation of gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "TFIIS is a transcription factor that regulates the initiation of transcription in eukaryotic cells.",
      "TFIIS interacts with nucleosomes and can influence their positioning on DNA.",
      "TFIIS has been shown to displace nucleosomes from the promoter regions of actively transcribed genes.",
      "Displacement of nucleosomes by TFIIS allows for the recruitment of RNA polymerase and other transcription factors.",
      "This interaction between TFIIS and nucleosomes is important for proper regulation of gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TFIIS does not regulate the initiation of transcription; it is involved in the process of transcription elongation by stimulating the intrinsic nuclease activity of RNA polymerase II to facilitate the cleavage of misincorporated nucleotides and allowing transcription to continue past a stalled transcription complex.\n2. FALSE [correction]: TFIIS specifically interacts with RNA polymerase II during transcription elongation, not directly with nucleosomes.\n3. FALSE [correction]: TFIIS does not displace nucleosomes from the promoter regions of actively transcribed genes as its role is not in nucleosome displacement but in transcription elongation.\n4. FALSE [correction]: Displacement of nucleosomes is generally facilitated by other factors such as chromatin remodelers and histone chaperones, not by TFIIS; TFIIS's role is to re-activate stalled RNA polymerase II rather than recruiting it.\n5. FALSE [correction]: The interaction between TFIIS and nucleosomes is not a direct one in the context of gene expression regulation; rather, TFIIS interacts with RNA polymerase II to ensure proper transcription elongation.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, origins of replication near yeast centromeres fire early.",
    "llama-2-7b-chat-hf_fact_raw": "1. Origins of replication near yeast centromeres fire early.",
    "llama-2-7b-chat-hf_fact": [
      "Origins of replication near yeast centromeres fire early."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n\nOrigins of replication near yeast centromeres are known to fire early in the S phase of the cell cycle. This is part of the well-characterized timing of replication in yeast, where different origins fire at specific times during S phase.",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-7b-chat-hf_response": "Mammalian GA-sequences are characterized by the following properties:\n1. Long range orientation: Mammalian GA-sequences are typically long, with a range of 10-20 nucleotides, and are oriented in a head-to-head or head-to-tail manner.\n2. High GC content: Mammalian GA-sequences have a high GC content, typically ranging from 50-70%, which is higher than the GC content of non-GA sequences.\n3. Low complexity: Mammalian GA-sequences have low complexity, with a low number of nucleotides and a low frequency of palindromic or imperfect repeats.\n4. High stability: Mammalian GA-sequences are highly stable, with a high Tm value (melting temperature) and a low frequency of secondary structure formation.\n5. Evolutionary conservation: Mammalian GA-sequences are highly conserved across species, indicating their functional importance in mammalian cells.\n6. Regulation of transcriptional elongation: Mammalian GA-sequences are involved in the regulation of transcriptional elongation, with some GA-sequences acting as enhancers or silencers of gene expression.\n7. Chromatin remodeling: Mammalian GA-sequences can also be involved in chromatin remodeling, with some GA-sequences acting as recognition elements for chromatin-remodeling complexes.\n8. Non-coding RNA function: Some mammalian GA-sequences have been shown to function as non-coding RNAs, with roles in regulating gene expression, chromatin structure, and cellular processes.\n9. Genetic variation: Mammalian GA-sequences can be subject to genetic variation, with some studies suggesting that certain GA-sequences may be associated with disease susceptibility or resistance.\n10. Evolutionary origins: Mammalian GA-sequences have evolved from a common ancestor with other eukaryotic GA-sequences, and share many similarities with other GA-sequences found in organisms such as yeast and Drosophila.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mammalian GA-sequences typically range from 10-20 nucleotides in length.\n2. The GC content of mammalian GA-sequences typically ranges from 50-70%.\n3. Mammalian GA-sequences have a high melting temperature (Tm) indicating high stability.\n4. Mammalian GA-sequences are highly conserved across different mammalian species.\n5. Some mammalian GA-sequences have been shown to function as non-coding RNAs.",
    "llama-2-7b-chat-hf_fact": [
      "Mammalian GA-sequences typically range from 10-20 nucleotides in length.",
      "The GC content of mammalian GA-sequences typically ranges from 50-70%.",
      "Mammalian GA-sequences have a high melting temperature (Tm) indicating high stability.",
      "Mammalian GA-sequences are highly conserved across different mammalian species.",
      "Some mammalian GA-sequences have been shown to function as non-coding RNAs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mammalian GA-sequences, or GA-repeats, typically do not have a defined length of 10-20 nucleotides. GA-rich sequences or GA repeats can vary in length and are often longer than 20 nucleotides, especially in regulatory regions or microsatellites.\n\n2. UNKNOWN: Without specific context, it is difficult to accurately determine the typical GC content of mammalian GA-sequences since GA-rich sequences could theoretically have a lower GC content. GC content can vary widely depending on the specific sequence and its genomic context.\n\n3. FALSE [correction]: The melting temperature (Tm) of a nucleotide sequence is influenced by its GC content; since GA-sequences are not GC-rich (they are by definition rich in GA, which are AT base pairs), they would generally not have a high melting temperature indicating high stability. AT base pairs have two hydrogen bonds (compared to three in GC pairs) and typically lead to lower stability and lower Tm.\n\n4. UNKNOWN: The conservation of GA-sequences across different mammalian species can vary depending on the function and location of these sequences. While some GA-rich sequences may be highly conserved due to their importance in gene regulation or other functions, this is not universally true for all GA-sequences.\n\n5. TRUE: Some GA-rich sequences, indeed, function as non-coding RNAs, which can play a role in the regulation of gene expression. Non-coding RNAs do not encode for proteins but can have various structural, regulatory, or catalytic roles within the cell.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-7b-chat-hf_response": "There are 4 Groucho-related genes (GRG) contained in the mouse genome: Grm1, Grm2, Grm3, and Grm4.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are four Groucho-related genes in the mouse genome.\n2. The Groucho-related genes in the mouse genome are named Grm1, Grm2, Grm3, and Grm4.",
    "llama-2-7b-chat-hf_fact": [
      "There are four Groucho-related genes in the mouse genome.",
      "The Groucho-related genes in the mouse genome are named Grm1, Grm2, Grm3, and Grm4."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The Groucho-related genes are not named Grm1, Grm2, Grm3, and Grm4. Grm genes refer to glutamate receptors known as 'metabotropic glutamate receptors'. The Groucho/TLE family genes in mammals are typically referred to as Tle1, Tle2, Tle3, and Tle4 or Grg (Groucho-related gene).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-7b-chat-hf_response": "RNA polymerase II (RNAPII) is a complex of several subunits, and only one of the subunits, RNAPII subunit B (RPB1), carries RNA cleavage activity. RPB1 is responsible for the cleavage of the RNA transcript during transcription elongation, which is necessary for the proper termination of transcription.",
    "llama-2-7b-chat-hf_fact_raw": "1. RNA polymerase II (RNAPII) is a complex made up of several subunits.\n2. Only one subunit of RNA polymerase II, known as RPB1, carries RNA cleavage activity.\n3. The RPB1 subunit is responsible for the cleavage of the RNA transcript during transcription elongation.\n4. The cleavage activity of the RPB1 subunit is necessary for the proper termination of transcription.",
    "llama-2-7b-chat-hf_fact": [
      "RNA polymerase II (RNAPII) is a complex made up of several subunits.",
      "Only one subunit of RNA polymerase II, known as RPB1, carries RNA cleavage activity.",
      "The RPB1 subunit is responsible for the cleavage of the RNA transcript during transcription elongation.",
      "The cleavage activity of the RPB1 subunit is necessary for the proper termination of transcription."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: RNA cleavage activity is not a function of RNA polymerase II RPB1 or any of its subunits. RNA cleavage during transcription is carried out by separate factors, such as the cleavage and polyadenylation specificity factor (CPSF) in eukaryotes.\n3. FALSE [correction]: The RPB1 subunit is not responsible for cleavage of the RNA transcript during transcription elongation. RNA cleavage is a separate process carried out by other enzymes and factors.\n4. FALSE [correction]: The cleavage activity necessary for proper termination of transcription is not a role of the RPB1 subunit of RNA polymerase II. Instead, cleavage factors and the process of polyadenylation play key roles in transcription termination.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-7b-chat-hf_response": "Ohdo syndrome is caused by mutations in the gene encoding the protein neuroserpin, which is involved in the regulation of blood coagulation and inflammation. Specifically, mutations in the SERPINI1 gene on chromosome 1q21 can lead to the development of Ohdo syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ohdo syndrome is caused by mutations in the gene encoding the protein neuroserpin.\n2. Neuroserpin is involved in the regulation of blood coagulation and inflammation.\n3. Mutations in the SERPINI1 gene can lead to Ohdo syndrome.\n4. The SERPINI1 gene is located on chromosome 1q21.",
    "llama-2-7b-chat-hf_fact": [
      "Ohdo syndrome is caused by mutations in the gene encoding the protein neuroserpin.",
      "Neuroserpin is involved in the regulation of blood coagulation and inflammation.",
      "Mutations in the SERPINI1 gene can lead to Ohdo syndrome.",
      "The SERPINI1 gene is located on chromosome 1q21."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ohdo syndrome is not caused by mutations in the gene encoding neuroserpin.\n2. TRUE\n3. FALSE [correction]: Mutations in the MED12 gene can lead to Ohdo syndrome.\n4. FALSE [correction]: The SERPINI1 gene is located on chromosome 3q26.1.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-7b-chat-hf_response": "The R/Bioconductor package \"psychgene\" has been developed for the analysis of psychiatric disease genes. It provides a comprehensive set of tools for the analysis of genetic data in psychiatric disorders, including gene-level association analysis, pathway analysis, and gene-set enrichment analysis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"psychgene\" is an R/Bioconductor package.\n2. \"psychgene\" is developed for the analysis of psychiatric disease genes.\n3. It includes tools for gene-level association analysis related to psychiatric disorders.\n4. The package offers pathway analysis tools.\n5. Gene-set enrichment analysis is a feature provided by the \"psychgene\" package.",
    "llama-2-7b-chat-hf_fact": [
      "The \"psychgene\" is an R/Bioconductor package.",
      "\"psychgene\" is developed for the analysis of psychiatric disease genes.",
      "It includes tools for gene-level association analysis related to psychiatric disorders.",
      "The package offers pathway analysis tools.",
      "Gene-set enrichment analysis is a feature provided by the \"psychgene\" package."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The \"psychgene\" is not known to be an R/Bioconductor package; it seems to be a fabricated term.\n2. FALSE [correction]: Since \"psychgene\" is not an established R/Bioconductor package, it is not developed for the analysis of psychiatric disease genes.\n3. FALSE [correction]: As \"psychgene\" is not a recognized package, it does not include tools for gene-level association analysis related to psychiatric disorders.\n4. FALSE [correction]: \"psychgene\" does not offer pathway analysis tools as it is not an actual R/Bioconductor package.\n5. FALSE [correction]: Gene-set enrichment analysis is not a feature provided by the \"psychgene\" package since the package does not exist.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_response": "Swirl sign, also known as the \"whirlpool sign,\" is a radiological finding observed in some cases of intracerebral hemorrhage (ICH). It is characterized by a spiral or whirlpool-like configuration of the blood clot or hematoma in the affected brain area.\nThe swirl sign is thought to occur due to the rotation of the blood clot or hematoma around its center of gravity, which is often caused by the blood flow in the surrounding vasculature. This rotation can lead to the formation of a spiral or whirlpool-like pattern in the clot or hematoma, which can be visualized on CT or MRI scans.\nThe swirl sign can be observed in various locations in the brain, including the cerebral cortex, basal ganglia, thalamus, and cerebellum. It is more commonly seen in hemorrhages that occur in the deeper brain structures, such as those in the basal ganglia or thalamus.\nThe swirl sign is not specific to ICH and can also be seen in other conditions such as subarachnoid hemorrhage, cerebral vasculitis, and brain tumors. However, its presence is often associated with a poorer prognosis in ICH patients, as it may indicate a larger and more extensive hemorrhage.\nThe swirl sign can be detected on CT or MRI scans, typically within the first 24-48 hours after the onset of symptoms. The sign may be more visible on MRI than on CT, as it is more sensitive to the subtle changes in water content in the brain tissue.\nIn conclusion, the swirl sign is a radiological finding that can be observed in some cases of intracerebral hemorrhage. It is characterized by a spiral or whirlpool-like configuration of the blood clot or hematoma in the affected brain area, and is often associated with a poorer prognosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Swirl sign is a radiological finding observed in some cases of intracerebral hemorrhage (ICH).\n2. It is characterized by a spiral or whirlpool-like configuration of the blood clot or hematoma in the brain.\n3. The swirl sign is thought to occur due to the rotation of the blood clot or hematoma around its center of gravity.\n4. The swirl sign can be observed in various locations in the brain, such as the cerebral cortex, basal ganglia, thalamus, and cerebellum.\n5. The presence of the swirl sign is often associated with a poorer prognosis in ICH patients.",
    "llama-2-7b-chat-hf_fact": [
      "Swirl sign is a radiological finding observed in some cases of intracerebral hemorrhage (ICH).",
      "It is characterized by a spiral or whirlpool-like configuration of the blood clot or hematoma in the brain.",
      "The swirl sign is thought to occur due to the rotation of the blood clot or hematoma around its center of gravity.",
      "The swirl sign can be observed in various locations in the brain, such as the cerebral cortex, basal ganglia, thalamus, and cerebellum.",
      "The presence of the swirl sign is often associated with a poorer prognosis in ICH patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The swirl sign is characterized by the presence of mixed density within a hematoma on a CT scan, which often suggests active bleeding, rather than a spiral or whirlpool-like configuration.\n3. FALSE [correction]: The swirl sign is thought to represent active or ongoing bleeding within the hematoma, rather than the rotation of the blood clot or hematoma around its center of gravity.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-7b-chat-hf_response": "Arabidopsis ROF1 (RNA polymerase II-associated factor 1) expression is induced by various environmental and developmental signals, including:\n1. Light: Light signals can induce ROF1 expression in Arabidopsis, leading to increased transcriptional activity and gene expression.\n2. Temperature: ROF1 expression is also temperature-sensitive, with higher expression at higher temperatures.\n3. Water availability: ROF1 expression can be induced in response to drought or other stress conditions, suggesting its role in regulating gene expression related to stress response.\n4. Hormones: ROF1 expression can be regulated by various hormones, including auxin, cytokinin, and ethylene, which can affect gene expression related to cell growth and differentiation.\n5. Developmental cues: ROF1 expression can also be regulated by developmental signals, such as those related to cell division and differentiation, leading to changes in gene expression during plant development.",
    "llama-2-7b-chat-hf_fact_raw": "1. Light signals can induce expression of Arabidopsis ROF1.\n2. Arabidopsis ROF1 expression is sensitive to temperature changes, with higher expression at higher temperatures.\n3. Drought or other stress conditions can induce ROF1 expression in Arabidopsis.\n4. Auxin, cytokinin, and ethylene hormones can regulate the expression of Arabidopsis ROF1.\n5. Developmental signals related to cell division and differentiation can regulate Arabidopsis ROF1 expression.",
    "llama-2-7b-chat-hf_fact": [
      "Light signals can induce expression of Arabidopsis ROF1.",
      "Arabidopsis ROF1 expression is sensitive to temperature changes, with higher expression at higher temperatures.",
      "Drought or other stress conditions can induce ROF1 expression in Arabidopsis.",
      "Auxin, cytokinin, and ethylene hormones can regulate the expression of Arabidopsis ROF1.",
      "Developmental signals related to cell division and differentiation can regulate Arabidopsis ROF1 expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Light signals can indeed induce the expression of many genes in plants, including Arabidopsis, although the specific induction of ROF1 by light would need to be confirmed by scientific studies specific to that gene.\n2. TRUE: Gene expression in Arabidopsis, as in other plants, can be sensitive to temperature changes, with some genes showing higher expression at higher temperatures.\n3. TRUE: Stress conditions such as drought can induce the expression of stress-responsive genes in Arabidopsis, and ROF1 could be among those as a response to environmental stress.\n4. TRUE: Hormones like auxin, cytokinin, and ethylene are known to regulate various aspects of plant growth and development, which could include the expression of certain genes like ROF1.\n5. TRUE: Developmental signals, which include those related to cell division and differentiation, can regulate gene expression in plants, and it is plausible that Arabidopsis ROF1 expression could be influenced by such signals.\n\nIt is important to note that without specific scientific literature references, the responses have been provided based on general plant molecular biology knowledge. The regulation of a particular gene, such as ROF1 in Arabidopsis, would need to be substantiated by experimental evidence.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-7b-chat-hf_response": "The most common cause of hereditary renal amyloidosis is the protein transthyretin (TTR). TTR amyloidosis, also known as familial amyloidotic polyneuropathy (FAP), is a group of inherited disorders that result from mutations in the TTR gene, leading to the accumulation of abnormal TTR proteins in various tissues, including the kidneys, and causing progressive damage and loss of function.",
    "llama-2-7b-chat-hf_fact_raw": "1. The most common cause of hereditary renal amyloidosis is the protein transthyretin (TTR).\n2. TTR amyloidosis, also known as familial amyloidotic polyneuropathy (FAP), is a group of inherited disorders.\n3. Mutations in the TTR gene lead to the accumulation of abnormal TTR proteins.\n4. Abnormal TTR proteins can accumulate in various tissues, including the kidneys.\n5. The accumulation of abnormal TTR proteins in tissues causes progressive damage and loss of function.",
    "llama-2-7b-chat-hf_fact": [
      "The most common cause of hereditary renal amyloidosis is the protein transthyretin (TTR).",
      "TTR amyloidosis, also known as familial amyloidotic polyneuropathy (FAP), is a group of inherited disorders.",
      "Mutations in the TTR gene lead to the accumulation of abnormal TTR proteins.",
      "Abnormal TTR proteins can accumulate in various tissues, including the kidneys.",
      "The accumulation of abnormal TTR proteins in tissues causes progressive damage and loss of function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The most common cause of hereditary renal amyloidosis is not the protein transthyretin (TTR) but mutations in the genes encoding for fibronectin or apo-lipoprotein A.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-7b-chat-hf_response": "Yes, the proteome of the mouse hippocampus has been extensively analyzed. The hippocampus is a complex brain region involved in various cognitive and emotional processes, and its proteome has been studied in detail to gain insights into its function and dysfunction in various diseases.\nSome of the key studies on the proteome of the mouse hippocampus include:\n1. The first comprehensive analysis of the mouse hippocampal proteome was published in 2003 by a group led by Dr. Eric Johnson at the University of California, Los Angeles (UCLA). This study identified over 2,000 proteins in the hippocampus and provided a framework for understanding the regional distribution of proteins in the brain.\n2. In 2006, a study by Dr. David W. Andrews at the University of California, San Diego, used a proteomics approach to investigate changes in the hippocampal proteome following seizures in mice. The study identified several proteins that were differentially expressed in the hippocampus after seizures, including proteins involved in excitotoxicity and inflammation.\n3. A 2011 study by Dr. Mark S. Sonders and colleagues at the University of Pennsylvania used a combination of mass spectrometry and antibody-based methods to identify and quantify proteins in the mouse hippocampus. The study identified over 1,000 proteins in the hippocampus and provided insights into the regional distribution of proteins in the brain.\n4. In 2013, a study by Dr. Michael E. Greenberg at Harvard Medical School used a proteomics approach to investigate changes in the hippocampal proteome following exposure to the psychostimulant drug cocaine. The study identified several proteins that were differentially expressed in the hippocampus after cocaine exposure, including proteins involved in synaptic plasticity and neurotransmission.\n5. A 2016 study by Dr. Renee M. Ryan and colleagues at the University of California, San Francisco, used a combination of mass spectrometry and bioinformatics tools to identify and characterize the proteins in the mouse hippocamp",
    "llama-2-7b-chat-hf_fact_raw": "1. The first comprehensive analysis of the mouse hippocampal proteome was published in 2003 by a group led by Dr. Eric Johnson at UCLA.\n2. The study by Dr. Eric Johnson's group in 2003 identified over 2,000 proteins in the mouse hippocampus.\n3. The 2006 study by Dr. David W. Andrews at the University of California, San Diego, identified several proteins differentially expressed in the hippocampus after seizures in mice.\n4. Dr. Mark S. Sonders and colleagues at the University of Pennsylvania identified over 1,000 proteins in the mouse hippocampus in a 2011 study.\n5. In 2013, a study by Dr. Michael E. Greenberg at Harvard Medical School identified several proteins that were differentially expressed in the mouse hippocampus after exposure to cocaine.",
    "llama-2-7b-chat-hf_fact": [
      "The first comprehensive analysis of the mouse hippocampal proteome was published in 2003 by a group led by Dr. Eric Johnson at UCLA.",
      "The study by Dr. Eric Johnson's group in 2003 identified over 2,000 proteins in the mouse hippocampus.",
      "The 2006 study by Dr. David W. Andrews at the University of California, San Diego, identified several proteins differentially expressed in the hippocampus after seizures in mice.",
      "Dr. Mark S. Sonders and colleagues at the University of Pennsylvania identified over 1,000 proteins in the mouse hippocampus in a 2011 study.",
      "In 2013, a study by Dr. Michael E. Greenberg at Harvard Medical School identified several proteins that were differentially expressed in the mouse hippocampus after exposure to cocaine."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without the specific reference or title of the publication, the veracity of the statement regarding the timing and lead researcher of the first comprehensive analysis of the mouse hippocampal proteome cannot be confirmed.\n2. UNKNOWN: The number of proteins identified in Dr. Eric Johnson's study is not verifiable without access to the specific study details.\n3. UNKNOWN: Without accessing the specific publication by Dr. David W. Andrews, the details about the 2006 study and its findings regarding proteins differentially expressed after seizures in mice cannot be verified.\n4. UNKNOWN: The statement about Dr. Mark S. Sonders and colleagues' study is not verifiable without the relevant publication or source of this information. The year and the number of proteins identified are specific, but there is no way to confirm the details without additional data.\n5. UNKNOWN: The statement concerning Dr. Michael E. Greenberg's study at Harvard Medical School and its findings regarding differential protein expression after exposure to cocaine cannot be verified without additional context or reference to the specific study.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-7b-chat-hf_response": "No, mouse chromosomes are not acrocentric. Acrocentric chromosomes are characterized by a large centromere and a short arm (p arm), and are typically found in mammalian species such as humans and primates. Mouse chromosomes, on the other hand, are metacentric, meaning that the centromere is located near the middle of the chromosome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mouse chromosomes are not acrocentric.\n2. Acrocentric chromosomes have a large centromere and a short arm (p arm).\n3. Acrocentric chromosomes are found in mammalian species such as humans and primates.\n4. Mouse chromosomes are metacentric, which means that the centromere is located near the middle of the chromosome.",
    "llama-2-7b-chat-hf_fact": [
      "Mouse chromosomes are not acrocentric.",
      "Acrocentric chromosomes have a large centromere and a short arm (p arm).",
      "Acrocentric chromosomes are found in mammalian species such as humans and primates.",
      "Mouse chromosomes are metacentric, which means that the centromere is located near the middle of the chromosome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mouse chromosomes are indeed acrocentric.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Mouse chromosomes are acrocentric, which means the centromere is located near one end of the chromosome, creating a long arm (q arm) and a short arm (p arm).",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-7b-chat-hf_response": "There are several siRNA-based drugs in clinical trials for the treatment of pancreatic cancer, including:\n1. ONC205: ONC205 is an siRNA-based drug that targets the gene encoding the protein PD-L1 (programmed death-ligand 1). It is being developed by OncoGenex Pharmaceuticals and is currently in Phase 2 clinical trials for the treatment of pancreatic cancer.\n2. RX-0201: RX-0201 is an siRNA-based drug that targets the gene encoding the protein KRAS (Kirsten rat sarcoma viral oncogene homolog). It is being developed by Rexahn Pharmaceuticals and is currently in Phase 2 clinical trials for the treatment of pancreatic cancer.\n3. BSI-201: BSI-201 is an siRNA-based drug that targets the gene encoding the protein Bcl-2 (B-cell lymphoma 2). It is being developed by BioSight Pharmaceuticals and is currently in Phase 2 clinical trials for the treatment of pancreatic cancer.\nIt is important to note that these drugs are still in the experimental stage and have not yet been approved by regulatory authorities for use in humans.",
    "llama-2-7b-chat-hf_fact_raw": "1. ONC205 is an siRNA-based drug in Phase 2 clinical trials for the treatment of pancreatic cancer.\n2. ONC205 targets the gene encoding the protein PD-L1.\n3. RX-0201 is an siRNA-based drug in Phase 2 clinical trials for the treatment of pancreatic cancer.\n4. RX-0201 targets the gene encoding the protein KRAS.\n5. BSI-201 is an siRNA-based drug in Phase 2 clinical trials for the treatment of pancreatic cancer.",
    "llama-2-7b-chat-hf_fact": [
      "ONC205 is an siRNA-based drug in Phase 2 clinical trials for the treatment of pancreatic cancer.",
      "ONC205 targets the gene encoding the protein PD-L1.",
      "RX-0201 is an siRNA-based drug in Phase 2 clinical trials for the treatment of pancreatic cancer.",
      "RX-0201 targets the gene encoding the protein KRAS.",
      "BSI-201 is an siRNA-based drug in Phase 2 clinical trials for the treatment of pancreatic cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: BSI-201 (also known as Iniparib) is not an siRNA-based drug; it is a small molecule drug that was being investigated as a PARP inhibitor, mainly in clinical trials for the treatment of triple-negative breast cancer, not pancreatic cancer. It has also failed to show benefit in Phase 3 trials for breast cancer, leading to the cessation of its development for this indication.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-7b-chat-hf_response": "The HPG (Hexamethylene Glycol) pore is a type of ion channel that is found in the inner mitochondrial membrane. It is a small, non-selective pore that allows the passage of small molecules, such as ions and small metabolites, between the cytosol and the mitochondrial matrix. The HPG pore plays a critical role in regulating the metabolism of the mitochondria, particularly in the context of cellular stress and energy metabolism.",
    "llama-2-7b-chat-hf_fact_raw": "1. The HPG pore is found in the inner mitochondrial membrane.\n2. It is a type of ion channel.\n3. The HPG pore allows the passage of small molecules, including ions and small metabolites.\n4. The HPG pore is non-selective.\n5. It plays a critical role in regulating mitochondrial metabolism, especially during cellular stress and energy metabolism.",
    "llama-2-7b-chat-hf_fact": [
      "The HPG pore is found in the inner mitochondrial membrane.",
      "It is a type of ion channel.",
      "The HPG pore allows the passage of small molecules, including ions and small metabolites.",
      "The HPG pore is non-selective.",
      "It plays a critical role in regulating mitochondrial metabolism, especially during cellular stress and energy metabolism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The term \"HPG pore\" appears to be incorrect or a typo, as there is no widely recognized pore with this exact name in the inner mitochondrial membrane. A commonly known pore is the \"MPT pore,\" which stands for mitochondrial permeability transition pore.\n2. UNKNOWN: Without the correct terminology of the pore, it is unclear whether it refers to an ion channel or another type of pore. Assuming the correction to \"MPT pore,\" it is a type of pore that can allow ions to pass, but it is not an ion channel in the strictest sense.\n3. TRUE: Assuming the correction to \"MPT pore,\" this statement would be true. The mitochondrial permeability transition pore allows the passage of small molecules, including ions and small metabolites, across the mitochondrial membrane.\n4. TRUE: Assuming the correction to \"MPT pore,\" this statement would again be true, as the mitochondrial permeability transition pore is relatively non-selective, allowing a variety of molecules to pass through when it is open.\n5. TRUE: Assuming the correction to \"MPT pore,\" this statement is true. The mitochondrial permeability transition pore plays a critical role in regulating mitochondrial metabolism and can be involved in cellular stress responses and energy metabolism.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-7b-chat-hf_response": "The 959 Nematode Genomes initiative is a research project aimed at sequencing and analyzing the genomes of 959 species of nematodes, which are a group of microscopic worms that include parasitic and free-living species. The initiative was launched in 2017 and is led by the University of California, Riverside (UCR) in collaboration with several other institutions.\nNematodes are a diverse group of organisms that play important roles in ecosystems, including as plant parasites, decomposers, and symbionts. However, their genomes have been relatively understudied compared to those of other organisms, such as animals and plants. The 959 Nematode Genomes initiative aims to change this by generating high-quality genome sequences for a large number of nematode species, which will provide new insights into their evolution, biology, and interactions with their environments.\nThe initiative is using a combination of next-generation sequencing technologies and bioinformatic tools to generate genome assemblies for the 959 nematode species. The project also includes a comprehensive analysis of the genomes, including the identification of genes, regulatory elements, and other features. The data generated by the initiative will be made publicly available through a database, which will provide a valuable resource for researchers studying nematodes and their roles in ecosystems.\nOverall, the 959 Nematode Genomes initiative is an ambitious and exciting project that will help to advance our understanding of these fascinating organisms and their importance in the natural world.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 nematode species.\n2. The initiative was launched in 2017.\n3. The project is led by the University of California, Riverside (UCR) in collaboration with other institutions.\n4. The initiative employs next-generation sequencing technologies and bioinformatic tools to generate genome assemblies.\n5. The data from the 959 Nematode Genomes initiative will be made publicly available through a database.",
    "llama-2-7b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 nematode species.",
      "The initiative was launched in 2017.",
      "The project is led by the University of California, Riverside (UCR) in collaboration with other institutions.",
      "The initiative employs next-generation sequencing technologies and bioinformatic tools to generate genome assemblies.",
      "The data from the 959 Nematode Genomes initiative will be made publicly available through a database."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The 959 Nematode Genomes initiative, also known as the 959 Nematode Genomes Project or the \"959 Project\", was initially conceived around 2007-2008, with projects like the 1000 Nematode Genomes Project which are related in scope.\n3. UNKNOWN: Without specific current information, the specific institutions leading the project cannot be confirmed. While the University of California, Riverside has prominent researchers in nematology, leadership in a specific project may change or be shared among various institutions and researchers.\n4. TRUE: It is logical that a genome sequencing initiative such as the 959 Nematode Genomes initiative would employ next-generation sequencing technologies and bioinformatic tools; these are standard methods for contemporary genome sequencing projects.\n5. TRUE: In keeping with the conventions of most modern genomic research efforts, datasets generated are generally expected to be made publicly available through databases, often in accordance with data-sharing policies that promote open science.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for analyzing Non-invasive prenatal testing (NIPT) data. Some of the popular ones include:\n1. NIPT: This package provides a set of functions for analyzing NIPT data, including data cleaning, filtering, and statistical analysis.\n2. Prenat: This package provides a comprehensive set of functions for the analysis of NIPT data, including data cleaning, filtering, and statistical analysis.\n3. PrenatalTesting: This package provides a set of functions for analyzing NIPT data, including data cleaning, filtering, and statistical analysis.\n4. NIPTAnalysis: This package provides a set of functions for analyzing NIPT data, including data cleaning, filtering, and statistical analysis.\n5. PrenatalGenetics: This package provides a set of functions for analyzing NIPT data, including data cleaning, filtering, and statistical analysis.\nIt is important to note that these packages may have different functionalities and user interfaces, and the choice of package may depend on the specific requirements of the analysis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R package \"NIPT\" has been developed for analyzing Non-invasive prenatal testing data.\n2. The R package \"Prenat\" is designed for the analysis of Non-invasive prenatal testing data.\n3. \"PrenatalTesting\" is an R package created for analyzing NIPT data.\n4. \"NIPTAnalysis\" is an R package that provides functions for the analysis of NIPT data.\n5. The R package \"PrenatalGenetics\" includes functions for analyzing Non-invasive prenatal testing data.",
    "llama-2-7b-chat-hf_fact": [
      "The R package \"NIPT\" has been developed for analyzing Non-invasive prenatal testing data.",
      "The R package \"Prenat\" is designed for the analysis of Non-invasive prenatal testing data.",
      "\"PrenatalTesting\" is an R package created for analyzing NIPT data.",
      "\"NIPTAnalysis\" is an R package that provides functions for the analysis of NIPT data.",
      "The R package \"PrenatalGenetics\" includes functions for analyzing Non-invasive prenatal testing data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nUnfortunately, without specific information about R packages up to my last update in early 2023, I cannot confirm the existence or the purpose of these R packages. The R language and the Comprehensive R Archive Network (CRAN) host a wide range of packages for various types of data analysis, and unless specific and updated information on these packages is provided, their existence and functions remain unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "llama-2-7b-chat-hf_response": "Achenbach's syndrome is a rare genetic disorder that affects the development of the brain and nervous system. It is characterized by a combination of intellectual disability, seizures, and distinctive facial features, including a flat nasal bridge, widely spaced eyes, and a small jaw. Other symptoms can include delayed speech and language development, motor delays, and behavioral problems. The exact cause of Achenbach's syndrome is not known, but it is thought to be due to a mutation in a gene that is important for brain development. The disorder is usually diagnosed in early childhood and can be identified through a combination of clinical evaluation, imaging studies, and genetic testing. Treatment for Achenbach's syndrome typically involves a multidisciplinary approach, including medication for seizures and behavioral problems, as well as therapies to help improve cognitive and motor function.",
    "llama-2-7b-chat-hf_fact_raw": "1. Achenbach's syndrome is a rare genetic disorder affecting the development of the brain and nervous system.\n2. The syndrome is characterized by intellectual disability, seizures, and distinctive facial features such as a flat nasal bridge, widely spaced eyes, and a small jaw.\n3. Symptoms of Achenbach's syndrome can include delayed speech and language development, motor delays, and behavioral problems.\n4. Achenbach's syndrome is typically diagnosed through clinical evaluation, imaging studies, and genetic testing.\n5. Treatment for Achenbach's syndrome involves a multidisciplinary approach, including medication and therapies to improve cognitive and motor function.",
    "llama-2-7b-chat-hf_fact": [
      "Achenbach's syndrome is a rare genetic disorder affecting the development of the brain and nervous system.",
      "The syndrome is characterized by intellectual disability, seizures, and distinctive facial features such as a flat nasal bridge, widely spaced eyes, and a small jaw.",
      "Symptoms of Achenbach's syndrome can include delayed speech and language development, motor delays, and behavioral problems.",
      "Achenbach's syndrome is typically diagnosed through clinical evaluation, imaging studies, and genetic testing.",
      "Treatment for Achenbach's syndrome involves a multidisciplinary approach, including medication and therapies to improve cognitive and motor function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Achenbach's syndrome is not a genetic disorder; it is a condition characterized by spontaneous bruising of the hands or fingers. \n2. FALSE [correction]: The description of distinctive facial features and other symptoms pertains to a different condition, not Achenbach's syndrome.\n3. FALSE [correction]: These symptoms are not associated with Achenbach's syndrome but may relate to other developmental disorders. Achenbach's syndrome is characterized by paroxysmal hand hematoma or \"blue finger syndrome.\"\n4. FALSE [correction]: Achenbach's syndrome would not typically require imaging studies or genetic testing for diagnosis. It is a benign, self-limiting condition usually diagnosed based on clinical presentation and patient history.\n5. FALSE [correction]: Since Achenbach's syndrome is generally a benign and self-limiting condition that resolves spontaneously, a multidisciplinary approach including medication and therapies to improve cognitive and motor function is not relevant to this condition.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-7b-chat-hf_response": "Long repeat expansions are typically detected using algorithms that are designed to identify repetitive sequences in DNA. Some common algorithms used for this purpose include:\n1. RepeatMasker: This is a widely used algorithm that can identify repetitive sequences in DNA, including long repeat expansions. It works by comparing the query sequence to a database of known repeat sequences and identifying any matches.\n2. RepeatFinder: This algorithm is similar to RepeatMasker, but it is more sensitive and can identify smaller repeat elements. It uses a probabilistic approach to identify repeat sequences and can be used to detect both short and long repeat expansions.\n3. Gapped Repeat Finder: This algorithm uses a combination of computational and statistical methods to identify repeat sequences in DNA. It can be used to detect both short and long repeat expansions and is particularly useful for identifying repeat sequences that are interrupted by gaps in the DNA sequence.\n4. Long Repeat Finder: This algorithm is specifically designed to identify long repeat expansions in DNA. It uses a combination of computational and statistical methods to identify repeat sequences and can be used to detect both repetitive and non-repetitive sequences.\n5. HMMER: This algorithm uses a hidden Markov model to identify repeat sequences in DNA. It can be used to detect both short and long repeat expansions and is particularly useful for identifying repeat sequences that are highly conserved across different species.\nThese algorithms are widely used in bioinformatics and genomics to identify long repeat expansions in DNA sequences. The choice of algorithm will depend on the specific research question and the characteristics of the DNA sequence being analyzed.",
    "llama-2-7b-chat-hf_fact_raw": "1. RepeatMasker is an algorithm used to identify repetitive sequences in DNA, including long repeat expansions.\n2. RepeatFinder is an algorithm that uses a probabilistic approach to detect short and long repeat expansions.\n3. Gapped Repeat Finder is used to identify repeat sequences in DNA that may be interrupted by gaps.\n4. Long Repeat Finder is an algorithm designed specifically to identify long repeat expansions in DNA.\n5. HMMER is an algorithm that employs a hidden Markov model to identify repeat sequences in DNA.",
    "llama-2-7b-chat-hf_fact": [
      "RepeatMasker is an algorithm used to identify repetitive sequences in DNA, including long repeat expansions.",
      "RepeatFinder is an algorithm that uses a probabilistic approach to detect short and long repeat expansions.",
      "Gapped Repeat Finder is used to identify repeat sequences in DNA that may be interrupted by gaps.",
      "Long Repeat Finder is an algorithm designed specifically to identify long repeat expansions in DNA.",
      "HMMER is an algorithm that employs a hidden Markov model to identify repeat sequences in DNA."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. FALSE [correction]: There is no widely recognized algorithm specifically known as \"Gapped Repeat Finder.\" Algorithms like RepeatMasker can identify repeat sequences and sometimes account for gaps, but Gapped Repeat Finder is not a standard name for such an algorithm.\n4. UNKNOWN\n5. FALSE [correction]: HMMER is an algorithm that employs hidden Markov models, but it is primarily used for protein sequence analysis and identifying sequence homology, not specifically for identifying repeat sequences in DNA.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-7b-chat-hf_response": "Neuroligin-3 has been implicated in the development and progression of certain types of brain tumors, including:\n* Glioblastoma (GBM): Neuroligin-3 is overexpressed in a majority of GBM cases and has been linked to tumor progression and poor prognosis.\n* Medulloblastoma: Neuroligin-3 is also overexpressed in medulloblastoma, a type of pediatric brain cancer that originates in the cerebellum.\n* Other brain tumors: Neuroligin-3 has also been found to be overexpressed in other types of brain tumors, including pineal parenchymal tumors, meningioma, and acoustic neuroma.\nIt's worth noting that the exact role of neuroligin-3 in the development and progression of these tumors is still being studied and debated, and more research is needed to fully understand its involvement.",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuroligin-3 is implicated in the development and progression of certain types of brain tumors.\n2. Neuroligin-3 is overexpressed in a majority of glioblastoma (GBM) cases.\n3. The overexpression of neuroligin-3 in glioblastoma has been linked to tumor progression and poor prognosis.\n4. Neuroligin-3 is overexpressed in medulloblastoma, a pediatric brain cancer that originates in the cerebellum.\n5. Other brain tumors, including pineal parenchymal tumors, meningioma, and acoustic neuroma, have been found to have overexpression of neuroligin-3.",
    "llama-2-7b-chat-hf_fact": [
      "Neuroligin-3 is implicated in the development and progression of certain types of brain tumors.",
      "Neuroligin-3 is overexpressed in a majority of glioblastoma (GBM) cases.",
      "The overexpression of neuroligin-3 in glioblastoma has been linked to tumor progression and poor prognosis.",
      "Neuroligin-3 is overexpressed in medulloblastoma, a pediatric brain cancer that originates in the cerebellum.",
      "Other brain tumors, including pineal parenchymal tumors, meningioma, and acoustic neuroma, have been found to have overexpression of neuroligin-3."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Neuroligin-3 has been implicated in the development and progression of certain types of brain tumors. Research has shown that it might play a role in promoting the growth of these tumors.\n2. TRUE: Neuroligin-3 has been reported to be overexpressed in a majority of glioblastoma (GBM) cases. Several studies suggest that it is associated with the aggressive nature of GBM.\n3. TRUE: The correlation between the overexpression of neuroligin-3 in glioblastoma and tumor progression as well as poor prognosis has been established in the scientific literature.\n4. TRUE: Neuroligin-3 is indeed overexpressed in medulloblastoma, and its overexpression has been linked to the disease's severity and prognosis.\n5. UNKNOWN: While neuroligin-3 has been found to be overexpressed in some brain tumors besides glioblastoma and medulloblastoma, the specific mention of pineal parenchymal tumors, meningioma, and acoustic neuroma having overexpression of neuroligin-3 cannot be confirmed without further context or references to specific studies. Therefore, the statement is UNKNOWN without additional information.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-7b-chat-hf_response": "Gas vesicles in bacteria are typically around 10-50 nanometers (nm) in diameter, although they can range in size from a few nm to several hundred nm.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gas vesicles in bacteria are around 10-50 nanometers in diameter.\n2. The size of gas vesicles can vary from a few nanometers to several hundred nanometers.",
    "llama-2-7b-chat-hf_fact": [
      "Gas vesicles in bacteria are around 10-50 nanometers in diameter.",
      "The size of gas vesicles can vary from a few nanometers to several hundred nanometers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gas vesicles in bacteria are typically around 45-200 nanometers in diameter, not 10-50 nanometers.\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-7b-chat-hf_response": "BET (Bromodomain and Extra-Terminal) proteins are a family of proteins that play a crucial role in regulating gene expression by modifying chromatin structure. Here are some of the BET proteins that have been identified:\n1. BRD2 (Bromodomain-Containing Protein 2): This protein is the most well-studied member of the BET family and has been implicated in a variety of cellular processes, including transcriptional activation, DNA damage response, and cancer.\n2. BRD3 (Bromodomain-Containing Protein 3): Similar to BRD2, BRD3 has been linked to a range of cellular processes, including transcriptional regulation, cell proliferation, and cancer.\n3. BRDT (Bromodomain-Containing Protein T): This protein is a member of the BET family that is primarily expressed in the testis and has been implicated in the regulation of gene expression during spermatogenesis.\n4. BRDM2 (Bromodomain-Containing Protein 2-Like 2): This protein is a paralog of BRD2 and shares similar functions and properties.\n5. BRD4 (Bromodomain-Containing Protein 4): This protein is a member of the BET family that has been implicated in a variety of cellular processes, including transcriptional regulation, cell proliferation, and cancer.\n6. BRD3L1 (Bromodomain-Containing Protein 3-Like 1): This protein is a paralog of BRD3 and shares similar functions and properties.\n7. BRD3L2 (Bromodomain-Containing Protein 3-Like 2): This protein is another paralog of BRD3 that has been implicated in similar cellular processes.\n8. BRD4L (Bromodomain-Containing Protein 4-Like): This protein is a paralog of BRD4 that has been linked to a range of cellular processes, including transcriptional regulation and cancer.\n9. BET1 (Bromodomain-Containing Protein 1): This protein is a member of the BET family that is primarily expressed in the brain and has been imp",
    "llama-2-7b-chat-hf_fact_raw": "1. BET proteins regulate gene expression by modifying chromatin structure.\n2. BRD2 (Bromodomain-Containing Protein 2) is implicated in transcriptional activation, DNA damage response, and cancer.\n3. BRD3 (Bromodomain-Containing Protein 3) is linked to transcriptional regulation, cell proliferation, and cancer.\n4. BRDT (Bromodomain-Containing Protein T) is primarily expressed in the testis and implicated in gene expression regulation during spermatogenesis.\n5. BRD4 (Bromodomain-Containing Protein 4) is implicated in transcriptional regulation, cell proliferation, and cancer.",
    "llama-2-7b-chat-hf_fact": [
      "BET proteins regulate gene expression by modifying chromatin structure.",
      "BRD2 (Bromodomain-Containing Protein 2) is implicated in transcriptional activation, DNA damage response, and cancer.",
      "BRD3 (Bromodomain-Containing Protein 3) is linked to transcriptional regulation, cell proliferation, and cancer.",
      "BRDT (Bromodomain-Containing Protein T) is primarily expressed in the testis and implicated in gene expression regulation during spermatogenesis.",
      "BRD4 (Bromodomain-Containing Protein 4) is implicated in transcriptional regulation, cell proliferation, and cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAll the statements provided fall in line with commonly known functions or characteristics associated with BET (Bromodomain and ExtraTerminal domain) proteins and specifically the BRD family members mentioned. They are indeed related to chromatin remodeling, transcriptional regulation, and have been implicated in various cellular processes, including those related to cancer and spermatogenesis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-7b-chat-hf_response": "One algorithm that has been developed for predicting protein subcellular localization using deep learning is the \"DeepLoc\" algorithm. It was proposed by the group of Zhang et al. in 2015 and has been shown to achieve state-of-the-art performance on several protein subcellular localization benchmarks.\nDeepLoc is a deep learning-based method that uses a convolutional neural network (CNN) to predict protein subcellular localization. The algorithm takes as input a protein sequence and outputs a probability distribution over the possible subcellular localizations (such as cytoplasm, nucleus, membrane, etc.). The CNN is trained on a large dataset of protein sequences and their corresponding subcellular localizations, and the learning process is optimized using a combination of cross-entropy loss and transfer learning.\nDeepLoc has been shown to outperform other machine learning-based localization methods, including support vector machines (SVMs) and random forests, on several benchmark datasets. It has also been used to predict the localization of proteins in a variety of organisms, including bacteria, yeast, and humans.\nOverall, DeepLoc is a powerful tool for predicting protein subcellular localization using deep learning, and it has the potential to be used for a wide range of applications in bioinformatics and functional genomics.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"DeepLoc\" algorithm for predicting protein subcellular localization using deep learning was proposed by Zhang et al. in 2015.\n2. DeepLoc uses a convolutional neural network (CNN) to predict protein subcellular localization.\n3. The DeepLoc algorithm requires a protein sequence as input and outputs a probability distribution over possible subcellular localizations.\n4. The CNN in DeepLoc is trained on a large dataset of protein sequences with their corresponding subcellular localizations.\n5. DeepLoc has been used to predict the localization of proteins in organisms including bacteria, yeast, and humans.",
    "llama-2-7b-chat-hf_fact": [
      "The \"DeepLoc\" algorithm for predicting protein subcellular localization using deep learning was proposed by Zhang et al. in 2015.",
      "DeepLoc uses a convolutional neural network (CNN) to predict protein subcellular localization.",
      "The DeepLoc algorithm requires a protein sequence as input and outputs a probability distribution over possible subcellular localizations.",
      "The CNN in DeepLoc is trained on a large dataset of protein sequences with their corresponding subcellular localizations.",
      "DeepLoc has been used to predict the localization of proteins in organisms including bacteria, yeast, and humans."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The \"DeepLoc\" algorithm was proposed by Almagro Armenteros et al. in 2017, not by Zhang et al. in 2015.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-7b-chat-hf_response": "MULTOVL is not a term or a protein that I am familiar with in the context of molecular biology. It is possible that it is a misspelling or a term used in a specific context or field that I am not aware of. Can you please provide more information or context about where you encountered this term?",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-7b-chat-hf_response": "Yes, GDF15 has been identified as a potential biomarker for metformin treatment. Studies have shown that GDF15 levels are increased in response to metformin treatment in patients with type 2 diabetes, and that this increase is associated with improved insulin sensitivity and glucose metabolism. Therefore, GDF15 could potentially be used as a biomarker to monitor the effectiveness of metformin treatment and to identify patients who are likely to respond to this medication.",
    "llama-2-7b-chat-hf_fact_raw": "1. GDF15 has been identified as a potential biomarker for metformin treatment.\n2. GDF15 levels increase in response to metformin treatment in patients with type 2 diabetes.\n3. The increase in GDF15 levels is associated with improved insulin sensitivity and glucose metabolism.\n4. GDF15 could potentially be used to monitor the effectiveness of metformin treatment.\n5. GDF15 could help identify patients who are likely to respond to metformin.",
    "llama-2-7b-chat-hf_fact": [
      "GDF15 has been identified as a potential biomarker for metformin treatment.",
      "GDF15 levels increase in response to metformin treatment in patients with type 2 diabetes.",
      "The increase in GDF15 levels is associated with improved insulin sensitivity and glucose metabolism.",
      "GDF15 could potentially be used to monitor the effectiveness of metformin treatment.",
      "GDF15 could help identify patients who are likely to respond to metformin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nNote: Each statement's truth is contingent upon the latest scientific research up to the knowledge cutoff date. The potential use of GDF15 as a biomarker for metformin treatment, its association with improved insulin sensitivity and glucose metabolism, and its potential in identifying patients likely to respond to treatment are all subject to ongoing research and future validation.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-7b-chat-hf_response": "Yes, recursive splicing is more common in short introns. Recursive splicing, also known as intron circularization, occurs when the splicing machinery recognizes and splices the same intron multiple times, resulting in the formation of a circular splicing pattern. This type of splicing is more likely to occur in short introns, which have a shorter length and may have a higher concentration of splicing sites, making it more likely for the splicing machinery to encounter the same intron multiple times.",
    "llama-2-7b-chat-hf_fact_raw": "1. Recursive splicing is more common in short introns.\n2. Recursive splicing is also known as intron circularization.\n3. Recursive splicing occurs when the splicing machinery splices the same intron multiple times.\n4. The formation of a circular splicing pattern results from recursive splicing.\n5. Short introns may have a higher concentration of splicing sites, which can lead to recursive splicing.",
    "llama-2-7b-chat-hf_fact": [
      "Recursive splicing is more common in short introns.",
      "Recursive splicing is also known as intron circularization.",
      "Recursive splicing occurs when the splicing machinery splices the same intron multiple times.",
      "The formation of a circular splicing pattern results from recursive splicing.",
      "Short introns may have a higher concentration of splicing sites, which can lead to recursive splicing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Recursive splicing is more common in long introns where it facilitates the removal of long intronic sequences in a stepwise fashion.\n2. FALSE [correction]: Recursive splicing is not synonymous with intron circularization. In recursive splicing, a multi-step process removes long introns by creating lariat structures at \"recursive splice sites\" within an intron, which are then resolved in subsequent splicing reactions. In contrast, intron circularization typically refers to the formation of a circular RNA molecule from an excised intron.\n3. TRUE\n4. FALSE [correction]: The formation of a circular splicing pattern is not a direct result of recursive splicing. While recursive splicing involves the creation of intermediate lariat structures during the removal of long introns, it does not necessarily result in circular RNA. Circular RNAs can be produced from exons or introns by back-splicing or intron circularization, which are distinct processes from recursive splicing.\n5. FALSE [correction]: It is not necessarily the concentration of splicing sites that leads to recursive splicing but rather the presence of recursive splice sites within long introns that allow them to be spliced in a piecewise manner. These recursive splice sites provide a mechanism to splice out such introns gradually rather than as one large entity.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-7b-chat-hf_response": "TALE-iD is a method used for identifying the functional elements in a genome, such as enhancers, silencers, and promoters, by using a technique called CRISPR-Cas9-based genome editing. TALE-iD stands for TALE-based Identification of Regulatory Elements, and it is used to identify the specific locations in the genome where these functional elements are located.",
    "llama-2-7b-chat-hf_fact_raw": "1. TALE-iD is used for identifying functional elements in a genome.\n2. Functional elements that TALE-iD can identify include enhancers, silencers, and promoters.\n3. TALE-iD uses the CRISPR-Cas9-based genome editing technique.\n4. The acronym TALE-iD stands for TALE-based Identification of Regulatory Elements.\n5. TALE-iD identifies the specific locations in the genome where functional elements are located.",
    "llama-2-7b-chat-hf_fact": [
      "TALE-iD is used for identifying functional elements in a genome.",
      "Functional elements that TALE-iD can identify include enhancers, silencers, and promoters.",
      "TALE-iD uses the CRISPR-Cas9-based genome editing technique.",
      "The acronym TALE-iD stands for TALE-based Identification of Regulatory Elements.",
      "TALE-iD identifies the specific locations in the genome where functional elements are located."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: TALE-iD does not use the CRISPR-Cas9-based genome editing technique. It is based on transcription activator-like effector (TALE) technology.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-7b-chat-hf_response": "There are several Lisp frameworks that have been developed for image processing, including:\n1. CL-Image: A Lisp library for image processing, featuring functions for image manipulation, filtering, and analysis.\n2. Lisp-Image: A Lisp image processing framework with support for image manipulation, analysis, and visualization.\n3. ImageTk: A Lisp interface to the Tk image processing toolkit, providing a simple and easy-to-use image processing environment.\n4. Drew: A Lisp image processing system that provides a high-level interface for image manipulation and analysis, with support for a wide range of image formats.\n5. Image-Lisp: A Lisp image processing library that provides a wide range of image processing functions, including filtering, resizing, and color manipulation.\nThese are just a few examples of the many Lisp frameworks available for image processing. Each one has its own unique features and capabilities, so it's worth exploring each one to determine which one is the best fit for your needs.",
    "llama-2-7b-chat-hf_fact_raw": "1. CL-Image is a Lisp library for image processing.\n2. Lisp-Image is a framework that supports image manipulation, analysis, and visualization.\n3. ImageTk is a Lisp interface to the Tk image processing toolkit.\n4. Drew is a Lisp image processing system with support for a wide range of image formats.\n5. Image-Lisp provides a variety of image processing functions such as filtering, resizing, and color manipulation.",
    "llama-2-7b-chat-hf_fact": [
      "CL-Image is a Lisp library for image processing.",
      "Lisp-Image is a framework that supports image manipulation, analysis, and visualization.",
      "ImageTk is a Lisp interface to the Tk image processing toolkit.",
      "Drew is a Lisp image processing system with support for a wide range of image formats.",
      "Image-Lisp provides a variety of image processing functions such as filtering, resizing, and color manipulation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: The correct name seems to be CL-Image, not Lisp-Image, per the first statement.\n3. FALSE [correction]: ImageTk is not a Lisp interface; it is part of the Python Imaging Library (PIL) that provides an interface to the Tk toolkit which is commonly used with Tcl/Tk, not Lisp.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-7b-chat-hf_response": "In Saccharomyces cerevisiae (baker's yeast), approximately 800-900 genes are the result of an ancient whole genome duplication. This duplication event occurred around 1000-2000 million years ago and is thought to have played a key role in the evolution of eukaryotic cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. In Saccharomyces cerevisiae, approximately 800-900 genes are the result of an ancient whole genome duplication.\n2. The whole genome duplication event in Saccharomyces cerevisiae occurred around 1000-2000 million years ago.\n3. The whole genome duplication is thought to have played a key role in the evolution of eukaryotic cells.",
    "llama-2-7b-chat-hf_fact": [
      "In Saccharomyces cerevisiae, approximately 800-900 genes are the result of an ancient whole genome duplication.",
      "The whole genome duplication event in Saccharomyces cerevisiae occurred around 1000-2000 million years ago.",
      "The whole genome duplication is thought to have played a key role in the evolution of eukaryotic cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The whole genome duplication event in Saccharomyces cerevisiae is estimated to have occurred around 100 million years ago, not 1000-2000 million years ago.\n3. FALSE [correction]: The whole genome duplication in Saccharomyces cerevisiae is thought to have played a key role in the evolution of this particular species and possibly some related yeasts, not in the evolution of eukaryotic cells in general, which encompasses a much broader group of organisms. Whole genome duplications, though, have occurred in the ancestry of other eukaryotes and may have played a role in their evolution.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-2-7b-chat-hf_response": "Estrogen-related receptor β (Esrrb) binds to the complex of estrogen and estrogen-binding proteins, such as sex hormone-binding globulin (SHBG) and corticosteroid-binding globulin (CBG).",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-7b-chat-hf_response": "ZCCHC17 is a zinc finger CCHC-type histone triad-containing protein that plays a crucial role in regulating gene expression by modulating the structure of chromatin. It is involved in the epigenetic modification of histone proteins, particularly histone H3, and helps to maintain the proper organization of chromatin structures during cell division. Additionally, ZCCHC17 has been implicated in the regulation of stem cell self-renewal and differentiation, as well as in the development and progression of certain cancers.",
    "llama-2-7b-chat-hf_fact_raw": "1. ZCCHC17 is a zinc finger CCHC-type histone triad-containing protein.\n2. ZCCHC17 is involved in regulating gene expression by modulating the structure of chromatin.\n3. It is involved in the epigenetic modification of histone proteins, particularly histone H3.\n4. ZCCHC17 helps maintain the organization of chromatin structures during cell division.\n5. ZCCHC17 has been implicated in the regulation of stem cell self-renewal and differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "ZCCHC17 is a zinc finger CCHC-type histone triad-containing protein.",
      "ZCCHC17 is involved in regulating gene expression by modulating the structure of chromatin.",
      "It is involved in the epigenetic modification of histone proteins, particularly histone H3.",
      "ZCCHC17 helps maintain the organization of chromatin structures during cell division.",
      "ZCCHC17 has been implicated in the regulation of stem cell self-renewal and differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nRationale:\n- ZCCHC17 is indeed known to be a zinc finger protein, as the name suggests.\n- Zinc finger proteins, in general, are often involved in regulating gene expression by interacting with DNA or RNA, which would involve chromatin structure to some degree.\n- Statements 3 through 5 pertain to very specific functions that ZCCHC17 may or may not have. Without specific literature or scientific studies confirming or denying these roles, one cannot accurately state the veracity of these statements. They are specific assertions that would require detailed biological knowledge or a specific context from the passage that has not been provided.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-7b-chat-hf_response": "The nuclear pore basket, also known as the nuclear pore complex (NPC), is composed of several proteins in human cells. The main proteins that make up the NPC are:\n1. Nucleoporin 1 (Nup1): This protein forms the central channel of the NPC and is responsible for nucleocytoplasmic transport.\n2. Nucleoporin 2 (Nup2): This protein forms the outer layer of the NPC and helps to regulate the transport of molecules between the nucleus and cytoplasm.\n3. Nucleoporin 3 (Nup3): This protein is involved in the assembly and maintenance of the NPC.\n4. Nucleoporin 4 (Nup4): This protein is a component of the NPC and helps to regulate the transport of molecules between the nucleus and cytoplasm.\n5. Nucleoporin 5 (Nup5): This protein is involved in the assembly and maintenance of the NPC.\n6. Nucleoporin 6 (Nup6): This protein is a component of the NPC and helps to regulate the transport of molecules between the nucleus and cytoplasm.\n7. Nucleoporin 7 (Nup7): This protein is involved in the assembly and maintenance of the NPC.\n8. Nucleoporin 8 (Nup8): This protein is a component of the NPC and helps to regulate the transport of molecules between the nucleus and cytoplasm.\n9. Nucleoporin 9 (Nup9): This protein is involved in the assembly and maintenance of the NPC.\n10. Nucleoporin 10 (Nup10): This protein is a component of the NPC and helps to regulate the transport of molecules between the nucleus and cytoplasm.\nThese proteins work together to form a complex that spans the nuclear envelope and regulates the transport of molecules between the nucleus and cytoplasm.",
    "llama-2-7b-chat-hf_fact_raw": "1. Nucleoporin 1 (Nup1) is a protein that forms the central channel of the nuclear pore complex (NPC) in human cells.\n2. Nucleoporin 2 (Nup2) is a protein that forms the outer layer of the NPC and helps regulate transport between the nucleus and cytoplasm in human cells.\n3. Nucleoporin 3 (Nup3) is involved in the assembly and maintenance of the NPC in human cells.\n4. Nucleoporin 4 (Nup4) is a component of the NPC that helps to regulate transport of molecules between the nucleus and cytoplasm in human cells.\n5. Nucleoporin 5 (Nup5) is involved in the assembly and maintenance of the NPC in human cells.",
    "llama-2-7b-chat-hf_fact": [
      "Nucleoporin 1 (Nup1) is a protein that forms the central channel of the nuclear pore complex (NPC) in human cells.",
      "Nucleoporin 2 (Nup2) is a protein that forms the outer layer of the NPC and helps regulate transport between the nucleus and cytoplasm in human cells.",
      "Nucleoporin 3 (Nup3) is involved in the assembly and maintenance of the NPC in human cells.",
      "Nucleoporin 4 (Nup4) is a component of the NPC that helps to regulate transport of molecules between the nucleus and cytoplasm in human cells.",
      "Nucleoporin 5 (Nup5) is involved in the assembly and maintenance of the NPC in human cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There is no specific protein designated as Nucleoporin 1 (Nup1) forming the central channel of the nuclear pore complex (NPC) in human cells. Nucleoporins are a family of proteins, and the central channel of the NPC is formed by multiple nucleoporins, but not one specifically called Nup1.\n2. FALSE [correction]: Similar to statement 1, there is no specific protein known as Nucleoporin 2 (Nup2) that forms the outer layer of the NPC. The NPC structure is complex, and its layered structure is composed of multiple nucleoporins.\n3. UNKNOWN: There are nucleoporins that are involved in the assembly and maintenance of the NPC in human cells, but the specific role attributed to a protein dubbed Nucleoporin 3 (Nup3) cannot be confirmed as there is no standardized designation for a Nup3 as it relates to human nucleoporins.\n4. UNKNOWN: As with statements 1, 2, and 3, there isn't widely recognized, standardized naming like Nucleoporin 4 (Nup4), and the specific role of such a protein in regulating transport of molecules cannot be confirmed without more context.\n5. UNKNOWN: Similarly to the other statements regarding specific nucleoporins, there is no standard designation of a Nucleoporin 5 (Nup5), and so the role attributed to it cannot be confirmed without additional context. Nucleoporins do play roles in the assembly and maintenance of the NPC, but the specifics regarding Nup5 are unclear.\n\nIn general, the statements are based on real concepts (nucleoporins and their function in the NPC), but the designations (Nup1, Nup2, etc.) do not match standard nomenclature, and their specified roles cannot be confirmed without more accurate identifiers or context.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-7b-chat-hf_response": "Gepotidacin is a topoisomerase II inhibitor. Specifically, it is a type II topoisomerase inhibitor that selectively binds to and inhibits the activity of topoisomerase IIα (TopoIIα) in cancer cells, leading to the accumulation of topoisomerase II-mediated DNA damage and ultimately causing cell death.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gepotidacin is a topoisomerase II inhibitor.\n2. It selectively binds to and inhibits the activity of topoisomerase IIα (TopoIIα).\n3. Gepotidacin's action leads to the accumulation of DNA damage mediated by topoisomerase II.\n4. The accumulation of DNA damage ultimately causes cell death in cancer cells.",
    "llama-2-7b-chat-hf_fact": [
      "Gepotidacin is a topoisomerase II inhibitor.",
      "It selectively binds to and inhibits the activity of topoisomerase IIα (TopoIIα).",
      "Gepotidacin's action leads to the accumulation of DNA damage mediated by topoisomerase II.",
      "The accumulation of DNA damage ultimately causes cell death in cancer cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\n[correction]: The provided statements relate to the specific mode of action and effects of the drug Gepotidacin, including its target and impact on cells. Given that the specialized information required to verify these statements is not available, and without additional context, it is not possible to confidently confirm or deny the accuracy of the statements. Therefore, the response to each of the four statements is UNKNOWN. For accurate information, consulting current scientific literature on Gepotidacin would be necessary.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-7b-chat-hf_response": "Canvas SPW (Small Molecule Wide-range) is a type of protein-protein interaction (PPI) assay that uses a small molecule ligand to capture and immobilize protein-protein interactions in a high-throughput manner. The assay is based on the concept of a \"canvas\" of small molecules that bind to specific protein-protein interactions, allowing for the detection and quantification of multiple interactions in a single assay.\nIn the Canvas SPW assay, a library of small molecules is used to capture and immobilize protein-protein interactions. The small molecules are designed to bind specifically to the interface between two proteins, creating a \"canvas\" of molecules that capture the interactions between the proteins. The captured interactions are then detected using a variety of methods, such as mass spectrometry or fluorescence microscopy.\nThe advantages of the Canvas SPW assay include:\n1. High-throughput: The assay can be performed in a high-throughput manner, allowing for the simultaneous detection and quantification of multiple protein-protein interactions.\n2. Sensitivity: The small molecule ligands used in the assay are highly specific and sensitive, allowing for the detection of weak protein-protein interactions.\n3. Multiplexing: The Canvas SPW assay can be multiplexed, allowing for the detection of multiple protein-protein interactions in a single assay.\n4. Low sample consumption: The assay requires only small amounts of sample material, making it ideal for studying rare or precious samples.\n5. Versatility: The Canvas SPW assay can be used to study protein-protein interactions in a variety of systems, including cellular, tissue, and biochemical assays.\n6. Cost-effective: The assay is relatively low-cost compared to other PPI assays, making it a cost-effective tool for protein-protein interaction research.\n7. Easy to use: The assay is relatively simple to perform and does not require extensive training or expertise.\n8. High accuracy: The assay provides highly accurate results, with low background and high specificity.\nIn summary, Canvas SPW is a powerful tool for studying protein-protein interactions in a high-throughput and cost-effective",
    "llama-2-7b-chat-hf_fact_raw": "1. Canvas SPW is a protein-protein interaction assay that uses small molecule ligands to capture and immobilize protein-protein interactions.\n2. The small molecules in the Canvas SPW assay are designed to specifically bind to the interface between two proteins.\n3. Methods such as mass spectrometry or fluorescence microscopy can be used to detect the captured interactions in a Canvas SPW assay.\n4. The Canvas SPW assay requires only small amounts of sample material.\n5. The assay is designed to be high-throughput, allowing for the detection and quantification of multiple protein-protein interactions simultaneously.",
    "llama-2-7b-chat-hf_fact": [
      "Canvas SPW is a protein-protein interaction assay that uses small molecule ligands to capture and immobilize protein-protein interactions.",
      "The small molecules in the Canvas SPW assay are designed to specifically bind to the interface between two proteins.",
      "Methods such as mass spectrometry or fluorescence microscopy can be used to detect the captured interactions in a Canvas SPW assay.",
      "The Canvas SPW assay requires only small amounts of sample material.",
      "The assay is designed to be high-throughput, allowing for the detection and quantification of multiple protein-protein interactions simultaneously."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe responses to statements 1 and 2 are marked as UNKNOWN because, without additional context or information, it is not possible to confirm or deny the details about the design and working principle of a specific protein-protein interaction assay named \"Canvas SPW.\" However, statements 3, 4, and 5 about general characteristics commonly associated with modern protein-protein interaction assays (such as the use of detection methods like mass spectrometry or fluorescence microscopy, low sample material requirements, and high-throughput capabilities) are generally true for these types of assays.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-7b-chat-hf_response": "STING (Stimulator of Interferon Genes) is a protein that plays a crucial role in the innate immune response. STING agonists are compounds that activate STING and trigger an immune response. Here are some examples of STING agonists:\n1. PolyICLC: PolyICLC is a synthetic analog of the immunostimulatory CpG DNA, which is a common STING agonist.\n2. CpG ODN: CpG ODNs (CpG oligodeoxynucleotides) are synthetic CpG-containing DNA molecules that activate STING and stimulate an immune response.\n3. DNA-based vaccines: Some DNA-based vaccines, such as the HPV vaccine, contain STING agonists that can stimulate an immune response.\n4. Small molecule agonists: Some small molecules, such as cyclic dinucleotides (CDNs), have been identified as STING agonists and can stimulate an immune response.\n5. Peptide agonists: Some peptides, such as the peptide STING agonist, have been identified as STING agonists and can stimulate an immune response.\n6. Viral mimics: Some viral mimics, such as polyI:C, can activate STING and stimulate an immune response.\n7. Lipid agonists: Some lipid molecules, such as 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), have been identified as STING agonists and can stimulate an immune response.\n8. Glycosaminoglycan: Some glycosaminoglycans, such as heparan sulfate, have been identified as STING agonists and can stimulate an immune response.\n9. Protein agonists: Some proteins, such as the protein STING agonist, have been identified as STING agonists and can stimulate an immune response.\n10. Plant-derived compounds: Some plant-derived compounds, such as the flavonoid quercetin, have been identified as ST",
    "llama-2-7b-chat-hf_fact_raw": "1. PolyICLC is a synthetic analog of immunostimulatory CpG DNA and acts as a STING agonist.\n2. CpG ODNs (CpG oligodeoxynucleotides) are synthetic molecules that contain CpG and activate STING to stimulate an immune response.\n3. Some DNA-based vaccines, like the HPV vaccine, include STING agonists that stimulate an immune response.\n4. Cyclic dinucleotides (CDNs) are small molecule STING agonists that can stimulate an immune response.\n5. The peptide STING agonist is a type of peptide that acts as a STING agonist to stimulate an immune response.",
    "llama-2-7b-chat-hf_fact": [
      "PolyICLC is a synthetic analog of immunostimulatory CpG DNA and acts as a STING agonist.",
      "CpG ODNs (CpG oligodeoxynucleotides) are synthetic molecules that contain CpG and activate STING to stimulate an immune response.",
      "Some DNA-based vaccines, like the HPV vaccine, include STING agonists that stimulate an immune response.",
      "Cyclic dinucleotides (CDNs) are small molecule STING agonists that can stimulate an immune response.",
      "The peptide STING agonist is a type of peptide that acts as a STING agonist to stimulate an immune response."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: PolyICLC is a synthetic double-stranded RNA, not DNA, which acts as an agonist for TLR3 and RIG-I-like receptors, not specifically a STING agonist.\n2. FALSE [correction]: CpG ODNs (CpG oligodeoxynucleotides) are synthetic molecules that contain unmethylated CpG motifs that mimic bacterial DNA, which activate Toll-like receptor 9 (TLR9), not STING, to stimulate an immune response.\n3. FALSE [correction]: The HPV vaccine does not contain STING agonists; it includes virus-like particles (VLPs) to stimulate an immune response. DNA-based vaccines may be designed to enhance STING pathway activation, but this is not specific to the HPV vaccine.\n4. TRUE\n5. UNKNOWN (without further information on the specific peptide, it is difficult to determine the accuracy of this statement).",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-7b-chat-hf_response": "SLIC-CAGE (Slicing-based Chromatin Accessibility Genome Engineering) is a genome engineering technology that allows for the precise modification of chromatin structure and accessibility. It is a powerful tool for studying the interplay between chromatin structure and gene expression, and for manipulating gene expression in a precise and targeted manner.\nIn SLIC-CAGE, a specific DNA sequence is identified and targeted using a CRISPR-Cas13 system. The CRISPR-Cas13 system is programmed to recognize a specific protospacer adjacent motif (PAM) sequence in the target DNA, and when the CRISPR-Cas13 complex binds to the target site, it cleaves the DNA. The cleavage event is then used as a signal to introduce a specific DNA modification, such as a base modification or a DNA insertion, at the target site.\nThe SLIC-CAGE technology takes advantage of the fact that the CRISPR-Cas13 system can also be used as a \"slicing\" tool, cutting the DNA at specific locations and creating a double-stranded break. This break can then be repaired by the cell's own repair machinery, leading to the introduction of specific DNA modifications.\nSLIC-CAGE has a number of advantages over other genome engineering technologies. It is highly precise and efficient, with a high on-target rate and low off-target rate. It also allows for the simultaneous modification of multiple sites in the genome, making it a powerful tool for studying the interplay between multiple genetic elements. Additionally, the SLIC-CAGE technology can be used to modify the genome of a wide range of organisms, including bacteria, yeast, and mammalian cells.\nOverall, SLIC-CAGE is a powerful tool for manipulating the genome and studying the interplay between chromatin structure and gene expression. Its high precision and efficiency make it a valuable tool for a wide range of applications, including basic research, biotechnology, and medicine.",
    "llama-2-7b-chat-hf_fact_raw": "1. SLIC-CAGE stands for Slicing-based Chromatin Accessibility Genome Engineering.\n2. SLIC-CAGE uses a CRISPR-Cas13 system to target and cleave a specific DNA sequence.\n3. CRISPR-Cas13 is programmed to recognize a specific protospacer adjacent motif (PAM) sequence in the DNA.\n4. SLIC-CAGE can be used to introduce specific DNA modifications such as base modifications or DNA insertions.\n5. The technology has been applied to a variety of organisms, including bacteria, yeast, and mammalian cells.",
    "llama-2-7b-chat-hf_fact": [
      "SLIC-CAGE stands for Slicing-based Chromatin Accessibility Genome Engineering.",
      "SLIC-CAGE uses a CRISPR-Cas13 system to target and cleave a specific DNA sequence.",
      "CRISPR-Cas13 is programmed to recognize a specific protospacer adjacent motif (PAM) sequence in the DNA.",
      "SLIC-CAGE can be used to introduce specific DNA modifications such as base modifications or DNA insertions.",
      "The technology has been applied to a variety of organisms, including bacteria, yeast, and mammalian cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: SLIC-CAGE uses a CRISPR-Cas9 system to target specific DNA sequences, not CRISPR-Cas13 which targets RNA.\n3. FALSE [correction]: CRISPR-Cas13 is programmed to recognize and cleave RNA, whereas CRISPR-Cas9 requires the recognition of a specific PAM sequence in DNA.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-7b-chat-hf_response": "LEM-3 (LEM domain-containing protein 3) is a protein that plays several important roles in the cell, including:\n1. Chromatin remodeling: LEM-3 is involved in the remodeling of chromatin structure, particularly during transcriptional elongation. It helps to displace nucleosomes and facilitate the binding of RNA polymerase to the DNA template.\n2. Transcriptional regulation: LEM-3 can bind to specific DNA sequences and modulate the recruitment of transcription factors, thereby regulating gene expression.\n3. Cell cycle progression: LEM-3 has been implicated in the regulation of the G1/S checkpoint and the progression of cells through the cell cycle. It may play a role in the regulation of cyclin-dependent kinase activity and the stability of cyclins.\n4. Apoptosis: LEM-3 has been shown to promote apoptosis (programmed cell death) in certain contexts, such as during cancer development or in response to DNA damage.\n5. Nuclear organization: LEM-3 is involved in the organization of nuclear structures, such as the nuclear lamina and the nuclear pore complex. It may play a role in maintaining the integrity of these structures and in regulating nuclear transport.",
    "llama-2-7b-chat-hf_fact_raw": "1. LEM-3 is involved in the remodeling of chromatin structure particularly during transcriptional elongation.\n2. LEM-3 can bind to specific DNA sequences and regulate gene expression by modulating the recruitment of transcription factors.\n3. LEM-3 has a role in regulating the G1/S checkpoint and the progression of the cell cycle.\n4. LEM-3 promotes apoptosis in certain contexts, such as during cancer development or in response to DNA damage.\n5. LEM-3 is implicated in the organization of nuclear structures, including the nuclear lamina and the nuclear pore complex.",
    "llama-2-7b-chat-hf_fact": [
      "LEM-3 is involved in the remodeling of chromatin structure particularly during transcriptional elongation.",
      "LEM-3 can bind to specific DNA sequences and regulate gene expression by modulating the recruitment of transcription factors.",
      "LEM-3 has a role in regulating the G1/S checkpoint and the progression of the cell cycle.",
      "LEM-3 promotes apoptosis in certain contexts, such as during cancer development or in response to DNA damage.",
      "LEM-3 is implicated in the organization of nuclear structures, including the nuclear lamina and the nuclear pore complex."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nReasoning: Each statement pertains to specific molecular or cellular biology claims that require specialized knowledge or scientific literature for validation. Without the appropriate context or reference to the scientific research that discusses LEM-3, it is not possible to determine the truthfulness of these statements. LEM-3 (LAP2-Emerin-MAN1 domain-containing protein 3) is indeed a type of protein that may be involved in various cellular processes, but without specific sources to substantiate the claims made in these statements, they remain unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I apologize, but I'm a large language model, I cannot provide you with the releases of tmVar as it is a fictional software. Therefore, I cannot provide you with any information about its releases. However, I can assist you with any other questions or tasks you may have. Please feel free to ask me anything!",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-7b-chat-hf_response": "There is no comprehensive database of somatic mutations in normal cells. The majority of genetic mutation databases, such as COSMIC, Cancer Genome Atlas (TCGA), and ExAC, focus on identifying somatic mutations in cancer cells. These databases contain information on mutations found in cancer tissues, but do not include data on mutations present in normal tissues.\nHowever, there are some recent studies that have begun to investigate the genetic landscape of normal tissues, including the identification of somatic mutations in non-cancerous cells. For example, the \"Mutational Signature of Somatic Mutations in Normal Tissues\" study published in the journal Nature in 2019 found that normal tissues, such as liver, lung, and blood, have a low rate of somatic mutations, and that these mutations tend to be concentrated in specific genes and genomic regions.\nIt's worth noting that while there are no comprehensive databases of somatic mutations in normal cells, there are several resources that provide information on the frequency and distribution of genetic mutations in different tissues and populations, such as the 1000 Genomes Project and the Exome Aggregation Consortium (ExAC). These resources can be useful for understanding the genetic variation in different populations and tissues, but they do not provide direct information on somatic mutations in normal cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no comprehensive database of somatic mutations in normal cells.\n2. Databases like COSMIC, Cancer Genome Atlas (TCGA), and ExAC focus on somatic mutations in cancer cells.\n3. The \"Mutational Signature of Somatic Mutations in Normal Tissues\" study was published in the journal Nature in 2019.\n4. The study mentioned above found that normal tissues have a low rate of somatic mutations.\n5. Resources such as the 1000 Genomes Project and the Exome Aggregation Consortium (ExAC) provide information on genetic variation in different populations and tissues.",
    "llama-2-7b-chat-hf_fact": [
      "There is no comprehensive database of somatic mutations in normal cells.",
      "Databases like COSMIC, Cancer Genome Atlas (TCGA), and ExAC focus on somatic mutations in cancer cells.",
      "The \"Mutational Signature of Somatic Mutations in Normal Tissues\" study was published in the journal Nature in 2019.",
      "The study mentioned above found that normal tissues have a low rate of somatic mutations.",
      "Resources such as the 1000 Genomes Project and the Exome Aggregation Consortium (ExAC) provide information on genetic variation in different populations and tissues."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The correct name of the study is \"The landscape of somatic mutations in normal human tissues,\" and it was published in the journal Science in 2020.\n4. FALSE [correction]: The study found that all tissues analyzed exhibited somatic mutations and that the rates varied between different types of tissues.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-7b-chat-hf_response": "Yes, there are several graph kernel libraries available that are implemented in Java. Here are some popular ones:\n1. JGraphT: JGraphT is a Java library for graph theory that provides a simple and efficient way to create, manipulate, and analyze graphs. It supports a wide range of graph algorithms and can be used for both directed and undirected graphs.\n2. Weka: Weka is a Java library for data mining and machine learning that includes a graph kernel module. The graph kernel module provides a set of classes and interfaces for implementing graph-based algorithms, including graph kernel methods.\n3. GraphCrunch: GraphCrunch is a Java library for graph processing that provides a simple and efficient way to perform graph computations. It supports a wide range of graph algorithms and can be used for both directed and undirected graphs.\n4. GraphXR: GraphXR is a Java library for graph processing that provides a set of classes and interfaces for implementing graph-based algorithms. It supports a wide range of graph algorithms and can be used for both directed and undirected graphs.\n5. GraphMol: GraphMol is a Java library for molecular graph processing that provides a simple and efficient way to perform graph computations on molecular graphs. It supports a wide range of graph algorithms and can be used for both directed and undirected graphs.\nThese libraries can be used for various applications such as social network analysis, recommendation systems, fraud detection, and more. However, it is important to note that the availability and quality of these libraries may vary, and you should carefully evaluate them based on your specific requirements before selecting one for your project.",
    "llama-2-7b-chat-hf_fact_raw": "1. JGraphT is a Java library for graph theory that provides tools to create, manipulate, and analyze graphs.\n2. Weka is a Java library for data mining and machine learning that includes a graph kernel module.\n3. GraphCrunch is a Java library for graph processing supporting a range of graph algorithms.\n4. GraphXR is a Java library for graph processing that provides classes and interfaces for graph-based algorithms.\n5. GraphMol is a Java library for molecular graph processing that supports algorithms for directed and undirected graphs.",
    "llama-2-7b-chat-hf_fact": [
      "JGraphT is a Java library for graph theory that provides tools to create, manipulate, and analyze graphs.",
      "Weka is a Java library for data mining and machine learning that includes a graph kernel module.",
      "GraphCrunch is a Java library for graph processing supporting a range of graph algorithms.",
      "GraphXR is a Java library for graph processing that provides classes and interfaces for graph-based algorithms.",
      "GraphMol is a Java library for molecular graph processing that supports algorithms for directed and undirected graphs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Weka is a Java library for data mining and machine learning, but it does not predominantly feature a graph kernel module.\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: GraphMol is not a Java library; it's likely a confusion with RDKit's Cheminformatics and Machine Learning software, which includes a tool called 'Mol' for molecular graph processing but is not itself a Java library.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_response": "The SHERLOCKv2 platform has integrated four advances in molecular diagnostics:\n1. CRISPR-Cas13: SHERLOCKv2 uses the CRISPR-Cas13 system to detect target RNA molecules by degrading them, allowing for highly sensitive and specific detection.\n2. RNA-targeted probes: The platform utilizes RNA-targeted probes that are complementary to the target RNA sequence, allowing for efficient and specific binding to the target.\n3. Enzymatic amplification: SHERLOCKv2 employs enzymatic amplification of the target RNA using a thermostable DNA polymerase, which allows for efficient amplification of the target sequence.\n4. Digital PCR: The platform uses digital PCR to quantify the amount of the target RNA in the sample, providing a highly accurate and sensitive measure of the target.",
    "llama-2-7b-chat-hf_fact_raw": "1. SHERLOCKv2 uses the CRISPR-Cas13 system to detect target RNA molecules.\n2. The platform employs RNA-targeted probes that are complementary to the target RNA sequence.\n3. SHERLOCKv2 uses enzymatic amplification with a thermostable DNA polymerase for amplification of the target RNA.\n4. Digital PCR is utilized in the SHERLOCKv2 platform to quantify the amount of the target RNA.",
    "llama-2-7b-chat-hf_fact": [
      "SHERLOCKv2 uses the CRISPR-Cas13 system to detect target RNA molecules.",
      "The platform employs RNA-targeted probes that are complementary to the target RNA sequence.",
      "SHERLOCKv2 uses enzymatic amplification with a thermostable DNA polymerase for amplification of the target RNA.",
      "Digital PCR is utilized in the SHERLOCKv2 platform to quantify the amount of the target RNA."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: SHERLOCKv2 typically uses isothermal amplification methods such as Recombinase Polymerase Amplification (RPA) for amplification of the target RNA, not a thermostable DNA polymerase which is associated with PCR.\n4. FALSE [correction]: SHERLOCKv2 does not utilize digital PCR. Instead, it uses collateral activity of Cas enzymes for detection, which can be read out via various methods, including lateral flow strips, fluorescence, or other reporting systems.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-7b-chat-hf_response": "The Bartender algorithm is a machine learning algorithm used for feature selection and dimensionality reduction in high-dimensional datasets. It was introduced by A. Smola and B. Schölkopf in 2004.\nThe algorithm works by iteratively selecting the most relevant features and projecting the data onto a lower-dimensional space. The selection of features is based on the idea of \"drinking\" from a set of candidate features, where the algorithm selects the feature that is most likely to be relevant to the underlying pattern in the data.\nThe algorithm can be summarized in the following steps:\n1. Initialize the set of selected features: The algorithm starts with an empty set of selected features.\n2. Drink from the candidate set: The algorithm selects a candidate feature from the set of all possible features and computes the projection of the data onto the subspace defined by that feature.\n3. Evaluate the relevance of the selected feature: The algorithm evaluates the relevance of the selected feature to the underlying pattern in the data using a relevance measure, such as mutual information.\n4. Select the most relevant feature: The algorithm selects the feature that has the highest relevance measure and adds it to the set of selected features.\n5. Project the data onto the selected subspace: The algorithm projects the data onto the subspace defined by the selected features using a linear projection.\n6. Repeat steps 2-5: The algorithm repeats steps 2-5 until a stopping criterion is reached, such as a maximum number of iterations or a minimum level of relevance.\n7. Output the selected features: The algorithm outputs the set of selected features that have been identified as most relevant to the underlying pattern in the data.\nThe Bartender algorithm has several advantages over other feature selection algorithms, including:\n* It can handle high-dimensional datasets: The algorithm can handle datasets with a large number of features, making it particularly useful for applications where the number of features is much larger than the number of samples.\n* It is robust to noise: The algorithm is robust to noise in the data, as it uses a relevance measure to evaluate the relevance of each feature rather than simply selecting the most highly correlated features.\n* It can handle non-linear relationships: The algorithm can handle non-linear relationships between the features and the underlying pattern in the data, as it projects the data onto a lower-dimensional space using a linear projection.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Bartender algorithm was introduced by A. Smola and B. Schölkopf in 2004.\n2. It is used for feature selection and dimensionality reduction in high-dimensional datasets.\n3. The Bartender algorithm selects features based on their relevance to the underlying pattern in the data, using a measure such as mutual information.\n4. The algorithm can handle datasets with a large number of features, making it suitable for applications with more features than samples.\n5. It is designed to be robust to noise and capable of handling non-linear relationships between features and the data.",
    "llama-2-7b-chat-hf_fact": [
      "The Bartender algorithm was introduced by A. Smola and B. Schölkopf in 2004.",
      "It is used for feature selection and dimensionality reduction in high-dimensional datasets.",
      "The Bartender algorithm selects features based on their relevance to the underlying pattern in the data, using a measure such as mutual information.",
      "The algorithm can handle datasets with a large number of features, making it suitable for applications with more features than samples.",
      "It is designed to be robust to noise and capable of handling non-linear relationships between features and the data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Bartender algorithm was not introduced by A. Smola and B. Schölkopf in 2004; instead, they are known for methods such as Support Vector Machines and kernel methods.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nIt's important to clarify that while the statements 2 to 5 are generally true for many feature selection and dimensionality reduction algorithms (and could potentially be true for an algorithm like Bartender if it exists), due to the lack of specific information and confirmation that an algorithm named \"Bartender\" was introduced by the mentioned authors, the corrections and verifications for statements other than the first one are based on typical characteristics of such algorithms. If \"Bartender\" does not exist or has not been described in the literature by the given authors, the specific statements 2 to 5 become more hypothetical in nature.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-7b-chat-hf_response": "There are several web-based pedigree editors available, including:\n1. Pedigree.io: A free, web-based tool that allows users to create and edit family trees. It offers features such as drag-and-drop functionality, automatic merging of duplicate profiles, and the ability to add sources and citations.\n2. FamilySearch: A free, web-based platform that allows users to create and edit family trees. It offers features such as a large database of historical records, collaboration tools, and the ability to add sources and citations.\n3. MyHeritage: A web-based platform that allows users to create and edit family trees. It offers features such as a large database of historical records, collaboration tools, and the ability to add sources and citations.\n4. GenoPro: A commercial web-based tool that allows users to create and edit family trees. It offers features such as customizable templates, collaboration tools, and the ability to add sources and citations.\n5. FamilyTreeMaker: A commercial web-based tool that allows users to create and edit family trees. It offers features such as a large database of historical records, collaboration tools, and the ability to add sources and citations.\n6. Legacy Family Tree: A commercial web-based tool that allows users to create and edit family trees. It offers features such as a large database of historical records, collaboration tools, and the ability to add sources and citations.\n7. Ancestry.com: A commercial web-based platform that allows users to create and edit family trees. It offers features such as a large database of historical records, collaboration tools, and the ability to add sources and citations.\n8. WeRelate: A free, web-based platform that allows users to create and edit family trees. It offers features such as collaboration tools, and the ability to add sources and citations.\n9. WikiTree: A free, web-based platform that allows users to create and edit family trees. It offers features such as collaboration tools, and the ability to add sources and citations.\n10. Gramps: A free, open-source, web-based platform that allows users to create and edit family trees. It offers features such as collaboration tools, and the ability to add sources and citations.\nPlease note that this is not an exhaustive list and there may be other web-based pedigree editors",
    "llama-2-7b-chat-hf_fact_raw": "1. Pedigree.io is a free, web-based tool for creating and editing family trees.\n2. FamilySearch is a free, web-based platform that provides access to a large database of historical records for family tree creation and editing.\n3. MyHeritage is a web-based platform for creating and editing family trees and offers a large database of historical records.\n4. GenoPro is a commercial web-based tool that includes customizable templates for family tree creation and editing.\n5. Ancestry.com is a commercial web-based platform that allows users to create and edit family trees and also provides access to a large database of historical records.",
    "llama-2-7b-chat-hf_fact": [
      "Pedigree.io is a free, web-based tool for creating and editing family trees.",
      "FamilySearch is a free, web-based platform that provides access to a large database of historical records for family tree creation and editing.",
      "MyHeritage is a web-based platform for creating and editing family trees and offers a large database of historical records.",
      "GenoPro is a commercial web-based tool that includes customizable templates for family tree creation and editing.",
      "Ancestry.com is a commercial web-based platform that allows users to create and edit family trees and also provides access to a large database of historical records."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. FALSE [correction]: GenoPro is a commercial tool, but it is not web-based; it is a genealogy software that users download and install on their computers.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-7b-chat-hf_response": "There are several curated databases available for spider-venom toxins, including:\n1. ToxinDB: A comprehensive database of toxins from various sources, including spiders, snakes, and scorpions.\n2. Spider Toxin Database (STD): A database of spider venom toxins, including their structures, functions, and pharmacological activities.\n3. Venom-DB: A database of venom peptides and proteins from various organisms, including spiders, snakes, and scorpions.\n4. Natural Products Alert (NPA): A database of natural products, including spider venom toxins, with information on their chemical structures, biological activities, and potential applications.\n5. ToxinTracer: A database of toxins from various sources, including spiders, snakes, and scorpions, with information on their structures, functions, and pharmacological activities.\n6. Spider Venom Toxin Database (SVTD): A database of spider venom toxins, including their structures, functions, and pharmacological activities.\n7. Venom-Tox: A database of venom peptides and proteins from various organisms, including spiders, snakes, and scorpions, with information on their structures, functions, and pharmacological activities.\n8. Toxinology: A database of toxins from various sources, including spiders, snakes, and scorpions, with information on their structures, functions, and pharmacological activities.\n9. Venomics: A database of venom peptides and proteins from various organisms, including spiders, snakes, and scorpions, with information on their structures, functions, and pharmacological activities.\n10. ToxinTech: A database of toxins from various sources, including spiders, snakes, and scorpions, with information on their structures, functions, and pharmacological activities.\nThese databases provide valuable information on the various spider-venom toxins and their potential applications in medicine, agriculture, and other fields.",
    "llama-2-7b-chat-hf_fact_raw": "1. ToxinDB is a comprehensive database of toxins from various sources, including spiders, snakes, and scorpions.\n2. The Spider Toxin Database (STD) includes information on spider venom toxins, such as their structures, functions, and pharmacological activities.\n3. Venom-DB is a database of venom peptides and proteins from various organisms, including spiders.\n4. Natural Products Alert (NPA) is a database that contains information on natural products like spider venom toxins, detailing their chemical structures and biological activities.\n5. The Spider Venom Toxin Database (SVTD) provides information on the structures, functions, and pharmacological activities of spider venom toxins.",
    "llama-2-7b-chat-hf_fact": [
      "ToxinDB is a comprehensive database of toxins from various sources, including spiders, snakes, and scorpions.",
      "The Spider Toxin Database (STD) includes information on spider venom toxins, such as their structures, functions, and pharmacological activities.",
      "Venom-DB is a database of venom peptides and proteins from various organisms, including spiders.",
      "Natural Products Alert (NPA) is a database that contains information on natural products like spider venom toxins, detailing their chemical structures and biological activities.",
      "The Spider Venom Toxin Database (SVTD) provides information on the structures, functions, and pharmacological activities of spider venom toxins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - ToxinDB is indeed a comprehensive database that includes information on toxins from various sources, including spiders, snakes, and scorpions.\n\n2. UNKNOWN - Without additional context, it's unclear if the Spider Toxin Database (STD) specifically exists and contains the information mentioned. A known database for spider toxins is ArachnoServer, but STD as described here may or may not be accurate.\n\n3. TRUE - Venom-DB is an actual database that provides information on venom peptides and proteins from various venomous organisms, including spiders.\n\n4. UNKNOWN - The Natural Products Alert (NPA) database does exist and is used for providing information on natural products, but without further context, it's not clear if it specifically includes detailed information on spider venom toxins.\n\n5. UNKNOWN - The statement about the Spider Venom Toxin Database (SVTD) could be true, since databases like ArachnoServer provide such information. However, without specific details or confirmation that a database with the exact name \"Spider Venom Toxin Database\" (SVTD) exists, it is difficult to determine the accuracy of this statement.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it seems that Axitinib does not prolong survival of pancreatic cancer patients. The text states that \"Axitinib, a tyrosine kinase inhibitor, has shown promise in the treatment of pancreatic cancer, but its effect on overall survival has been limited.\" This suggests that while Axitinib may have some benefits in treating pancreatic cancer, it has not been shown to significantly improve overall survival in these patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. Axitinib is a tyrosine kinase inhibitor.\n2. Axitinib has been used in the treatment of pancreatic cancer.\n3. Axitinib has not been shown to significantly improve overall survival in pancreatic cancer patients.",
    "llama-2-7b-chat-hf_fact": [
      "Axitinib is a tyrosine kinase inhibitor.",
      "Axitinib has been used in the treatment of pancreatic cancer.",
      "Axitinib has not been shown to significantly improve overall survival in pancreatic cancer patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n\nExplanation: Axitinib is indeed a tyrosine kinase inhibitor that is primarily used for the treatment of advanced renal cell carcinoma. However, its use in pancreatic cancer treatment is not well-known or as clearly documented as its use for renal cancer. Point 2 is thus marked as UNKNOWN because, without additional context or specific studies to reference, we cannot confirm or deny its usage in pancreatic cancer treatment. Similarly, point 3 is UNKNOWN because without specific studies or data regarding its efficacy in pancreatic cancer patients, we cannot make a definitive statement about its impact on overall survival in that patient population.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-7b-chat-hf_response": "MLP (Microtubule-associated protein) regulates F-actin dynamics through its interaction with the F-actin protein, actin-binding protein 1 (ABP-1). MLP interacts with ABP-1 and promotes the assembly and stability of F-actin structures.",
    "llama-2-7b-chat-hf_fact_raw": "1. MLP stands for Microtubule-associated protein.\n2. MLP regulates F-actin dynamics through its interaction with actin-binding protein 1 (ABP-1).\n3. MLP interacts with ABP-1 and promotes the assembly of F-actin structures.\n4. MLP interaction with ABP-1 helps in the stability of F-actin structures.",
    "llama-2-7b-chat-hf_fact": [
      "MLP stands for Microtubule-associated protein.",
      "MLP regulates F-actin dynamics through its interaction with actin-binding protein 1 (ABP-1).",
      "MLP interacts with ABP-1 and promotes the assembly of F-actin structures.",
      "MLP interaction with ABP-1 helps in the stability of F-actin structures."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MLP typically stands for Myosin Like Protein or Muscle LIM Protein, not Microtubule-associated protein. Microtubule-associated protein refers to MAPs.\n2. FALSE [correction]: MLP is commonly referred to Muscle LIM Protein in the context of muscle cells and it is known to interact with various proteins, but without specific context, it's not clear if it regulates F-actin dynamics through an interaction with a protein called ABP-1. ABP-1 is usually an acronym for Actin-Binding Protein 1, but it might not directly interact with MLP.\n3. UNKNOWN: Without specifying the context of MLP, it is not clear if MLP interacts with ABP-1 and promotes the assembly of F-actin structures. If MLP refers to Muscle LIM Protein, it interacts more commonly with cytoskeletal elements like actin in muscle cells, but direct interaction with ABP-1 and promoting assembly of F-actin structures would need a specific reference to be verified.\n4. UNKNOWN: Similar to the previous statement, without specific context, we cannot determine if MLP interaction with ABP-1 helps in the stability of F-actin structures. In general, proteins interacting with F-actin might stabilize the structure, but the statement needs a specific reference for MLP and its effects on F-actin stability through ABP-1.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-7b-chat-hf_response": "According to current estimates, there are approximately 100-150 pseudokinases in the human kinome. These pseudokinases are proteins that have some characteristics of kinases, such as the ability to bind ATP and interact with other proteins, but they do not have the catalytic activity of a true kinase.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are approximately 100-150 pseudokinases in the human kinome.\n2. Pseudokinases are proteins that can bind ATP.\n3. Pseudokinases interact with other proteins.\n4. Pseudokinases do not have the catalytic activity of a true kinase.",
    "llama-2-7b-chat-hf_fact": [
      "There are approximately 100-150 pseudokinases in the human kinome.",
      "Pseudokinases are proteins that can bind ATP.",
      "Pseudokinases interact with other proteins.",
      "Pseudokinases do not have the catalytic activity of a true kinase."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-7b-chat-hf_response": "ApoE mimetics are compounds that mimic the structure and function of apolipoprotein E (apoE), a protein involved in lipid metabolism and cholesterol transport. Here are three examples of apoE mimetics:\n1. ApoE mimetic peptides: These are small peptides that mimic the structure of apoE and have been shown to have anti-inflammatory and anti-atherogenic effects in various studies.\n2. ApoE-mimetic liposomes: These are liposomes that are engineered to mimic the structure of apoE and have been shown to be effective in reducing cholesterol accumulation in liver and improving insulin sensitivity in animal models of metabolic disorders.\n3. ApoE-mimetic small molecules: These are small molecules that mimic the structure of apoE and have been shown to have anti-inflammatory and anti-atherogenic effects in various studies. They have the potential to be used as therapeutic agents for the treatment of metabolic disorders such as atherosclerosis and Alzheimer's disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. ApoE mimetic peptides are designed to mimic the structure of apolipoprotein E.\n2. ApoE mimetic peptides have been studied for their anti-inflammatory and anti-atherogenic effects.\n3. ApoE-mimetic liposomes have been used to reduce cholesterol accumulation in the liver.\n4. ApoE-mimetic liposomes have improved insulin sensitivity in animal models of metabolic disorders.\n5. ApoE-mimetic small molecules have potential as therapeutic agents for treating metabolic disorders like atherosclerosis and Alzheimer's disease.",
    "llama-2-7b-chat-hf_fact": [
      "ApoE mimetic peptides are designed to mimic the structure of apolipoprotein E.",
      "ApoE mimetic peptides have been studied for their anti-inflammatory and anti-atherogenic effects.",
      "ApoE-mimetic liposomes have been used to reduce cholesterol accumulation in the liver.",
      "ApoE-mimetic liposomes have improved insulin sensitivity in animal models of metabolic disorders.",
      "ApoE-mimetic small molecules have potential as therapeutic agents for treating metabolic disorders like atherosclerosis and Alzheimer's disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-7b-chat-hf_response": "SAMHD1 (SAM and HD-like protein 1) is an enzyme that plays a crucial role in regulating the innate immune response to viral infections. There are sex differences in SAMHD1 activity, with studies suggesting that females have higher levels of SAMHD1 activity compared to males.\nOne study published in the journal Nature Communications found that female mice have higher levels of SAMHD1 activity in their brains compared to males, which may contribute to the higher susceptibility of females to certain neurodegenerative diseases, such as Alzheimer's disease.\nAnother study published in the journal Cell Reports found that female human cells have higher levels of SAMHD1 activity than male cells, which may make females more resistant to certain viral infections.\nThese findings suggest that sex differences in SAMHD1 activity may play a role in the different susceptibility of males and females to certain diseases, and may have important implications for the development of new treatments for these diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. SAMHD1 is an enzyme that helps regulate the innate immune response to viral infections.\n2. Studies suggest that females have higher levels of SAMHD1 activity than males.\n3. A study in Nature Communications reported higher levels of SAMHD1 activity in the brains of female mice compared to male mice.\n4. According to a study published in Cell Reports, female human cells exhibit higher levels of SAMHD1 activity than male cells.\n5. The differences in SAMHD1 activity may be linked to the varying susceptibility of males and females to certain diseases such as Alzheimer's.",
    "llama-2-7b-chat-hf_fact": [
      "SAMHD1 is an enzyme that helps regulate the innate immune response to viral infections.",
      "Studies suggest that females have higher levels of SAMHD1 activity than males.",
      "A study in Nature Communications reported higher levels of SAMHD1 activity in the brains of female mice compared to male mice.",
      "According to a study published in Cell Reports, female human cells exhibit higher levels of SAMHD1 activity than male cells.",
      "The differences in SAMHD1 activity may be linked to the varying susceptibility of males and females to certain diseases such as Alzheimer's."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific references to the studies in question and lacking additional context or information, it's not possible to verify the accuracy of statements 2, 3, 4, and 5. While it is known that SAMHD1 is an enzyme involved in the regulation of the immune response, the specifics about gender differences in SAMHD1 activity levels and their potential link to disease susceptibility cannot be confirmed without direct access to the cited studies or further details.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-7b-chat-hf_response": "No, RUNX2 (RUNX2, also known as AML1 or CBFA2) has been shown to promote astrocyte differentiation.",
    "llama-2-7b-chat-hf_fact_raw": "1. RUNX2 is also known as AML1 or CBFA2.\n2. RUNX2 has been shown to promote astrocyte differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "RUNX2 is also known as AML1 or CBFA2.",
      "RUNX2 has been shown to promote astrocyte differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: RUNX2 is important for osteoblast differentiation and skeletal morphogenesis, not astrocyte differentiation.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-7b-chat-hf_response": "The Cobb-Stansby excision arthroplasty is a surgical procedure that is performed to treat a condition called avascular necrosis of the femoral head, which is a condition where the blood supply to the femoral head (the ball of the hip joint) is disrupted, leading to the death of the bone tissue. This procedure is typically performed by an orthopedic surgeon in an operating room setting, and the location of the procedure will depend on the severity of the condition and the individual patient's needs.\nIn general, the Cobb-Stansby excision arthroplasty is performed through a surgical incision on the side of the hip, usually over the gluteus maximus muscle. The surgeon will then expose the femoral head and remove the dead bone tissue using a specialized instrument called a curette. The surgeon may also remove any bone spurs or other bone fragments that may be present.\nAfter the dead bone tissue has been removed, the surgeon will fill the resulting cavity with a special bone graft material or with a synthetic bone substitute. This helps to maintain the shape of the femoral head and promote healing. The incision is then closed, usually with sutures or staples, and the patient is taken to the recovery room for post-operative care.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is a surgical procedure to treat avascular necrosis of the femoral head.\n2. Avascular necrosis of the femoral head is a condition where the blood supply to the femoral head is disrupted.\n3. The procedure is typically performed by an orthopedic surgeon in an operating room setting.\n4. The Cobb-Stainsby excision arthroplasty involves removing dead bone tissue from the femoral head.\n5. After removal of dead bone tissue, the cavity is filled with bone graft material or a synthetic bone substitute.",
    "llama-2-7b-chat-hf_fact": [
      "The Cobb-Stainsby excision arthroplasty is a surgical procedure to treat avascular necrosis of the femoral head.",
      "Avascular necrosis of the femoral head is a condition where the blood supply to the femoral head is disrupted.",
      "The procedure is typically performed by an orthopedic surgeon in an operating room setting.",
      "The Cobb-Stainsby excision arthroplasty involves removing dead bone tissue from the femoral head.",
      "After removal of dead bone tissue, the cavity is filled with bone graft material or a synthetic bone substitute."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is not primarily used to treat avascular necrosis of the femoral head; it is a surgical procedure used for managing muscle imbalance in the hip, particularly for patients with poliomyelitis.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The Cobb-Stainsby excision arthroplasty does not involve removing dead bone tissue from the femoral head. It involves excising part of the capsule or soft tissues around the hip and attaching the tendons around the hip to the femoral head to balance the muscles.\n5. FALSE [correction]: After the excision, the procedure typically involves overlaying a portion of the capsule or other soft tissue over the femoral head and securing it, not filling a cavity with bone graft material or a synthetic bone substitute.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-7b-chat-hf_response": "GRHL2 over-expression has been shown to promote epithelial-to-mesenchymal transition (EMT) in various cell types, including cancer cells. EMT is a process by which epithelial cells lose their cell-cell adhesion and gain mesenchymal characteristics, such as increased motility and invasiveness. GRHL2 has been shown to play a key role in this process by regulating the expression of genes involved in EMT, such as E-cadherin and vimentin.",
    "llama-2-7b-chat-hf_fact_raw": "1. GRHL2 over-expression promotes epithelial-to-mesenchymal transition (EMT) in various cell types.\n2. EMT is a process where epithelial cells lose cell-cell adhesion and gain mesenchymal traits like increased motility and invasiveness.\n3. GRHL2 plays a key role in regulating genes involved in EMT.\n4. GRHL2 over-expression affects the expression of E-cadherin and vimentin genes, which are involved in EMT.",
    "llama-2-7b-chat-hf_fact": [
      "GRHL2 over-expression promotes epithelial-to-mesenchymal transition (EMT) in various cell types.",
      "EMT is a process where epithelial cells lose cell-cell adhesion and gain mesenchymal traits like increased motility and invasiveness.",
      "GRHL2 plays a key role in regulating genes involved in EMT.",
      "GRHL2 over-expression affects the expression of E-cadherin and vimentin genes, which are involved in EMT."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\n*Note that responses are based on the general scientific understanding and consensus on EMT and the role of GRHL2. However, since the information is highly specific and the validity of these statements may depend on the current body of research, it is advisable to consult the latest scientific literature for the most precise and up-to-date information.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-7b-chat-hf_response": "T-bet (T-box transcription factor Eomesodermin) and UCHL1 (ubiquitin C-terminal hydrolase 1) have been implicated in lung cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. T-bet (T-box transcription factor Eomesodermin) has been implicated in lung cancer.\n2. UCHL1 (ubiquitin C-terminal hydrolase 1) has been implicated in lung cancer.",
    "llama-2-7b-chat-hf_fact": [
      "T-bet (T-box transcription factor Eomesodermin) has been implicated in lung cancer.",
      "UCHL1 (ubiquitin C-terminal hydrolase 1) has been implicated in lung cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: T-bet (T-box transcription factor) should not be confused with Eomesodermin. T-bet is encoded by the gene TBX21, and it has been implicated in various immune responses, not specifically lung cancer.\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-7b-chat-hf_response": "GPR151 (G protein-coupled receptor 151) is an orphan receptor, meaning that it does not have a well-defined endogenous ligand or a clear physiological function. However, GPR151 has been found to be involved in a variety of cellular processes, including:\n1. Glucose metabolism: GPR151 has been shown to be involved in the regulation of glucose-stimulated insulin secretion and glucose uptake in insulin-sensitive cells.\n2. Lipid metabolism: GPR151 has been implicated in the regulation of lipid metabolism, including the expression of genes involved in lipid uptake and storage.\n3. Inflammation: GPR151 has been shown to play a role in the regulation of inflammatory responses, including the expression of genes involved in the production of pro-inflammatory cytokines.\n4. Cell proliferation and differentiation: GPR151 has been implicated in the regulation of cell proliferation and differentiation, including the expression of genes involved in cell cycle progression and differentiation.\n5. Neuroprotection: GPR151 has been shown to have neuroprotective effects, including the protection of neurons against oxidative stress and excitotoxicity.\nOverall, GPR151 is a multifunctional receptor that is involved in a variety of cellular processes, and its dysregulation has been implicated in a number of diseases, including metabolic disorders, inflammatory disorders, and neurodegenerative diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. GPR151 does not have a well-defined endogenous ligand or a clear physiological function.\n2. GPR151 is involved in the regulation of glucose-stimulated insulin secretion and glucose uptake in insulin-sensitive cells.\n3. GPR151 is implicated in the regulation of lipid metabolism, including the expression of genes involved in lipid uptake and storage.\n4. GPR151 plays a role in the regulation of inflammatory responses, including the expression of genes involved in the production of pro-inflammatory cytokines.\n5. GPR151 has neuroprotective effects, including the protection of neurons against oxidative stress and excitotoxicity.",
    "llama-2-7b-chat-hf_fact": [
      "GPR151 does not have a well-defined endogenous ligand or a clear physiological function.",
      "GPR151 is involved in the regulation of glucose-stimulated insulin secretion and glucose uptake in insulin-sensitive cells.",
      "GPR151 is implicated in the regulation of lipid metabolism, including the expression of genes involved in lipid uptake and storage.",
      "GPR151 plays a role in the regulation of inflammatory responses, including the expression of genes involved in the production of pro-inflammatory cytokines.",
      "GPR151 has neuroprotective effects, including the protection of neurons against oxidative stress and excitotoxicity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - GPR151 is an orphan receptor, which typically means its endogenous ligand or physiological function is not well-defined.\n2. FALSE [correction]: GPR151 does not have a well-established function, including regulation of glucose-stimulated insulin secretion and glucose uptake in insulin-sensitive cells. Such specific roles in glucose metabolism are not widely recognized or confirmed for this orphan receptor without further scientific evidence.\n3. FALSE [correction]: There is no consensus that GPR151 is implicated in the regulation of lipid metabolism, including the expression of genes involved in lipid uptake and storage. These functions are not typically attributed to GPR151 without specific and widely accepted research findings.\n4. FALSE [correction]: GPR151's role in the regulation of inflammatory responses, including the expression of genes involved in pro-inflammatory cytokines production, is not clearly established. Without well-defined physiological functions, such specific roles cannot be attributed to GPR151.\n5. FALSE [correction]: There is no widely recognized evidence that GPR151 has neuroprotective effects, such as protecting neurons against oxidative stress and excitotoxicity. Assigning such a role to GPR151 would require specific scientific support.\n\nThe knowledge about GPR151, like many orphan receptors, is limited and subject to ongoing research. Hence, statements about specific physiological roles require substantiation through scientific studies.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_response": "The Fluzone Intradermal Quadrivalent vaccine contains the following attenuated live viruses:\n1. H1N1\n2. H3N2\n3. B/Victoria\n4. B/Yamagata",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-7b-chat-hf_response": "The TNFR2 gene is associated with Systemic Lupus Erythematosus (SLE) in the 3' untranslated region (3' UTR). Specifically, mutations in the TNFR2 3' UTR have been identified as a risk factor for SLE.",
    "llama-2-7b-chat-hf_fact_raw": "1. The TNFR2 gene is associated with Systemic Lupus Erythematosus (SLE).\n2. The 3' untranslated region (3' UTR) of the TNFR2 gene is genetically associated with SLE.\n3. Mutations in the TNFR2 3' UTR have been identified as a risk factor for Systemic Lupus Erythematosus.",
    "llama-2-7b-chat-hf_fact": [
      "The TNFR2 gene is associated with Systemic Lupus Erythematosus (SLE).",
      "The 3' untranslated region (3' UTR) of the TNFR2 gene is genetically associated with SLE.",
      "Mutations in the TNFR2 3' UTR have been identified as a risk factor for Systemic Lupus Erythematosus."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-7b-chat-hf_response": "Currently, there is no licensed vaccine available for the prevention of peanut allergy. Researchers are actively working on developing a peanut allergy vaccine, but it is still in the experimental stage and has not yet been approved for use in humans.\nSeveral approaches are being explored to develop a peanut allergy vaccine, including:\n1. Oral immunotherapy: This involves gradually exposing individuals to small amounts of peanut protein in a controlled manner to build up tolerance.\n2. Epicutaneous immunotherapy: This involves delivering small amounts of peanut protein directly to the skin, where it is absorbed and can help build up tolerance.\n3. mRNA-based vaccines: This involves using messenger RNA (mRNA) to encode for peanut proteins, which are then expressed in the body and can help build up tolerance.\n4. Adjuvated vaccines: This involves using adjuvants, such as aluminum salts, to enhance the immune response to the peanut protein.\nWhile these approaches show promise, it may take several years before a peanut allergy vaccine becomes available for widespread use. It is important to note that a peanut allergy vaccine may not be effective for everyone and may not completely eliminate the risk of an allergic reaction. Therefore, it is crucial to continue to avoid peanuts and peanut products in the diet to prevent an allergic reaction.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no licensed vaccine available for the prevention of peanut allergy.\n2. Researchers are currently developing a peanut allergy vaccine, which is in the experimental stage.\n3. Oral immunotherapy as a potential vaccine strategy involves gradually exposing individuals to small amounts of peanut protein.\n4. Epicutaneous immunotherapy as a potential vaccine strategy involves delivering small amounts of peanut protein directly to the skin.\n5. mRNA-based vaccines as a potential strategy for peanut allergy involve using messenger RNA to encode for peanut proteins.",
    "llama-2-7b-chat-hf_fact": [
      "There is no licensed vaccine available for the prevention of peanut allergy.",
      "Researchers are currently developing a peanut allergy vaccine, which is in the experimental stage.",
      "Oral immunotherapy as a potential vaccine strategy involves gradually exposing individuals to small amounts of peanut protein.",
      "Epicutaneous immunotherapy as a potential vaccine strategy involves delivering small amounts of peanut protein directly to the skin.",
      "mRNA-based vaccines as a potential strategy for peanut allergy involve using messenger RNA to encode for peanut proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: mRNA-based vaccines for peanut allergy would involve using messenger RNA to encourage the body to produce proteins that can induce an immune response without producing an allergic reaction, not to encode for peanut proteins which could themselves be allergenic.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-7b-chat-hf_response": "The mouse Fxy gene is located on the X chromosome.",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse Fxy gene is located on the X chromosome.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse Fxy gene is located on the X chromosome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-7b-chat-hf_response": "MPE-seq is a method for sequencing RNA that is based on the chemistry of methidiumpropyl-EDTA (MPE), a reagent that selectively binds to RNA molecules and labels them for sequencing. The method involves treating the RNA sample with MPE, which selectively binds to the RNA molecules of interest, and then using a sequencing reaction to detect the MPE-labeled RNA fragments. The resulting sequencing data can be used to identify and quantify specific RNA molecules in the sample.",
    "llama-2-7b-chat-hf_fact_raw": "1. MPE-seq is a method for sequencing RNA.\n2. Methidiumpropyl-EDTA (MPE) is a reagent that selectively binds to RNA molecules.\n3. In MPE-seq, RNA samples are treated with MPE to label RNA molecules of interest.\n4. A sequencing reaction is used to detect MPE-labeled RNA fragments in the method.\n5. MPE-seq data can be used to identify and quantify specific RNA molecules in a sample.",
    "llama-2-7b-chat-hf_fact": [
      "MPE-seq is a method for sequencing RNA.",
      "Methidiumpropyl-EDTA (MPE) is a reagent that selectively binds to RNA molecules.",
      "In MPE-seq, RNA samples are treated with MPE to label RNA molecules of interest.",
      "A sequencing reaction is used to detect MPE-labeled RNA fragments in the method.",
      "MPE-seq data can be used to identify and quantify specific RNA molecules in a sample."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MPE-seq is not a method for sequencing RNA. It refers to methylation profiling by endonuclease digestion followed by sequencing, which is a method used for DNA methylation analysis.\n2. UNKNOWN: Methidiumpropyl-EDTA (MPE) could be confused with methidiumpropyl-EDTA Fe(II), which is sometimes used in footprinting assays to bind DNA, not RNA. However, without specific context, it's unclear if MPE refers to a reagent that selectively binds to RNA molecules.\n3. FALSE [correction]: In the context of DNA methylation analysis, MPE-seq does not treat RNA with MPE to label RNA molecules of interest, as it is associated with DNA methylation profiling.\n4. UNKNOWN: The description suggests a sequencing-related process, but without specificity, it's unclear what exactly is sequenced and how the MPE-labeled fragments relate to RNA or DNA.\n5. FALSE [correction]: MPE-seq data, if referring to methylation profiling by endonuclease digestion followed by sequencing, would not be used to identify and quantify specific RNA molecules, but rather to analyze DNA methylation patterns.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-7b-chat-hf_response": "GWAR (Genome-Wide Association Study) is typically implemented using a programming language that is well-suited for handling large datasets and performing statistical analysis. Some common programming languages used for GWAR include:\n1. R: R is a popular programming language for statistical computing and graphics, and is widely used in the field of genetics and genomics. It has a large number of packages and functions available for performing GWAS, including the \"gwas\" package.\n2. Python: Python is a versatile programming language that is widely used in bioinformatics and genomics. It has a number of libraries and tools available for performing GWAS, including the \"pygsa\" library.\n3. MATLAB: MATLAB is a programming language that is commonly used in bioinformatics and genomics for performing statistical analysis and data visualization. It has a number of toolboxes available for performing GWAS, including the \"genomics toolbox\".\n4. SAS: SAS is a software suite that is widely used in the field of statistics and data analysis. It has a number of procedures available for performing GWAS, including the \"genetics procedure\".\n5. Julia: Julia is a new programming language that is gaining popularity in the field of bioinformatics and genomics. It has a number of packages and libraries available for performing GWAS, including the \"GWAS\" package.\nIt's worth noting that the choice of programming language will depend on the specific requirements of the analysis and the preferences of the researcher.",
    "llama-2-7b-chat-hf_fact_raw": "1. R is a programming language used for statistical computing and graphics.\n2. Python is a programming language that has libraries and tools available for performing GWAS.\n3. MATLAB is commonly used in bioinformatics and genomics for statistical analysis and data visualization.\n4. SAS is a software suite used for statistics and data analysis, with procedures for performing GWAS.\n5. Julia is a programming language with packages available for performing GWAS.",
    "llama-2-7b-chat-hf_fact": [
      "R is a programming language used for statistical computing and graphics.",
      "Python is a programming language that has libraries and tools available for performing GWAS.",
      "MATLAB is commonly used in bioinformatics and genomics for statistical analysis and data visualization.",
      "SAS is a software suite used for statistics and data analysis, with procedures for performing GWAS.",
      "Julia is a programming language with packages available for performing GWAS."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nGWAS stands for Genome-Wide Association Studies, and while R, Python, MATLAB, SAS, and Julia are not exclusively used for GWAS, they all have libraries, packages, or procedures that can be applied to perform GWAS or related tasks in genetics and bioinformatics.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-7b-chat-hf_response": "Xaliproden (also known as deforolimus) is an investigational drug that has been shown to have potential in improving the prognosis of amyotrophic lateral sclerosis (ALS).\nStudies have suggested that xaliproden may slow down the progression of ALS by reducing the levels of a protein called SOD1, which is involved in the death of motor neurons in ALS patients. Additionally, xaliproden has been shown to increase the levels of a protein called neurotrophic factor, which can help to protect motor neurons from degeneration.\nWhile the results of these studies are promising, it's important to note that xaliproden is still an experimental drug and has not yet been approved by regulatory authorities for the treatment of ALS. Further research is needed to confirm its safety and effectiveness in humans.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xaliproden is an investigational drug.\n2. Research has suggested that xaliproden may slow down the progression of amyotrophic lateral sclerosis (ALS).\n3. Xaliproden may reduce the levels of the protein SOD1 that is involved in the death of motor neurons in ALS patients.\n4. Xaliproden has also been shown to increase the levels of a protein called neurotrophic factor.\n5. Xaliproden has not been approved by regulatory authorities for the treatment of ALS.",
    "llama-2-7b-chat-hf_fact": [
      "Xaliproden is an investigational drug.",
      "Research has suggested that xaliproden may slow down the progression of amyotrophic lateral sclerosis (ALS).",
      "Xaliproden may reduce the levels of the protein SOD1 that is involved in the death of motor neurons in ALS patients.",
      "Xaliproden has also been shown to increase the levels of a protein called neurotrophic factor.",
      "Xaliproden has not been approved by regulatory authorities for the treatment of ALS."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-7b-chat-hf_response": "In the case of the LiPS-A3S line, transgenes are inserted into chromosome 1.",
    "llama-2-7b-chat-hf_fact_raw": "1. In the LiPS-A3S line, transgenes are inserted into chromosome 1.",
    "llama-2-7b-chat-hf_fact": [
      "In the LiPS-A3S line, transgenes are inserted into chromosome 1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n\nExplanation: Without a specific reference to what the LiPS-A3S line is and what organism or context it pertains to, it is impossible to determine whether the statement about transgenes being inserted into chromosome 1 is true or false. The statement is too vague without additional context.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-7b-chat-hf_response": "There are several deep learning tools and models that can be used for predicting drug synergy. Some of the popular ones include:\n1. DeepDrug: This is a deep learning model that can predict drug synergy by analyzing the molecular structures of drugs and their targets. It uses a combination of convolutional neural networks (CNNs) and recurrent neural networks (RNNs) to predict the synergy between drugs.\n2. Drug2Drug: This is a deep learning model that predicts drug synergy by analyzing the chemical structures of drugs. It uses a combination of CNNs and RNNs to predict the interactions between drugs and their targets, and the resulting synergy.\n3. DrugSynth: This is a deep learning model that predicts drug synergy by analyzing the chemical structures of drugs and their targets. It uses a combination of CNNs and RNNs to predict the interactions between drugs and their targets, and the resulting synergy.\n4. SynergyNet: This is a deep learning model that predicts drug synergy by analyzing the molecular structures of drugs and their targets. It uses a combination of CNNs and RNNs to predict the interactions between drugs and their targets, and the resulting synergy.\n5. ChEA-Net: This is a deep learning model that predicts drug synergy by analyzing the chemical structures of drugs and their targets. It uses a combination of CNNs and RNNs to predict the interactions between drugs and their targets, and the resulting synergy.\n6. Graph Convolutional Networks (GCNs): GCNs are a type of deep learning model that can be used to predict drug synergy by analyzing the molecular structures of drugs and their targets. They use a graph structure to represent the interactions between drugs and their targets, and can learn to predict the synergy between them.\n7. Message Passing Neural Networks (MPNNs): MPNNs are a type of deep learning model that can be used to predict drug synergy by analyzing the molecular structures of drugs and their targets. They use a message passing mechanism to represent the interactions between drugs and their targets, and can learn to predict the synergy between them.\n8. Transformer Networks: Transformer",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepDrug is a deep learning model used to predict drug synergy, utilizing convolutional neural networks (CNNs) and recurrent neural networks (RNNs).\n2. Drug2Drug is a deep learning model that predicts drug synergy by analyzing chemical structures with CNNs and RNNs.\n3. DrugSynth is a deep learning model that predicts drug synergy through the analysis of chemical structures of drugs and their targets, using CNNs and RNNs.\n4. SynergyNet is a deep learning model for predicting drug synergy based on molecular structures, also using CNNs and RNNs.\n5. Graph Convolutional Networks (GCNs) are deep learning models that predict drug synergy by analyzing molecular structures of drugs and their targets using a graph structure.",
    "llama-2-7b-chat-hf_fact": [
      "DeepDrug is a deep learning model used to predict drug synergy, utilizing convolutional neural networks (CNNs) and recurrent neural networks (RNNs).",
      "Drug2Drug is a deep learning model that predicts drug synergy by analyzing chemical structures with CNNs and RNNs.",
      "DrugSynth is a deep learning model that predicts drug synergy through the analysis of chemical structures of drugs and their targets, using CNNs and RNNs.",
      "SynergyNet is a deep learning model for predicting drug synergy based on molecular structures, also using CNNs and RNNs.",
      "Graph Convolutional Networks (GCNs) are deep learning models that predict drug synergy by analyzing molecular structures of drugs and their targets using a graph structure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-7b-chat-hf_response": "The cloud-based platform that has been developed for comparing GWAS is called \"GWAS-to-GWAS\" (G2G). G2G is a web-based platform that allows researchers to compare genetic associations between different GWAS datasets, and to identify shared genetic signals across different studies. G2G was developed by the National Center for Biotechnology Information (NCBI) and is available for use at no cost.",
    "llama-2-7b-chat-hf_fact_raw": "1. A cloud-based platform for comparing GWAS is named \"GWAS-to-GWAS\" (G2G).\n2. G2G is a web-based platform designed to compare genetic associations between different GWAS datasets.\n3. G2G allows researchers to identify shared genetic signals across different studies.\n4. The National Center for Biotechnology Information (NCBI) developed the G2G platform.\n5. The G2G platform is available for use at no cost.",
    "llama-2-7b-chat-hf_fact": [
      "A cloud-based platform for comparing GWAS is named \"GWAS-to-GWAS\" (G2G).",
      "G2G is a web-based platform designed to compare genetic associations between different GWAS datasets.",
      "G2G allows researchers to identify shared genetic signals across different studies.",
      "The National Center for Biotechnology Information (NCBI) developed the G2G platform.",
      "The G2G platform is available for use at no cost."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific context or source details about \"GWAS-to-GWAS\" (G2G), it's not possible to verify the creator of the platform or whether it is free to use. G2G could be an acronym for a specific cloud-based platform for comparing GWAS, but without additional information, it is not possible to confirm the details surrounding its development by NCBI or its cost. However, the stated functions of G2G in statements 2 and 3 are generally what one would expect from such a comparative platform in the field of genomics.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-7b-chat-hf_response": "CMB305 is a monoclonal antibody that targets the CD305 receptor, which is overexpressed in many types of cancer, including sarcomas. Therefore, CMB305 has the potential to be used against sarcomas.",
    "llama-2-7b-chat-hf_fact_raw": "1. CMB305 is a monoclonal antibody.\n2. CMB305 targets the CD305 receptor.\n3. The CD305 receptor is overexpressed in many types of cancer, including sarcomas.\n4. CMB305 has the potential to be used against sarcomas.",
    "llama-2-7b-chat-hf_fact": [
      "CMB305 is a monoclonal antibody.",
      "CMB305 targets the CD305 receptor.",
      "The CD305 receptor is overexpressed in many types of cancer, including sarcomas.",
      "CMB305 has the potential to be used against sarcomas."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: CMB305 is designed to target NY-ESO-1, a cancer-testis antigen, not the CD305 receptor.\n3. UNKNOWN (without context, specifically indicating that CD305, which is also known as LAIR-1, is overexpressed in many types of cancer including sarcomas, this statement's accuracy cannot be evaluated. More commonly, NY-ESO-1 expression might be associated with certain cancers, which CMB305 targets.)\n4. TRUE (Given CMB305 is a cancer vaccine targeting NY-ESO-1, if the antigen is expressed in certain sarcomas, CMB305 has the potential to be used against these sarcomas.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-7b-chat-hf_response": "The Saint's Triad, also known as the Behcet's Syndrome, is a rare inflammatory disorder that affects the skin, joints, and eyes. The main manifestations of the Saint's Triad are:\n1. Skin manifestations: The most common skin manifestations of the Saint's Triad are oral aphthous ulcers, genital ulcers, and skin nodules. The ulcers are typically painful and can occur on the lips, tongue, or in the mouth. The skin nodules are usually firm, round, and painless.\n2. Joint manifestations: The Saint's Triad can also cause joint pain and swelling, particularly in the hands and feet. The joint pain can be severe and can cause difficulty moving the affected joints.\n3. Eye manifestations: The Saint's Triad can also cause eye problems, including uveitis, iritis, and scleritis. These eye problems can cause vision loss and eye pain.\nThese manifestations can occur alone or in combination and can vary in severity from person to person. It's important to note that the Saint's Triad is a rare condition and not everyone will experience all of these manifestations. If you are experiencing any of these symptoms, it's important to consult with a healthcare professional for proper diagnosis and treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Saint's Triad, also referred to as Behcet's Syndrome, is a rare inflammatory disorder.\n2. The disorder affects the skin, joints, and eyes.\n3. Skin manifestations of Saint's Triad include oral aphthous ulcers, genital ulcers, and skin nodules.\n4. Joint symptoms of Saint's Triad encompass pain and swelling, particularly in the hands and feet.\n5. Eye problems associated with Saint's Triad include uveitis, iritis, and scleritis.",
    "llama-2-7b-chat-hf_fact": [
      "Saint's Triad, also referred to as Behcet's Syndrome, is a rare inflammatory disorder.",
      "The disorder affects the skin, joints, and eyes.",
      "Skin manifestations of Saint's Triad include oral aphthous ulcers, genital ulcers, and skin nodules.",
      "Joint symptoms of Saint's Triad encompass pain and swelling, particularly in the hands and feet.",
      "Eye problems associated with Saint's Triad include uveitis, iritis, and scleritis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Saint's Triad is not the same as Behcet's Syndrome. Saint's Triad, also known as Saint's Syndrome, typically refers to the combination of hiatus hernia, gallstones, and diverticular disease. Behcet's Syndrome is a rare inflammatory disorder, but it is not synonymous with Saint's Triad.\n2. UNKNOWN (Since Saint's Triad does not refer to Behcet's Syndrome, the symptoms related to Behcet's Syndrome are not applicable to Saint's Triad. However, if this statement was actually referring to Behcet's Syndrome, it would be true as Behcet's Syndrome does affect the skin, joints, and eyes. The validity concerning Saint's Triad cannot be determined.)\n3. UNKNOWN (Similar to statement 2, this description fits Behcet's Syndrome, but if the statement is meant to describe Saint's Triad, the validity is unknown as Saint's Triad does not involve these symptoms.)\n4. UNKNOWN (The joint symptoms specified refer to Behcet's Syndrome. Whether this applies to Saint's Triad is unknown since Saint's Triad concerns different conditions. Without the correct context, we cannot determine the truth of the statement.)\n5. UNKNOWN (Again, this pertains to Behcet's Syndrome, not Saint's Triad. Without clarification, we cannot ascertain the truthfulness regarding Saint's Triad.)\n\nAs these symptoms are typical for Behcet's Syndrome, if the context involves a mistaken interchange of 'Saint's Triad' for 'Behcet's Syndrome,' then statements 2, 3, and 5 would indeed be true for Behcet's Syndrome but not for Saint's Triad.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-7b-chat-hf_response": "Overexpression of LY6K is associated with poorer prognosis in non-small cell lung cancer (NSCLC) patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. Overexpression of LY6K is associated with poorer prognosis in non-small cell lung cancer patients.",
    "llama-2-7b-chat-hf_fact": [
      "Overexpression of LY6K is associated with poorer prognosis in non-small cell lung cancer patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-7b-chat-hf_response": "During cytokinesis, the CDK (cyclin-dependent kinase) inhibitor p21 is dephosphorylated, leading to its activation and promotion of the separation of daughter cells.\nOther CDK targets that are dephosphorylated during cytokinesis include:\n1. Cyclin-dependent kinase 1 (CDK1): Dephosphorylation of CDK1 by the protein phosphatase Cdc25A is important for the progression of mitosis and the separation of daughter cells.\n2. Cyclin-dependent kinase 2 (CDK2): Dephosphorylation of CDK2 by the protein phosphatase Cdc25A is also important for the progression of mitosis and the separation of daughter cells.\n3. Cyclin-dependent kinase 4 (CDK4): Dephosphorylation of CDK4 by the protein phosphatase Cdc25A is important for the progression of mitosis and the separation of daughter cells.\n4. Cyclin-dependent kinase 6 (CDK6): Dephosphorylation of CDK6 by the protein phosphatase Cdc25A is important for the progression of mitosis and the separation of daughter cells.\n5. Cyclin-dependent kinase 9 (CDK9): Dephosphorylation of CDK9 by the protein phosphatase Cdc25A is important for the progression of mitosis and the separation of daughter cells.\nThese dephosphorylation events play a crucial role in regulating the activity of CDKs during cytokinesis, allowing for the proper separation of daughter cells and ensuring the proper progression of mitosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The CDK inhibitor p21 is dephosphorylated during cytokinesis.\n2. Dephosphorylation of cyclin-dependent kinase 1 (CDK1) by protein phosphatase Cdc25A occurs during cytokinesis.\n3. Protein phosphatase Cdc25A is responsible for dephosphorylating cyclin-dependent kinase 2 (CDK2) during cytokinesis.\n4. Cyclin-dependent kinase 4 (CDK4) is dephosphorylated by protein phosphatase Cdc25A during cytokinesis.\n5. Dephosphorylation of cyclin-dependent kinase 6 (CDK6) and cyclin-dependent kinase 9 (CDK9) by protein phosphatase Cdc25A is important for mitosis progression and cell separation during cytokinesis.",
    "llama-2-7b-chat-hf_fact": [
      "The CDK inhibitor p21 is dephosphorylated during cytokinesis.",
      "Dephosphorylation of cyclin-dependent kinase 1 (CDK1) by protein phosphatase Cdc25A occurs during cytokinesis.",
      "Protein phosphatase Cdc25A is responsible for dephosphorylating cyclin-dependent kinase 2 (CDK2) during cytokinesis.",
      "Cyclin-dependent kinase 4 (CDK4) is dephosphorylated by protein phosphatase Cdc25A during cytokinesis.",
      "Dephosphorylation of cyclin-dependent kinase 6 (CDK6) and cyclin-dependent kinase 9 (CDK9) by protein phosphatase Cdc25A is important for mitosis progression and cell separation during cytokinesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: There's not enough information to determine the phosphorylation state of p21 during cytokinesis without additional context.\n2. FALSE [correction]: Dephosphorylation of CDK1 during mitosis and entry into cytokinesis is mediated by the opposing phosphatase Cdc25C, not Cdc25A.\n3. UNKNOWN: Specific details about the dephosphorylation of CDK2 by Cdc25A during cytokinesis are not provided, and the role of Cdc25A in this process would need to be confirmed by scientific literature.\n4. UNKNOWN: The specific role of Cdc25A in dephosphorylating CDK4 during cytokinesis is not clear without further information.\n5. UNKNOWN: The specific roles of Cdc25A with respect to CDK6 and CDK9 during mitosis and cytokinesis aren't detailed here, and their precise involvement would require additional context from scientific research.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-7b-chat-hf_response": "Xanamem is a drug that inhibits the activity of protein kinase C (PKC), which is involved in various cellular signaling pathways. Specifically, it selectively inhibits the PKC delta and PKC epsilon isoforms, which are implicated in various physiological processes such as cell proliferation, differentiation, and survival. Xanamem has been used as a research tool to study the role of PKC in various biological processes and has also been investigated as a potential therapeutic agent for the treatment of certain diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xanamem is a drug that inhibits the activity of protein kinase C (PKC).\n2. It selectively inhibits the PKC delta and PKC epsilon isoforms.\n3. PKC is involved in cellular signaling pathways, including cell proliferation, differentiation, and survival.\n4. Xanamem has been used in research to study the role of PKC in biological processes.\n5. It has been investigated as a potential therapeutic agent for cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact": [
      "Xanamem is a drug that inhibits the activity of protein kinase C (PKC).",
      "It selectively inhibits the PKC delta and PKC epsilon isoforms.",
      "PKC is involved in cellular signaling pathways, including cell proliferation, differentiation, and survival.",
      "Xanamem has been used in research to study the role of PKC in biological processes.",
      "It has been investigated as a potential therapeutic agent for cancer and neurodegenerative disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements about Xanamem are specific, and without specific context or source information on the drug, its functions and uses cannot be accurately verified. However, the statement on PKC's role in cellular signaling is generally true as PKC is known to be involved in various cellular functions including the ones mentioned.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-7b-chat-hf_response": "Hof1 and Cyk3 are two proteins that interact in yeast and play a role in the regulation of various cellular processes, including cell division, metabolism, and stress response. The interaction between Hof1 and Cyk3 is important for the proper functioning of these processes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hof1 and Cyk3 are proteins found in yeast.\n2. The interaction between Hof1 and Cyk3 plays a role in the regulation of cell division in yeast.\n3. Hof1-Cyk3 interaction is involved in the regulation of metabolism in yeast.\n4. Hof1-Cyk3 interaction affects the stress response in yeast.\n5. The proper functioning of cell division, metabolism, and stress response in yeast depends on the Hof1-Cyk3 interaction.",
    "llama-2-7b-chat-hf_fact": [
      "Hof1 and Cyk3 are proteins found in yeast.",
      "The interaction between Hof1 and Cyk3 plays a role in the regulation of cell division in yeast.",
      "Hof1-Cyk3 interaction is involved in the regulation of metabolism in yeast.",
      "Hof1-Cyk3 interaction affects the stress response in yeast.",
      "The proper functioning of cell division, metabolism, and stress response in yeast depends on the Hof1-Cyk3 interaction."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: There is no specific evidence that the Hof1-Cyk3 interaction is involved in the regulation of metabolism in yeast. This interaction is known primarily for its role in cytokinesis, which is a part of cell division.\n4. UNKNOWN: Without specific information, it is unclear whether the Hof1-Cyk3 interaction affects the stress response in yeast.\n5. FALSE [correction]: While the Hof1-Cyk3 interaction is important for the proper functioning of cell division in yeast, there is no specific evidence to suggest it is also directly responsible for the regulation of metabolism or the stress response in yeast. Each of these processes may involve different regulatory proteins and pathways.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-7b-chat-hf_response": "T-UCRs (tumor-associated circular RNAs) have been implicated in gastric cancer, including:\n1. Circular RNA 00107 (circRNA00107): Up-regulated in gastric cancer tissues and cell lines, and promotes cell proliferation and invasion.\n2. Circular RNA 00201 (circRNA00201): Down-regulated in gastric cancer tissues and cell lines, and inhibits cell proliferation and invasion.\n3. Circular RNA 00301 (circRNA00301): Up-regulated in gastric cancer tissues and cell lines, and promotes cell proliferation and migration.\n4. Circular RNA 00401 (circRNA00401): Down-regulated in gastric cancer tissues and cell lines, and inhibits cell proliferation and invasion.\n5. Circular RNA 00501 (circRNA00501): Up-regulated in gastric cancer tissues and cell lines, and promotes cell proliferation and migration.\n6. Circular RNA 00601 (circRNA00601): Down-regulated in gastric cancer tissues and cell lines, and inhibits cell proliferation and invasion.\n7. Circular RNA 00701 (circRNA00701): Up-regulated in gastric cancer tissues and cell lines, and promotes cell proliferation and migration.\n8. Circular RNA 00801 (circRNA00801): Down-regulated in gastric cancer tissues and cell lines, and inhibits cell proliferation and invasion.\n9. Circular RNA 00901 (circRNA00901): Up-regulated in gastric cancer tissues and cell lines, and promotes cell proliferation and migration.\n10. Circular RNA 01001 (circRNA01001): Down-regulated in gastric cancer tissues and cell lines",
    "llama-2-7b-chat-hf_fact_raw": "1. Circular RNA 00107 (circRNA00107) is up-regulated in gastric cancer tissues and cell lines, and it promotes cell proliferation and invasion.\n2. Circular RNA 00201 (circRNA00201) is down-regulated in gastric cancer tissues and cell lines, and it inhibits cell proliferation and invasion.\n3. Circular RNA 00301 (circRNA00301) is up-regulated in gastric cancer tissues and cell lines, and it promotes cell proliferation and migration.\n4. Circular RNA 00401 (circRNA00401) is down-regulated in gastric cancer tissues and cell lines, and it inhibits cell proliferation and invasion.\n5. Circular RNA 00501 (circRNA00501) is up-regulated in gastric cancer tissues and cell lines, and it promotes cell proliferation and migration.",
    "llama-2-7b-chat-hf_fact": [
      "Circular RNA 00107 (circRNA00107) is up-regulated in gastric cancer tissues and cell lines, and it promotes cell proliferation and invasion.",
      "Circular RNA 00201 (circRNA00201) is down-regulated in gastric cancer tissues and cell lines, and it inhibits cell proliferation and invasion.",
      "Circular RNA 00301 (circRNA00301) is up-regulated in gastric cancer tissues and cell lines, and it promotes cell proliferation and migration.",
      "Circular RNA 00401 (circRNA00401) is down-regulated in gastric cancer tissues and cell lines, and it inhibits cell proliferation and invasion.",
      "Circular RNA 00501 (circRNA00501) is up-regulated in gastric cancer tissues and cell lines, and it promotes cell proliferation and migration."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements about specific circular RNAs' expression patterns and functions in gastric cancer are highly technical and would require access to specific scientific studies or literature to verify. Without access to the relevant research or context, I cannot determine the truthfulness of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-7b-chat-hf_response": "The Lupus Severity Index (LSI) is a clinical index used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease that affects multiple organ systems. The LSI is a composite measure that takes into account various clinical and laboratory parameters, including:\n1. Serum creatinine level\n2. Urinary protein-to-creatinine ratio\n3. Levels of certain autoantibodies (such as anti-double-stranded DNA and anti-smooth muscle antibodies)\n4. Disease activity score (using a combination of joint count, tender joint count, and swollen joint count)\n5. Patient global assessment of disease severity\n6. Physician global assessment of disease severity\n7. Organ involvement (based on physical examination and laboratory tests)\nThe LSI scores are calculated based on the values of these parameters, and the total score ranges from 0 to 100. Higher scores indicate more severe disease. The LSI has been shown to be a useful tool for assessing the severity of SLE and monitoring the response to treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).\n2. The LSI takes into account clinical and laboratory parameters like serum creatinine level and urinary protein-to-creatinine ratio.\n3. The index includes levels of certain autoantibodies such as anti-double-stranded DNA and anti-smooth muscle antibodies.\n4. The LSI scoring involves a disease activity score, which combines joint count, tender joint count, and swollen joint count.\n5. LSI scores range from 0 to 100, where higher scores indicate more severe disease.",
    "llama-2-7b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).",
      "The LSI takes into account clinical and laboratory parameters like serum creatinine level and urinary protein-to-creatinine ratio.",
      "The index includes levels of certain autoantibodies such as anti-double-stranded DNA and anti-smooth muscle antibodies.",
      "The LSI scoring involves a disease activity score, which combines joint count, tender joint count, and swollen joint count.",
      "LSI scores range from 0 to 100, where higher scores indicate more severe disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific information on the Lupus Severity Index (LSI), it is difficult to confirm its use and parameters. The term \"LSI\" is not a widely recognized standard acronym in the context of systemic lupus erythematosus (SLE) assessment; instead, other indices like the SLE Disease Activity Index (SLEDAI) or the British Isles Lupus Assessment Group (BILAG) index are more commonly used.\n\n2. UNKNOWN: As the existence and parameters of the Lupus Severity Index (LSI) cannot be confirmed, it is impossible to determine the accuracy of this statement. Common clinical and laboratory parameters for assessing SLE severity include serum creatinine and the urinary protein-to-creatinine ratio but it's unclear if these are part of an index referred to as the LSI.\n\n3. UNKNOWN: Since the legitimacy of the LSI is in question, it’s impossible to affirm whether it includes certain autoantibodies like anti-double-stranded DNA, which is relevant to SLE, and anti-smooth muscle antibodies, which are more commonly associated with autoimmune liver diseases.\n\n4. UNKNOWN: With no verifiable information available on the LSI, it is indeterminable if it uses a disease activity score that combines joint count, tender joint count, and swollen joint count. These parameters are often used in other rheumatological assessments but it's unclear regarding their use in an LSI.\n\n5. UNKNOWN: Due to the absence of credible details about the LSI and its scoring system, it is not possible to validate this statement. In SLE severity assessments, scoring ranges can differ based on the index or criteria used.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-7b-chat-hf_response": "ZSWIM6 is a gene that has been associated with various neurological disorders, including:\n1. Neurodevelopmental disorders: De novo mutations in ZSWIM6 have been identified in individuals with neurodevelopmental disorders, such as intellectual disability, autism spectrum disorder, and attention deficit hyperactivity disorder (ADHD).\n2. Epilepsy: ZSWIM6 mutations have been found to be associated with various forms of epilepsy, including infantile spasms, Lennox-Gastaut syndrome, and other types of epilepsy.\n3. Seizures: De novo mutations in ZSWIM6 have been identified in individuals with seizure disorders, including those with no known genetic cause.\n4. Brain malformations: ZSWIM6 mutations have been found to be associated with various brain malformations, including cortical malformations and hydrocephalus.\n5. Developmental delay: De novo mutations in ZSWIM6 have been identified in individuals with developmental delay, including those with global developmental delay and speech and language disorders.\nIt is important to note that the frequency and severity of these disorders may vary depending on the specific mutation and the individual affected.",
    "llama-2-7b-chat-hf_fact_raw": "1. De novo mutations in ZSWIM6 have been identified in individuals with neurodevelopmental disorders such as intellectual disability, autism spectrum disorder, and ADHD.\n2. ZSWIM6 mutations have been found to be associated with various forms of epilepsy, including infantile spasms and Lennox-Gastaut syndrome.\n3. De novo mutations in ZSWIM6 have been identified in individuals with seizure disorders.\n4. ZSWIM6 mutations have been associated with brain malformations, including cortical malformations and hydrocephalus.\n5. De novo mutations in ZSWIM6 have been identified in individuals with developmental delays, including global developmental delay and speech and language disorders.",
    "llama-2-7b-chat-hf_fact": [
      "De novo mutations in ZSWIM6 have been identified in individuals with neurodevelopmental disorders such as intellectual disability, autism spectrum disorder, and ADHD.",
      "ZSWIM6 mutations have been found to be associated with various forms of epilepsy, including infantile spasms and Lennox-Gastaut syndrome.",
      "De novo mutations in ZSWIM6 have been identified in individuals with seizure disorders.",
      "ZSWIM6 mutations have been associated with brain malformations, including cortical malformations and hydrocephalus.",
      "De novo mutations in ZSWIM6 have been identified in individuals with developmental delays, including global developmental delay and speech and language disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE\n",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-7b-chat-hf_response": "The Koos Classification is a system used to classify neurodegenerative diseases based on the type of protein aggregates present in the brain. The diseases that can be classified using the Koos Classification are:\n1. Alzheimer's disease (AD): characterized by the presence of amyloid-β (Aβ) peptide aggregates.\n2. Parkinson's disease (PD): characterized by the presence of α-synuclein (α-syn) aggregates.\n3. Progressive supranuclear palsy (PSP): characterized by the presence of tau protein aggregates.\n4. Multiple system atrophy (MSA): characterized by the presence of α-syn aggregates.\n5. Frontotemporal dementia (FTD): characterized by the presence of TDP-43 protein aggregates.\nIt's worth noting that this classification system is not exhaustive and there are other neurodegenerative diseases that can also be classified using this system, but these are the main ones.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Koos Classification is used to classify neurodegenerative diseases.\n2. Alzheimer's disease is characterized by the presence of amyloid-β peptide aggregates in the Koos Classification.\n3. Parkinson's disease is characterized by the presence of α-synuclein aggregates in the Koos Classification.\n4. Progressive supranuclear palsy is characterized by the presence of tau protein aggregates in the Koos Classification.\n5. Multiple system atrophy is characterized by the presence of α-synuclein aggregates in the Koos Classification.",
    "llama-2-7b-chat-hf_fact": [
      "The Koos Classification is used to classify neurodegenerative diseases.",
      "Alzheimer's disease is characterized by the presence of amyloid-β peptide aggregates in the Koos Classification.",
      "Parkinson's disease is characterized by the presence of α-synuclein aggregates in the Koos Classification.",
      "Progressive supranuclear palsy is characterized by the presence of tau protein aggregates in the Koos Classification.",
      "Multiple system atrophy is characterized by the presence of α-synuclein aggregates in the Koos Classification."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Koos Classification is not used to classify neurodegenerative diseases. It is typically associated with grading the severity of cerebral arteriovenous malformations.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nSince the Koos Classification is not related to neurodegenerative diseases, the specific characterizations of those diseases within that system cannot be determined as true or false.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-7b-chat-hf_response": "AZD8601 is a small molecule inhibitor of the enzyme PI3K (phosphatidylinositol 3-kinase). In vivo, AZD8601 has been shown to have a range of effects, including:\n1. Inhibition of tumor growth: AZD8601 has been shown to inhibit the growth of various types of tumors, including breast, lung, and colon cancer, both in vitro and in vivo.\n2. Induction of apoptosis: AZD8601 has been shown to induce apoptosis (programmed cell death) in cancer cells, which can lead to a decrease in tumor size.\n3. Inhibition of angiogenesis: AZD8601 has been shown to inhibit the formation of new blood vessels, which are necessary for tumor growth and survival.\n4. Enhancement of chemotherapy: AZD8601 has been shown to enhance the effectiveness of chemotherapy drugs in treating cancer, both in vitro and in vivo.\n5. Reduction of cancer stem cell population: AZD8601 has been shown to reduce the population of cancer stem cells, which are thought to be responsible for the initiation and maintenance of cancer.\n6. Immune modulation: AZD8601 has been shown to modulate the immune response, including the activation of immune cells and the production of cytokines.\n7. Anti-inflammatory effects: AZD8601 has been shown to have anti-inflammatory effects, including the inhibition of the production of pro-inflammatory cytokines.\n8. Neuroprotection: AZD8601 has been shown to have neuroprotective effects, including the protection of neurons against oxidative stress and excitotoxicity.\nIt is important to note that the specific effects of AZD8601 can vary depending on the type of cancer and the stage of disease, as well as the individual patient. Further research is needed to fully understand the in vivo effects of AZD8601 and its potential as a therapeutic agent.",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8601 is a small molecule inhibitor of the enzyme PI3K (phosphatidylinositol 3-kinase).\n2. AZD8601 has been shown to inhibit the growth of various types of tumors, including breast, lung, and colon cancer, in vivo.\n3. AZD8601 has been shown to induce apoptosis in cancer cells in vivo.\n4. AZD8601 has been shown to inhibit the formation of new blood vessels, necessary for tumor growth and survival, in vivo.\n5. AZD8601 has been shown to enhance the effectiveness of chemotherapy drugs in treating cancer in vivo.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8601 is a small molecule inhibitor of the enzyme PI3K (phosphatidylinositol 3-kinase).",
      "AZD8601 has been shown to inhibit the growth of various types of tumors, including breast, lung, and colon cancer, in vivo.",
      "AZD8601 has been shown to induce apoptosis in cancer cells in vivo.",
      "AZD8601 has been shown to inhibit the formation of new blood vessels, necessary for tumor growth and survival, in vivo.",
      "AZD8601 has been shown to enhance the effectiveness of chemotherapy drugs in treating cancer in vivo."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: AZD8601 is not a small molecule inhibitor of the enzyme PI3K; it is an mRNA-based therapy that encodes for VEGF-A, which is a protein involved in the signaling of endothelial cells that form blood vessels.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nGiven the current information, we cannot assess the veracity of statements 2 through 5 as they pertain to in vivo effects of AZD8601, and no specific research has been provided to support or refute these claims.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-7b-chat-hf_response": "SAHFs (Spatially-Arranged High-Fidelity Structures) are created through a process called \"chromatin remodeling,\" which involves the movement of nucleosomes along the DNA strand to create specific spatial arrangements of nucleosomes. This process is mediated by enzymes called chromatin remodelers, which use energy from ATP hydrolysis to move nucleosomes along the DNA strand. The specific arrangement of nucleosomes in SAHFs can have a significant impact on gene expression, as it can alter the accessibility of transcription factors and other regulatory proteins to the underlying DNA.",
    "llama-2-7b-chat-hf_fact_raw": "1. SAHFs are created through a process known as \"chromatin remodeling.\"\n2. Chromatin remodeling involves the movement of nucleosomes along the DNA strand.\n3. Enzymes called chromatin remodelers mediate the process of creating SAHFs.\n4. Chromatin remodelers use energy from ATP hydrolysis to move nucleosomes.\n5. The specific arrangement of nucleosomes in SAHFs affects gene expression by altering the accessibility of transcription factors and other regulatory proteins to DNA.",
    "llama-2-7b-chat-hf_fact": [
      "SAHFs are created through a process known as \"chromatin remodeling.\"",
      "Chromatin remodeling involves the movement of nucleosomes along the DNA strand.",
      "Enzymes called chromatin remodelers mediate the process of creating SAHFs.",
      "Chromatin remodelers use energy from ATP hydrolysis to move nucleosomes.",
      "The specific arrangement of nucleosomes in SAHFs affects gene expression by altering the accessibility of transcription factors and other regulatory proteins to DNA."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nSenescence-associated heterochromatin foci (SAHFs) are indeed related to chromatin remodeling, a process that involves the reorganization of chromatin. Chromatin remodelers can move nucleosomes along DNA to expose different regions for transcriptional activity or repression. These remodelers do use ATP hydrolysis to power the movement of nucleosomes, which inevitably impacts the accessibility of DNA to transcription factors and other regulatory proteins, thereby affecting gene expression.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-7b-chat-hf_response": "The PDZ (PSD-95/Discs-Large/ZO-1) domain is a protein-binding domain found in the SATB1 protein. The PDZ domain of SATB1 is involved in the regulation of chromatin remodeling and transcriptional activation. It interacts with other proteins, such as PML and histone deacetylases, to modulate their activity and play a role in the regulation of gene expression, particularly during embryonic development and cell differentiation.",
    "llama-2-7b-chat-hf_fact_raw": "1. The PDZ domain is a protein-binding domain present in the SATB1 protein.\n2. The PDZ domain of SATB1 is implicated in the regulation of chromatin remodeling.\n3. The PDZ domain in SATB1 is involved in transcriptional activation.\n4. SATB1's PDZ domain interacts with other proteins like PML and histone deacetylases to modulate their activity.\n5. The PDZ domain in SATB1 plays a role in regulation of gene expression during embryonic development and cell differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "The PDZ domain is a protein-binding domain present in the SATB1 protein.",
      "The PDZ domain of SATB1 is implicated in the regulation of chromatin remodeling.",
      "The PDZ domain in SATB1 is involved in transcriptional activation.",
      "SATB1's PDZ domain interacts with other proteins like PML and histone deacetylases to modulate their activity.",
      "The PDZ domain in SATB1 plays a role in regulation of gene expression during embryonic development and cell differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE - While the statement is true that SATB1 is implicated in chromatin remodeling, it needs clarification that the PDZ domain itself may not be the direct mediator of this function. SATB1 as a whole, including its PDZ domain, can be involved in the regulation of chromatin structure.\n3. TRUE - SATB1, including its PDZ domain, is indeed involved in transcriptional activation as part of its role in chromatin organization and regulation of gene expression.\n4. FALSE [correction]: The PDZ domain is typically known for mediating protein-protein interactions, but specific interactions of the SATB1 PDZ domain with proteins like PML and histone deacetylases are not universally recognized. SATB1 does interact with various proteins, but attributing these interactions specifically to the PDZ domain requires specific supporting evidence.\n5. TRUE - SATB1 plays a role in the regulation of gene expression during embryonic development and cell differentiation. However, the role of the PDZ domain specifically in these processes is less clear without additional context. The statement is true for SATB1 as a protein.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-7b-chat-hf_response": "The BLISS (Blocking, Loading, Isolation, and Separation of Signaling) technique is a method used to isolate and analyze protein-protein interactions (PPIs) in a cellular context. The basis of the BLISS technique is to use a combination of chemical and biochemical methods to isolate and analyze the interactions between specific protein pairs in a native cellular environment.\nThe BLISS technique consists of four main steps:\n1. Blocking: The first step is to block the activity of the proteins of interest using a specific inhibitor or small molecule. This step helps to prevent the proteins from interacting with other proteins in the cell and allows for the isolation of the specific interaction of interest.\n2. Loading: The second step is to load the proteins of interest with a fluorescent or radioactive tag. This allows for the visualization and detection of the proteins in the cell.\n3. Isolation: The third step is to isolate the proteins of interest using a combination of biochemical and cellular fractionation methods. This step helps to purify the proteins of interest and remove any non-specific interactions.\n4. Separation: The final step is to separate the proteins of interest based on their interactions using a combination of chromatography and spectroscopy methods. This step helps to identify the specific interactions between the proteins of interest and any other proteins in the cell.\nThe BLISS technique provides a powerful tool for studying PPIs in a cellular context, allowing researchers to identify and characterize specific interactions in a native and dynamic environment.",
    "llama-2-7b-chat-hf_fact_raw": "1. The BLISS technique is used to isolate and analyze protein-protein interactions in a cellular context.\n2. The basis of the BLISS technique involves using a combination of chemical and biochemical methods.\n3. The BLISS technique involves a step where the activity of proteins of interest is blocked using a specific inhibitor or small molecule.\n4. During the BLISS technique, proteins of interest are loaded with a fluorescent or radioactive tag for visualization and detection.\n5. The BLISS technique includes a separation step that utilizes chromatography and spectroscopy methods to identify specific interactions.",
    "llama-2-7b-chat-hf_fact": [
      "The BLISS technique is used to isolate and analyze protein-protein interactions in a cellular context.",
      "The basis of the BLISS technique involves using a combination of chemical and biochemical methods.",
      "The BLISS technique involves a step where the activity of proteins of interest is blocked using a specific inhibitor or small molecule.",
      "During the BLISS technique, proteins of interest are loaded with a fluorescent or radioactive tag for visualization and detection.",
      "The BLISS technique includes a separation step that utilizes chromatography and spectroscopy methods to identify specific interactions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe Bioluminescence-based ligand interaction assay system (BLISS) is indeed a method used to study protein-protein interactions in a cellular context, often employing a bioluminescent signal to quantify these interactions and may involve chemical and biochemical methods. However, without specific details on the precise steps of the BLISS process, such as whether it uses an inhibitor or small molecule to block activity (statement 3), how proteins are tagged (statement 4), or the exact separation methods used (statement 5), the veracity of statements 3, 4, and 5 cannot be ascertained with the information provided. These steps can vary significantly among different protein-protein interaction techniques and even within different variations of the BLISS method if they exist.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-7b-chat-hf_response": "Here are three NK3R antagonists:\n1. GR 127935: A potent and selective NK3R antagonist that has been shown to have potential in the treatment of various conditions, including cancer and neurological disorders.\n2. MK-0532: A highly selective and potent NK3R antagonist that has been shown to have potential in the treatment of gastrointestinal disorders, such as irritable bowel syndrome.\n3. BAY-60-2764: A potent and selective NK3R antagonist that has been shown to have potential in the treatment of various conditions, including cancer and neurological disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. GR 127935 is a selective NK3R antagonist.\n2. MK-0532 is a selective NK3R antagonist with potential applications in treating gastrointestinal disorders.\n3. BAY-60-2764 is a selective NK3R antagonist with applications in treating cancer and neurological disorders.",
    "llama-2-7b-chat-hf_fact": [
      "GR 127935 is a selective NK3R antagonist.",
      "MK-0532 is a selective NK3R antagonist with potential applications in treating gastrointestinal disorders.",
      "BAY-60-2764 is a selective NK3R antagonist with applications in treating cancer and neurological disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n\nNote: The specificity of GR 127935 as a selective NK3 receptor (NK3R) antagonist is correct based on the context provided. However, without additional context for the other two compounds (MK-0532 and BAY-60-2764) and their applications, it is not possible to verify the accuracy of those statements. They are not well-known compounds with widely recognized uses like some other pharmaceuticals, which makes it difficult to confirm the provided information without specific literature references or further context.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-7b-chat-hf_response": "The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is LY2835219.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-7b-chat-hf_response": "Vaxchora, a cholera vaccine made by GlaxoSmithKline, has been shown to have a protective efficacy of 70-80% against moderate to severe cholera in adults and children aged 1-50 years old, according to clinical trials.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora is a cholera vaccine made by GlaxoSmithKline.\n2. Clinical trials have shown that Vaxchora has a protective efficacy of 70-80% against moderate to severe cholera.\n3. The measured efficacy of Vaxchora covers both adults and children aged 1-50 years old.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora is a cholera vaccine made by GlaxoSmithKline.",
      "Clinical trials have shown that Vaxchora has a protective efficacy of 70-80% against moderate to severe cholera.",
      "The measured efficacy of Vaxchora covers both adults and children aged 1-50 years old."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Vaxchora is a cholera vaccine made by PaxVax, not GlaxoSmithKline.\n2. UNKNOWN (The efficacy rate provided might be correct, but without specific data from clinical trials, it can't be confirmed as true or false.)\n3. FALSE [correction]: The measured efficacy of Vaxchora primarily covers adults and is not indicated for children under 18 years of age.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-7b-chat-hf_response": "The first cholera vaccine approved in the US was the oral cholera vaccine, also known as the killed oral cholera vaccine (KOCV), which was approved by the US Food and Drug Administration (FDA) in 1993.",
    "llama-2-7b-chat-hf_fact_raw": "1. The first cholera vaccine approved in the US was an oral cholera vaccine.\n2. This vaccine is known as the killed oral cholera vaccine (KOCV).\n3. The vaccine was approved by the US Food and Drug Administration (FDA) in 1993.",
    "llama-2-7b-chat-hf_fact": [
      "The first cholera vaccine approved in the US was an oral cholera vaccine.",
      "This vaccine is known as the killed oral cholera vaccine (KOCV).",
      "The vaccine was approved by the US Food and Drug Administration (FDA) in 1993."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: This vaccine is known as the killed oral cholera vaccine (OCV), not KOCV.\n3. FALSE [correction]: The vaccine, Vaxchora, was approved by the US Food and Drug Administration (FDA) in 2016.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-7b-chat-hf_response": "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is a mutation in the CD40 ligand gene (CD40LG). This gene provides instructions for making a protein called CD40 ligand, which is involved in the activation of immune cells and the immune response. Mutations in the CD40LG gene can lead to a deficiency in CD40 ligand production, which can result in the immune system dysfunction and the development of CVID.",
    "llama-2-7b-chat-hf_fact_raw": "1. The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is a mutation in the CD40 ligand gene (CD40LG).\n2. The CD40LG gene is involved in the activation of immune cells and the immune response.\n3. Mutations in the CD40LG gene can lead to a deficiency in the production of CD40 ligand.\n4. A deficiency in CD40 ligand production can result in the development of common variable immunodeficiency (CVID).",
    "llama-2-7b-chat-hf_fact": [
      "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is a mutation in the CD40 ligand gene (CD40LG).",
      "The CD40LG gene is involved in the activation of immune cells and the immune response.",
      "Mutations in the CD40LG gene can lead to a deficiency in the production of CD40 ligand.",
      "A deficiency in CD40 ligand production can result in the development of common variable immunodeficiency (CVID)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is not a mutation in the CD40 ligand gene (CD40LG), but rather mutations in genes like ICOS, TNFRSF13B (TACI), TNFRSF13C (BAFFR), and other not well-defined genetic causes are implicated.\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-7b-chat-hf_response": "The IFIT1 gene has been found to be mutated in some cases of Systemic Lupus Erythematosus (SLE), and it is thought to play a role in the development and progression of the disease. Specifically, the IFIT1 gene encodes a protein called interferon-induced protein with tetratricopeptide repeats 1 (IFIT1), which is involved in the antiviral response and the regulation of inflammation. Mutations in the IFIT1 gene have been associated with an increased risk of SLE, and it is thought that these mutations may disrupt the normal function of the IFIT1 protein, leading to an imbalance in the immune system and the development of autoantibodies.",
    "llama-2-7b-chat-hf_fact_raw": "1. The IFIT1 gene has been found to be mutated in some cases of Systemic Lupus Erythematosus (SLE).\n2. The IFIT1 gene encodes a protein called interferon-induced protein with tetratricopeptide repeats 1 (IFIT1).\n3. IFIT1 protein is involved in the antiviral response and regulation of inflammation.\n4. Mutations in the IFIT1 gene have been associated with an increased risk of Systemic Lupus Erythematosus.\n5. The mutations in the IFIT1 gene may disrupt the normal function of the IFIT1 protein, leading to the development of autoantibodies.",
    "llama-2-7b-chat-hf_fact": [
      "The IFIT1 gene has been found to be mutated in some cases of Systemic Lupus Erythematosus (SLE).",
      "The IFIT1 gene encodes a protein called interferon-induced protein with tetratricopeptide repeats 1 (IFIT1).",
      "IFIT1 protein is involved in the antiviral response and regulation of inflammation.",
      "Mutations in the IFIT1 gene have been associated with an increased risk of Systemic Lupus Erythematosus.",
      "The mutations in the IFIT1 gene may disrupt the normal function of the IFIT1 protein, leading to the development of autoantibodies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe information provided does not include specific data or research findings to verify the statements about the IFIT1 gene mutations in relation to Systemic Lupus Erythematosus (SLE). While the second and third statements regarding the encoding and function of the IFIT1 protein are accurate, the claims about the association of IFIT1 gene mutations with SLE and their potential effect on IFIT1 protein function require referencing specific scientific research to be confirmed as true or false.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-7b-chat-hf_response": "The Liverpool Elbow Score (LES) is a clinical assessment tool used to evaluate the severity of elbow pain and stiffness in patients with medial epicondylitis, also known as golfer's elbow. The score is used to assess the patient's symptoms, functional ability, and quality of life, and can help guide treatment decisions. The LES consists of 5 components: pain, grip strength, range of motion, palpation, and functional ability. Each component is rated on a scale of 0-10, with higher scores indicating greater severity of symptoms. A total score of 0-20 indicates mild symptoms, 21-40 indicates moderate symptoms, and 41-60 indicates severe symptoms.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Liverpool Elbow Score is used to evaluate the severity of elbow pain and stiffness in patients with medial epicondylitis or golfer's elbow.\n2. The Liverpool Elbow Score helps to assess a patient's symptoms, functional ability, and quality of life.\n3. The Liverpool Elbow Score includes 5 components: pain, grip strength, range of motion, palpation, and functional ability.\n4. Each component of the Liverpool Elbow Score is rated on a scale of 0-10.\n5. A total Liverpool Elbow Score of 0-20 indicates mild symptoms, 21-40 indicates moderate symptoms, and 41-60 indicates severe symptoms.",
    "llama-2-7b-chat-hf_fact": [
      "The Liverpool Elbow Score is used to evaluate the severity of elbow pain and stiffness in patients with medial epicondylitis or golfer's elbow.",
      "The Liverpool Elbow Score helps to assess a patient's symptoms, functional ability, and quality of life.",
      "The Liverpool Elbow Score includes 5 components: pain, grip strength, range of motion, palpation, and functional ability.",
      "Each component of the Liverpool Elbow Score is rated on a scale of 0-10.",
      "A total Liverpool Elbow Score of 0-20 indicates mild symptoms, 21-40 indicates moderate symptoms, and 41-60 indicates severe symptoms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Liverpool Elbow Score is used to evaluate the overall function, pain, and quality of life in patients with various elbow pathologies, not specifically medial epicondylitis or golfer's elbow.\n2. TRUE\n3. FALSE [correction]: The Liverpool Elbow Score includes components such as pain, function, and social-psychological, but not specifically grip strength and palpation, and the number of components is not stated to be 5.\n4. FALSE [correction]: Each component of the Liverpool Elbow Score is rated on a scale of 1-5, not 0-10.\n5. FALSE [correction]: The Liverpool Elbow Score range and categories for mild, moderate, and severe symptoms are not standardly established as 0-20, 21-40, and 41-60 respectively. The interpretation of the score can vary and may not fit these precise ranges.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-7b-chat-hf_response": "The 100,000 Genomes Project is a large-scale genomics initiative launched in 2015 in the UK to accelerate the diagnosis and treatment of rare and undiagnosed genetic diseases, including sarcoma. Here are some efforts on sarcoma from the 100,000 Genomes Project:\n1. Data analysis: The 100,000 Genomes Project has generated a large amount of genomic data, including whole-genome sequencing data for over 16,000 cancer patients, including sarcoma patients. Researchers are analyzing these data to identify genetic mutations and other genomic changes that may be associated with sarcoma.\n2. Identification of new sarcoma subtypes: The 100,000 Genomes Project has identified new subtypes of sarcoma, including a subtype of leiomyosarcoma that is characterized by a specific genetic mutation. This subtype is found in approximately 10% of leiomyosarcomas and may have a different prognosis and response to treatment than other subtypes.\n3. Development of new diagnostic tests: The 100,000 Genomes Project has developed new diagnostic tests that use genomic data to identify specific genetic mutations in sarcoma tumors. These tests have the potential to improve the accuracy of sarcoma diagnosis and help guide treatment decisions.\n4. Identification of potential therapeutic targets: The 100,000 Genomes Project has identified potential therapeutic targets for sarcoma treatment, including genes that are commonly mutated in sarcoma tumors. These targets may be used to develop new therapies for sarcoma, including targeted therapies and immunotherapies.\n5. Collaboration with clinicians and researchers: The 100,000 Genomes Project has collaborated with clinicians and researchers to ensure that the genomic data generated through the project is used to improve the diagnosis and treatment of sarcoma. This collaboration has helped to ensure that the data is used in a way that is clinically relevant and has the potential to make a positive impact on patient outcomes.\nIn summary",
    "llama-2-7b-chat-hf_fact_raw": "1. The 100,000 Genomes Project was launched in 2015 in the UK.\n2. The project has sequenced the whole genomes of over 16,000 cancer patients, which includes sarcoma patients.\n3. A new subtype of leiomyosarcoma, characterized by a specific genetic mutation, was identified by the 100,000 Genomes Project.\n4. The 100,000 Genomes Project developed new diagnostic tests that leverage genomic data to identify specific mutations in sarcoma tumors.\n5. The project has discovered genes that are commonly mutated in sarcoma tumors and may serve as potential therapeutic targets for treatment.",
    "llama-2-7b-chat-hf_fact": [
      "The 100,000 Genomes Project was launched in 2015 in the UK.",
      "The project has sequenced the whole genomes of over 16,000 cancer patients, which includes sarcoma patients.",
      "A new subtype of leiomyosarcoma, characterized by a specific genetic mutation, was identified by the 100,000 Genomes Project.",
      "The 100,000 Genomes Project developed new diagnostic tests that leverage genomic data to identify specific mutations in sarcoma tumors.",
      "The project has discovered genes that are commonly mutated in sarcoma tumors and may serve as potential therapeutic targets for treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: As of my knowledge cutoff date in March 2023, the 100,000 Genomes Project has sequenced the whole genomes of tens of thousands of cancer patients, but the exact number of sarcoma patients is not specified; hence, the statement about over 16,000 sarcoma patients cannot be confirmed without specific data.\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-7b-chat-hf_response": "No, protein ALEX1 does not contain armadillo repeats.",
    "llama-2-7b-chat-hf_fact_raw": "1. Protein ALEX1 does not contain armadillo repeats.",
    "llama-2-7b-chat-hf_fact": [
      "Protein ALEX1 does not contain armadillo repeats."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n\n(Note: This response is based on the assumption that the given statement is correct regarding the composition of the protein ALEX1. In scientific contexts, such details can be very specific and are best verified by consulting the latest research or protein databases.)",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-7b-chat-hf_response": "Enzymes that remove histone modifications include:\n1. Histone demethylases: These enzymes remove methyl groups from histone proteins, leading to changes in chromatin structure and gene expression. Examples of histone demethylases include KDM4B, KDM5A, and KDM5B.\n2. Histone acetyltransferases (HATs): These enzymes add acetyl groups to histone proteins, leading to changes in chromatin structure and gene expression. Examples of HATs include p300 and CBP (CREB-binding protein).\n3. Histone deacetylases (HDACs): These enzymes remove acetyl groups from histone proteins, leading to changes in chromatin structure and gene expression. Examples of HDACs include HDAC1, HDAC2, and HDAC3.\n4. Histone ubiquitin ligases: These enzymes remove histone proteins from chromatin by attaching ubiquitin tags, leading to changes in chromatin structure and gene expression. Examples of histone ubiquitin ligases include RING1B and RING1A.\n5. Hydroxamate-specific histone demethylases: These enzymes remove methyl groups from histone proteins in a hydroxamate-sensitive manner, leading to changes in chromatin structure and gene expression. Examples of hydroxamate-specific histone demethylases include KDM1A and KDM4B.\n6. Arginine methyltransferases: These enzymes add methyl groups to histone proteins at arginine residues, leading to changes in chromatin structure and gene expression. Examples of arginine methyltransferases include PRMT1 and PRMT5.\n7. Prolyl isomerases: These enzymes catalyze the isomerization of proline residues in histone proteins, leading to changes in chromatin structure and gene expression. Examples of prolyl isomerases include PIN1 and PIN2.\n8. Chromodomain-containing proteins: These enzymes recognize and bind to specific histone modifications, leading to changes in chromatin structure and gene expression. Examples of chromod",
    "llama-2-7b-chat-hf_fact_raw": "1. Histone demethylases such as KDM4B, KDM5A, and KDM5B remove methyl groups from histone proteins.\n2. Histone acetyltransferases (HATs) like p300 and CBP add acetyl groups to histone proteins.\n3. Histone deacetylases (HDACs), including HDAC1, HDAC2, and HDAC3, remove acetyl groups from histone proteins.\n4. Histone ubiquitin ligases such as RING1B and RING1A remove histone proteins from chromatin by attaching ubiquitin tags.\n5. Hydroxamate-specific histone demethylases like KDM1A and KDM4B remove methyl groups from histone proteins in a hydroxamate-sensitive manner.",
    "llama-2-7b-chat-hf_fact": [
      "Histone demethylases such as KDM4B, KDM5A, and KDM5B remove methyl groups from histone proteins.",
      "Histone acetyltransferases (HATs) like p300 and CBP add acetyl groups to histone proteins.",
      "Histone deacetylases (HDACs), including HDAC1, HDAC2, and HDAC3, remove acetyl groups from histone proteins.",
      "Histone ubiquitin ligases such as RING1B and RING1A remove histone proteins from chromatin by attaching ubiquitin tags.",
      "Hydroxamate-specific histone demethylases like KDM1A and KDM4B remove methyl groups from histone proteins in a hydroxamate-sensitive manner."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Histone demethylases such as KDM4B, KDM5A, and KDM5B are enzymes that specifically remove methyl groups from histone proteins, altering the chromatin structure and influencing gene expression.\n2. TRUE: Histone acetyltransferases (HATs) like p300 and CBP are enzymes that add acetyl groups to histone proteins, which is associated with transcriptional activation and a more open chromatin structure.\n3. TRUE: Histone deacetylases (HDACs), including HDAC1, HDAC2, and HDAC3, are a class of enzymes that remove acetyl groups from histone proteins, generally leading to a more compact chromatin structure and transcriptional repression.\n4. FALSE [correction]: Histone ubiquitin ligases such as RING1B and RING1A do not remove histone proteins from chromatin; instead, they add ubiquitin tags to histones, which can signal for different processes, including histone removal under certain conditions.\n5. TRUE: Hydroxamate-containing compounds are inhibitors that target specific histone demethylases, and histone demethylases like KDM1A (also known as LSD1) and KDM4B can remove methyl groups from histone proteins. However, the phrase \"hydroxamate-specific histone demethylases\" is not standard terminology. Histone demethylases can be inhibited by hydroxamate-based inhibitors, but it would be more accurate to call them hydroxamate-sensitive than hydroxamate-specific.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-7b-chat-hf_response": "Head CT scans do not directly increase the risk of developing a brain tumor. However, there is some evidence to suggest that repeated exposure to ionizing radiation from CT scans may increase the risk of developing a brain tumor over time. This is because ionizing radiation has the potential to damage the DNA in cells, which can lead to mutations and an increased risk of cancer.\nThe American Association of Neurological Surgeons states that the risk of developing a brain tumor from a single CT scan is low, but the risk may be higher for people who have multiple CT scans over time. However, the organization notes that the overall risk of developing a brain tumor from CT scans is still relatively low, and the benefits of the scans in diagnosing and treating medical conditions often outweigh the potential risks.\nIt's important to weigh the potential risks and benefits of CT scans on an individual basis, and to discuss any concerns with a healthcare provider. They can help determine the appropriate use of CT scans and monitor for any potential side effects.",
    "llama-2-7b-chat-hf_fact_raw": "1. Repeated exposure to ionizing radiation from CT scans may increase the risk of developing a brain tumor over time.\n2. Ionizing radiation has the potential to damage the DNA in cells.\n3. The American Association of Neurological Surgeons states that the risk of developing a brain tumor from a single CT scan is low.\n4. The risk of developing a brain tumor from CT scans may be higher for people who have multiple CT scans over time.\n5. The overall risk of developing a brain tumor from CT scans is considered relatively low according to the American Association of Neurological Surgeons.",
    "llama-2-7b-chat-hf_fact": [
      "Repeated exposure to ionizing radiation from CT scans may increase the risk of developing a brain tumor over time.",
      "Ionizing radiation has the potential to damage the DNA in cells.",
      "The American Association of Neurological Surgeons states that the risk of developing a brain tumor from a single CT scan is low.",
      "The risk of developing a brain tumor from CT scans may be higher for people who have multiple CT scans over time.",
      "The overall risk of developing a brain tumor from CT scans is considered relatively low according to the American Association of Neurological Surgeons."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are generally consistent with the understanding that while ionizing radiation can cause DNA damage, which increases the risk of cancer, the risk from a single CT scan is low. However, repeated exposure could potentially increase this risk. The American Association of Neurological Surgeons and other health organizations recognize both the benefits and the risks associated with the use of CT scans and suggest that the overall risk of developing cancer from medical imaging is low but not negligible, especially with repeated exposure.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-7b-chat-hf_response": "Otx2 is associated with neural pluripotency.",
    "llama-2-7b-chat-hf_fact_raw": "1. Otx2 is associated with neural pluripotency.",
    "llama-2-7b-chat-hf_fact": [
      "Otx2 is associated with neural pluripotency."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Otx2 is not primarily associated with neural pluripotency. It is a homeobox gene involved in the development of the brain and sensory organs. The concept of \"pluripotency\" refers to the ability of a stem cell to differentiate into any cell type, which is a property generally associated with specific stem cell factors such as Oct4, Sox2, and Nanog, not Otx2.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-7b-chat-hf_response": "According to the information provided, there are 10 DNaseI hypersensitive sites (DHS) that mark the murine beta globin locus region.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are 10 DNaseI hypersensitive sites (DHS) that mark the murine beta globin locus region.",
    "llama-2-7b-chat-hf_fact": [
      "There are 10 DNaseI hypersensitive sites (DHS) that mark the murine beta globin locus region."
    ],
    "llama-2-7b-chat-hf_judge_raw": "UNKNOWN\n\nThe number of DNaseI hypersensitive sites can vary depending on the specific regulatory regions within the genome being described and the species. Data on the exact number of sites can be obtained from specific scientific studies or genetic databases. Without specific information from the context provided, it's not possible to confirm or correct this statement.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-7b-chat-hf_response": "Sure! Here are some European influenza vaccines that are currently available or have been approved in the past:\n1. Fluarix Tetra: This is a quadrivalent vaccine that protects against four strains of influenza: two A strains and two B strains. It is manufactured by GlaxoSmithKline (GSK) and is approved for use in the European Union (EU).\n2. Flulaval: This is a trivalent vaccine that protects against three strains of influenza: two A strains and one B strain. It is manufactured by Sanofi Pasteur and is approved for use in the EU.\n3. Aggrivax: This is a quadrivalent vaccine that protects against four strains of influenza: two A strains and two B strains. It is manufactured by BioProtection Systems and is approved for use in the EU.\n4. Fluad: This is a quadrivalent vaccine that protects against four strains of influenza: two A strains and two B strains. It is manufactured by Novartis and is approved for use in the EU.\n5. Vaxigrip: This is a trivalent vaccine that protects against three strains of influenza: two A strains and one B strain. It is manufactured by Sanofi Pasteur and is approved for use in the EU.\n6. Fluvirin: This is a trivalent vaccine that protects against three strains of influenza: two A strains and one B strain. It is manufactured by Novartis and is approved for use in the EU.\n7. Fluarix: This is a quadrivalent vaccine that protects against four strains of influenza: two A strains and two B strains. It is manufactured by GSK and is approved for use in the EU.\n8. Flucelvax: This is a quadrivalent vaccine that protects against four strains of influenza: two A strains and two B strains. It is manufactured by BioProtection Systems and is approved for use in the EU.\n9. Vaxigrip Tetra: This is a quadrivalent vaccine that protects against four strains of",
    "llama-2-7b-chat-hf_fact_raw": "1. Fluarix Tetra is a quadrivalent influenza vaccine approved for use in the European Union.\n2. Flulaval is a trivalent influenza vaccine approved for use in the European Union.\n3. Fluad is a quadrivalent influenza vaccine approved for use in the European Union.\n4. Vaxigrip is a trivalent influenza vaccine approved for use in the European Union.\n5. Fluvirin is a trivalent influenza vaccine approved for use in the European Union.",
    "llama-2-7b-chat-hf_fact": [
      "Fluarix Tetra is a quadrivalent influenza vaccine approved for use in the European Union.",
      "Flulaval is a trivalent influenza vaccine approved for use in the European Union.",
      "Fluad is a quadrivalent influenza vaccine approved for use in the European Union.",
      "Vaxigrip is a trivalent influenza vaccine approved for use in the European Union.",
      "Fluvirin is a trivalent influenza vaccine approved for use in the European Union."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Flulaval is a quadrivalent influenza vaccine approved for use in the European Union.\n3. FALSE [correction]: Fluad is an adjuvanted trivalent influenza vaccine approved for use in the European Union.\n4. FALSE [correction]: Vaxigrip is a quadrivalent influenza vaccine approved for use in the European Union.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-7b-chat-hf_response": "Yes, the Paramyxovirus geneome is segmented, negative-sense RNA.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-7b-chat-hf_response": "Roflumilast cream is effective for treating plaque psoriasis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roflumilast cream is used for treating plaque psoriasis.",
    "llama-2-7b-chat-hf_fact": [
      "Roflumilast cream is used for treating plaque psoriasis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-7b-chat-hf_response": "There are several tools that have been developed for identifying and visualizing non-coding RNA (ncRNA) promoters. Here are some of the commonly used tools:\n1. CpG Island Finder: This tool identifies CpG islands in the genome, which are known to be enriched in ncRNA promoters.\n2. ProbeFinder: This tool predicts the location of probes for ncRNA transcripts in the GenBank database, which can be used to identify ncRNA promoters.\n3. RNAhybrid: This tool predicts the secondary and tertiary structure of RNA molecules, including ncRNAs, and can be used to identify potential promoter regions.\n4. Infernal: This tool uses a Bayesian approach to predict the location of ncRNA promoters based on the sequence and structure of the RNA molecule.\n5. RNApromoter: This tool uses a machine learning approach to predict the location of ncRNA promoters based on the sequence and structure of the RNA molecule.\n6. Cis-regulatory element annotation system (CREAS): This tool predicts the location of transcription factor binding sites, including those that are associated with ncRNA promoters.\n7. RNAProFinder: This tool predicts the location of ncRNA promoters based on the sequence and structure of the RNA molecule, as well as the presence of specific motifs.\n8. DeepSEA: This tool uses a deep learning approach to predict the location of ncRNA promoters based on the sequence and structure of the RNA molecule.\n9. RNApromoter-M: This tool uses a machine learning approach to predict the location of ncRNA promoters based on the sequence and structure of the RNA molecule, as well as the presence of specific motifs.\n10. Prognosticate: This tool predicts the location of ncRNA promoters based on the sequence and structure of the RNA molecule, as well as the presence of specific motifs.\nThese tools can be used to identify potential ncRNA promoters in a genome, and can be useful for understanding the regulation of",
    "llama-2-7b-chat-hf_fact_raw": "1. CpG Island Finder is a tool that identifies CpG islands, which are regions known to be enriched in ncRNA promoters.\n2. ProbeFinder predicts the location of probes for ncRNA transcripts in the GenBank database.\n3. RNAhybrid is a tool that predicts the secondary and tertiary structure of RNA molecules and can help identify potential promoter regions.\n4. Infernal uses a Bayesian approach to predict the location of ncRNA promoters based on sequence and structure.\n5. RNApromoter uses a machine learning approach to predict the location of ncRNA promoters based on sequence and structure.",
    "llama-2-7b-chat-hf_fact": [
      "CpG Island Finder is a tool that identifies CpG islands, which are regions known to be enriched in ncRNA promoters.",
      "ProbeFinder predicts the location of probes for ncRNA transcripts in the GenBank database.",
      "RNAhybrid is a tool that predicts the secondary and tertiary structure of RNA molecules and can help identify potential promoter regions.",
      "Infernal uses a Bayesian approach to predict the location of ncRNA promoters based on sequence and structure.",
      "RNApromoter uses a machine learning approach to predict the location of ncRNA promoters based on sequence and structure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: CpG Island Finder is a tool that identifies CpG islands, which are regions with a high frequency of CG dinucleotides that are often associated with gene promoters, but it does not specifically enrich for ncRNA promoters.\n2. FALSE [correction]: ProbeFinder is typically used for designing probes for quantitative PCR and does not predict the location of probes for ncRNA transcripts in the GenBank database.\n3. FALSE [correction]: RNAhybrid is a tool that predicts hybridization sites of a small RNA within a larger RNA sequence and does not predict the secondary and tertiary structure of RNA molecules or identify potential promoter regions.\n4. TRUE: Infernal uses a Bayesian approach to predict RNA structure and can be used to locate ncRNA genes and their promoters.\n5. UNKNOWN: The statement about RNApromoter might be plausible, considering the name. However, without specific information about a tool named RNApromoter, I cannot confidently confirm or deny the accuracy of the statement. There are tools that use machine learning to predict promoters, but without confirming the existence of a specific tool called RNApromoter, the statement remains uncertain.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-7b-chat-hf_response": "SWIM (SWI/SNF Chromatin Modification) is a tool that uses chromatin immunoprecipitation sequencing (ChIP-seq) data to identify genes that are regulated by the SWI/SNF chromatin remodeling complex in various cancer types, including glioblastoma. Here are some examples of genes that SWIM has identified as down-regulated in glioblastoma:\n1. TP53: Tumor suppressor gene that is frequently mutated in glioblastoma.\n2. PTEN: Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a tumor suppressor that is down-regulated in many types of cancer, including glioblastoma.\n3. CDKN2A: Cyclin-dependent kinase inhibitor 2A (CDKN2A) is a tumor suppressor gene that is frequently mutated or lost in glioblastoma.\n4. CDKN1A: Cyclin-dependent kinase inhibitor 1A (CDKN1A) is a tumor suppressor gene that is down-regulated in many types of cancer, including glioblastoma.\n5. APC: Adenomatous polyposis coli (APC) is a tumor suppressor gene that is frequently mutated in many types of cancer, including glioblastoma.\n6. BRCA1: BReast CAncer 1 (BRCA1) is a tumor suppressor gene that is down-regulated in many types of cancer, including glioblastoma.\n7. MLH1: MutL homolog 1 (MLH1) is a tumor suppressor gene that is down-regulated in many types of cancer, including glioblastoma.\n8. MSH2: MutS homolog 2 (MSH2) is a tumor suppressor gene that is down-regulated in many types of cancer, including glioblastoma.\n9. MSH6: MutS homolog 6 (MSH6) is a tumor suppressor gene that is down-regulated in many types of cancer, including glioblastoma.\n10. PML: Promyelocytic leukemia (PML) is a tum",
    "llama-2-7b-chat-hf_fact_raw": "1. TP53 is a tumor suppressor gene identified by SWIM as being down-regulated in glioblastoma.\n2. PTEN (Phosphatase and tensin homolog deleted on chromosome 10) is identified by SWIM as a tumor suppressor gene that is down-regulated in glioblastoma.\n3. CDKN2A (Cyclin-dependent kinase inhibitor 2A) is a tumor suppressor gene identified by SWIM as being frequently mutated or lost in glioblastoma.\n4. CDKN1A (Cyclin-dependent kinase inhibitor 1A) is a tumor suppressor gene identified by SWIM as being down-regulated in glioblastoma.\n5. APC (Adenomatous polyposis coli) is a tumor suppressor gene identified by SWIM as being frequently mutated in glioblastoma.",
    "llama-2-7b-chat-hf_fact": [
      "TP53 is a tumor suppressor gene identified by SWIM as being down-regulated in glioblastoma.",
      "PTEN (Phosphatase and tensin homolog deleted on chromosome 10) is identified by SWIM as a tumor suppressor gene that is down-regulated in glioblastoma.",
      "CDKN2A (Cyclin-dependent kinase inhibitor 2A) is a tumor suppressor gene identified by SWIM as being frequently mutated or lost in glioblastoma.",
      "CDKN1A (Cyclin-dependent kinase inhibitor 1A) is a tumor suppressor gene identified by SWIM as being down-regulated in glioblastoma.",
      "APC (Adenomatous polyposis coli) is a tumor suppressor gene identified by SWIM as being frequently mutated in glioblastoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: PTEN (Phosphatase and tensin homolog deleted on chromosome ten) is a tumor suppressor gene that is down-regulated in glioblastoma, but there is no information given about PTEN being identified by SWIM.\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: APC (Adenomatous polyposis coli) is a tumor suppressor gene that is frequently mutated in colorectal tumors, not specifically in glioblastoma.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for studying Topological Associated Domains (TADs), including:\n1. TADbit: This package provides a comprehensive set of tools for the analysis of TADs, including the ability to identify TAD boundaries, quantify TAD size and shape, and detect changes in TAD structure between different samples.\n2. TADtrackR: This package provides a framework for the analysis of TADs in Chromatin Immunoprecipitation sequencing (ChIP-seq) data, including the ability to identify TADs, quantify their size and shape, and detect changes in TAD structure between different samples.\n3. TADseq: This package provides a set of tools for the analysis of TADs in RNA sequencing (RNA-seq) data, including the ability to identify TADs, quantify their expression levels, and detect changes in TAD expression between different samples.\n4. TADHunter: This package provides a tool for the automatic detection of TADs in ChIP-seq data, including the ability to identify TAD boundaries, quantify TAD size and shape, and detect changes in TAD structure between different samples.\n5. TADmap: This package provides a tool for the visualization and analysis of TADs in ChIP-seq data, including the ability to create maps of TADs, visualize the distribution of TADs across the genome, and detect changes in TAD structure between different samples.\n6. TADtrack: This package provides a tool for the analysis of TADs in ChIP-seq data, including the ability to identify TAD boundaries, quantify TAD size and shape, and detect changes in TAD structure between different samples.\n7. TAD-seq: This package provides a tool for the analysis of TADs in RNA-seq data, including the ability to identify TADs, quantify their expression levels, and detect changes in TAD expression between different samples.\n8. TAD-detector: This package provides a tool for the automatic detection of TADs in ChIP-seq data, including the ability to identify TAD boundaries, quantify TAD size and shape, and detect changes in TAD structure between different samples.\n9. TAD-finder: This package provides a tool for the automatic detection of TADs in Ch",
    "llama-2-7b-chat-hf_fact_raw": "1. TADbit is an R package developed for the analysis of Topological Associated Domains (TADs).\n2. TADtrackR is an R package that allows analysis of TADs in Chromatin Immunoprecipitation sequencing (ChIP-seq) data.\n3. TADseq is an R package designed for the analysis of TADs in RNA sequencing (RNA-seq) data.\n4. TADHunter is an R package that provides automatic detection of TADs in ChIP-seq data.\n5. TADmap is an R package that offers tools for the visualization and analysis of TADs in ChIP-seq data.",
    "llama-2-7b-chat-hf_fact": [
      "TADbit is an R package developed for the analysis of Topological Associated Domains (TADs).",
      "TADtrackR is an R package that allows analysis of TADs in Chromatin Immunoprecipitation sequencing (ChIP-seq) data.",
      "TADseq is an R package designed for the analysis of TADs in RNA sequencing (RNA-seq) data.",
      "TADHunter is an R package that provides automatic detection of TADs in ChIP-seq data.",
      "TADmap is an R package that offers tools for the visualization and analysis of TADs in ChIP-seq data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWhile TADbit is indeed an R package developed for the analysis of Topologically Associating Domains (TADs), I am unable to verify the accuracy of the statements regarding TADtrackR, TADseq, TADHunter, and TADmap due to the lack of specific information on these supposed packages. These names do not correspond to well-known packages in the bioinformatics community as of my last update, and they may either be fictional, lesser-known tools, or simply incorrect. Therefore, without additional context or sources, their veracity cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-7b-chat-hf_response": "The Bioconductor package \"RosettaRegulon\" has been developed for accessing bacterial regulatory networks. RosettaRegulon is a collection of tools and resources for analyzing and predicting the regulatory interactions in bacteria, including the regulatory networks, transcriptional regulatory sites, and gene expression profiles. It integrates various types of data, including genomic, transcriptomic, and proteomic data, to provide a comprehensive view of bacterial regulatory networks.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Bioconductor package \"RosettaRegulon\" is developed for accessing bacterial regulatory networks.\n2. RosettaRegulon includes tools for analyzing and predicting regulatory interactions in bacteria.\n3. RosettaRegulon provides resources for studying transcriptional regulatory sites and gene expression profiles in bacteria.\n4. RosettaRegulon integrates genomic, transcriptomic, and proteomic data for the analysis of bacterial regulatory networks.",
    "llama-2-7b-chat-hf_fact": [
      "The Bioconductor package \"RosettaRegulon\" is developed for accessing bacterial regulatory networks.",
      "RosettaRegulon includes tools for analyzing and predicting regulatory interactions in bacteria.",
      "RosettaRegulon provides resources for studying transcriptional regulatory sites and gene expression profiles in bacteria.",
      "RosettaRegulon integrates genomic, transcriptomic, and proteomic data for the analysis of bacterial regulatory networks."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Bioconductor package \"Regulon\" is developed for accessing bacterial regulatory networks, not \"RosettaRegulon\".\n2. TRUE, provided the first statement's package name \"RosettaRegulon\" is corrected to simply \"Regulon.\"\n3. TRUE, provided the first statement's package name \"RosettaRegulon\" is corrected to simply \"Regulon.\"\n4. FALSE [correction]: Bioconductor packages typically integrate genomic and transcriptomic data, but it is unclear if \"Regulon\" specifically integrates proteomic data for the analysis of bacterial regulatory networks without more context.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-7b-chat-hf_response": "The end products of the shikimate pathway are:\n1. Aromatic amino acids: phenylalanine, tyrosine, and tryptophan.\n2. Quinates: quinic acid and shikimate.\n3. Acids: erythrose-4-phosphate, 3-phosphoglycerate, and succinic acid.\n4. Fatty acids: acyl-CoA derivatives.\n5. Amino sugars: gentisic acid and salicinic acid.\n6. Alcohols: erythritol and sorbitol.\n7. Carboxylic acids: 3-hydroxybutyric acid and 3-hydroxyvaleric acid.\n8. Amines: putrescine and spermidine.\nPlease note that this list is not exhaustive and the end products of the shikimate pathway may vary depending on the specific organism and the stage of the pathway.",
    "llama-2-7b-chat-hf_fact_raw": "1. The shikimate pathway produces aromatic amino acids: phenylalanine, tyrosine, and tryptophan.\n2. Quinic acid and shikimate are end products of the shikimate pathway.\n3. The shikimate pathway results in the formation of erythrose-4-phosphate, 3-phosphoglycerate, and succinic acid.\n4. Acyl-CoA derivatives are produced as fatty acids from the shikimate pathway.\n5. Gentisic acid and salicinic acid are types of amino sugars produced by the shikimate pathway.",
    "llama-2-7b-chat-hf_fact": [
      "The shikimate pathway produces aromatic amino acids: phenylalanine, tyrosine, and tryptophan.",
      "Quinic acid and shikimate are end products of the shikimate pathway.",
      "The shikimate pathway results in the formation of erythrose-4-phosphate, 3-phosphoglycerate, and succinic acid.",
      "Acyl-CoA derivatives are produced as fatty acids from the shikimate pathway.",
      "Gentisic acid and salicinic acid are types of amino sugars produced by the shikimate pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Quinic acid and shikimate are intermediates, not end products, of the shikimate pathway. The end products are the aromatic amino acids: phenylalanine, tyrosine, and tryptophan.\n3. FALSE [correction]: Erythrose-4-phosphate and phosphoenolpyruvate are two primary inputs into the shikimate pathway, and 3-phosphoglycerate is part of glycolysis, but succinic acid is not a result of the shikimate pathway; it is a component of the citric acid cycle.\n4. FALSE [correction]: Acyl-CoA derivatives are produced as fatty acids via fatty acid synthesis, not from the shikimate pathway.\n5. FALSE [correction]: Gentisic acid and salicylic acid are not amino sugars, nor are they produced by the shikimate pathway. The shikimate pathway produces aromatic amino acids and aromatic secondary metabolites, but these compounds are not amino sugars. Gentisic acid and salicylic acid are examples of aromatic compounds that can be derived from shikimic acid but are not classified as amino sugars.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-7b-chat-hf_response": "Yes, cabergoline is sometimes used to treat Nelson's syndrome, which is a rare condition that occurs after surgical removal of a pituitary tumor. Cabergoline is a dopamine receptor agonist that can help to reduce the size of the remaining tumor tissue and alleviate symptoms such as prolactinoma, hyperprolactinemia, and visual disturbances. However, it is important to note that cabergoline is not a standard treatment for Nelson's syndrome and its use for this condition is off-label. The most common treatment for Nelson's syndrome is surgical intervention, followed by radiation therapy and medications to reduce prolactin levels.",
    "llama-2-7b-chat-hf_fact_raw": "1. Nelson's syndrome is a rare condition that can occur after surgical removal of a pituitary tumor.\n2. Cabergoline is a dopamine receptor agonist.\n3. Cabergoline is sometimes used off-label to treat Nelson's syndrome.\n4. The most common treatment for Nelson's syndrome includes surgical intervention.\n5. Following surgery for Nelson's syndrome, radiation therapy and medications to reduce prolactin levels may also be used.",
    "llama-2-7b-chat-hf_fact": [
      "Nelson's syndrome is a rare condition that can occur after surgical removal of a pituitary tumor.",
      "Cabergoline is a dopamine receptor agonist.",
      "Cabergoline is sometimes used off-label to treat Nelson's syndrome.",
      "The most common treatment for Nelson's syndrome includes surgical intervention.",
      "Following surgery for Nelson's syndrome, radiation therapy and medications to reduce prolactin levels may also be used."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Cabergoline is often used to treat conditions like prolactinomas or Parkinson's disease. Treatment of Nelson's syndrome typically doesn't involve drugs that reduce prolactin levels.\n4. TRUE\n5. FALSE [correction]: Radiation therapy and medications may be used following surgery for Nelson's syndrome, but they are typically aimed at reducing ACTH (adrenocorticotropic hormone) levels, not specifically prolactin levels. Nelson’s syndrome is associated with the overproduction of ACTH after the removal of the adrenal glands.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-7b-chat-hf_response": "Liebenberg syndrome is a rare genetic disorder characterized by progressive muscle weakness, muscle wasting, and muscle cramps, primarily affecting the limbs. The main manifestation of Liebenberg syndrome is proximal muscle weakness, which refers to the loss of muscle mass and strength in the upper arms and legs. This can lead to difficulty with walking, balance, and other daily activities. Other symptoms may include muscle cramps, spasms, and twitching, as well as a high risk of respiratory muscle weakness, which can lead to breathing difficulties.",
    "llama-2-7b-chat-hf_fact_raw": "1. Liebenberg syndrome is a rare genetic disorder.\n2. The main manifestation of Liebenberg syndrome is proximal muscle weakness.\n3. Proximal muscle weakness in Liebenberg syndrome affects the upper arms and legs.\n4. Individuals with Liebenberg syndrome may experience difficulty with walking and balance.\n5. There is a high risk of respiratory muscle weakness in people with Liebenberg syndrome, which can cause breathing difficulties.",
    "llama-2-7b-chat-hf_fact": [
      "Liebenberg syndrome is a rare genetic disorder.",
      "The main manifestation of Liebenberg syndrome is proximal muscle weakness.",
      "Proximal muscle weakness in Liebenberg syndrome affects the upper arms and legs.",
      "Individuals with Liebenberg syndrome may experience difficulty with walking and balance.",
      "There is a high risk of respiratory muscle weakness in people with Liebenberg syndrome, which can cause breathing difficulties."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: Liebenberg syndrome is characterized by the development of upper limb features in the lower limbs, mainly elbow-like features in the knees.\n3. FALSE [correction]: Liebenberg syndrome's main manifestation is not muscle weakness, but rather the development of upper limb-like features in the lower limbs.\n4. UNKNOWN\n5. UNKNOWN\n\nThe Liebenberg syndrome is quite rare and the information provided contains inaccuracies regarding its manifestations, leading to the corrections provided above. The specific medical conditions and risk factors associated with Liebenberg syndrome may be documented in medical literature, but are not widely recognized outside of specialist circles, leading to the \"UNKNOWN\" responses for some items.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-7b-chat-hf_response": "There are several orally bioavailable MPS1 kinase inhibitors that have been identified and investigated for their potential therapeutic applications. Here are some examples:\n1. Ruxolitinib: Ruxolitinib is a potent and selective MPS1 inhibitor that has been approved for the treatment of myelofibrosis, a type of blood cancer. It is available in oral form and has been shown to inhibit MPS1 activity in vitro and in vivo.\n2. PF-06700600: PF-06700600 is a highly selective and potent MPS1 inhibitor that has shown promise in preclinical studies for the treatment of various cancers, including breast, lung, and ovarian cancer. It is currently in clinical development.\n3. BAY 80-6946: BAY 80-6946 is a small molecule inhibitor of MPS1 that has been shown to inhibit MPS1 activity in vitro and in vivo. It is currently in clinical development for the treatment of various cancers.\n4. AZD-1475: AZD-1475 is a potent and selective MPS1 inhibitor that has shown promise in preclinical studies for the treatment of various cancers, including breast, lung, and ovarian cancer. It is currently in clinical development.\n5. GDC-0980: GDC-0980 is a highly selective and potent MPS1 inhibitor that has shown promise in preclinical studies for the treatment of various cancers, including breast, lung, and ovarian cancer. It is currently in clinical development.\nIt is important to note that this list is not exhaustive and there may be other orally bioavailable MPS1 kinase inhibitors in various stages of development. Additionally, the development of these inhibitors is ongoing, and their efficacy and safety in humans have not yet been fully established.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ruxolitinib is an orally available and approved treatment for myelofibrosis.\n2. PF-06700600 is an orally bioavailable MPS1 inhibitor in clinical development.\n3. BAY 80-6946 is an orally bioavailable MPS1 inhibitor currently in clinical development.\n4. AZD-1475 is an orally bioavailable MPS1 inhibitor in clinical development for various cancers.\n5. GDC-0980 is an orally bioavailable MPS1 inhibitor in clinical development for various cancers.",
    "llama-2-7b-chat-hf_fact": [
      "Ruxolitinib is an orally available and approved treatment for myelofibrosis.",
      "PF-06700600 is an orally bioavailable MPS1 inhibitor in clinical development.",
      "BAY 80-6946 is an orally bioavailable MPS1 inhibitor currently in clinical development.",
      "AZD-1475 is an orally bioavailable MPS1 inhibitor in clinical development for various cancers.",
      "GDC-0980 is an orally bioavailable MPS1 inhibitor in clinical development for various cancers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: BAY 80-6946, also known as copanlisib, is a PI3K inhibitor, not an MPS1 inhibitor, and it is approved for the treatment of follicular lymphoma.\n4. FALSE [correction]: AZD-1475 is not a known compound in the context of publicly available information up to the knowledge cutoff in 2023. Thus, its status as an MPS1 inhibitor cannot be verified.\n5. FALSE [correction]: GDC-0980, also known as apitolisib, is a dual PI3K/mTOR inhibitor, not an MPS1 inhibitor, and it has been in clinical development for cancer treatment.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-7b-chat-hf_response": "Golimumab, a tumor necrosis factor-alpha (TNF-alpha) inhibitor, is approved for the treatment of certain autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. However, it has not been specifically tested or approved for the treatment of diabetes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Golimumab is a tumor necrosis factor-alpha (TNF-alpha) inhibitor.\n2. Golimumab is approved for the treatment of certain autoimmune diseases.\n3. The autoimmune diseases golimumab is approved for include rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.\n4. Golimumab has not been specifically tested for the treatment of diabetes.\n5. Golimumab is not approved for the treatment of diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "Golimumab is a tumor necrosis factor-alpha (TNF-alpha) inhibitor.",
      "Golimumab is approved for the treatment of certain autoimmune diseases.",
      "The autoimmune diseases golimumab is approved for include rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.",
      "Golimumab has not been specifically tested for the treatment of diabetes.",
      "Golimumab is not approved for the treatment of diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-7b-chat-hf_response": "Progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is caused by a mutation in the LMNA gene, which is located on chromosome 1. Progeria is an autosomal dominant disorder, meaning that a single copy of the mutated gene is enough to cause the condition. Individuals with progeria have a 50% chance of passing the mutated gene to each of their children, regardless of whether they are affected or not.",
    "llama-2-7b-chat-hf_fact_raw": "1. Progeria is also known as Hutchinson-Gilford progeria syndrome (HGPS).\n2. Progeria is caused by a mutation in the LMNA gene.\n3. The LMNA gene is located on chromosome 1.\n4. Progeria is an autosomal dominant disorder.\n5. Individuals with progeria have a 50% chance of passing the mutated gene to each of their children.",
    "llama-2-7b-chat-hf_fact": [
      "Progeria is also known as Hutchinson-Gilford progeria syndrome (HGPS).",
      "Progeria is caused by a mutation in the LMNA gene.",
      "The LMNA gene is located on chromosome 1.",
      "Progeria is an autosomal dominant disorder.",
      "Individuals with progeria have a 50% chance of passing the mutated gene to each of their children."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Progeria is typically not inherited; most cases are due to a new mutation. It is a very rare condition and not typically seen as autosomal dominant because individuals with progeria seldom live to reproduce.\n5. FALSE [correction]: Because most cases of progeria are not inherited but instead caused by new (de novo) mutations, affected individuals usually do not have the chance to pass on the gene to their children. Furthermore, as mentioned, individuals with progeria often do not survive to reproductive age.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-7b-chat-hf_response": "Common variants at 12q14 and 12q24 have been associated with various diseases and conditions, including:\n12q14:\n* Bipolar disorder: Variants in this region have been implicated in the risk of developing bipolar disorder.\n* Schizophrenia: Some studies have found associations between variants in this region and the risk of schizophrenia.\n* Major depressive disorder: Some studies have suggested that variants in this region may be associated with an increased risk of major depressive disorder.\n* Obesity: Variants in this region have been linked to an increased risk of obesity and metabolic disorders.\n12q24:\n* Prostate cancer: Variants in this region have been associated with an increased risk of prostate cancer.\n* Breast cancer: Some studies have found associations between variants in this region and an increased risk of breast cancer.\n* Colorectal cancer: Variants in this region have been linked to an increased risk of colorectal cancer.\nIt's important to note that these associations are based on observational studies and more research is needed to confirm these findings and understand the underlying mechanisms.",
    "llama-2-7b-chat-hf_fact_raw": "1. Variants at 12q14 have been implicated in the risk of developing bipolar disorder.\n2. Studies have found associations between variants at 12q14 and the risk of schizophrenia.\n3. Variants at 12q14 may be associated with an increased risk of major depressive disorder.\n4. Variants at 12q14 have been linked to an increased risk of obesity and metabolic disorders.\n5. Variants at 12q24 have been associated with an increased risk of prostate cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Variants at 12q14 have been implicated in the risk of developing bipolar disorder.",
      "Studies have found associations between variants at 12q14 and the risk of schizophrenia.",
      "Variants at 12q14 may be associated with an increased risk of major depressive disorder.",
      "Variants at 12q14 have been linked to an increased risk of obesity and metabolic disorders.",
      "Variants at 12q24 have been associated with an increased risk of prostate cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nIt is known that genetic variants, such as those on chromosome 12q14, can be associated with a variety of conditions, including psychiatric disorders. Similarly, variants on other regions like 12q24 have been studied for associations with different diseases, including various forms of cancer. The statements provided are consistent with such genetic research findings, but it should be noted that genetic associations do not imply causation, and these findings would be specific to the studies that identified these associations. Without specific study details, the responses are based on the general understanding that such associations are possible and have been identified in genetic research.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-7b-chat-hf_response": "Roundabout (Robo) receptors are activated by a variety of ligands, including:\n1. Robo1 and Robo2 are activated by the ligand Roundabout (Robo), also known as Rnd1 and Rnd2.\n2. Robo3 is activated by the ligands Rho-associated protein kinase (Rock) and Dishevelled (Dvl).\n3. Robo4 is activated by the ligand Rho-GTPase-activating protein (GAP) domain-containing protein (RGAP).\nThese ligands bind to the extracellular domain of the Robo receptors, leading to their activation and modulation of downstream signaling pathways involved in cell migration, differentiation, and survival.",
    "llama-2-7b-chat-hf_fact_raw": "1. Robo1 and Robo2 receptors are activated by the ligand Roundabout (Rnd1 and Rnd2).\n2. The ligand Rho-associated protein kinase (Rock) activates Robo3 receptors.\n3. The ligand Dishevelled (Dvl) activates Robo3 receptors.\n4. Robo4 receptors are activated by the ligand Rho-GTPase-activating protein (GAP) domain-containing protein (RGAP).\n5. The ligands of Robo receptors bind to the extracellular domain, leading to activation and modulation of signaling pathways.",
    "llama-2-7b-chat-hf_fact": [
      "Robo1 and Robo2 receptors are activated by the ligand Roundabout (Rnd1 and Rnd2).",
      "The ligand Rho-associated protein kinase (Rock) activates Robo3 receptors.",
      "The ligand Dishevelled (Dvl) activates Robo3 receptors.",
      "Robo4 receptors are activated by the ligand Rho-GTPase-activating protein (GAP) domain-containing protein (RGAP).",
      "The ligands of Robo receptors bind to the extracellular domain, leading to activation and modulation of signaling pathways."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Robo1 and Robo2 receptors are activated by the ligand Slit, not Roundabout (Rnd1 and Rnd2).\n2. FALSE [correction]: The ligand for Robo3 receptors is not Rho-associated protein kinase (Rock). Robo receptors are generally activated by Slit proteins, but Rock is a downstream effector of Rho-GTPase, which can interact with the signaling pathways of Robo receptors.\n3. UNKNOWN: Without specific literature or studies to cite, the activation of Robo3 receptors by the ligand Dishevelled (Dvl) cannot be confirmed as true or false.\n4. UNKNOWN: The ligand for Robo4 activation is not well known in general descriptions, and without specific scientific literature to refer to, it’s not possible to confirm if Rho-GTPase-activating protein (GAP) domain-containing protein (RGAP) acts as a ligand.\n5. TRUE: Ligands of Robo receptors, such as Slit proteins, do bind to the extracellular domain, leading to activation and modulation of signaling pathways like axon guidance and cell migration.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-7b-chat-hf_response": "TFII-I does not play a direct role in megakaryopoiesis. TFII-I is a general transcription factor that is involved in the initiation of transcription in eukaryotic cells, but it is not specifically involved in the regulation of megakaryocyte differentiation or platelet production.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFII-I does not play a direct role in megakaryopoiesis.\n2. TFII-I is a general transcription factor involved in the initiation of transcription in eukaryotic cells.\n3. TFII-I is not specifically involved in the regulation of megakaryocyte differentiation.\n4. TFII-I is not specifically involved in platelet production.",
    "llama-2-7b-chat-hf_fact": [
      "TFII-I does not play a direct role in megakaryopoiesis.",
      "TFII-I is a general transcription factor involved in the initiation of transcription in eukaryotic cells.",
      "TFII-I is not specifically involved in the regulation of megakaryocyte differentiation.",
      "TFII-I is not specifically involved in platelet production."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TFII-I does play a direct role in megakaryopoiesis, which is the process that leads to the production of megakaryocytes, cells that give rise to platelets.\n2. TRUE\n3. FALSE [correction]: TFII-I is specifically involved in the regulation of megakaryocyte differentiation, as it plays a role in megakaryopoiesis.\n4. FALSE [correction]: Since TFII-I contributes to megakaryocyte differentiation, and megakaryocytes are the precursor cells for platelets, it is involved in platelet production.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-7b-chat-hf_response": "Yes, atenolol is metabolized by the cytochrome P450 enzyme CYP2D6. CYP2D6 is one of the most important enzymes responsible for the metabolism of atenolol, and it is estimated that approximately 30-40% of the drug is metabolized by this enzyme. The metabolism of atenolol by CYP2D6 can result in the formation of active metabolites, such as the beta-hydroxy and N-oxide metabolites, which contribute to the drug's therapeutic effects.",
    "llama-2-7b-chat-hf_fact_raw": "1. Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.\n2. CYP2D6 is responsible for the metabolism of approximately 30-40% of atenolol.\n3. The metabolism of atenolol by CYP2D6 results in the formation of active metabolites.\n4. Beta-hydroxy and N-oxide metabolites are formed from atenolol metabolism by CYP2D6.\n5. These metabolites contribute to the therapeutic effects of atenolol.",
    "llama-2-7b-chat-hf_fact": [
      "Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.",
      "CYP2D6 is responsible for the metabolism of approximately 30-40% of atenolol.",
      "The metabolism of atenolol by CYP2D6 results in the formation of active metabolites.",
      "Beta-hydroxy and N-oxide metabolites are formed from atenolol metabolism by CYP2D6.",
      "These metabolites contribute to the therapeutic effects of atenolol."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Atenolol is not significantly metabolized by the cytochrome P450 system; it is primarily eliminated unchanged in the urine.\n2. FALSE [correction]: Since atenolol is not significantly metabolized by the cytochrome P450 system, CYP2D6 is not responsible for the metabolism of any significant percentage of atenolol.\n3. FALSE [correction]: Atenolol does not have active metabolites as it is not significantly metabolized; it is excreted largely unchanged.\n4. FALSE [correction]: Since atenolol is not significantly metabolized by CYP2D6, beta-hydroxy and N-oxide metabolites are not formed from its metabolism by CYP2D6.\n5. FALSE [correction]: As atenolol is largely excreted unchanged and does not have active metabolites, these metabolites do not contribute to its therapeutic effects.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I must inform you that ExpansionHunter is a fictional tool, and therefore does not have any versions. It is a term that is often used in the context of gene editing and genome engineering, but it is not a real tool or software program.\nHowever, there are several tools and software programs that are used in the field of gene editing and genome engineering, including:\n1. CRISPR-Cas9: A popular gene editing tool that uses a small RNA molecule to guide an enzyme called Cas9 to a specific location in the genome, where it can make a cut in the DNA.\n2. TALENs: Another gene editing tool that uses a DNA-binding protein to recognize a specific sequence of DNA and make a cut in the genome.\n3. ZFNs: A type of gene editing tool that uses a zinc finger protein to recognize a specific sequence of DNA and make a cut in the genome.\n4. Homology-directed repair (HDR): A process by which the cell repairs a break in the DNA by using a template with a similar sequence to the broken DNA.\n5. Non-homologous end joining (NHEJ): A process by which the cell repairs a break in the DNA by simply joining the two ends of the break without using a template.\nThese are just a few examples of the many tools and techniques that are used in gene editing and genome engineering.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-7b-chat-hf_response": "Adamts18 does not play a direct role in hormone receptor signaling.",
    "llama-2-7b-chat-hf_fact_raw": "1. Adamts18 does not directly participate in hormone receptor signaling.",
    "llama-2-7b-chat-hf_fact": [
      "Adamts18 does not directly participate in hormone receptor signaling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n\nWithout further information in the provided context about Adamts18 or specific studies, mechanisms, or direct roles in relation to hormone receptor signaling, it is not possible to accurately determine the veracity of the statement about the protein's involvement or lack thereof in that biological process.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-7b-chat-hf_response": "Thiazovivin is a small molecule inhibitor of the histone acetyltransferase (HAT) enzyme p300. It works by competitively inhibiting the enzymatic activity of p300, thereby reducing the acetylation of histone proteins and altering chromatin structure, leading to changes in gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. Thiazovivin is a small molecule inhibitor.\n2. Thiazovivin inhibits the histone acetyltransferase (HAT) enzyme p300.\n3. It competes with the substrate for enzymatic activity of p300.\n4. Thiazovivin reduces the acetylation of histone proteins.\n5. Thiazovivin leads to changes in gene expression by altering chromatin structure.",
    "llama-2-7b-chat-hf_fact": [
      "Thiazovivin is a small molecule inhibitor.",
      "Thiazovivin inhibits the histone acetyltransferase (HAT) enzyme p300.",
      "It competes with the substrate for enzymatic activity of p300.",
      "Thiazovivin reduces the acetylation of histone proteins.",
      "Thiazovivin leads to changes in gene expression by altering chromatin structure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Thiazovivin is known to be a ROCK inhibitor (Rho-associated protein kinase inhibitor), not a histone acetyltransferase (HAT) enzyme p300 inhibitor.\n3. FALSE [correction]: Since Thiazovivin is not an inhibitor of the HAT enzyme p300, it does not compete with the substrate for enzymatic activity of p300.\n4. UNKNOWN: The statement is related to histone acetylation, which would be true for a HAT inhibitor, but since Thiazovivin is not a HAT inhibitor, whether it reduces the acetylation of histone proteins is not clear without the specific context or additional information.\n5. UNKNOWN: While altering chromatin structure can lead to changes in gene expression, this statement would be speculative for Thiazovivin without further context, as its primary known mechanism is ROCK inhibition and any effects on gene expression related to chromatin changes would need to be specifically established.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  }
]